Carrel name: keyword-antibody-cord Creating study carrel named keyword-antibody-cord Initializing database file: cache/cord-002710-e8im13go.json key: cord-002710-e8im13go authors: Taschuk, Ryan; Scruten, Erin; Woodbury, Murray; Cashman, Neil; Potter, Andrew; Griebel, Philip; Tikoo, Suresh K.; Napper, Scott title: Induction of PrP(Sc)-specific systemic and mucosal immune responses in white-tailed deer with an oral vaccine for chronic wasting disease date: 2017-10-02 journal: Prion DOI: 10.1080/19336896.2017.1367083 sha: doc_id: 2710 cord_uid: e8im13go file: cache/cord-004167-r2s0gks8.json key: cord-004167-r2s0gks8 authors: Cutts, Julia C.; Agius, Paul A.; Zaw Lin; Powell, Rosanna; Moore, Kerryn; Draper, Bridget; Simpson, Julie A.; Fowkes, Freya J. I. title: Pregnancy-specific malarial immunity and risk of malaria in pregnancy and adverse birth outcomes: a systematic review date: 2020-01-16 journal: BMC Med DOI: 10.1186/s12916-019-1467-6 sha: doc_id: 4167 cord_uid: r2s0gks8 file: cache/cord-001435-ebl8yc92.json key: cord-001435-ebl8yc92 authors: Hoppe, Sebastian; Bier, Frank F.; von Nickisch-Rosenegk, Markus title: Identification of Antigenic Proteins of the Nosocomial Pathogen Klebsiella pneumoniae date: 2014-10-21 journal: PLoS One DOI: 10.1371/journal.pone.0110703 sha: doc_id: 1435 cord_uid: ebl8yc92 file: cache/cord-001060-9g8rwsm1.json key: cord-001060-9g8rwsm1 authors: Arruebo, Manuel; Vilaboa, Nuria; Sáez-Gutierrez, Berta; Lambea, Julio; Tres, Alejandro; Valladares, Mónica; González-Fernández, África title: Assessment of the Evolution of Cancer Treatment Therapies date: 2011-08-12 journal: Cancers (Basel) DOI: 10.3390/cancers3033279 sha: doc_id: 1060 cord_uid: 9g8rwsm1 file: cache/cord-005827-wjkbrfkn.json key: cord-005827-wjkbrfkn authors: Schmidt, Rüdiger; Scheuermann, Ernst-Heinrich; Viertel, Achim; Geiger, Helmut; Scharrer, Inge title: Antiphospholipidantikörpersyndrom date: 1999 journal: Med Klin (Munich) DOI: 10.1007/bf03044707 sha: doc_id: 5827 cord_uid: wjkbrfkn file: cache/cord-001074-qevosik3.json key: cord-001074-qevosik3 authors: Selvarajah, Suganya; Sexton, Nicole R.; Kahle, Kristen M.; Fong, Rachel H.; Mattia, Kimberly-Anne; Gardner, Joy; Lu, Kai; Liss, Nathan M.; Salvador, Beatriz; Tucker, David F.; Barnes, Trevor; Mabila, Manu; Zhou, Xiangdong; Rossini, Giada; Rucker, Joseph B.; Sanders, David Avram; Suhrbier, Andreas; Sambri, Vittorio; Michault, Alain; Muench, Marcus O.; Doranz, Benjamin J.; Simmons, Graham title: A Neutralizing Monoclonal Antibody Targeting the Acid-Sensitive Region in Chikungunya Virus E2 Protects from Disease date: 2013-09-12 journal: PLoS Negl Trop Dis DOI: 10.1371/journal.pntd.0002423 sha: doc_id: 1074 cord_uid: qevosik3 file: cache/cord-003435-ke0az7nf.json key: cord-003435-ke0az7nf authors: Schlake, Thomas; Thess, Andreas; Thran, Moritz; Jordan, Ingo title: mRNA as novel technology for passive immunotherapy date: 2018-10-17 journal: Cell Mol Life Sci DOI: 10.1007/s00018-018-2935-4 sha: doc_id: 3435 cord_uid: ke0az7nf file: cache/cord-002153-e0zhq18g.json key: cord-002153-e0zhq18g authors: Yang, Danlin; Frego, Lee; Lasaro, Marcio; Truncali, Kristopher; Kroe-Barrett, Rachel; Singh, Sanjaya title: Efficient Qualitative and Quantitative Determination of Antigen-induced Immune Responses date: 2016-07-29 journal: J Biol Chem DOI: 10.1074/jbc.m116.736660 sha: doc_id: 2153 cord_uid: e0zhq18g file: cache/cord-005913-1vo1o6w8.json key: cord-005913-1vo1o6w8 authors: Matis, Louis A.; Rollins, Scott A. title: Complement-specific antibodies: Designing novel anti-inflammatories date: 1995 journal: Nat Med DOI: 10.1038/nm0895-839 sha: doc_id: 5913 cord_uid: 1vo1o6w8 file: cache/cord-001726-d7iwkatn.json key: cord-001726-d7iwkatn authors: Henry, Kevin A.; Arbabi-Ghahroudi, Mehdi; Scott, Jamie K. title: Beyond phage display: non-traditional applications of the filamentous bacteriophage as a vaccine carrier, therapeutic biologic, and bioconjugation scaffold date: 2015-08-04 journal: Front Microbiol DOI: 10.3389/fmicb.2015.00755 sha: doc_id: 1726 cord_uid: d7iwkatn file: cache/cord-009446-8keu2uay.json key: cord-009446-8keu2uay authors: Kreer, Christoph; Gruell, Henning; Mora, Thierry; Walczak, Aleksandra M.; Klein, Florian title: Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies date: 2020-01-01 journal: Vaccines (Basel) DOI: 10.3390/vaccines8010013 sha: doc_id: 9446 cord_uid: 8keu2uay file: cache/cord-002846-la9svzml.json key: cord-002846-la9svzml authors: Strohl, William R. title: Current progress in innovative engineered antibodies date: 2017-08-18 journal: Protein Cell DOI: 10.1007/s13238-017-0457-8 sha: doc_id: 2846 cord_uid: la9svzml file: cache/cord-016966-b23o5roz.json key: cord-016966-b23o5roz authors: Verhoef, Jan; Snippe, Harm title: Immune response in human pathology: infections caused by bacteria, viruses, fungi, and parasites date: 2005 journal: Principles of Immunopharmacology DOI: 10.1007/3-7643-7408-x_7 sha: doc_id: 16966 cord_uid: b23o5roz file: cache/cord-001566-kkaxha7d.json key: cord-001566-kkaxha7d authors: Zhang, Mao-Yu; Lu, Jin-Jian; Wang, Liang; Gao, Zi-Chao; Hu, Hao; Ung, Carolina Oi Lam; Wang, Yi-Tao title: Development of Monoclonal Antibodies in China: Overview and Prospects date: 2015-02-25 journal: Biomed Res Int DOI: 10.1155/2015/168935 sha: doc_id: 1566 cord_uid: kkaxha7d file: cache/cord-005409-8mbqkzpu.json key: cord-005409-8mbqkzpu authors: Cichon, G; Boeckh-Herwig, S; Schmidt, HH; Wehnes, E; Müller, T; Pring-Akerblom, P; Burger, R title: Complement activation by recombinant adenoviruses date: 2002-01-24 journal: Gene Ther DOI: 10.1038/sj.gt.3301611 sha: doc_id: 5409 cord_uid: 8mbqkzpu file: cache/cord-010248-ln800g5z.json key: cord-010248-ln800g5z authors: Sissons, J.G. Patrick; Oldstone, Michael B.A. title: Antibody-Mediated Destruction of Virus-Infected Cells date: 2008-02-29 journal: Adv Immunol DOI: 10.1016/s0065-2776(08)60045-0 sha: doc_id: 10248 cord_uid: ln800g5z file: cache/cord-018404-jdu4h00e.json key: cord-018404-jdu4h00e authors: DuBourdieu, Dan title: Colostrum Antibodies, Egg Antibodies and Monoclonal Antibodies Providing Passive Immunity for Animals date: 2019-03-11 journal: Nutraceuticals in Veterinary Medicine DOI: 10.1007/978-3-030-04624-8_18 sha: doc_id: 18404 cord_uid: jdu4h00e file: cache/cord-015683-a9a82of4.json key: cord-015683-a9a82of4 authors: Gupta, Varsha; Sengupta, Manjistha; Prakash, Jaya; Tripathy, Baishnab Charan title: Molecular Diagnostics date: 2016-10-23 journal: Basic and Applied Aspects of Biotechnology DOI: 10.1007/978-981-10-0875-7_9 sha: doc_id: 15683 cord_uid: a9a82of4 file: cache/cord-009581-bvihkf1r.json key: cord-009581-bvihkf1r authors: Hurd, Eric R.; Dowdle, Walter; Casey, Helen; Ziff, Morris title: Virus antibody levels in systemic lupus erythematosus date: 2005-11-22 journal: Arthritis Rheum DOI: 10.1002/art.1780150308 sha: doc_id: 9581 cord_uid: bvihkf1r file: cache/cord-004247-lagv3tp7.json key: cord-004247-lagv3tp7 authors: Hooft van Huijsduijnen, Rob; Kojima, Somei; Carter, Dee; Okabe, Hisafumi; Sato, Akihide; Akahata, Wataru; Wells, Timothy N. C.; Katsuno, Kei title: Reassessing therapeutic antibodies for neglected and tropical diseases date: 2020-01-30 journal: PLoS Negl Trop Dis DOI: 10.1371/journal.pntd.0007860 sha: doc_id: 4247 cord_uid: lagv3tp7 file: cache/cord-010680-lc1onm53.json key: cord-010680-lc1onm53 authors: Patel, Ami; Bah, Mamadou A.; Weiner, David B. title: In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies date: 2020-03-10 journal: BioDrugs DOI: 10.1007/s40259-020-00412-3 sha: doc_id: 10680 cord_uid: lc1onm53 file: cache/cord-010570-ytv7dwr0.json key: cord-010570-ytv7dwr0 authors: Casadevall, Arturo; Scharff, Matthew D. title: Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases date: 1995-07-17 journal: Clin Infect Dis DOI: 10.1093/clinids/21.1.150 sha: doc_id: 10570 cord_uid: ytv7dwr0 file: cache/cord-015742-nt44jcjm.json key: cord-015742-nt44jcjm authors: Garwes, D.J.; Lucas, M.H.; Higgins, D.A.; Pike, B.V.; Cartwright, S.F. title: Antigenicity of structural components from porcine transmissible gastroenteritis virus date: 2002-11-13 journal: Vet Microbiol DOI: 10.1016/0378-1135(79)90034-8 sha: doc_id: 15742 cord_uid: nt44jcjm file: cache/cord-010578-uib9h1lb.json key: cord-010578-uib9h1lb authors: Mawle, Alison C.; Nisenbaum, Rosane; Dobbins, James G.; Gary, Howard E.; Stewart, John A.; Reyes, Michele; Steele, Lea; Schmid, D. Scott; Reeves, William C. title: Seroepidemiology of Chronic Fatigue Syndrome: A Case-Control Study date: 1995-12-17 journal: Clin Infect Dis DOI: 10.1093/clinids/21.6.1386 sha: doc_id: 10578 cord_uid: uib9h1lb file: cache/cord-009690-kbwz7xop.json key: cord-009690-kbwz7xop authors: Toubanaki, Dimitra K.; Margaroni, Maritsa; Prapas, Athanasios; Karagouni, Evdokia title: Development of a Nanoparticle-based Lateral Flow Strip Biosensor for Visual Detection of Whole Nervous Necrosis Virus Particles date: 2020-04-16 journal: Sci Rep DOI: 10.1038/s41598-020-63553-z sha: doc_id: 9690 cord_uid: kbwz7xop file: cache/cord-016960-xhzvp35g.json key: cord-016960-xhzvp35g authors: Berencsi, György; Szomor, Katalin N. title: Fetal and Neonatal Illnesses Caused or Influenced by Maternal Transplacental IgG and/or Therapeutic Antibodies Applied During Pregnancy date: 2012-03-08 journal: Maternal Fetal Transmission of Human Viruses and their Influence on Tumorigenesis DOI: 10.1007/978-94-007-4216-1_9 sha: doc_id: 16960 cord_uid: xhzvp35g file: cache/cord-022439-8wy7rpqv.json key: cord-022439-8wy7rpqv authors: DENMAN, A.M. title: Viral Etiology of Polymyositis/Dermatomyositis date: 2013-11-17 journal: Polymyositis and Dermatomyositis DOI: 10.1016/b978-0-409-95191-2.50010-0 sha: doc_id: 22439 cord_uid: 8wy7rpqv file: cache/cord-010991-fp8hljbq.json key: cord-010991-fp8hljbq authors: Rather, Shabeer Ahmad; Sharma, Sukesh Chander; Mahmood, Akhtar title: Antibodies generated against dextransucrase exhibit potential anticariostatic properties in Streptococcus mutans date: 2020-01-03 journal: Appl Microbiol Biotechnol DOI: 10.1007/s00253-019-10327-x sha: doc_id: 10991 cord_uid: fp8hljbq file: cache/cord-010088-s9tfvtao.json key: cord-010088-s9tfvtao authors: nan title: Oral Abstracts date: 2013-11-01 journal: Vox Sang DOI: 10.1111/vox.12100_1 sha: doc_id: 10088 cord_uid: s9tfvtao file: cache/cord-017070-05vlz5dn.json key: cord-017070-05vlz5dn authors: Dimitrov, Dimiter S. title: Human Monoclonal Antibodies Against HIV and Emerging Viruses date: 2008 journal: National Institute of Allergy and Infectious Diseases, NIH DOI: 10.1007/978-1-59745-569-5_34 sha: doc_id: 17070 cord_uid: 05vlz5dn file: cache/cord-021402-wq770ik9.json key: cord-021402-wq770ik9 authors: Relford, Roberta L.; DiMarco, Anthony title: New Diagnostic Tools for Infectious Disease date: 2009-05-15 journal: Consultations in Feline Internal Medicine DOI: 10.1016/b0-72-160423-4/50009-3 sha: doc_id: 21402 cord_uid: wq770ik9 file: cache/cord-021770-zn7na974.json key: cord-021770-zn7na974 authors: Slifka, Mark K.; Amanna, Ian J. title: Passive Immunization date: 2017-07-17 journal: Plotkin's Vaccines DOI: 10.1016/b978-0-323-35761-6.00008-0 sha: doc_id: 21770 cord_uid: zn7na974 file: cache/cord-254531-pv55re2x.json key: cord-254531-pv55re2x authors: Mestecky, Jiri; Russell, Michael W. title: Specific antibody activity, glycan heterogeneity and polyreactivity contribute to the protective activity of S-IgA at mucosal surfaces date: 2009-06-04 journal: Immunol Lett DOI: 10.1016/j.imlet.2009.03.013 sha: doc_id: 254531 cord_uid: pv55re2x file: cache/cord-018811-zhwr3h07.json key: cord-018811-zhwr3h07 authors: Oxford, John; Gilbert, Anthony; Lambkin-Williams, Robert title: Influenza Vaccines Have a Short but Illustrious History of Dedicated Science Enabling the Rapid Global Production of A/Swine (H1N1) Vaccine in the Current Pandemic date: 2010-06-18 journal: Influenza Vaccines for the Future DOI: 10.1007/978-3-0346-0279-2_6 sha: doc_id: 18811 cord_uid: zhwr3h07 file: cache/cord-018840-ts2g1ux7.json key: cord-018840-ts2g1ux7 authors: Katragkou, Aspasia; Roilides, Emmanuel; Walsh, Thomas J. title: Role of Immunoglobulin Therapy to Prevent and Treat Infections date: 2018-06-19 journal: Management of Infections in the Immunocompromised Host DOI: 10.1007/978-3-319-77674-3_17 sha: doc_id: 18840 cord_uid: ts2g1ux7 file: cache/cord-009571-mygj2nd4.json key: cord-009571-mygj2nd4 authors: nan title: Proceedings of the 42nd annual meeting of the american rheumatism association a section of the arthritis foundation june 1 & 2, 1978 new york city abstracts of papers presented date: 2005-11-23 journal: Arthritis Rheum DOI: 10.1002/art.1780210508 sha: doc_id: 9571 cord_uid: mygj2nd4 file: cache/cord-023731-jqgervt7.json key: cord-023731-jqgervt7 authors: FENNER, FRANK; BACHMANN, PETER A.; GIBBS, E. PAUL J.; MURPHY, FREDERICK A.; STUDDERT, MICHAEL J.; WHITE, DAVID O. title: Laboratory Diagnosis of Viral Diseases date: 2014-06-27 journal: Veterinary Virology DOI: 10.1016/b978-0-12-253055-5.50017-7 sha: doc_id: 23731 cord_uid: jqgervt7 file: cache/cord-048360-n9sih438.json key: cord-048360-n9sih438 authors: Villard, Viviane; Agak, George W.; Frank, Géraldine; Jafarshad, Ali; Servis, Catherine; Nébié, Issa; Sirima, Sodiomon B.; Felger, Ingrid; Arevalo-Herrera, Myriam; Herrera, Socrates; Heitz, Frederic; Bäcker, Volker; Druilhe, Pierre; Kajava, Andrey V.; Corradin, Giampietro title: Rapid Identification of Malaria Vaccine Candidates Based on α-Helical Coiled Coil Protein Motif date: 2007-07-25 journal: PLoS One DOI: 10.1371/journal.pone.0000645 sha: doc_id: 48360 cord_uid: n9sih438 file: cache/cord-102704-wfuzk2dp.json key: cord-102704-wfuzk2dp authors: Meza, Diana K.; Broos, Alice; Becker, Daniel J.; Behdenna, Abdelkader; Willett, Brian J.; Viana, Mafalda; Streicker, Daniel G. title: Predicting the presence and titer of rabies virus neutralizing antibodies from low-volume serum samples in low-containment facilities date: 2020-04-30 journal: bioRxiv DOI: 10.1101/2020.04.24.060095 sha: doc_id: 102704 cord_uid: wfuzk2dp file: cache/cord-030999-27wennun.json key: cord-030999-27wennun authors: Altmann, Daniel M title: Adaptive immunity to SARS-CoV-2 date: 2020-07-09 journal: Oxf Open Immunol DOI: 10.1093/oxfimm/iqaa003 sha: doc_id: 30999 cord_uid: 27wennun file: cache/cord-133453-23rfdkuw.json key: cord-133453-23rfdkuw authors: Chen, Jiahui; Gao, Kaifu; Wang, Rui; Wei, Guowei title: Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies date: 2020-10-13 journal: nan DOI: nan sha: doc_id: 133453 cord_uid: 23rfdkuw file: cache/cord-255683-2eq24jth.json key: cord-255683-2eq24jth authors: Chen, Weizao; Zhu, Zhongyu; Liao, Huaxin; Quinnan, Gerald V.; Broder, Christopher C.; Haynes, Barton F.; Dimitrov, Dimiter S. title: Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins date: 2010-02-04 journal: Viruses DOI: 10.3390/v2020547 sha: doc_id: 255683 cord_uid: 2eq24jth file: cache/cord-103432-cdmoazrl.json key: cord-103432-cdmoazrl authors: Richardson, Eve; Galson, Jacob D.; Kellam, Paul; Kelly, Dominic F.; Smith, Sarah E.; Palser, Anne; Watson, Simon; Deane, Charlotte M. title: A computational method for immune repertoire mining that identifies novel binders from different clonotypes, demonstrated by identifying anti-Pertussis toxoid antibodies date: 2020-06-02 journal: bioRxiv DOI: 10.1101/2020.06.02.121129 sha: doc_id: 103432 cord_uid: cdmoazrl file: cache/cord-260340-dujd28gg.json key: cord-260340-dujd28gg authors: Chenoweth, Alicia M; Wines, Bruce D; Anania, Jessica C; Mark Hogarth, P title: Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs date: 2020-04-12 journal: Immunol Cell Biol DOI: 10.1111/imcb.12326 sha: doc_id: 260340 cord_uid: dujd28gg file: cache/cord-023053-j061ywrl.json key: cord-023053-j061ywrl authors: BARLOUGH, J. E. title: Cats, coronaviruses and coronavirus antibody tests date: 2008-04-10 journal: J Small Anim Pract DOI: 10.1111/j.1748-5827.1985.tb02210.x sha: doc_id: 23053 cord_uid: j061ywrl file: cache/cord-031060-0o9agjiq.json key: cord-031060-0o9agjiq authors: Yuan, Tom Z; Lujan Hernandez, Ana G; Keane, Erica; Liu, Qiang; Axelrod, Fumiko; Kailasan, Shweta; Noonan-Shueh, Madeleine; Aman, M Javad; Sato, Aaron K; Abdiche, Yasmina N title: Rapid exploration of the epitope coverage produced by an Ebola survivor to guide the discovery of therapeutic antibody cocktails date: 2020-08-01 journal: Antib Ther DOI: 10.1093/abt/tbaa016 sha: doc_id: 31060 cord_uid: 0o9agjiq file: cache/cord-254821-px4fe7mn.json key: cord-254821-px4fe7mn authors: Infantino, Maria; Grossi, Valentina; Lari, Barbara; Bambi, Riccardo; Perri, Alessandro; Manneschi, Matteo; Terenzi, Giovanni; Liotti, Irene; Ciotta, Giovanni; Taddei, Cristina; Benucci, Maurizio; Casprini, Patrizia; Veneziani, Francesca; Fabbri, Sergio; Pompetti, Adolfo; Manfredi, Mariangela title: Diagnostic accuracy of an automated chemiluminescent immunoassay for anti‐SARS‐CoV‐2 IgM and IgG antibodies: an Italian experience date: 2020-05-10 journal: J Med Virol DOI: 10.1002/jmv.25932 sha: doc_id: 254821 cord_uid: px4fe7mn file: cache/cord-103255-4k13re9y.json key: cord-103255-4k13re9y authors: Daniell, Henry; Streatfield, Stephen J; Wycoff, Keith title: Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants date: 2001-05-01 journal: Trends in Plant Science DOI: 10.1016/s1360-1385(01)01922-7 sha: doc_id: 103255 cord_uid: 4k13re9y file: cache/cord-255936-hfa9w2dg.json key: cord-255936-hfa9w2dg authors: Jin, Junyeong; Park, Changhoon; Cho, Sun-Hee; Chung, Junho title: The level of decoy epitope in PCV2 vaccine affects the neutralizing activity of sera in the immunized animals date: 2018-02-12 journal: Biochemical and Biophysical Research Communications DOI: 10.1016/j.bbrc.2018.01.141 sha: doc_id: 255936 cord_uid: hfa9w2dg file: cache/cord-267744-asjvf123.json key: cord-267744-asjvf123 authors: Lee, Yu-Ching; Leu, Sy-Jye C.; Hu, Chaur-Jong; Shih, Neng-Yao; Huang, I-Jen; Wu, Hsueh-Hsia; Hsieh, Wen-Shyang; Chiang, Bor-Luen; Chiu, Wen-Ta; Yang, Yi-Yuan title: Chicken single-chain variable fragments against the SARS-CoV spike protein date: 2007-07-23 journal: J Virol Methods DOI: 10.1016/j.jviromet.2007.06.010 sha: doc_id: 267744 cord_uid: asjvf123 file: cache/cord-022310-yc6xtw0s.json key: cord-022310-yc6xtw0s authors: Lappin, Michael R. title: Microbiology and Infectious Disease date: 2011-12-15 journal: Small Animal Clinical Diagnosis by Laboratory Methods DOI: 10.1016/b978-1-4377-0657-4.00015-6 sha: doc_id: 22310 cord_uid: yc6xtw0s file: cache/cord-032598-i0jm3p1s.json key: cord-032598-i0jm3p1s authors: Hu, Jing; Gao, Mingyan; Wang, Zuobin; Chen, Yujuan; Song, Zhengxun; Xu, Hongmei title: Direct imaging of antigen–antibody binding by atomic force microscopy date: 2020-09-24 journal: Appl Nanosci DOI: 10.1007/s13204-020-01558-w sha: doc_id: 32598 cord_uid: i0jm3p1s file: cache/cord-102908-sr7j8z9c.json key: cord-102908-sr7j8z9c authors: Mersmann, Sophia F.; Johns, Emma; Yong, Tracer; McEwan, Will A.; James, Leo C.; Cohen, Edward A.K.; Grove, Joe title: Learning to count: determining the stoichiometry of bio-molecular complexes using fluorescence microscopy and statistical modelling date: 2020-07-24 journal: bioRxiv DOI: 10.1101/2020.07.23.217745 sha: doc_id: 102908 cord_uid: sr7j8z9c file: cache/cord-103077-sh4w2mye.json key: cord-103077-sh4w2mye authors: Lu, Shuai; Li, Yuguang; Wang, Fei; Nan, Xiaofei; Zhang, Shoutao title: Leveraging Sequential and Spatial Neighbors Information by Using CNNs Linked With GCNs for Paratope Prediction date: 2020-10-16 journal: bioRxiv DOI: 10.1101/2020.10.15.339168 sha: doc_id: 103077 cord_uid: sh4w2mye file: cache/cord-256652-ent4vu3z.json key: cord-256652-ent4vu3z authors: Tan, Joshua; Sack, Brandon K; Oyen, David; Zenklusen, Isabelle; Piccoli, Luca; Barbieri, Sonia; Foglierini, Mathilde; Fregni, Chiara Silacci; Marcandalli, Jessica; Jongo, Said; Abdulla, Salim; Perez, Laurent; Corradin, Giampietro; Varani, Luca; Sallusto, Federica; Sim, B Kim Lee; Hoffman, Stephen L; Kappe, Stefan H I; Daubenberger, Claudia; Wilson, Ian A; Lanzavecchia, Antonio title: A public antibody lineage that potently inhibits malaria infection by dual binding to the circumsporozoite protein date: 2018-03-19 journal: Nat Med DOI: 10.1038/nm.4513 sha: doc_id: 256652 cord_uid: ent4vu3z file: cache/cord-295099-ghc85pf5.json key: cord-295099-ghc85pf5 authors: Sun, Zehua; Yan, Lixin; Tang, Jiansong; Qian, Qian; Lenberg, Jerica; Zhu, Dandan; Liu, Wan; Wu, Kao; Wang, Yilin; Lu, Shiqiang title: Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies date: 2018-01-02 journal: Virus Res DOI: 10.1016/j.virusres.2017.10.011 sha: doc_id: 295099 cord_uid: ghc85pf5 file: cache/cord-267015-mprsdi2e.json key: cord-267015-mprsdi2e authors: Zhu, Zhongyu; Bossart, Katharine N; Bishop, Kimberly A; Crameri, Gary; Dimitrov, Antony S; McEachern, Jennifer A; Feng, Yang; Middleton, Deborah; Wang, Lin-Fa; Broder, Christopher C; Dimitrov, Dimiter S title: Exceptionally Potent Cross-Reactive Neutralization of Nipah and Hendra Viruses by a Human Monoclonal Antibody date: 2008-03-15 journal: J Infect Dis DOI: 10.1086/528801 sha: doc_id: 267015 cord_uid: mprsdi2e file: cache/cord-261274-y74smbtd.json key: cord-261274-y74smbtd authors: Crouch, C. F; Oliver, S; Hearle, D. C; Buckley, A; Chapman, A. J; Francis, M. J title: Lactogenic immunity following vaccination of cattle with bovine coronavirus date: 2000-09-15 journal: Vaccine DOI: 10.1016/s0264-410x(00)00177-8 sha: doc_id: 261274 cord_uid: y74smbtd file: cache/cord-257465-9yrf7ofy.json key: cord-257465-9yrf7ofy authors: Finlay, William J. J.; Bloom, Laird; Grant, Joanne; Franklin, Edward; Shúilleabháin, Deirdre Ní; Cunningham, Orla title: Phage Display: A Powerful Technology for the Generation of High-Specificity Affinity Reagents from Alternative Immune Sources date: 2016-05-23 journal: Protein Chromatography DOI: 10.1007/978-1-4939-6412-3_6 sha: doc_id: 257465 cord_uid: 9yrf7ofy file: cache/cord-269023-g21a9ik2.json key: cord-269023-g21a9ik2 authors: Mukherjee, Siddhartha title: Before Virus, After Virus: A Reckoning date: 2020-10-15 journal: Cell DOI: 10.1016/j.cell.2020.09.042 sha: doc_id: 269023 cord_uid: g21a9ik2 file: cache/cord-104226-bb4lyvhy.json key: cord-104226-bb4lyvhy authors: nan title: Monoclonal antiprothrombinase (3D4.3) prevents mortality from murine hepatitis virus (MHV-3) infection date: 1992-09-01 journal: J Exp Med DOI: nan sha: doc_id: 104226 cord_uid: bb4lyvhy file: cache/cord-267601-3ahmyicn.json key: cord-267601-3ahmyicn authors: Renegar, Kathryn B. title: Passive Immunization: Systemic and Mucosal date: 2007-05-09 journal: Mucosal Immunology DOI: 10.1016/b978-012491543-5/50050-4 sha: doc_id: 267601 cord_uid: 3ahmyicn file: cache/cord-282081-qaagup4d.json key: cord-282081-qaagup4d authors: Flicker, Sabine; Zettl, Ines; Tillib, Sergei V. title: Nanobodies—Useful Tools for Allergy Treatment? date: 2020-09-30 journal: Front Immunol DOI: 10.3389/fimmu.2020.576255 sha: doc_id: 282081 cord_uid: qaagup4d file: cache/cord-275946-ofd2ipvs.json key: cord-275946-ofd2ipvs authors: Cheng, Matthew P.; Yansouni, Cedric P.; Basta, Nicole E.; Desjardins, Michaël; Kanjilal, Sanjat; Paquette, Katryn; Caya, Chelsea; Semret, Makeda; Quach, Caroline; Libman, Michael; Mazzola, Laura; Sacks, Jilian A.; Dittrich, Sabine; Papenburg, Jesse title: Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus-2: A Narrative Review date: 2020-06-04 journal: Ann Intern Med DOI: 10.7326/m20-2854 sha: doc_id: 275946 cord_uid: ofd2ipvs file: cache/cord-281760-34wuttqw.json key: cord-281760-34wuttqw authors: Pereira, E.P.V.; van Tilburg, M.F.; Florean, E.O.P.T.; Guedes, M.I.F. title: Egg yolk antibodies (IgY) and their applications in human and veterinary health: A review date: 2019-05-22 journal: Int Immunopharmacol DOI: 10.1016/j.intimp.2019.05.015 sha: doc_id: 281760 cord_uid: 34wuttqw file: cache/cord-048239-oluq7v0h.json key: cord-048239-oluq7v0h authors: Oliphant, Theodore; Engle, Michael; Nybakken, Grant E; Doane, Chris; Johnson, Syd; Huang, Ling; Gorlatov, Sergey; Mehlhop, Erin; Marri, Anantha; Chung, Kyung Min; Ebel, Gregory D; Kramer, Laura D; Fremont, Daved H; Diamond, Michael S title: Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus date: 2005-04-24 journal: Nat Med DOI: 10.1038/nm1240 sha: doc_id: 48239 cord_uid: oluq7v0h file: cache/cord-268417-6eyetb5i.json key: cord-268417-6eyetb5i authors: Mandel, Benjamin title: Neutralization of Animal Viruses date: 1978-12-31 journal: Advances in Virus Research DOI: 10.1016/s0065-3527(08)60101-3 sha: doc_id: 268417 cord_uid: 6eyetb5i file: cache/cord-275402-z92b18mb.json key: cord-275402-z92b18mb authors: Diamant, Eran; Torgeman, Amram; Ozeri, Eyal; Zichel, Ran title: Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs date: 2015-05-29 journal: Toxins (Basel) DOI: 10.3390/toxins7061854 sha: doc_id: 275402 cord_uid: z92b18mb file: cache/cord-274557-2071770h.json key: cord-274557-2071770h authors: Späth, Peter J.; Granata, Guido; La Marra, Fabiola; Kuijpers, Taco W.; Quinti, Isabella title: On the Dark Side of Therapies with Immunoglobulin Concentrates: The Adverse Events date: 2015-02-05 journal: Front Immunol DOI: 10.3389/fimmu.2015.00011 sha: doc_id: 274557 cord_uid: 2071770h file: cache/cord-279105-e2zjxjox.json key: cord-279105-e2zjxjox authors: Lee, Cheryl Yi-Pin; Lin, Raymond T. P.; Renia, Laurent; Ng, Lisa F. P. title: Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control date: 2020-04-24 journal: Front Immunol DOI: 10.3389/fimmu.2020.00879 sha: doc_id: 279105 cord_uid: e2zjxjox file: cache/cord-283641-2u16otbf.json key: cord-283641-2u16otbf authors: Vainionpää, R.; Waris, M.; Leinikki, P. title: Diagnostic Techniques: Serological and Molecular Approaches date: 2015-03-06 journal: Reference Module in Biomedical Sciences DOI: 10.1016/b978-0-12-801238-3.02558-7 sha: doc_id: 283641 cord_uid: 2u16otbf file: cache/cord-296576-d23b9fjl.json key: cord-296576-d23b9fjl authors: Bernard, Serge; Shirai, June; Lantier, Isabelle; Bottreau, Elisabeth; Aynaud, Jean Marie title: Lactogenic Immunity to Transmissible Gastroenteritis (TGE) of swine induced by the attenuated nouzilly strain of TGE virus: Passive protection of piglets and detection of serum and milk antibody classes by ELISA date: 1990-01-31 journal: Veterinary Immunology and Immunopathology DOI: 10.1016/0165-2427(90)90076-5 sha: doc_id: 296576 cord_uid: d23b9fjl file: cache/cord-278281-bdoavpsb.json key: cord-278281-bdoavpsb authors: NEMOTO, Manabu; KANNO, Toru; BANNAI, Hiroshi; TSUJIMURA, Koji; YAMANAKA, Takashi; KOKADO, Hiroshi title: Antibody response to equine coronavirus in horses inoculated with a bovine coronavirus vaccine date: 2017-10-06 journal: J Vet Med Sci DOI: 10.1292/jvms.17-0414 sha: doc_id: 278281 cord_uid: bdoavpsb file: cache/cord-267736-rya9w6sh.json key: cord-267736-rya9w6sh authors: Kang, Xiaoping; Li, Yuchang; Fan, Li; Lin, Fang; Wei, Jingjing; Zhu, Xiaolei; Hu, Yi; Li, Jing; Chang, Guohui; Zhu, Qingyu; Liu, Hong; Yang, Yinhui title: Development of an ELISA-array for simultaneous detection of five encephalitis viruses date: 2012-02-27 journal: Virol J DOI: 10.1186/1743-422x-9-56 sha: doc_id: 267736 cord_uid: rya9w6sh file: cache/cord-277076-yvsyo4l9.json key: cord-277076-yvsyo4l9 authors: Berger, A.; Preiser, W. title: SARS date: 2019-09-12 journal: Encyclopedia of Environmental Health DOI: 10.1016/b978-0-444-63951-6.00624-0 sha: doc_id: 277076 cord_uid: yvsyo4l9 file: cache/cord-291626-lxa8pvt3.json key: cord-291626-lxa8pvt3 authors: Pelfrene, E.; Mura, M.; Cavaleiro Sanches, A.; Cavaleri, M. title: Monoclonal antibodies as anti-infective products: a promising future? date: 2019-01-31 journal: Clinical Microbiology and Infection DOI: 10.1016/j.cmi.2018.04.024 sha: doc_id: 291626 cord_uid: lxa8pvt3 file: cache/cord-292874-6zjqflhz.json key: cord-292874-6zjqflhz authors: SØRENSEN, MORTEN DRÆBY; SØRENSEN, BRIAN; GONZALEZ‐DOSAL, REGINA; MELCHJORSEN, CONNIE JENNING; WEIBEL, JENS; WANG, JING; JUN, CHEN WIE; HUANMING, YANG; KRISTENSEN, PETER title: Severe Acute Respiratory Syndrome (SARS): Development of Diagnostics and Antivirals date: 2006-05-10 journal: Ann N Y Acad Sci DOI: 10.1196/annals.1354.072 sha: doc_id: 292874 cord_uid: 6zjqflhz file: cache/cord-277894-0qw0t78s.json key: cord-277894-0qw0t78s authors: NAYLOR, MJ; MONCKTON, RP; LEHRBACH, PR; DEANE, EM title: Canine coronavirus in Australian dogs date: 2008-03-10 journal: Aust Vet J DOI: 10.1111/j.1751-0813.2001.tb10718.x sha: doc_id: 277894 cord_uid: 0qw0t78s file: cache/cord-295033-5fd9bu60.json key: cord-295033-5fd9bu60 authors: Parma, Y.R.; Chacana, P.A.; Rogé, A.; Kahl, A.; Cangelosi, A.; Geoghegan, P.; Lucchesi, P.M.A.; Fernández-Miyakawa, M.E. title: Antibodies anti-Shiga toxin 2 B subunit from chicken egg yolk: Isolation, purification and neutralization efficacy date: 2011-09-15 journal: Toxicon DOI: 10.1016/j.toxicon.2011.07.009 sha: doc_id: 295033 cord_uid: 5fd9bu60 file: cache/cord-298910-2601n7a9.json key: cord-298910-2601n7a9 authors: Leu, Sy-Jye; Lee, Yu-Ching; Shih, Neng-Yao; Huang, I-Jen; Liu, Ko-Jiunn; Lu, Hsu-Feng; Huang, Shih-Yi; Yang, Yi-Yuan title: Generation and characterization of anti-α-enolase single-chain antibodies in chicken date: 2010-10-15 journal: Vet Immunol Immunopathol DOI: 10.1016/j.vetimm.2010.06.001 sha: doc_id: 298910 cord_uid: 2601n7a9 file: cache/cord-300701-vkzya7uq.json key: cord-300701-vkzya7uq authors: Ijaz, M. K.; Sabara, M. I.; Frenchick, P. J.; Babiuk, L. A. title: Effect of different routes of immunization with bovine rotavirus on lactogenic antibody response in mice date: 1987-12-31 journal: Antiviral Research DOI: 10.1016/s0166-3542(87)80006-2 sha: doc_id: 300701 cord_uid: vkzya7uq file: cache/cord-302974-t1t89p8y.json key: cord-302974-t1t89p8y authors: Mathur, Gagan; Mathur, Sweta title: Antibody Testing For Covid-19: Can It Be Used As A Screening Tool In Areas With Low Prevalence? date: 2020-05-15 journal: Am J Clin Pathol DOI: 10.1093/ajcp/aqaa082 sha: doc_id: 302974 cord_uid: t1t89p8y file: cache/cord-283826-lgyc3sro.json key: cord-283826-lgyc3sro authors: Stiehm, E. Richard; Orange, Jordan S.; Ballow, Mark; Lehman, Heather title: Therapeutic Use of Immunoglobulins date: 2010-11-05 journal: Adv Pediatr DOI: 10.1016/j.yapd.2010.08.005 sha: doc_id: 283826 cord_uid: lgyc3sro file: cache/cord-297684-9q3oopaz.json key: cord-297684-9q3oopaz authors: Dobaño, Carlota; Vidal, Marta; Santano, Rebeca; Jiménez, Alfons; Chi, Jordi; Barrios, Diana; Ruiz-Olalla, Gemma; Melero, Natalia Rodrigo; Carolis, Carlo; Parras, Daniel; Serra, Pau; de Aguirre, Paula Martínez; Carmona-Torre, Francisco; Reina, Gabriel; Santamaria, Pere; Mayor, Alfredo; García-Basteiro, Alberto; Izquierdo, Luis; Aguilar, Ruth; Moncunill, Gemma title: Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A and G against SARS-CoV-2 antigens date: 2020-06-12 journal: bioRxiv DOI: 10.1101/2020.06.11.147363 sha: doc_id: 297684 cord_uid: 9q3oopaz file: cache/cord-274756-nnm1n09a.json key: cord-274756-nnm1n09a authors: Varadé, Jezabel; Magadán, Susana; González-Fernández, África title: Human immunology and immunotherapy: main achievements and challenges date: 2020-09-02 journal: Cell Mol Immunol DOI: 10.1038/s41423-020-00530-6 sha: doc_id: 274756 cord_uid: nnm1n09a file: cache/cord-305039-grsv06j7.json key: cord-305039-grsv06j7 authors: Flego, Michela; Ascione, Alessandro; Cianfriglia, Maurizio; Vella, Stefano title: Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases date: 2013-01-04 journal: BMC Med DOI: 10.1186/1741-7015-11-4 sha: doc_id: 305039 cord_uid: grsv06j7 file: cache/cord-305893-2vcy0f6i.json key: cord-305893-2vcy0f6i authors: Bagheri, Vahid; Nejatollahi, Foroogh; Esmaeili, Seyed Alireza; Momtazi, Amir Abbas; Motamedifar, Mohamad; Sahebkar, Amirhossein title: Neutralizing human recombinant antibodies against herpes simplex virus type 1 glycoproteins B from a phage-displayed scFv antibody library date: 2017-01-15 journal: Life Sciences DOI: 10.1016/j.lfs.2016.11.018 sha: doc_id: 305893 cord_uid: 2vcy0f6i file: cache/cord-290783-ipoelk4h.json key: cord-290783-ipoelk4h authors: Crouch, C. F. title: Vaccination against enteric rota and coronaviruses in cattle and pigs: Enhancement of lactogenic immunity date: 1985-09-30 journal: Vaccine DOI: 10.1016/s0264-410x(85)90056-8 sha: doc_id: 290783 cord_uid: ipoelk4h file: cache/cord-285760-y37ji92k.json key: cord-285760-y37ji92k authors: Connell, Anna R.; Connell, Jeff; Leahy, T. Ronan; Hassan, Jaythoon title: Mumps Outbreaks in Vaccinated Populations—Is It Time to Re-assess the Clinical Efficacy of Vaccines? date: 2020-09-18 journal: Front Immunol DOI: 10.3389/fimmu.2020.02089 sha: doc_id: 285760 cord_uid: y37ji92k file: cache/cord-282817-vtzpf2wr.json key: cord-282817-vtzpf2wr authors: Byrne, Hannah; Conroy, Paul J.; Whisstock, James C.; O’Kennedy, Richard J. title: A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications date: 2013-10-02 journal: Trends Biotechnol DOI: 10.1016/j.tibtech.2013.08.007 sha: doc_id: 282817 cord_uid: vtzpf2wr file: cache/cord-312787-j7ye7ed5.json key: cord-312787-j7ye7ed5 authors: Loemba, H. D.; Mounir, S.; Mardassi, H.; Archambault, D.; Dea, S. title: Kinetics of humoral immune response to the major structural proteins of the porcine reproductive and respiratory syndrome virus date: 1996 journal: Arch Virol DOI: 10.1007/bf01718333 sha: doc_id: 312787 cord_uid: j7ye7ed5 file: cache/cord-296928-wu14k7u9.json key: cord-296928-wu14k7u9 authors: Hofmann, Tim; Krah, Simon; Sellmann, Carolin; Zielonka, Stefan; Doerner, Achim title: Greatest Hits—Innovative Technologies for High Throughput Identification of Bispecific Antibodies date: 2020-09-08 journal: Int J Mol Sci DOI: 10.3390/ijms21186551 sha: doc_id: 296928 cord_uid: wu14k7u9 file: cache/cord-302312-1pm17l5d.json key: cord-302312-1pm17l5d authors: Quinteros, Daniela A.; Bermúdez, José M.; Ravetti, Soledad; Cid, Alicia; Allemandi, Daniel A.; Palma, Santiago D. title: Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery date: 2017-03-31 journal: Nanostructures for Drug Delivery DOI: 10.1016/b978-0-323-46143-6.00025-7 sha: doc_id: 302312 cord_uid: 1pm17l5d file: cache/cord-302382-eifh95zm.json key: cord-302382-eifh95zm authors: Owji, Hajar; Negahdaripour, Manica; Hajighahramani, Nasim title: Immunotherapeutic approaches to curtail COVID-19 date: 2020-08-21 journal: Int Immunopharmacol DOI: 10.1016/j.intimp.2020.106924 sha: doc_id: 302382 cord_uid: eifh95zm file: cache/cord-304214-66nxk4e8.json key: cord-304214-66nxk4e8 authors: Sanders, John W.; Ponzio, Todd A. title: Vectored immunoprophylaxis: an emerging adjunct to traditional vaccination date: 2017-02-10 journal: Trop Dis Travel Med Vaccines DOI: 10.1186/s40794-017-0046-0 sha: doc_id: 304214 cord_uid: 66nxk4e8 file: cache/cord-311811-nrodyagi.json key: cord-311811-nrodyagi authors: Schutzer, Steven E. title: The use of host factors in microbial forensics date: 2019-12-06 journal: Microbial Forensics DOI: 10.1016/b978-0-12-815379-6.00014-3 sha: doc_id: 311811 cord_uid: nrodyagi file: cache/cord-309067-aemjbkfj.json key: cord-309067-aemjbkfj authors: Kennedy, Melissa title: Methodology in diagnostic virology date: 2005-03-01 journal: Vet Clin North Am Exot Anim Pract DOI: 10.1016/j.cvex.2004.09.009 sha: doc_id: 309067 cord_uid: aemjbkfj file: cache/cord-307320-fxs31d66.json key: cord-307320-fxs31d66 authors: Ubah, Obinna; Palliyil, Soumya title: Monoclonal Antibodies and Antibody Like Fragments Derived from Immunised Phage Display Libraries date: 2018-03-17 journal: Recombinant Antibodies for Infectious Diseases DOI: 10.1007/978-3-319-72077-7_6 sha: doc_id: 307320 cord_uid: fxs31d66 file: cache/cord-317501-yblzopc3.json key: cord-317501-yblzopc3 authors: Kuhn, Philipp; Fühner, Viola; Unkauf, Tobias; Moreira, Gustavo Marcal Schmidt Garcia; Frenzel, André; Miethe, Sebastian; Hust, Michael title: Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display date: 2016-06-21 journal: Proteomics Clin Appl DOI: 10.1002/prca.201600002 sha: doc_id: 317501 cord_uid: yblzopc3 file: cache/cord-313312-h607itv2.json key: cord-313312-h607itv2 authors: Mok, Darren Z. L.; Chan, Kuan Rong title: The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines date: 2020-05-08 journal: Viruses DOI: 10.3390/v12050520 sha: doc_id: 313312 cord_uid: h607itv2 file: cache/cord-319746-6bccxgbd.json key: cord-319746-6bccxgbd authors: Saxena, Latika; Khanna, Madhu title: Production and Characterization of Human Monoclonal Antibodies from the Cells of A(H1N1)pdm2009 Influenza Virus Infected Indian Donors date: 2015-12-31 journal: Procedia in Vaccinology DOI: 10.1016/j.provac.2015.05.009 sha: doc_id: 319746 cord_uid: 6bccxgbd file: cache/cord-324316-ulb8d5fe.json key: cord-324316-ulb8d5fe authors: Bramstedt, Katrina A. title: Antibodies as Currency: COVID-19’s Golden Passport date: 2020-08-25 journal: J Bioeth Inq DOI: 10.1007/s11673-020-09996-5 sha: doc_id: 324316 cord_uid: ulb8d5fe file: cache/cord-327287-e5k2gcse.json key: cord-327287-e5k2gcse authors: May, Jori E.; Siniard, Rance C.; Marques, Marisa title: The challenges of diagnosing heparin‐induced thrombocytopenia in patients with COVID‐19 date: 2020-08-02 journal: Res Pract Thromb Haemost DOI: 10.1002/rth2.12416 sha: doc_id: 327287 cord_uid: e5k2gcse file: cache/cord-321901-zpi7uis1.json key: cord-321901-zpi7uis1 authors: Roberts, Anjeanette; Wood, John; Subbarao, Kanta; Ferguson, Morag; Wood, David; Cherian, Thomas title: Animal models and antibody assays for evaluating candidate SARS vaccines: Summary of a technical meeting 25–26 August 2005, London, UK date: 2006-11-30 journal: Vaccine DOI: 10.1016/j.vaccine.2006.07.009 sha: doc_id: 321901 cord_uid: zpi7uis1 file: cache/cord-329857-pcsuu597.json key: cord-329857-pcsuu597 authors: Chan, Kuan Rong; Ong, Eugenia Z; Mok, Darren ZL; Ooi, Eng Eong title: Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases date: 2015-11-02 journal: Expert Rev Anti Infect Ther DOI: 10.1586/14787210.2015.1079127 sha: doc_id: 329857 cord_uid: pcsuu597 file: cache/cord-327883-s9nbr5y8.json key: cord-327883-s9nbr5y8 authors: nan title: Section Virology date: 1990-03-31 journal: Zentralblatt für Bakteriologie DOI: 10.1016/s0934-8840(11)80039-3 sha: doc_id: 327883 cord_uid: s9nbr5y8 file: cache/cord-328935-mn8r972x.json key: cord-328935-mn8r972x authors: Hodgins, Douglas C.; Chattha, Kuldeep; Vlasova, Anastasia; Parreño, Viviana; Corbeil, Lynette B.; Renukaradhya, Gourapura J.; Saif, Linda J. title: Mucosal Veterinary Vaccines: Comparative Vaccinology date: 2015-03-13 journal: Mucosal Immunology DOI: 10.1016/b978-0-12-415847-4.00068-9 sha: doc_id: 328935 cord_uid: mn8r972x file: cache/cord-352172-g0jiaenw.json key: cord-352172-g0jiaenw authors: Stoevesandt, Oda; Taussig, Michael J; He, Mingyue title: Protein microarrays: high-throughput tools for proteomics date: 2014-01-09 journal: Expert Rev Proteomics DOI: 10.1586/epr.09.2 sha: doc_id: 352172 cord_uid: g0jiaenw file: cache/cord-336280-tsx409e3.json key: cord-336280-tsx409e3 authors: Byrne, Barry; Stack, Edwina; Gilmartin, Niamh; O'Kennedy, Richard title: Antibody-Based Sensors: Principles, Problems and Potential for Detection of Pathogens and Associated Toxins date: 2009-06-05 journal: Sensors (Basel) DOI: 10.3390/s90604407 sha: doc_id: 336280 cord_uid: tsx409e3 file: cache/cord-316287-4i1grvlr.json key: cord-316287-4i1grvlr authors: Yim, Sung Sun; Bang, Hyun Bae; Kim, Young Hwan; Lee, Yong Jae; Jeong, Gu Min; Jeong, Ki Jun title: Rapid Isolation of Antibody from a Synthetic Human Antibody Library by Repeated Fluorescence-Activated Cell Sorting (FACS) date: 2014-10-10 journal: PLoS One DOI: 10.1371/journal.pone.0108225 sha: doc_id: 316287 cord_uid: 4i1grvlr file: cache/cord-326673-p8qbxi57.json key: cord-326673-p8qbxi57 authors: Kitching, R. P.; Salt, J. S. title: The interference by maternally-derived antibody with active immunization of farm animals against foot-and-mouth disease date: 1995-12-31 journal: British Veterinary Journal DOI: 10.1016/s0007-1935(95)80127-8 sha: doc_id: 326673 cord_uid: p8qbxi57 file: cache/cord-319884-d8n0aokl.json key: cord-319884-d8n0aokl authors: Natesan, Mohan; Ulrich, Robert G. title: Protein Microarrays and Biomarkers of Infectious Disease date: 2010-12-16 journal: Int J Mol Sci DOI: 10.3390/ijms11125165 sha: doc_id: 319884 cord_uid: d8n0aokl file: cache/cord-354790-xx6imhzb.json key: cord-354790-xx6imhzb authors: Lambour, Jennifer; Naranjo-Gomez, Mar; Piechaczyk, Marc; Pelegrin, Mireia title: Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play date: 2016-08-17 journal: Emerg Microbes Infect DOI: 10.1038/emi.2016.97 sha: doc_id: 354790 cord_uid: xx6imhzb file: cache/cord-321369-xzu2faol.json key: cord-321369-xzu2faol authors: Andreano, Emanuele; Nicastri, Emanuele; Paciello, Ida; Pileri, Piero; Manganaro, Noemi; Piccini, Giulia; Manenti, Alessandro; Pantano, Elisa; Kabanova, Anna; Troisi, Marco; Vacca, Fabiola; Cardamone, Dario; De Santi, Concetta; Benincasa, Linda; Agrati, Chiara; Capobianchi, Maria Rosaria; Castilletti, Concetta; Emiliozzi, Arianna; Fabbiani, Massimiliano; Montagnani, Francesca; Depau, Lorenzo; Brunetti, Jlenia; Bracci, Luisa; Montomoli, Emanuele; Sala, Claudia; Ippolito, Giuseppe; Rappuoli, Rino title: Extremely potent human monoclonal antibodies from convalescent Covid-19 patients date: 2020-10-07 journal: bioRxiv DOI: 10.1101/2020.10.07.328302 sha: doc_id: 321369 cord_uid: xzu2faol file: cache/cord-345296-4z7yfj5s.json key: cord-345296-4z7yfj5s authors: Ho, Mei-Shang; Chen, Wei-Ju; Chen, Hour-Young; Lin, Szu-Fong; Wang, Min-Chin; Di, Jiali; Lu, Yen-Ta; Liu, Ching-Lung; Chang, Shan-Chwen; Chao, Chung-Liang; King, Chwan-Chuen; Chiou, Jeng-Min; Su, Ih-Jen; Yang, Jyh-Yuan title: Neutralizing Antibody Response and SARS Severity date: 2005-11-17 journal: Emerg Infect Dis DOI: 10.3201/eid1111.040659 sha: doc_id: 345296 cord_uid: 4z7yfj5s file: cache/cord-349669-o3eelqcw.json key: cord-349669-o3eelqcw authors: Stadlbauer, Daniel; Baine, Ian; Amanat, Fatima; Jiang, Kaijun; Lally, Kimberly; Krammer, Florian; Jhang, Jeffrey S.; Arinsburg, Suzanne A. title: Anti‐SARS‐CoV‐2 Spike Antibodies are Stable in Convalescent Plasma when Stored at 4° Celsius for at Least 6 Weeks date: 2020-08-14 journal: Transfusion DOI: 10.1111/trf.16047 sha: doc_id: 349669 cord_uid: o3eelqcw file: cache/cord-330324-4hqhty5o.json key: cord-330324-4hqhty5o authors: Yu, Meng; Stevens, Vicky; Berry, Jody D.; Crameri, Gary; McEachern, Jennifer; Tu, Changchun; Shi, Zhengli; Liang, Guodong; Weingartl, Hana; Cardosa, Jane; Eaton, Bryan T.; Wang, Lin-Fa title: Determination and application of immunodominant regions of SARS coronavirus spike and nucleocapsid proteins recognized by sera from different animal species date: 2008-02-29 journal: Journal of Immunological Methods DOI: 10.1016/j.jim.2007.11.009 sha: doc_id: 330324 cord_uid: 4hqhty5o file: cache/cord-327629-ep28ay11.json key: cord-327629-ep28ay11 authors: Herron, J.B.T.; Dennis, J.; Brennan, P.A. title: Coronavirus antibody positive tests and continued use of personal protective equipment throughout the pandemic date: 2020-06-20 journal: Br J Oral Maxillofac Surg DOI: 10.1016/j.bjoms.2020.06.021 sha: doc_id: 327629 cord_uid: ep28ay11 file: cache/cord-337464-otwps68u.json key: cord-337464-otwps68u authors: Parray, Hilal Ahmed; Shukla, Shivangi; Samal, Sweety; Shrivastava, Tripti; Ahmed, Shubbir; Sharma, Chandresh; Kumar, Rajesh title: Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives date: 2020-05-27 journal: Int Immunopharmacol DOI: 10.1016/j.intimp.2020.106639 sha: doc_id: 337464 cord_uid: otwps68u file: cache/cord-023364-ut56gczm.json key: cord-023364-ut56gczm authors: nan title: EDUCATION DAY MONDAY: PLENARY SESSION 1 MONDAY: PARALLEL SESSIONS date: 2005-06-08 journal: Vox Sang DOI: 10.1111/j.1423-0410.2005.00651.x sha: doc_id: 23364 cord_uid: ut56gczm file: cache/cord-335316-x2t5h5gu.json key: cord-335316-x2t5h5gu authors: Madariaga, M. L. L.; Guthmiller, J.; Schrantz, S.; Jansen, M.; Christenson, C.; Kumar, M.; Prochaska, M.; Wool, G.; Durkin, A.; Oh, W. H.; Trockman, L.; Vigneswaran, J.; Keskey, R.; Shaw, D. G.; Dugan, H.; Zheng, N.; Cobb, M.; Utset, H.; Wang, J.; Stovicek, O.; Bethel, C.; Matushek, S.; Giurcanu, M.; Beavis, K.; diSabato, D.; Meltzer, D.; Ferguson, M.; Kress, J. P.; Shanmugarajah, K.; Matthews, J.; Fung, J.; Wilson, P.; Alverdy, J. C.; Donington, J. title: Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial date: 2020-06-23 journal: nan DOI: 10.1101/2020.06.21.20132944 sha: doc_id: 335316 cord_uid: x2t5h5gu file: cache/cord-335311-l73hsik0.json key: cord-335311-l73hsik0 authors: Chan, Conrad E. Z.; Lim, Angeline P. C.; MacAry, Paul A.; Hanson, Brendon J. title: The role of phage display in therapeutic antibody discovery date: 2014-08-18 journal: Int Immunol DOI: 10.1093/intimm/dxu082 sha: doc_id: 335311 cord_uid: l73hsik0 file: cache/cord-339879-92esdjy9.json key: cord-339879-92esdjy9 authors: Delhalle, Sylvie; Schmit, Jean-Claude; Chevigné, Andy title: Phages and HIV-1: From Display to Interplay date: 2012-04-13 journal: Int J Mol Sci DOI: 10.3390/ijms13044727 sha: doc_id: 339879 cord_uid: 92esdjy9 file: cache/cord-350029-1y5ex4d5.json key: cord-350029-1y5ex4d5 authors: McDade, Thomas W.; Sancilio, Amelia title: Beyond serosurveys: Human biology and the measurement of SARS‐Cov‐2 antibodies date: 2020-08-09 journal: Am J Hum Biol DOI: 10.1002/ajhb.23483 sha: doc_id: 350029 cord_uid: 1y5ex4d5 file: cache/cord-330218-l5q3n3ri.json key: cord-330218-l5q3n3ri authors: Foss, Stian; Watkinson, Ruth; Sandlie, Inger; James, Leo C; Andersen, Jan Terje title: TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity date: 2015-10-26 journal: Immunol Rev DOI: 10.1111/imr.12363 sha: doc_id: 330218 cord_uid: l5q3n3ri file: cache/cord-338517-1mxcssjj.json key: cord-338517-1mxcssjj authors: Ishay, Yuval; Kessler, Asa; Schwarts, Asaf; Ilan, Yaron title: Antibody response to SARS‐Co‐V‐2, diagnostic and therapeutic implications date: 2020-08-26 journal: Hepatol Commun DOI: 10.1002/hep4.1600 sha: doc_id: 338517 cord_uid: 1mxcssjj file: cache/cord-354137-6oe8nj1j.json key: cord-354137-6oe8nj1j authors: Wang, Hua; Shen, Guoli; Yu, Ruqin title: Aspects of recent development of immunosensors date: 2008-05-20 journal: Electrochemical Sensors, Biosensors and their Biomedical Applications DOI: 10.1016/b978-012373738-0.50011-8 sha: doc_id: 354137 cord_uid: 6oe8nj1j file: cache/cord-331786-wgt7kg6f.json key: cord-331786-wgt7kg6f authors: Diego-Martin, Borja; González, Beatriz; Vazquez-Vilar, Marta; Selma, Sara; Mateos-Fernández, Rubén; Gianoglio, Silvia; Fernández-del-Carmen, Asun; Orzáez, Diego title: Pilot production of SARS-CoV-2 related proteins in plants: a proof of concept for rapid repurposing of indoors farms into biomanufacturing facilities date: 2020-10-13 journal: bioRxiv DOI: 10.1101/2020.10.13.331306 sha: doc_id: 331786 cord_uid: wgt7kg6f file: cache/cord-335121-ro3x3qa3.json key: cord-335121-ro3x3qa3 authors: Ingram, George A.; Al-Yaman, Fadwa title: A comparative assessment of four serological methods used in the detection and measurement of anti-parasite antibodies in the serum of the amphibian, bufo viridis date: 1988-04-30 journal: International Journal for Parasitology DOI: 10.1016/0020-7519(88)90147-6 sha: doc_id: 335121 cord_uid: ro3x3qa3 file: cache/cord-344445-slv7r9u7.json key: cord-344445-slv7r9u7 authors: Vakharia, Kunal title: The right to know: ethical implications of antibody testing for healthcare workers and overlooked societal implications date: 2020-06-03 journal: J Med Ethics DOI: 10.1136/medethics-2020-106467 sha: doc_id: 344445 cord_uid: slv7r9u7 file: cache/cord-355610-7xy4s483.json key: cord-355610-7xy4s483 authors: Hu, Dan; Zhu, Zhongyu; Li, Shun; Deng, Yongqiang; Wu, Yanling; Zhang, Nana; Puri, Vinita; Wang, Chunyu; Zou, Peng; Lei, Cheng; Tian, Xiaolong; Wang, Yulu; Zhao, Qi; Li, Wei; Prabakaran, Ponraj; Feng, Yang; Cardosa, Jane; Qin, Chengfeng; Zhou, Xiaohui; Dimitrov, Dimiter S.; Ying, Tianlei title: A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III date: 2019-06-26 journal: PLoS Pathog DOI: 10.1371/journal.ppat.1007836 sha: doc_id: 355610 cord_uid: 7xy4s483 file: cache/cord-328753-qwdxgk4z.json key: cord-328753-qwdxgk4z authors: Lafaye, Pierre; Li, Tengfei title: Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases date: 2018-09-25 journal: Comp Immunol Microbiol Infect Dis DOI: 10.1016/j.cimid.2018.09.009 sha: doc_id: 328753 cord_uid: qwdxgk4z file: cache/cord-339520-odly2fwg.json key: cord-339520-odly2fwg authors: Madic, J.; Magdalena, J.; Quak, J.; van Oirschot, J. T. title: Isotype-specific antibody responses to bovine herpesvirus 1 in sera and mucosal secretions of calves after experimental reinfection and after reactivation date: 1995-07-31 journal: Veterinary Immunology and Immunopathology DOI: 10.1016/0165-2427(94)05379-7 sha: doc_id: 339520 cord_uid: odly2fwg file: cache/cord-342242-cynpob7b.json key: cord-342242-cynpob7b authors: Godakova, Svetlana A.; Noskov, Anatoly N.; Vinogradova, Irina D.; Ugriumova, Galina A.; Solovyev, Andrey I.; Esmagambetov, Ilias B.; Tukhvatulin, Amir I.; Logunov, Denis Y.; Naroditsky, Boris S.; Shcheblyakov, Dmitry V.; Gintsburg, Aleksandr L. title: Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice date: 2019-08-07 journal: Toxins (Basel) DOI: 10.3390/toxins11080464 sha: doc_id: 342242 cord_uid: cynpob7b file: cache/cord-354700-bdpp3qmf.json key: cord-354700-bdpp3qmf authors: Lanzavecchia, Antonio title: Dissecting human antibody responses: useful, basic and surprising findings date: 2018-01-23 journal: EMBO Mol Med DOI: 10.15252/emmm.201808879 sha: doc_id: 354700 cord_uid: bdpp3qmf file: cache/cord-340305-jtvn9tlm.json key: cord-340305-jtvn9tlm authors: Cimolai, Nevio title: A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19 date: 2020-09-19 journal: SN Compr Clin Med DOI: 10.1007/s42399-020-00533-4 sha: doc_id: 340305 cord_uid: jtvn9tlm file: cache/cord-341305-zf97tcwe.json key: cord-341305-zf97tcwe authors: Ge, Shikun; Xu, Long; Li, Ben; Zhong, Fagang; Liu, Xiang; Zhang, Xiaoying title: Canine Parvovirus is diagnosed and neutralized by chicken IgY-scFv generated against the virus capsid protein date: 2020-09-03 journal: Vet Res DOI: 10.1186/s13567-020-00832-7 sha: doc_id: 341305 cord_uid: zf97tcwe file: cache/cord-023346-8sqbqjm1.json key: cord-023346-8sqbqjm1 authors: nan title: MONDAY: POSTERS date: 2005-06-08 journal: Vox Sang DOI: 10.1111/j.1423-0410.2005.00652.x sha: doc_id: 23346 cord_uid: 8sqbqjm1 file: cache/cord-354325-r73datur.json key: cord-354325-r73datur authors: Berger, Mitchell; Shankar, Vidya; Vafai, Abbas title: Therapeutic Applications of Monoclonal Antibodies date: 2002-07-31 journal: The American Journal of the Medical Sciences DOI: 10.1097/00000441-200207000-00004 sha: doc_id: 354325 cord_uid: r73datur file: cache/cord-023354-f2ciho6o.json key: cord-023354-f2ciho6o authors: nan title: TUESDAY PLENARY SESSION 3 TUESDAY: POSTERS date: 2005-06-08 journal: Vox Sang DOI: 10.1111/j.1423-0410.2005.00654.x sha: doc_id: 23354 cord_uid: f2ciho6o Reading metadata file and updating bibliogrpahics === updating bibliographic database Building study carrel named keyword-antibody-cord === file2bib.sh === id: cord-261274-y74smbtd author: Crouch, C. F title: Lactogenic immunity following vaccination of cattle with bovine coronavirus date: 2000-09-15 pages: extension: .txt txt: ./txt/cord-261274-y74smbtd.txt cache: ./cache/cord-261274-y74smbtd.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-261274-y74smbtd.txt' === file2bib.sh === id: cord-102704-wfuzk2dp author: Meza, Diana K. title: Predicting the presence and titer of rabies virus neutralizing antibodies from low-volume serum samples in low-containment facilities date: 2020-04-30 pages: extension: .txt txt: ./txt/cord-102704-wfuzk2dp.txt cache: ./cache/cord-102704-wfuzk2dp.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-102704-wfuzk2dp.txt' === file2bib.sh === id: cord-023053-j061ywrl author: BARLOUGH, J. E. title: Cats, coronaviruses and coronavirus antibody tests date: 2008-04-10 pages: extension: .txt txt: ./txt/cord-023053-j061ywrl.txt cache: ./cache/cord-023053-j061ywrl.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-023053-j061ywrl.txt' === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 8083 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 7173 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 7526 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 7287 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 7684 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 7596 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 7145 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 10468 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 7861 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 8451 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === id: cord-103255-4k13re9y author: Daniell, Henry title: Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants date: 2001-05-01 pages: extension: .txt txt: ./txt/cord-103255-4k13re9y.txt cache: ./cache/cord-103255-4k13re9y.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-103255-4k13re9y.txt' === file2bib.sh === id: cord-032598-i0jm3p1s author: Hu, Jing title: Direct imaging of antigen–antibody binding by atomic force microscopy date: 2020-09-24 pages: extension: .txt txt: ./txt/cord-032598-i0jm3p1s.txt cache: ./cache/cord-032598-i0jm3p1s.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-032598-i0jm3p1s.txt' === file2bib.sh === id: cord-260340-dujd28gg author: Chenoweth, Alicia M title: Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs date: 2020-04-12 pages: extension: .txt txt: ./txt/cord-260340-dujd28gg.txt cache: ./cache/cord-260340-dujd28gg.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-260340-dujd28gg.txt' === file2bib.sh === id: cord-267744-asjvf123 author: Lee, Yu-Ching title: Chicken single-chain variable fragments against the SARS-CoV spike protein date: 2007-07-23 pages: extension: .txt txt: ./txt/cord-267744-asjvf123.txt cache: ./cache/cord-267744-asjvf123.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-267744-asjvf123.txt' === file2bib.sh === id: cord-255936-hfa9w2dg author: Jin, Junyeong title: The level of decoy epitope in PCV2 vaccine affects the neutralizing activity of sera in the immunized animals date: 2018-02-12 pages: extension: .txt txt: ./txt/cord-255936-hfa9w2dg.txt cache: ./cache/cord-255936-hfa9w2dg.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-255936-hfa9w2dg.txt' === file2bib.sh === id: cord-103077-sh4w2mye author: Lu, Shuai title: Leveraging Sequential and Spatial Neighbors Information by Using CNNs Linked With GCNs for Paratope Prediction date: 2020-10-16 pages: extension: .txt txt: ./txt/cord-103077-sh4w2mye.txt cache: ./cache/cord-103077-sh4w2mye.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-103077-sh4w2mye.txt' === file2bib.sh === id: cord-277894-0qw0t78s author: NAYLOR, MJ title: Canine coronavirus in Australian dogs date: 2008-03-10 pages: extension: .txt txt: ./txt/cord-277894-0qw0t78s.txt cache: ./cache/cord-277894-0qw0t78s.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-277894-0qw0t78s.txt' === file2bib.sh === id: cord-282081-qaagup4d author: Flicker, Sabine title: Nanobodies—Useful Tools for Allergy Treatment? date: 2020-09-30 pages: extension: .txt txt: ./txt/cord-282081-qaagup4d.txt cache: ./cache/cord-282081-qaagup4d.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-282081-qaagup4d.txt' === file2bib.sh === id: cord-254821-px4fe7mn author: Infantino, Maria title: Diagnostic accuracy of an automated chemiluminescent immunoassay for anti‐SARS‐CoV‐2 IgM and IgG antibodies: an Italian experience date: 2020-05-10 pages: extension: .txt txt: ./txt/cord-254821-px4fe7mn.txt cache: ./cache/cord-254821-px4fe7mn.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-254821-px4fe7mn.txt' === file2bib.sh === id: cord-021402-wq770ik9 author: Relford, Roberta L. title: New Diagnostic Tools for Infectious Disease date: 2009-05-15 pages: extension: .txt txt: ./txt/cord-021402-wq770ik9.txt cache: ./cache/cord-021402-wq770ik9.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-021402-wq770ik9.txt' === file2bib.sh === id: cord-009581-bvihkf1r author: Hurd, Eric R. title: Virus antibody levels in systemic lupus erythematosus date: 2005-11-22 pages: extension: .txt txt: ./txt/cord-009581-bvihkf1r.txt cache: ./cache/cord-009581-bvihkf1r.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-009581-bvihkf1r.txt' === file2bib.sh === id: cord-305893-2vcy0f6i author: Bagheri, Vahid title: Neutralizing human recombinant antibodies against herpes simplex virus type 1 glycoproteins B from a phage-displayed scFv antibody library date: 2017-01-15 pages: extension: .txt txt: ./txt/cord-305893-2vcy0f6i.txt cache: ./cache/cord-305893-2vcy0f6i.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-305893-2vcy0f6i.txt' === file2bib.sh === id: cord-005409-8mbqkzpu author: Cichon, G title: Complement activation by recombinant adenoviruses date: 2002-01-24 pages: extension: .txt txt: ./txt/cord-005409-8mbqkzpu.txt cache: ./cache/cord-005409-8mbqkzpu.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-005409-8mbqkzpu.txt' === file2bib.sh === id: cord-015742-nt44jcjm author: Garwes, D.J. title: Antigenicity of structural components from porcine transmissible gastroenteritis virus date: 2002-11-13 pages: extension: .txt txt: ./txt/cord-015742-nt44jcjm.txt cache: ./cache/cord-015742-nt44jcjm.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-015742-nt44jcjm.txt' === file2bib.sh === id: cord-300701-vkzya7uq author: Ijaz, M. K. title: Effect of different routes of immunization with bovine rotavirus on lactogenic antibody response in mice date: 1987-12-31 pages: extension: .txt txt: ./txt/cord-300701-vkzya7uq.txt cache: ./cache/cord-300701-vkzya7uq.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-300701-vkzya7uq.txt' === file2bib.sh === id: cord-283641-2u16otbf author: Vainionpää, R. title: Diagnostic Techniques: Serological and Molecular Approaches date: 2015-03-06 pages: extension: .txt txt: ./txt/cord-283641-2u16otbf.txt cache: ./cache/cord-283641-2u16otbf.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-283641-2u16otbf.txt' === file2bib.sh === id: cord-010578-uib9h1lb author: Mawle, Alison C. title: Seroepidemiology of Chronic Fatigue Syndrome: A Case-Control Study date: 1995-12-17 pages: extension: .txt txt: ./txt/cord-010578-uib9h1lb.txt cache: ./cache/cord-010578-uib9h1lb.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-010578-uib9h1lb.txt' === file2bib.sh === id: cord-001566-kkaxha7d author: Zhang, Mao-Yu title: Development of Monoclonal Antibodies in China: Overview and Prospects date: 2015-02-25 pages: extension: .txt txt: ./txt/cord-001566-kkaxha7d.txt cache: ./cache/cord-001566-kkaxha7d.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-001566-kkaxha7d.txt' === file2bib.sh === id: cord-292874-6zjqflhz author: SØRENSEN, MORTEN DRÆBY title: Severe Acute Respiratory Syndrome (SARS): Development of Diagnostics and Antivirals date: 2006-05-10 pages: extension: .txt txt: ./txt/cord-292874-6zjqflhz.txt cache: ./cache/cord-292874-6zjqflhz.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-292874-6zjqflhz.txt' === file2bib.sh === id: cord-267736-rya9w6sh author: Kang, Xiaoping title: Development of an ELISA-array for simultaneous detection of five encephalitis viruses date: 2012-02-27 pages: extension: .txt txt: ./txt/cord-267736-rya9w6sh.txt cache: ./cache/cord-267736-rya9w6sh.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-267736-rya9w6sh.txt' === file2bib.sh === id: cord-254531-pv55re2x author: Mestecky, Jiri title: Specific antibody activity, glycan heterogeneity and polyreactivity contribute to the protective activity of S-IgA at mucosal surfaces date: 2009-06-04 pages: extension: .txt txt: ./txt/cord-254531-pv55re2x.txt cache: ./cache/cord-254531-pv55re2x.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-254531-pv55re2x.txt' === file2bib.sh === id: cord-005913-1vo1o6w8 author: Matis, Louis A. title: Complement-specific antibodies: Designing novel anti-inflammatories date: 1995 pages: extension: .txt txt: ./txt/cord-005913-1vo1o6w8.txt cache: ./cache/cord-005913-1vo1o6w8.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-005913-1vo1o6w8.txt' === file2bib.sh === id: cord-015683-a9a82of4 author: Gupta, Varsha title: Molecular Diagnostics date: 2016-10-23 pages: extension: .txt txt: ./txt/cord-015683-a9a82of4.txt cache: ./cache/cord-015683-a9a82of4.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-015683-a9a82of4.txt' === file2bib.sh === id: cord-048360-n9sih438 author: Villard, Viviane title: Rapid Identification of Malaria Vaccine Candidates Based on α-Helical Coiled Coil Protein Motif date: 2007-07-25 pages: extension: .txt txt: ./txt/cord-048360-n9sih438.txt cache: ./cache/cord-048360-n9sih438.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-048360-n9sih438.txt' === file2bib.sh === id: cord-278281-bdoavpsb author: NEMOTO, Manabu title: Antibody response to equine coronavirus in horses inoculated with a bovine coronavirus vaccine date: 2017-10-06 pages: extension: .txt txt: ./txt/cord-278281-bdoavpsb.txt cache: ./cache/cord-278281-bdoavpsb.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-278281-bdoavpsb.txt' === file2bib.sh === id: cord-302974-t1t89p8y author: Mathur, Gagan title: Antibody Testing For Covid-19: Can It Be Used As A Screening Tool In Areas With Low Prevalence? date: 2020-05-15 pages: extension: .txt txt: ./txt/cord-302974-t1t89p8y.txt cache: ./cache/cord-302974-t1t89p8y.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-302974-t1t89p8y.txt' === file2bib.sh === id: cord-031060-0o9agjiq author: Yuan, Tom Z title: Rapid exploration of the epitope coverage produced by an Ebola survivor to guide the discovery of therapeutic antibody cocktails date: 2020-08-01 pages: extension: .txt txt: ./txt/cord-031060-0o9agjiq.txt cache: ./cache/cord-031060-0o9agjiq.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-031060-0o9agjiq.txt' === file2bib.sh === id: cord-005827-wjkbrfkn author: Schmidt, Rüdiger title: Antiphospholipidantikörpersyndrom date: 1999 pages: extension: .txt txt: ./txt/cord-005827-wjkbrfkn.txt cache: ./cache/cord-005827-wjkbrfkn.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-005827-wjkbrfkn.txt' === file2bib.sh === id: cord-267015-mprsdi2e author: Zhu, Zhongyu title: Exceptionally Potent Cross-Reactive Neutralization of Nipah and Hendra Viruses by a Human Monoclonal Antibody date: 2008-03-15 pages: extension: .txt txt: ./txt/cord-267015-mprsdi2e.txt cache: ./cache/cord-267015-mprsdi2e.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-267015-mprsdi2e.txt' === file2bib.sh === id: cord-009690-kbwz7xop author: Toubanaki, Dimitra K. title: Development of a Nanoparticle-based Lateral Flow Strip Biosensor for Visual Detection of Whole Nervous Necrosis Virus Particles date: 2020-04-16 pages: extension: .txt txt: ./txt/cord-009690-kbwz7xop.txt cache: ./cache/cord-009690-kbwz7xop.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-009690-kbwz7xop.txt' === file2bib.sh === id: cord-255683-2eq24jth author: Chen, Weizao title: Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins date: 2010-02-04 pages: extension: .txt txt: ./txt/cord-255683-2eq24jth.txt cache: ./cache/cord-255683-2eq24jth.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-255683-2eq24jth.txt' === file2bib.sh === id: cord-103432-cdmoazrl author: Richardson, Eve title: A computational method for immune repertoire mining that identifies novel binders from different clonotypes, demonstrated by identifying anti-Pertussis toxoid antibodies date: 2020-06-02 pages: extension: .txt txt: ./txt/cord-103432-cdmoazrl.txt cache: ./cache/cord-103432-cdmoazrl.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-103432-cdmoazrl.txt' === file2bib.sh === id: cord-290783-ipoelk4h author: Crouch, C. F. title: Vaccination against enteric rota and coronaviruses in cattle and pigs: Enhancement of lactogenic immunity date: 1985-09-30 pages: extension: .txt txt: ./txt/cord-290783-ipoelk4h.txt cache: ./cache/cord-290783-ipoelk4h.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-290783-ipoelk4h.txt' === file2bib.sh === id: cord-010991-fp8hljbq author: Rather, Shabeer Ahmad title: Antibodies generated against dextransucrase exhibit potential anticariostatic properties in Streptococcus mutans date: 2020-01-03 pages: extension: .txt txt: ./txt/cord-010991-fp8hljbq.txt cache: ./cache/cord-010991-fp8hljbq.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-010991-fp8hljbq.txt' === file2bib.sh === id: cord-296576-d23b9fjl author: Bernard, Serge title: Lactogenic Immunity to Transmissible Gastroenteritis (TGE) of swine induced by the attenuated nouzilly strain of TGE virus: Passive protection of piglets and detection of serum and milk antibody classes by ELISA date: 1990-01-31 pages: extension: .txt txt: ./txt/cord-296576-d23b9fjl.txt cache: ./cache/cord-296576-d23b9fjl.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-296576-d23b9fjl.txt' === file2bib.sh === id: cord-004247-lagv3tp7 author: Hooft van Huijsduijnen, Rob title: Reassessing therapeutic antibodies for neglected and tropical diseases date: 2020-01-30 pages: extension: .txt txt: ./txt/cord-004247-lagv3tp7.txt cache: ./cache/cord-004247-lagv3tp7.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-004247-lagv3tp7.txt' === file2bib.sh === id: cord-304214-66nxk4e8 author: Sanders, John W. title: Vectored immunoprophylaxis: an emerging adjunct to traditional vaccination date: 2017-02-10 pages: extension: .txt txt: ./txt/cord-304214-66nxk4e8.txt cache: ./cache/cord-304214-66nxk4e8.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-304214-66nxk4e8.txt' === file2bib.sh === id: cord-279105-e2zjxjox author: Lee, Cheryl Yi-Pin title: Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control date: 2020-04-24 pages: extension: .txt txt: ./txt/cord-279105-e2zjxjox.txt cache: ./cache/cord-279105-e2zjxjox.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-279105-e2zjxjox.txt' === file2bib.sh === id: cord-277076-yvsyo4l9 author: Berger, A. title: SARS date: 2019-09-12 pages: extension: .txt txt: ./txt/cord-277076-yvsyo4l9.txt cache: ./cache/cord-277076-yvsyo4l9.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-277076-yvsyo4l9.txt' === file2bib.sh === id: cord-291626-lxa8pvt3 author: Pelfrene, E. title: Monoclonal antibodies as anti-infective products: a promising future? date: 2019-01-31 pages: extension: .txt txt: ./txt/cord-291626-lxa8pvt3.txt cache: ./cache/cord-291626-lxa8pvt3.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-291626-lxa8pvt3.txt' === file2bib.sh === id: cord-002153-e0zhq18g author: Yang, Danlin title: Efficient Qualitative and Quantitative Determination of Antigen-induced Immune Responses date: 2016-07-29 pages: extension: .txt txt: ./txt/cord-002153-e0zhq18g.txt cache: ./cache/cord-002153-e0zhq18g.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-002153-e0zhq18g.txt' === file2bib.sh === id: cord-298910-2601n7a9 author: Leu, Sy-Jye title: Generation and characterization of anti-α-enolase single-chain antibodies in chicken date: 2010-10-15 pages: extension: .txt txt: ./txt/cord-298910-2601n7a9.txt cache: ./cache/cord-298910-2601n7a9.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-298910-2601n7a9.txt' === file2bib.sh === id: cord-275946-ofd2ipvs author: Cheng, Matthew P. title: Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus-2: A Narrative Review date: 2020-06-04 pages: extension: .txt txt: ./txt/cord-275946-ofd2ipvs.txt cache: ./cache/cord-275946-ofd2ipvs.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-275946-ofd2ipvs.txt' === file2bib.sh === id: cord-001060-9g8rwsm1 author: Arruebo, Manuel title: Assessment of the Evolution of Cancer Treatment Therapies date: 2011-08-12 pages: extension: .txt txt: ./txt/cord-001060-9g8rwsm1.txt cache: ./cache/cord-001060-9g8rwsm1.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-001060-9g8rwsm1.txt' === file2bib.sh === id: cord-023731-jqgervt7 author: FENNER, FRANK title: Laboratory Diagnosis of Viral Diseases date: 2014-06-27 pages: extension: .txt txt: ./txt/cord-023731-jqgervt7.txt cache: ./cache/cord-023731-jqgervt7.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-023731-jqgervt7.txt' === file2bib.sh === id: cord-017070-05vlz5dn author: Dimitrov, Dimiter S. title: Human Monoclonal Antibodies Against HIV and Emerging Viruses date: 2008 pages: extension: .txt txt: ./txt/cord-017070-05vlz5dn.txt cache: ./cache/cord-017070-05vlz5dn.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-017070-05vlz5dn.txt' === file2bib.sh === id: cord-312787-j7ye7ed5 author: Loemba, H. D. title: Kinetics of humoral immune response to the major structural proteins of the porcine reproductive and respiratory syndrome virus date: 1996 pages: extension: .txt txt: ./txt/cord-312787-j7ye7ed5.txt cache: ./cache/cord-312787-j7ye7ed5.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-312787-j7ye7ed5.txt' === file2bib.sh === id: cord-016966-b23o5roz author: Verhoef, Jan title: Immune response in human pathology: infections caused by bacteria, viruses, fungi, and parasites date: 2005 pages: extension: .txt txt: ./txt/cord-016966-b23o5roz.txt cache: ./cache/cord-016966-b23o5roz.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-016966-b23o5roz.txt' === file2bib.sh === id: cord-010570-ytv7dwr0 author: Casadevall, Arturo title: Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases date: 1995-07-17 pages: extension: .txt txt: ./txt/cord-010570-ytv7dwr0.txt cache: ./cache/cord-010570-ytv7dwr0.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-010570-ytv7dwr0.txt' === file2bib.sh === id: cord-257465-9yrf7ofy author: Finlay, William J. J. title: Phage Display: A Powerful Technology for the Generation of High-Specificity Affinity Reagents from Alternative Immune Sources date: 2016-05-23 pages: extension: .txt txt: ./txt/cord-257465-9yrf7ofy.txt cache: ./cache/cord-257465-9yrf7ofy.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-257465-9yrf7ofy.txt' === file2bib.sh === id: cord-296928-wu14k7u9 author: Hofmann, Tim title: Greatest Hits—Innovative Technologies for High Throughput Identification of Bispecific Antibodies date: 2020-09-08 pages: extension: .txt txt: ./txt/cord-296928-wu14k7u9.txt cache: ./cache/cord-296928-wu14k7u9.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-296928-wu14k7u9.txt' === file2bib.sh === id: cord-002710-e8im13go author: Taschuk, Ryan title: Induction of PrP(Sc)-specific systemic and mucosal immune responses in white-tailed deer with an oral vaccine for chronic wasting disease date: 2017-10-02 pages: extension: .txt txt: ./txt/cord-002710-e8im13go.txt cache: ./cache/cord-002710-e8im13go.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-002710-e8im13go.txt' === file2bib.sh === id: cord-327287-e5k2gcse author: May, Jori E. title: The challenges of diagnosing heparin‐induced thrombocytopenia in patients with COVID‐19 date: 2020-08-02 pages: extension: .txt txt: ./txt/cord-327287-e5k2gcse.txt cache: ./cache/cord-327287-e5k2gcse.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-327287-e5k2gcse.txt' === file2bib.sh === id: cord-104226-bb4lyvhy author: nan title: Monoclonal antiprothrombinase (3D4.3) prevents mortality from murine hepatitis virus (MHV-3) infection date: 1992-09-01 pages: extension: .txt txt: ./txt/cord-104226-bb4lyvhy.txt cache: ./cache/cord-104226-bb4lyvhy.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-104226-bb4lyvhy.txt' === file2bib.sh === id: cord-004167-r2s0gks8 author: Cutts, Julia C. title: Pregnancy-specific malarial immunity and risk of malaria in pregnancy and adverse birth outcomes: a systematic review date: 2020-01-16 pages: extension: .txt txt: ./txt/cord-004167-r2s0gks8.txt cache: ./cache/cord-004167-r2s0gks8.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-004167-r2s0gks8.txt' === file2bib.sh === id: cord-001074-qevosik3 author: Selvarajah, Suganya title: A Neutralizing Monoclonal Antibody Targeting the Acid-Sensitive Region in Chikungunya Virus E2 Protects from Disease date: 2013-09-12 pages: extension: .txt txt: ./txt/cord-001074-qevosik3.txt cache: ./cache/cord-001074-qevosik3.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-001074-qevosik3.txt' === file2bib.sh === id: cord-102908-sr7j8z9c author: Mersmann, Sophia F. title: Learning to count: determining the stoichiometry of bio-molecular complexes using fluorescence microscopy and statistical modelling date: 2020-07-24 pages: extension: .txt txt: ./txt/cord-102908-sr7j8z9c.txt cache: ./cache/cord-102908-sr7j8z9c.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-102908-sr7j8z9c.txt' === file2bib.sh === id: cord-001435-ebl8yc92 author: Hoppe, Sebastian title: Identification of Antigenic Proteins of the Nosocomial Pathogen Klebsiella pneumoniae date: 2014-10-21 pages: extension: .txt txt: ./txt/cord-001435-ebl8yc92.txt cache: ./cache/cord-001435-ebl8yc92.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-001435-ebl8yc92.txt' === file2bib.sh === id: cord-030999-27wennun author: Altmann, Daniel M title: Adaptive immunity to SARS-CoV-2 date: 2020-07-09 pages: extension: .txt txt: ./txt/cord-030999-27wennun.txt cache: ./cache/cord-030999-27wennun.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-030999-27wennun.txt' === file2bib.sh === id: cord-048239-oluq7v0h author: Oliphant, Theodore title: Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus date: 2005-04-24 pages: extension: .txt txt: ./txt/cord-048239-oluq7v0h.txt cache: ./cache/cord-048239-oluq7v0h.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-048239-oluq7v0h.txt' === file2bib.sh === id: cord-009446-8keu2uay author: Kreer, Christoph title: Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies date: 2020-01-01 pages: extension: .txt txt: ./txt/cord-009446-8keu2uay.txt cache: ./cache/cord-009446-8keu2uay.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-009446-8keu2uay.txt' === file2bib.sh === id: cord-133453-23rfdkuw author: Chen, Jiahui title: Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies date: 2020-10-13 pages: extension: .txt txt: ./txt/cord-133453-23rfdkuw.txt cache: ./cache/cord-133453-23rfdkuw.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-133453-23rfdkuw.txt' === file2bib.sh === id: cord-295033-5fd9bu60 author: Parma, Y.R. title: Antibodies anti-Shiga toxin 2 B subunit from chicken egg yolk: Isolation, purification and neutralization efficacy date: 2011-09-15 pages: extension: .txt txt: ./txt/cord-295033-5fd9bu60.txt cache: ./cache/cord-295033-5fd9bu60.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-295033-5fd9bu60.txt' === file2bib.sh === id: cord-256652-ent4vu3z author: Tan, Joshua title: A public antibody lineage that potently inhibits malaria infection by dual binding to the circumsporozoite protein date: 2018-03-19 pages: extension: .txt txt: ./txt/cord-256652-ent4vu3z.txt cache: ./cache/cord-256652-ent4vu3z.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-256652-ent4vu3z.txt' === file2bib.sh === id: cord-018840-ts2g1ux7 author: Katragkou, Aspasia title: Role of Immunoglobulin Therapy to Prevent and Treat Infections date: 2018-06-19 pages: extension: .txt txt: ./txt/cord-018840-ts2g1ux7.txt cache: ./cache/cord-018840-ts2g1ux7.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-018840-ts2g1ux7.txt' === file2bib.sh === id: cord-324316-ulb8d5fe author: Bramstedt, Katrina A. title: Antibodies as Currency: COVID-19’s Golden Passport date: 2020-08-25 pages: extension: .txt txt: ./txt/cord-324316-ulb8d5fe.txt cache: ./cache/cord-324316-ulb8d5fe.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-324316-ulb8d5fe.txt' === file2bib.sh === id: cord-282817-vtzpf2wr author: Byrne, Hannah title: A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications date: 2013-10-02 pages: extension: .txt txt: ./txt/cord-282817-vtzpf2wr.txt cache: ./cache/cord-282817-vtzpf2wr.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-282817-vtzpf2wr.txt' === file2bib.sh === id: cord-302312-1pm17l5d author: Quinteros, Daniela A. title: Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery date: 2017-03-31 pages: extension: .txt txt: ./txt/cord-302312-1pm17l5d.txt cache: ./cache/cord-302312-1pm17l5d.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-302312-1pm17l5d.txt' === file2bib.sh === id: cord-319746-6bccxgbd author: Saxena, Latika title: Production and Characterization of Human Monoclonal Antibodies from the Cells of A(H1N1)pdm2009 Influenza Virus Infected Indian Donors date: 2015-12-31 pages: extension: .txt txt: ./txt/cord-319746-6bccxgbd.txt cache: ./cache/cord-319746-6bccxgbd.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-319746-6bccxgbd.txt' === file2bib.sh === id: cord-002846-la9svzml author: Strohl, William R. title: Current progress in innovative engineered antibodies date: 2017-08-18 pages: extension: .txt txt: ./txt/cord-002846-la9svzml.txt cache: ./cache/cord-002846-la9svzml.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-002846-la9svzml.txt' === file2bib.sh === id: cord-283826-lgyc3sro author: Stiehm, E. Richard title: Therapeutic Use of Immunoglobulins date: 2010-11-05 pages: extension: .txt txt: ./txt/cord-283826-lgyc3sro.txt cache: ./cache/cord-283826-lgyc3sro.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-283826-lgyc3sro.txt' === file2bib.sh === id: cord-285760-y37ji92k author: Connell, Anna R. title: Mumps Outbreaks in Vaccinated Populations—Is It Time to Re-assess the Clinical Efficacy of Vaccines? date: 2020-09-18 pages: extension: .txt txt: ./txt/cord-285760-y37ji92k.txt cache: ./cache/cord-285760-y37ji92k.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-285760-y37ji92k.txt' === file2bib.sh === id: cord-344445-slv7r9u7 author: Vakharia, Kunal title: The right to know: ethical implications of antibody testing for healthcare workers and overlooked societal implications date: 2020-06-03 pages: extension: .txt txt: ./txt/cord-344445-slv7r9u7.txt cache: ./cache/cord-344445-slv7r9u7.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-344445-slv7r9u7.txt' === file2bib.sh === id: cord-349669-o3eelqcw author: Stadlbauer, Daniel title: Anti‐SARS‐CoV‐2 Spike Antibodies are Stable in Convalescent Plasma when Stored at 4° Celsius for at Least 6 Weeks date: 2020-08-14 pages: extension: .txt txt: ./txt/cord-349669-o3eelqcw.txt cache: ./cache/cord-349669-o3eelqcw.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-349669-o3eelqcw.txt' === file2bib.sh === id: cord-345296-4z7yfj5s author: Ho, Mei-Shang title: Neutralizing Antibody Response and SARS Severity date: 2005-11-17 pages: extension: .txt txt: ./txt/cord-345296-4z7yfj5s.txt cache: ./cache/cord-345296-4z7yfj5s.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-345296-4z7yfj5s.txt' === file2bib.sh === id: cord-327629-ep28ay11 author: Herron, J.B.T. title: Coronavirus antibody positive tests and continued use of personal protective equipment throughout the pandemic date: 2020-06-20 pages: extension: .txt txt: ./txt/cord-327629-ep28ay11.txt cache: ./cache/cord-327629-ep28ay11.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-327629-ep28ay11.txt' === file2bib.sh === id: cord-267601-3ahmyicn author: Renegar, Kathryn B. title: Passive Immunization: Systemic and Mucosal date: 2007-05-09 pages: extension: .txt txt: ./txt/cord-267601-3ahmyicn.txt cache: ./cache/cord-267601-3ahmyicn.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-267601-3ahmyicn.txt' === file2bib.sh === id: cord-307320-fxs31d66 author: Ubah, Obinna title: Monoclonal Antibodies and Antibody Like Fragments Derived from Immunised Phage Display Libraries date: 2018-03-17 pages: extension: .txt txt: ./txt/cord-307320-fxs31d66.txt cache: ./cache/cord-307320-fxs31d66.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-307320-fxs31d66.txt' === file2bib.sh === id: cord-305039-grsv06j7 author: Flego, Michela title: Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases date: 2013-01-04 pages: extension: .txt txt: ./txt/cord-305039-grsv06j7.txt cache: ./cache/cord-305039-grsv06j7.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-305039-grsv06j7.txt' === file2bib.sh === id: cord-001726-d7iwkatn author: Henry, Kevin A. title: Beyond phage display: non-traditional applications of the filamentous bacteriophage as a vaccine carrier, therapeutic biologic, and bioconjugation scaffold date: 2015-08-04 pages: extension: .txt txt: ./txt/cord-001726-d7iwkatn.txt cache: ./cache/cord-001726-d7iwkatn.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-001726-d7iwkatn.txt' === file2bib.sh === id: cord-350029-1y5ex4d5 author: McDade, Thomas W. title: Beyond serosurveys: Human biology and the measurement of SARS‐Cov‐2 antibodies date: 2020-08-09 pages: extension: .txt txt: ./txt/cord-350029-1y5ex4d5.txt cache: ./cache/cord-350029-1y5ex4d5.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-350029-1y5ex4d5.txt' === file2bib.sh === id: cord-326673-p8qbxi57 author: Kitching, R. P. title: The interference by maternally-derived antibody with active immunization of farm animals against foot-and-mouth disease date: 1995-12-31 pages: extension: .txt txt: ./txt/cord-326673-p8qbxi57.txt cache: ./cache/cord-326673-p8qbxi57.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-326673-p8qbxi57.txt' === file2bib.sh === id: cord-321369-xzu2faol author: Andreano, Emanuele title: Extremely potent human monoclonal antibodies from convalescent Covid-19 patients date: 2020-10-07 pages: extension: .txt txt: ./txt/cord-321369-xzu2faol.txt cache: ./cache/cord-321369-xzu2faol.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-321369-xzu2faol.txt' === file2bib.sh === id: cord-010680-lc1onm53 author: Patel, Ami title: In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies date: 2020-03-10 pages: extension: .txt txt: ./txt/cord-010680-lc1onm53.txt cache: ./cache/cord-010680-lc1onm53.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-010680-lc1onm53.txt' === file2bib.sh === id: cord-329857-pcsuu597 author: Chan, Kuan Rong title: Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases date: 2015-11-02 pages: extension: .txt txt: ./txt/cord-329857-pcsuu597.txt cache: ./cache/cord-329857-pcsuu597.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-329857-pcsuu597.txt' === file2bib.sh === id: cord-274557-2071770h author: Späth, Peter J. title: On the Dark Side of Therapies with Immunoglobulin Concentrates: The Adverse Events date: 2015-02-05 pages: extension: .txt txt: ./txt/cord-274557-2071770h.txt cache: ./cache/cord-274557-2071770h.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-274557-2071770h.txt' === file2bib.sh === id: cord-003435-ke0az7nf author: Schlake, Thomas title: mRNA as novel technology for passive immunotherapy date: 2018-10-17 pages: extension: .txt txt: ./txt/cord-003435-ke0az7nf.txt cache: ./cache/cord-003435-ke0az7nf.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-003435-ke0az7nf.txt' === file2bib.sh === id: cord-321901-zpi7uis1 author: Roberts, Anjeanette title: Animal models and antibody assays for evaluating candidate SARS vaccines: Summary of a technical meeting 25–26 August 2005, London, UK date: 2006-11-30 pages: extension: .txt txt: ./txt/cord-321901-zpi7uis1.txt cache: ./cache/cord-321901-zpi7uis1.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-321901-zpi7uis1.txt' === file2bib.sh === id: cord-335316-x2t5h5gu author: Madariaga, M. L. L. title: Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial date: 2020-06-23 pages: extension: .txt txt: ./txt/cord-335316-x2t5h5gu.txt cache: ./cache/cord-335316-x2t5h5gu.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-335316-x2t5h5gu.txt' === file2bib.sh === id: cord-313312-h607itv2 author: Mok, Darren Z. L. title: The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines date: 2020-05-08 pages: extension: .txt txt: ./txt/cord-313312-h607itv2.txt cache: ./cache/cord-313312-h607itv2.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-313312-h607itv2.txt' === file2bib.sh === id: cord-335121-ro3x3qa3 author: Ingram, George A. title: A comparative assessment of four serological methods used in the detection and measurement of anti-parasite antibodies in the serum of the amphibian, bufo viridis date: 1988-04-30 pages: extension: .txt txt: ./txt/cord-335121-ro3x3qa3.txt cache: ./cache/cord-335121-ro3x3qa3.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-335121-ro3x3qa3.txt' === file2bib.sh === id: cord-021770-zn7na974 author: Slifka, Mark K. title: Passive Immunization date: 2017-07-17 pages: extension: .txt txt: ./txt/cord-021770-zn7na974.txt cache: ./cache/cord-021770-zn7na974.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-021770-zn7na974.txt' === file2bib.sh === id: cord-339520-odly2fwg author: Madic, J. title: Isotype-specific antibody responses to bovine herpesvirus 1 in sera and mucosal secretions of calves after experimental reinfection and after reactivation date: 1995-07-31 pages: extension: .txt txt: ./txt/cord-339520-odly2fwg.txt cache: ./cache/cord-339520-odly2fwg.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-339520-odly2fwg.txt' === file2bib.sh === id: cord-010248-ln800g5z author: Sissons, J.G. Patrick title: Antibody-Mediated Destruction of Virus-Infected Cells date: 2008-02-29 pages: extension: .txt txt: ./txt/cord-010248-ln800g5z.txt cache: ./cache/cord-010248-ln800g5z.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 14 resourceName b'cord-010248-ln800g5z.txt' === file2bib.sh === id: cord-316287-4i1grvlr author: Yim, Sung Sun title: Rapid Isolation of Antibody from a Synthetic Human Antibody Library by Repeated Fluorescence-Activated Cell Sorting (FACS) date: 2014-10-10 pages: extension: .txt txt: ./txt/cord-316287-4i1grvlr.txt cache: ./cache/cord-316287-4i1grvlr.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-316287-4i1grvlr.txt' === file2bib.sh === id: cord-281760-34wuttqw author: Pereira, E.P.V. title: Egg yolk antibodies (IgY) and their applications in human and veterinary health: A review date: 2019-05-22 pages: extension: .txt txt: ./txt/cord-281760-34wuttqw.txt cache: ./cache/cord-281760-34wuttqw.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-281760-34wuttqw.txt' === file2bib.sh === id: cord-354700-bdpp3qmf author: Lanzavecchia, Antonio title: Dissecting human antibody responses: useful, basic and surprising findings date: 2018-01-23 pages: extension: .txt txt: ./txt/cord-354700-bdpp3qmf.txt cache: ./cache/cord-354700-bdpp3qmf.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-354700-bdpp3qmf.txt' === file2bib.sh === id: cord-330324-4hqhty5o author: Yu, Meng title: Determination and application of immunodominant regions of SARS coronavirus spike and nucleocapsid proteins recognized by sera from different animal species date: 2008-02-29 pages: extension: .txt txt: ./txt/cord-330324-4hqhty5o.txt cache: ./cache/cord-330324-4hqhty5o.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-330324-4hqhty5o.txt' === file2bib.sh === id: cord-354790-xx6imhzb author: Lambour, Jennifer title: Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play date: 2016-08-17 pages: extension: .txt txt: ./txt/cord-354790-xx6imhzb.txt cache: ./cache/cord-354790-xx6imhzb.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-354790-xx6imhzb.txt' === file2bib.sh === id: cord-340305-jtvn9tlm author: Cimolai, Nevio title: A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19 date: 2020-09-19 pages: extension: .txt txt: ./txt/cord-340305-jtvn9tlm.txt cache: ./cache/cord-340305-jtvn9tlm.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-340305-jtvn9tlm.txt' === file2bib.sh === id: cord-319884-d8n0aokl author: Natesan, Mohan title: Protein Microarrays and Biomarkers of Infectious Disease date: 2010-12-16 pages: extension: .txt txt: ./txt/cord-319884-d8n0aokl.txt cache: ./cache/cord-319884-d8n0aokl.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-319884-d8n0aokl.txt' === file2bib.sh === id: cord-328753-qwdxgk4z author: Lafaye, Pierre title: Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases date: 2018-09-25 pages: extension: .txt txt: ./txt/cord-328753-qwdxgk4z.txt cache: ./cache/cord-328753-qwdxgk4z.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-328753-qwdxgk4z.txt' === file2bib.sh === id: cord-022310-yc6xtw0s author: Lappin, Michael R. title: Microbiology and Infectious Disease date: 2011-12-15 pages: extension: .txt txt: ./txt/cord-022310-yc6xtw0s.txt cache: ./cache/cord-022310-yc6xtw0s.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-022310-yc6xtw0s.txt' === file2bib.sh === id: cord-338517-1mxcssjj author: Ishay, Yuval title: Antibody response to SARS‐Co‐V‐2, diagnostic and therapeutic implications date: 2020-08-26 pages: extension: .txt txt: ./txt/cord-338517-1mxcssjj.txt cache: ./cache/cord-338517-1mxcssjj.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-338517-1mxcssjj.txt' === file2bib.sh === id: cord-331786-wgt7kg6f author: Diego-Martin, Borja title: Pilot production of SARS-CoV-2 related proteins in plants: a proof of concept for rapid repurposing of indoors farms into biomanufacturing facilities date: 2020-10-13 pages: extension: .txt txt: ./txt/cord-331786-wgt7kg6f.txt cache: ./cache/cord-331786-wgt7kg6f.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-331786-wgt7kg6f.txt' === file2bib.sh === id: cord-352172-g0jiaenw author: Stoevesandt, Oda title: Protein microarrays: high-throughput tools for proteomics date: 2014-01-09 pages: extension: .txt txt: ./txt/cord-352172-g0jiaenw.txt cache: ./cache/cord-352172-g0jiaenw.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-352172-g0jiaenw.txt' === file2bib.sh === id: cord-341305-zf97tcwe author: Ge, Shikun title: Canine Parvovirus is diagnosed and neutralized by chicken IgY-scFv generated against the virus capsid protein date: 2020-09-03 pages: extension: .txt txt: ./txt/cord-341305-zf97tcwe.txt cache: ./cache/cord-341305-zf97tcwe.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-341305-zf97tcwe.txt' === file2bib.sh === id: cord-355610-7xy4s483 author: Hu, Dan title: A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III date: 2019-06-26 pages: extension: .txt txt: ./txt/cord-355610-7xy4s483.txt cache: ./cache/cord-355610-7xy4s483.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-355610-7xy4s483.txt' === file2bib.sh === id: cord-016960-xhzvp35g author: Berencsi, György title: Fetal and Neonatal Illnesses Caused or Influenced by Maternal Transplacental IgG and/or Therapeutic Antibodies Applied During Pregnancy date: 2012-03-08 pages: extension: .txt txt: ./txt/cord-016960-xhzvp35g.txt cache: ./cache/cord-016960-xhzvp35g.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 5 resourceName b'cord-016960-xhzvp35g.txt' === file2bib.sh === id: cord-317501-yblzopc3 author: Kuhn, Philipp title: Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display date: 2016-06-21 pages: extension: .txt txt: ./txt/cord-317501-yblzopc3.txt cache: ./cache/cord-317501-yblzopc3.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-317501-yblzopc3.txt' === file2bib.sh === id: cord-335311-l73hsik0 author: Chan, Conrad E. Z. title: The role of phage display in therapeutic antibody discovery date: 2014-08-18 pages: extension: .txt txt: ./txt/cord-335311-l73hsik0.txt cache: ./cache/cord-335311-l73hsik0.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-335311-l73hsik0.txt' === file2bib.sh === id: cord-327883-s9nbr5y8 author: nan title: Section Virology date: 1990-03-31 pages: extension: .txt txt: ./txt/cord-327883-s9nbr5y8.txt cache: ./cache/cord-327883-s9nbr5y8.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-327883-s9nbr5y8.txt' === file2bib.sh === id: cord-330218-l5q3n3ri author: Foss, Stian title: TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity date: 2015-10-26 pages: extension: .txt txt: ./txt/cord-330218-l5q3n3ri.txt cache: ./cache/cord-330218-l5q3n3ri.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-330218-l5q3n3ri.txt' === file2bib.sh === id: cord-354137-6oe8nj1j author: Wang, Hua title: Aspects of recent development of immunosensors date: 2008-05-20 pages: extension: .txt txt: ./txt/cord-354137-6oe8nj1j.txt cache: ./cache/cord-354137-6oe8nj1j.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-354137-6oe8nj1j.txt' === file2bib.sh === id: cord-337464-otwps68u author: Parray, Hilal Ahmed title: Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives date: 2020-05-27 pages: extension: .txt txt: ./txt/cord-337464-otwps68u.txt cache: ./cache/cord-337464-otwps68u.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-337464-otwps68u.txt' === file2bib.sh === id: cord-274756-nnm1n09a author: Varadé, Jezabel title: Human immunology and immunotherapy: main achievements and challenges date: 2020-09-02 pages: extension: .txt txt: ./txt/cord-274756-nnm1n09a.txt cache: ./cache/cord-274756-nnm1n09a.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-274756-nnm1n09a.txt' === file2bib.sh === id: cord-342242-cynpob7b author: Godakova, Svetlana A. title: Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice date: 2019-08-07 pages: extension: .txt txt: ./txt/cord-342242-cynpob7b.txt cache: ./cache/cord-342242-cynpob7b.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-342242-cynpob7b.txt' === file2bib.sh === id: cord-336280-tsx409e3 author: Byrne, Barry title: Antibody-Based Sensors: Principles, Problems and Potential for Detection of Pathogens and Associated Toxins date: 2009-06-05 pages: extension: .txt txt: ./txt/cord-336280-tsx409e3.txt cache: ./cache/cord-336280-tsx409e3.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-336280-tsx409e3.txt' === file2bib.sh === id: cord-354325-r73datur author: Berger, Mitchell title: Therapeutic Applications of Monoclonal Antibodies date: 2002-07-31 pages: extension: .txt txt: ./txt/cord-354325-r73datur.txt cache: ./cache/cord-354325-r73datur.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-354325-r73datur.txt' === file2bib.sh === id: cord-268417-6eyetb5i author: Mandel, Benjamin title: Neutralization of Animal Viruses date: 1978-12-31 pages: extension: .txt txt: ./txt/cord-268417-6eyetb5i.txt cache: ./cache/cord-268417-6eyetb5i.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-268417-6eyetb5i.txt' === file2bib.sh === id: cord-328935-mn8r972x author: Hodgins, Douglas C. title: Mucosal Veterinary Vaccines: Comparative Vaccinology date: 2015-03-13 pages: extension: .txt txt: ./txt/cord-328935-mn8r972x.txt cache: ./cache/cord-328935-mn8r972x.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-328935-mn8r972x.txt' === file2bib.sh === id: cord-339879-92esdjy9 author: Delhalle, Sylvie title: Phages and HIV-1: From Display to Interplay date: 2012-04-13 pages: extension: .txt txt: ./txt/cord-339879-92esdjy9.txt cache: ./cache/cord-339879-92esdjy9.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 5 resourceName b'cord-339879-92esdjy9.txt' === file2bib.sh === id: cord-010088-s9tfvtao author: nan title: Oral Abstracts date: 2013-11-01 pages: extension: .txt txt: ./txt/cord-010088-s9tfvtao.txt cache: ./cache/cord-010088-s9tfvtao.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-010088-s9tfvtao.txt' === file2bib.sh === id: cord-009571-mygj2nd4 author: nan title: Proceedings of the 42nd annual meeting of the american rheumatism association a section of the arthritis foundation june 1 & 2, 1978 new york city abstracts of papers presented date: 2005-11-23 pages: extension: .txt txt: ./txt/cord-009571-mygj2nd4.txt cache: ./cache/cord-009571-mygj2nd4.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-009571-mygj2nd4.txt' === file2bib.sh === id: cord-023346-8sqbqjm1 author: nan title: MONDAY: POSTERS date: 2005-06-08 pages: extension: .txt txt: ./txt/cord-023346-8sqbqjm1.txt cache: ./cache/cord-023346-8sqbqjm1.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 23 resourceName b'cord-023346-8sqbqjm1.txt' === file2bib.sh === id: cord-023364-ut56gczm author: nan title: EDUCATION DAY MONDAY: PLENARY SESSION 1 MONDAY: PARALLEL SESSIONS date: 2005-06-08 pages: extension: .txt txt: ./txt/cord-023364-ut56gczm.txt cache: ./cache/cord-023364-ut56gczm.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 12 resourceName b'cord-023364-ut56gczm.txt' === file2bib.sh === id: cord-023354-f2ciho6o author: nan title: TUESDAY PLENARY SESSION 3 TUESDAY: POSTERS date: 2005-06-08 pages: extension: .txt txt: ./txt/cord-023354-f2ciho6o.txt cache: ./cache/cord-023354-f2ciho6o.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 11 resourceName b'cord-023354-f2ciho6o.txt' Que is empty; done keyword-antibody-cord === reduce.pl bib === id = cord-001435-ebl8yc92 author = Hoppe, Sebastian title = Identification of Antigenic Proteins of the Nosocomial Pathogen Klebsiella pneumoniae date = 2014-10-21 pages = extension = .txt mime = text/plain words = 9619 sentences = 545 flesch = 50 summary = Hence, a cDNA-based expression library was constructed and screened via microarrays to detect novel antigens of Klebsiella pneumoniae, a prominent agent of nosocomial infections well-known for its extensive antibiotics resistance, especially by extended-spectrum beta-lactamases (ESBL). After specificity analysis, homology survey and 3d structural modelling, one epitope sequence GAVVALSTTFA of KPN_00363, an ion channel protein, was identified harboring specificity for K. By identifying several novel antigens and their linear epitope sites, we have paved the way for crucial future research and applications including the design of point-of-care devices, vaccine development and serological screenings for a highly relevant nosocomial pathogen. Incubation with antibodies reactive to either of those two bacterial species resulted in signal intensities in the neighbourhood of the negative control independent of sequence alterations, see Figure 11 . In contrast, the other two proteins displaying linear epitopes, KPN_00363 and KPN_00459, indicated some specificity with the antibodies tested and two linear consensus sequences could be derived, GAVVALSTTFA and GIAFGAVELFD, respectively. cache = ./cache/cord-001435-ebl8yc92.txt txt = ./txt/cord-001435-ebl8yc92.txt === reduce.pl bib === id = cord-133453-23rfdkuw author = Chen, Jiahui title = Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies date = 2020-10-13 pages = extension = .txt mime = text/plain words = 8184 sentences = 485 flesch = 54 summary = By integrating genetics, biophysics, deep learning, and algebraic topology, we deduce that some of the mutations such as M153I, S254F, and S255F may weaken the binding of S protein and antibodies, and potentially disrupt the efficacy and reliability of antibody therapies and vaccines in the development. The vaccination mechanism is to stimulate the primary immune response of the human body, which will activate T cells and B cells to generate the antibodies and long-lived memory cells that prevent infectious diseases, which is one of the most effective and economical means for combating with COVID-19 at this stage. Notably, understanding how mutations have changed the SARS-CoV-2 structure, function, infectivity, activity, and virulence is of great importance for coming up with life-saving strategies in virus control, containment, prevention, and medication, especially in the antibodies and vaccines development. Next, we study the BFE changes ∆∆G induced by 39 mutations on the SARS-CoV-2 S protein RBD for the antibody Fab 2-4 (PDB: 6XEY) in Figure 6 . cache = ./cache/cord-133453-23rfdkuw.txt txt = ./txt/cord-133453-23rfdkuw.txt === reduce.pl bib === id = cord-023053-j061ywrl author = BARLOUGH, J. E. title = Cats, coronaviruses and coronavirus antibody tests date = 2008-04-10 pages = extension = .txt mime = text/plain words = 3611 sentences = 156 flesch = 35 summary = In domestic and exotic cats, FIPV is the aetiologic agent of a lethal disease-feline infectious peritonitis (FIP)-characterized by fibrinous serositis, vasculitis, and formation of disseminated pyogranulomas (Wolfe & Griesemer. Laboratory test procedures for detection of coronavirus antibody in feline sera include biological assays such as virus neutralization (VN); non-biological, immunochemical techniques such as indirect immunofluorescence assay (IFA), enzyme-linked immunosorbent assay (ELISA), and kinetics-based ELISA (KELA); and other methods such as agar gel immunodiffusion and passive haemagglutination , though the availability of such tests varies worldwide. The serodiagnostic potential of these assays (i.e., their ability to identify cats with active FIP and/or potential virus carriers/excretors) is thus limited not only by the widespread distribution of serum coronavirus antibody in the feline population, but also by the possibility that non-FIPV coronaviruses may be responsible for some of the seroconversions that they detect. cache = ./cache/cord-023053-j061ywrl.txt txt = ./txt/cord-023053-j061ywrl.txt === reduce.pl bib === id = cord-003435-ke0az7nf author = Schlake, Thomas title = mRNA as novel technology for passive immunotherapy date = 2018-10-17 pages = extension = .txt mime = text/plain words = 15190 sentences = 850 flesch = 40 summary = Recombinant technologies further expanded the available therapies based on mAbs. In vitro antibody selection technologies like phage or ribosome display were developed to enable the generation of highly specific human mAbs out of libraries that may even be naïve for the specific antigens [31] [32] [33] [34] [35] [36] 1 Schematic illustration comparing active immunization and passive antibody immunotherapies. While T cell engineering for adoptive transfer inevitably requires the use of nucleic acids encoding a target-specific receptor, antibody immunotherapy can deploy recombinant proteins. However, the effects of mRNA modifications on translation, immunostimulation and resulting protein expression appear to be variable, for instance dependent on the type of target cells. In comparison to a single transfer of cells with retroviral CAR expression, an mRNA-encoded receptor required three consecutive lymphocyte infusions to obtain a comparable antitumor effect [262] . cache = ./cache/cord-003435-ke0az7nf.txt txt = ./txt/cord-003435-ke0az7nf.txt === reduce.pl bib === id = cord-017070-05vlz5dn author = Dimitrov, Dimiter S. title = Human Monoclonal Antibodies Against HIV and Emerging Viruses date = 2008 pages = extension = .txt mime = text/plain words = 6662 sentences = 299 flesch = 38 summary = These antibodies also protected uninfected animals from SARS-CoV infection, e.g., passive transfer of immune serum to naive mice prevented virus replication in the lower respiratory tract following intranasal challenge (61) . Recently, an improved method for Epstein-Barr virus transformation of human B cells has been developed based on CpG oligonucleotide (CpG 2006) that increases the B cell immortalization efficiency from 1-2% to 30-100%, and used for selection of hmAbs specific for SARS-CoV proteins (68) . We have recently identified a novel cross-reactive potent SARS-CoV-neutralizing hmAb, m396, by using a fragment containing residues 317 through 518 as a selecting antigen for panning of a large human antibody library constructed from the B lymphocytes of healthy volunteers (75) . These antibodies specific for SARS-CoV, HeV, and NiV have potential for further development into a clinically useful product for prophylaxis and perhaps treatment of the diseases caused by these infections. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association cache = ./cache/cord-017070-05vlz5dn.txt txt = ./txt/cord-017070-05vlz5dn.txt === reduce.pl bib === id = cord-048360-n9sih438 author = Villard, Viviane title = Rapid Identification of Malaria Vaccine Candidates Based on α-Helical Coiled Coil Protein Motif date = 2007-07-25 pages = extension = .txt mime = text/plain words = 4794 sentences = 228 flesch = 45 summary = To identify malaria antigens for vaccine development, we selected α-helical coiled coil domains of proteins predicted to be present in the parasite erythrocytic stage. Here, we focus on the Pf parasite erythrocytic stage, a target of protective antibodies and describe a straightforward, rapid procedure based on bioinformatic analysis of a-helical coiled-coil motifs and peptide synthesis. With regard to the structural features and cellular location prediction of the proteins corresponding to the peptides selected for ADCI assays ( Table 1) , 15 of the proteins contain a pentapeptide conforming to the PEXEL consensus [19, 20; 21, 22] , but that none of these have a position within the amino acid sequence that conforms to the location of known active PEXEL motifs (see Materials and Methods and membrane segments, and none of them has a GPI anchor. In conclusion, an approach combining a genome-wide search by bioinformatics of a-helical coiled coil protein motifs and chemical synthesis can lead to the rapid identification and development of new malaria vaccine candidates. cache = ./cache/cord-048360-n9sih438.txt txt = ./txt/cord-048360-n9sih438.txt === reduce.pl bib === id = cord-002153-e0zhq18g author = Yang, Danlin title = Efficient Qualitative and Quantitative Determination of Antigen-induced Immune Responses date = 2016-07-29 pages = extension = .txt mime = text/plain words = 7931 sentences = 369 flesch = 43 summary = Our workflow consists of the following two steps: 1) the use of surface plasmon resonance to quantify antigen-specific antibodies and evaluate their apparent binding affinities, and 2) the recovery of serum IgGs using an automated small scale purification system, followed by the determination of their epitope diversity using hydrogen deuterium exchange coupled with mass spectrometry. To increase the efficiency of our therapeutic antibody generation process to achieve long term success, we developed alternative methods for assessing the quality of polyclonal antibodies in immune sera, surface plasmon resonance (SPR) 2 and hydrogen deuterium exchange (HDX) coupled with mass spectrometry. In this report, we describe the following: the method development and establishment of the detection limits of our techniques, a proof-of-concept study using sera from IL-13 immunized mice, the creation of a workflow named Quality of Antibody Response (QAR), and finally the implementation of this workflow for a therapeutic anti-B-cell activating factor (BAFF) antibody generation campaign to guide the selection of optimal animal donors for hybridoma generation. cache = ./cache/cord-002153-e0zhq18g.txt txt = ./txt/cord-002153-e0zhq18g.txt === reduce.pl bib === id = cord-016960-xhzvp35g author = Berencsi, György title = Fetal and Neonatal Illnesses Caused or Influenced by Maternal Transplacental IgG and/or Therapeutic Antibodies Applied During Pregnancy date = 2012-03-08 pages = extension = .txt mime = text/plain words = 17693 sentences = 1045 flesch = 42 summary = The importance of maternal anti-idiotypic antibodies are believed to prime the fetal immune system with epitopes of etiologic agents infected the mother during her whole life before pregnancy and delivery. Neonatal lupus is a model of passively acquired autoimmunity in which a mother-, who may have systemic lupus erythematosus (SLE) or Sj€ ogren's syndrome (SS) or may be entirely asymptomatic-synthesizes antibodies to SSA/Ro and/or SSB/ La ribonucleoproteins that enter the fetal circulation via trophoblast FcRn receptors and presumably cause tissue injury (Lee 1990 ) as mentioned above. Teplizumab (CD3-specific, hOKT3g1-Ala-Ala), a humanized Fc mutated anti-CD3 monoclonal antibody induced tolerance, on the progression of type 1 diabetes in patients with recent-onset disease even 2 years after the first diagnosis (Herold et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells cache = ./cache/cord-016960-xhzvp35g.txt txt = ./txt/cord-016960-xhzvp35g.txt === reduce.pl bib === id = cord-255683-2eq24jth author = Chen, Weizao title = Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins date = 2010-02-04 pages = extension = .txt mime = text/plain words = 5927 sentences = 290 flesch = 47 summary = Ig Ms (IgMs) are on average significantly less divergent from germline antibodies and are relevant for the development of vaccine immunogens but are underexplored compared to IgGs. Here we describe the identification and characterization of several human IgM-derived mAbs against HIV-1 which were selected from a large phage-displayed naive human antibody library constructed from blood, lymph nodes and spleens of 59 healthy donors. To find whether the activity of the antibodies is related to antibody size and how the viral infection could be affected by cross-linking of HIV-1 Envs, we generated a single-chain Fv fragment (scFv) (scFv m19) of m19 and a human IgG1 Fc-fusion protein (m19Fc) of scFv m19; m19 was selected for further characterization because its light chain was relatively less divergent from the germline ( Figure 1b) and was the only one which did not contain any somatic mutations in the CDR3 of the light chain. cache = ./cache/cord-255683-2eq24jth.txt txt = ./txt/cord-255683-2eq24jth.txt === reduce.pl bib === id = cord-002846-la9svzml author = Strohl, William R. title = Current progress in innovative engineered antibodies date = 2017-08-18 pages = extension = .txt mime = text/plain words = 13114 sentences = 605 flesch = 43 summary = The second most targeted protein is CD3E, found in 32 clinical stage or approved molecules, of which 26 are T cell-redirecting bispecific antibody candidates (Table 6) . For example, 10 of them bind two soluble antigens such as IL13 and IL4 (e.g., SAR156597; NCT02345070), nine bind two receptors on the , IgG-scFv fusion, Mabtyrin (IgG with non-antibody binding scaffold "centyrin" fused to C-terminal end of heavy chains); (C) IgGs to which additional antigen combining sites have been added within the structure (e.g., two-in-one antibodies, MAT "Modular Antibody Technology" platform from F-Star); (D) Engineered antibody fragments linked by short peptide linkers which can be made into bivalent, trivalent, or tetravalent formats addressing two to three targets (e.g., bispecific T-cell engager (BiTE), Nanobody platform, dual-affinity re-targeting (DART) antibodies, "tandem antibody" structures (TandAbs)); (E) Chemically coupled IgGs. Brennan et al., 1985; Garrido et al., 1990 Innovative antibodies Mack et al., 1995; Schlereth et al., 2005; Baeuerle et al., 2008 TandAb Antibody fragmentWilliam R. cache = ./cache/cord-002846-la9svzml.txt txt = ./txt/cord-002846-la9svzml.txt === reduce.pl bib === id = cord-021402-wq770ik9 author = Relford, Roberta L. title = New Diagnostic Tools for Infectious Disease date = 2009-05-15 pages = extension = .txt mime = text/plain words = 3166 sentences = 157 flesch = 36 summary = The most common laboratory methodologies used to identify an infectious agent include visualization of the organism via cytology/biopsy, isolation of the agent in microbiological culture, immunodiagnostics/serology, and nucleic acid technology. Fluorescent antibody and immunoblot assays are performed in commercial laboratories, whereas numerous patient-side rapid ELISA and latex agglutination kits are available for antigen detection. Until the introduction of nucleic acid amplification by the PCR, detection of an organism's DNA or RNA often was impossible because of the small amount of antigen present in a sample. In the ELISA and IFA antibody assays, a specific antigen from the infectious agent in question is fixed to a solid surface (microtiter plate or glass slide, respectively) and the patient's serum is added. The SVN assay evaluates the ability of antibodies in a patient's serum to prevent the infection of culture cells or embryonated eggs with a known specific virus. cache = ./cache/cord-021402-wq770ik9.txt txt = ./txt/cord-021402-wq770ik9.txt === reduce.pl bib === id = cord-102704-wfuzk2dp author = Meza, Diana K. title = Predicting the presence and titer of rabies virus neutralizing antibodies from low-volume serum samples in low-containment facilities date = 2020-04-30 pages = extension = .txt mime = text/plain words = 3183 sentences = 192 flesch = 43 summary = Despite small conflicts, titer predictions were correlated across tests repeated on different dates both for dog samples (r = 0.93), and for a second dataset of sera from wild common vampire bats (r = 0.72, N = 41), indicating repeatability. The pmRFFIT enables high-throughput detection of rabies virus neutralizing antibodies in low-biocontainment settings and is suited to studies in wild or captive animals where large serum volumes cannot be obtained. The binomial and log-normal models fit to 193 this data subset included only the fixed effect of the virus-infected N2A cell counts, but the random 194 effects were identical to those explained above (i.e. test date and field). A final distinction is that 316 instead of scoring microscope field or wells as virus positive or negative, the pmRFFIT predicts 317 serological status and RVNA titer from infected cell counts in a single serum dilution using statistical 318 cache = ./cache/cord-102704-wfuzk2dp.txt txt = ./txt/cord-102704-wfuzk2dp.txt === reduce.pl bib === id = cord-015742-nt44jcjm author = Garwes, D.J. title = Antigenicity of structural components from porcine transmissible gastroenteritis virus date = 2002-11-13 pages = extension = .txt mime = text/plain words = 3604 sentences = 177 flesch = 43 summary = Incubation of 3H-uridine TGEV with sera from sows inoculated with viral antigen resulted in the formation of immune complexes that were retained by membrane filters (Fig. 2) . Sera from sows inoculated with whole virus, SP antigen or SVP antigen preparations produced virus complexes that were retained most efficient Samples of 3H-uridine labelled TGEV containing 4000 ct/min were incubated for 2 h at 37°C in dilutions of test sera followed by incubation with rabbit anti-porcine IgG serum. Analysis of the immunoglobulin classes responsible for neutralising activity after inoculation of sows by the intramammary route showed that IgG was the predominant antibody species in both serum and colostrum, consistent with previous findings with inactivated TGEV Lucas et al., 1974) but differing from the stimulation of IgA to ferritin reported by Bourne et al. 9, which received SP antigen, produced neutralising antibody of the IgA class in the colostrum and was the only animal capable of protecting her piglets against challenge with live virus. cache = ./cache/cord-015742-nt44jcjm.txt txt = ./txt/cord-015742-nt44jcjm.txt === reduce.pl bib === id = cord-023731-jqgervt7 author = FENNER, FRANK title = Laboratory Diagnosis of Viral Diseases date = 2014-06-27 pages = extension = .txt mime = text/plain words = 6992 sentences = 320 flesch = 39 summary = Having allocated it to a particular family (e.g., Adenoviridae), one can then go on to determine the species or serotype (e.g., canine Immunodiffusion Antibody neutralizes infectivity of virion; inhibits cytopathology, reduces plaques, or protects animals Antibody inhibits viral hemagglutination Antigen-antibody complex binds complement, which is thereafter unavailable for the lysis of hemolysissensitized sheep red blood cells Antibody-aggregated virions are visible by electron microscopy Antibody labeled with fluorochrome binds to intracellular antigen; fluoresces by UV microscopy Peroxidase-labeled antibody binds to intracellular antigen; colored precipitate forms on adding substrate Enzyme-labeled antibody (or antigen) binds to antigen (or antibody); substrate changes color Radiolabeled antibody (or antigen) binds to antigen (or antibody), e.g., attached to solid phase Antibodies and soluble antigens produce visible lines of precipitate in a gel adenovirus 1) by more discriminating serological procedures. cache = ./cache/cord-023731-jqgervt7.txt txt = ./txt/cord-023731-jqgervt7.txt === reduce.pl bib === id = cord-010991-fp8hljbq author = Rather, Shabeer Ahmad title = Antibodies generated against dextransucrase exhibit potential anticariostatic properties in Streptococcus mutans date = 2020-01-03 pages = extension = .txt mime = text/plain words = 6593 sentences = 363 flesch = 48 summary = For vaccine development, attention was paid on the purified antigens involved in the pathogenesis of dental caries for the development of potentially safer vaccines, which may reduce the viability of bacteria in the saliva, impairing the surface adhesion and inhibiting the metabolically active enzymes involved in caries formation (Chen and Wang 2010) . mutans have shown encouraging results related to dental caries protection, but were limited by the cross-reactive epitopes against human heart and skeleton muscle tissues as detected by indirect immunofluorescence and crossed immunoelectrophoresis (Kt et al. In the present study, we have tried to evaluate the effect of anti-dextransucrase antibodies on caries formation by using purified dextransucrase as the antigen from S. Protein samples of the liver, heart, spleen, kidney of mice, rat and liver, kidney of rabbit were analysed by western blot analysis to evaluate the cross reactivity of purified antibody with mammalian tissues Fig. 5a . cache = ./cache/cord-010991-fp8hljbq.txt txt = ./txt/cord-010991-fp8hljbq.txt === reduce.pl bib === id = cord-009690-kbwz7xop author = Toubanaki, Dimitra K. title = Development of a Nanoparticle-based Lateral Flow Strip Biosensor for Visual Detection of Whole Nervous Necrosis Virus Particles date = 2020-04-16 pages = extension = .txt mime = text/plain words = 6767 sentences = 381 flesch = 47 summary = title: Development of a Nanoparticle-based Lateral Flow Strip Biosensor for Visual Detection of Whole Nervous Necrosis Virus Particles The principle of viral particles detection based on lateral flow biosensor with functionalized nanoparticles is presented in Fig. 1 . Nodavirus intact particles (virions), obtained either from SSN-1 cell culture supernatants or homogenized tissue samples, are directly applied on the LFB. The sample contains the nodavirus particles (virions) and is applied on the conjugation pad next to functionalized gold nanoparticles (Au) with polyclonal anti-nodavirus antibody. Application of that conjugate on the LFB resulted in a strong signal in the control zone, confirming the successful conjugation of anti-nodavirus antibody to Au nanoparticles (Fig. 2e) . To enable on site analysis of nodavirus, we developed and optimized a paper LFB based on gold nanoparticles for easy, specific and sensitive visual detection of nodavirus viral particles (virions) in biological samples. cache = ./cache/cord-009690-kbwz7xop.txt txt = ./txt/cord-009690-kbwz7xop.txt === reduce.pl bib === id = cord-260340-dujd28gg author = Chenoweth, Alicia M title = Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs date = 2020-04-12 pages = extension = .txt mime = text/plain words = 10121 sentences = 516 flesch = 40 summary = This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a "scaffolding" role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. Most therapeutic mAbs are IgG in origin and the heavy-chain subclass determines many of their biological properties including their long plasma half-life 3 ; complement activation, which is important in the action of some cytotoxic mAbs [4] [5] [6] and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FccR, the subject of this review. Therapy with an IgG1 anti-cancer cell mAb may then be compromised by the inhibitory action of FccRIIb upon the ITAM signaling of the activating FccR as both types of receptor would be coengaged on such an effector cell by the mAb bound to the target cell. cache = ./cache/cord-260340-dujd28gg.txt txt = ./txt/cord-260340-dujd28gg.txt === reduce.pl bib === id = cord-010680-lc1onm53 author = Patel, Ami title = In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies date = 2020-03-10 pages = extension = .txt mime = text/plain words = 13044 sentences = 659 flesch = 41 summary = Some of these hurdles may be overcome through transient in vivo gene delivery platforms, such as non-viral synthetic plasmid DNA and messenger RNA vectors that are engineered to encode optimized mAb genes. In this review, we focus on nucleic acid delivery of antibody employing synthetic plasmid DNA vector platforms, and RNA delivery, these being important approaches that are advancing simple, rapid, in vivo expression and having an impact in animal models of infectious diseases and cancer, among others. The original studies surrounding in vivo antibody gene delivery focused primarily on gene delivery using recombinant viral vectors such as AAV and adenovirus (Ad), which were advanced clinically, building on work in the traditional gene therapy-based field. Additional studies to help evaluate fully human pDNA-mAbs in mouse models would be highly informative for both non-viral and viral delivery and provide an important path forward for preclinical evaluation of in vivo-delivered antibodies [109] . cache = ./cache/cord-010680-lc1onm53.txt txt = ./txt/cord-010680-lc1onm53.txt === reduce.pl bib === id = cord-004167-r2s0gks8 author = Cutts, Julia C. title = Pregnancy-specific malarial immunity and risk of malaria in pregnancy and adverse birth outcomes: a systematic review date = 2020-01-16 pages = extension = .txt mime = text/plain words = 8593 sentences = 422 flesch = 38 summary = Antibody responses to pregnancy-specific pRBC and VAR2CSA antigens, measured at delivery, were associated with placental malaria (9 studies) and may therefore represent markers of infection, rather than correlates of protection. To summarize, evidence from studies included in narrative terms suggests that whilst high avidity Abs and anti-adhesion Abs measured at delivery may be associated with protection from placental infection [65] and reduced placental parasitaemia [38] , respectively, total IgG responses to VAR2CSA antigens and pregnancy-specific pRBC are positively associated with the presence of placental malaria [34, 39, 64, [68] [69] [70] [71] [72] 76] . Overall, the majority of estimates included in this review, and studies included in narrative terms, indicate that when measured at delivery, antibody responses to pregnancy-specific pRBC and VAR2CSA antigens are associated with the presence of placental infection and may therefore represent markers of infection, rather than correlates of protection. cache = ./cache/cord-004167-r2s0gks8.txt txt = ./txt/cord-004167-r2s0gks8.txt === reduce.pl bib === id = cord-001566-kkaxha7d author = Zhang, Mao-Yu title = Development of Monoclonal Antibodies in China: Overview and Prospects date = 2015-02-25 pages = extension = .txt mime = text/plain words = 3524 sentences = 196 flesch = 44 summary = This paper aims to provide a comprehensive review of mAbs development in China through systematic analysis of drug registry, patent applications, clinical trials, academic publication, and ongoing R&D projects. Over the past three decades, monoclonal antibodies (mAbs) have achieved a dramatic development from scientific tools to powerful human therapeutic agents [1] (see Figure 1 ). Development of this class of therapeutic agents started as early as 1980s but achieved no clinical or commercial success until 2002 when adalimumab became the first human mAb approved by the US Food and Drug Administration (FDA) [14] . R&D of mAbs in China began in the 1980s [16] and the first mAb therapeutic agent (Murine Monoclonal Antibody against Human CD3 Antigen of T Lymphocyte for Injection) was introduced in 1999 [17] . This paper aims to provide a comprehensive review of mAb development in China through systematic analysis of product registry, patent application, clinical trials, academic publication, and ongoing R&D projects. cache = ./cache/cord-001566-kkaxha7d.txt txt = ./txt/cord-001566-kkaxha7d.txt === reduce.pl bib === id = cord-103255-4k13re9y author = Daniell, Henry title = Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants date = 2001-05-01 pages = extension = .txt mime = text/plain words = 4362 sentences = 205 flesch = 42 summary = The production of recombinant proteins in plants has many potential advantages for generating biopharmaceuticals relevant to clinical medicine. In the decade since the expression and assembly of immunoglobulin (Ig) heavy and light chains into functional antibodies was first shown in transgenic tobacco, plants have proven to be versatile production systems for many forms of antibodies. Other advantages of tobacco include its relative ease of genetic manipulation, production of large numbers of seeds (up to a million per plant) and an impending need to explore alternate uses for this hazardous crop. However, the most attractive species for expressing subunit vaccine components should have high levels of soluble protein that is stable during storage; seed crops such as cereals are particularly suitable. Induction of a protective antibody response to foot and mouth disease in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1 cache = ./cache/cord-103255-4k13re9y.txt txt = ./txt/cord-103255-4k13re9y.txt === reduce.pl bib === id = cord-261274-y74smbtd author = Crouch, C. F title = Lactogenic immunity following vaccination of cattle with bovine coronavirus date = 2000-09-15 pages = extension = .txt mime = text/plain words = 4173 sentences = 177 flesch = 53 summary = Abstract In order to investigate the ability of an oil adjuvanted vaccine containing bovine coronavirus antigen to enhance lactogenic immunity in the calf, pregnant cows and heifers were vaccinated and specific virus neutralising antibody levels determined in serum, colostrum and milk. Pre-existing antibody titres (as a result of natural infection) in the serum of these animals were found to be significantly increased as a result of a single shot vaccination carried out between 2 and 12 weeks before calving. This hypothesis was supported by the observations on the magnitude of the antibody titres found in the colostrum and milk of cows vaccinated at dierent times pre-calving with a vaccine containing 150 antigen units of BCoV. This report indicates that a single dose of coronavirus vaccine administered to the pregnant heifer 2 to 12 weeks before calving is capable of signi®cantly increasing the titre and duration of speci®c antibody present in colostrum and milk. cache = ./cache/cord-261274-y74smbtd.txt txt = ./txt/cord-261274-y74smbtd.txt === reduce.pl bib === id = cord-267744-asjvf123 author = Lee, Yu-Ching title = Chicken single-chain variable fragments against the SARS-CoV spike protein date = 2007-07-23 pages = extension = .txt mime = text/plain words = 4057 sentences = 212 flesch = 52 summary = Following the immunization of chickens with these recombinant spike proteins, two single-chain variable fragment (scFv) antibody libraries were established with short or long linkers to contain 5 × 10(7) and 9 × 10(6) transformants, respectively. In a comparison of nucleotide sequences with the chicken germline gene, we found that all clones varied in the complementarity-determining regions, that two scFv antibodies reacted significantly with SARS-CoV-infected Vero cells, and that those two specific scFv antibodies recognized the same region of the spike protein spanning amino acid residues 750–1000. The current study aimed to show that monoclonal IgY scFv antibodies which bind specifically to the S protein and SARS-CoV-infected Vero cells can be isolated from chickens immunized with Escherichia coli-derived S proteins. Cellular lysates containing single-chain variable fragment (scFv) antibodies from various Ssc (A) and Lsc (B) library clones were examined for their binding to SARS-CoV-infected cell lysates using a commercially available kit. cache = ./cache/cord-267744-asjvf123.txt txt = ./txt/cord-267744-asjvf123.txt === reduce.pl bib === id = cord-254531-pv55re2x author = Mestecky, Jiri title = Specific antibody activity, glycan heterogeneity and polyreactivity contribute to the protective activity of S-IgA at mucosal surfaces date = 2009-06-04 pages = extension = .txt mime = text/plain words = 4108 sentences = 237 flesch = 36 summary = In addition to mechanical barriers and a variety of innate defense factors, mucosal immunoglobulins (Igs) provide protection by two complementary mechanisms: specific antibody activity and innate, Ig glycan-mediated binding, both of which serve to contain the mucosal microbiota in its physiological niche. Bacteria Table 1 Examples of glycans as adhesion sites and receptors for selected bacteria and viruses that colonize, or infect, mucosal surfaces (adapted from [1, 26, 29, [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] 132] endogenous to the intestinal tract, oral cavity, and probably also the respiratory and genital tracts, are coated in vivo with S-IgA [9, 13, 17, [31] [32] [33] [34] [35] [36] [37] [38] [39] that limits their epithelial adherence and penetration, thereby confining them to the mucosal surfaces. Parallel structural and functional exploration of the principles of adaptive (specific antibody) and innate (glycan) S-IgA-mediated immunity is likely to generate novel approaches to the design of broadly protective compounds that work by selectively interfering with the adherence and penetration of pathogens, or that contain the commensal microbiota residing at mucosal surfaces. cache = ./cache/cord-254531-pv55re2x.txt txt = ./txt/cord-254531-pv55re2x.txt === reduce.pl bib === id = cord-283641-2u16otbf author = Vainionpää, R. title = Diagnostic Techniques: Serological and Molecular Approaches date = 2015-03-06 pages = extension = .txt mime = text/plain words = 4400 sentences = 222 flesch = 40 summary = For diagnostic purposes the following approaches can be used: demonstration of presence of infectious virus or its structural components directly from a patient's specimens or investigation of specific antibody response in serum specimens. Glossary EIA Enzyme immunoassays are methods used to estimate virus-specific IgG and IgM antibodies or virus antigens by enzyme-labeled conjugates. Nucleic acid testing has become the main approach for the demonstration of the presence of virus while cultivation is used by fewer specialized laboratories and antigen detection methods have moved to the point of care. Diagnostic applications of the measurement of the avidity of IgG antibodies against specific antigens have been developed to help distinguish serological responses due to acute infections from those of chronic or past infections. In immunofluorescence tests, cells from a clinical specimen are fixed on a glass slide and viral antigens present in the cells are detected by fluorescein-labeled virus-specific antibodies. cache = ./cache/cord-283641-2u16otbf.txt txt = ./txt/cord-283641-2u16otbf.txt === reduce.pl bib === id = cord-004247-lagv3tp7 author = Hooft van Huijsduijnen, Rob title = Reassessing therapeutic antibodies for neglected and tropical diseases date = 2020-01-30 pages = extension = .txt mime = text/plain words = 6756 sentences = 314 flesch = 42 summary = This mAb was protective in an in vitro, antigen-dependent, cellular cytotoxicity assay with rat macrophages or eosinophils and also in vivo during the early phase of infection Second, beyond the cell-surface proteins, schistosomes also express a large number of glycans as part of their glycoprotein and glycolipid repertoire, and an antibody response against those glycans is mounted by the infected host [80] . In addition to antibodies that directly target and inhibit the fungal pathogen, mAbs can be directed to checkpoints that control the host immune response. In addition to highlighting the potential of mAbs as therapeutics, these studies have demonstrated the diversity of inhibitory actions that mAbs can perform on cryptococcal cells, which can include opsonization and increased phagocytosis, inhibition of fungal growth, capsular polysaccharide release and biofilm formation, antibody-mediated target cleavage, and augmentation of the host response [104] [105] [106] [107] . cache = ./cache/cord-004247-lagv3tp7.txt txt = ./txt/cord-004247-lagv3tp7.txt === reduce.pl bib === id = cord-005827-wjkbrfkn author = Schmidt, Rüdiger title = Antiphospholipidantikörpersyndrom date = 1999 pages = extension = .txt mime = text/plain words = 3372 sentences = 429 flesch = 28 summary = Other clinical manifestations associated with APA include migraine, chorea, hemolytic anemia, heart valve disease, Budd-Chiari syndrome, perpetual pancreatitic episodes, intestinal infarctions, malignant hypertension, livedo reticularis, pre-eclampsia, fetal growth retardation or catastrophic antiphospholipid syndrome. 1Kfidiger Schmidt I , Ernst-Heinrich Scheuermann ~ , Achim Viertel 1, Helmut Geiger 1 , lnge Scharrer 2 Budd-Chiari-Syndrom, rezidivierende Pankreaufiden, intestinale Apoplexie, maligne Hypertonie;Livedo reticularis, Pr~ieklampsie, fetate WachstumsverzSgenmgen oder das sogenannte,,katastrophale Antiphospholipidantik6rpersy ndrom,_ Ira Gegensatzzum ,prim~en Antiphospholipidantik6rpersyndrom'" rinden sich Lupusantikoagulanziea und An¡250 beim ,,se-kund~iren Antiphospholipidantik/Srpersyndrom" im t(ahmen ron Autoimmun-erkrankutlget1, von.Neoplasfen und Infektionen oder sind mit dem Gebrauch bestimmter Medikamente assoziiert. Other clinical manifestations associated with APA include migraine, ch0rea, hemolytic anemia, heart Valve disease, Budd-Chiari syndrome, perpemal pancreatitic episodes, intestinal infarcfions, malignant hypertension, livedo reticularis, pre-eclampsia, fetal growth retardation or catastrophic anfiphos[10] ; dieses zeigt zudem eine fa-mili~ire H~iufung [48] sowie eine Assoziation mit HLA DR.7, DR4, DQw7 und DR.w53 [75] . el al Antiphospholipid antibodies and the anti-phospholipid syndrome in systemic lupus erythematosus cache = ./cache/cord-005827-wjkbrfkn.txt txt = ./txt/cord-005827-wjkbrfkn.txt === reduce.pl bib === id = cord-001060-9g8rwsm1 author = Arruebo, Manuel title = Assessment of the Evolution of Cancer Treatment Therapies date = 2011-08-12 pages = extension = .txt mime = text/plain words = 10511 sentences = 488 flesch = 34 summary = These therapies can be used in isolation or in combination with other cancer treatments, thereby taking advantage of their ability to target tumors (actively or passively), to respond to physical or chemical stimulation (internal or external) and to deliver therapeutic genes to the cell nuclei. Compared to conventional therapies, nanoparticles show six clear advantages in cancer treatment and/or diagnosis: (1) they can be synthesized in specific sizes and with surface characteristics to penetrate tumors by taking advantage of the enhanced permeation and retention effect (EPR) (a mechanism known as passive targeting); (2) they can be engineered to target tumor cells by surface functionalization with biomolecules that attach to tumor-specific cell markers (a mechanism known as active targeting); (3) they can be engineered to penetrate cells and physiological barriers (e.g., blood-brain barrier, blood-retinal barrier); (4) they can increase the plasma half-life of carried chemotherapeutic drugs, which are usually highly hydrophobic; (5) they can protect a therapeutic payload from biological degradation; and (6) they can be synthesized as multifunctional platforms for combined imaging and therapeutic applications (theragnostic nanoparticles). cache = ./cache/cord-001060-9g8rwsm1.txt txt = ./txt/cord-001060-9g8rwsm1.txt === reduce.pl bib === id = cord-256652-ent4vu3z author = Tan, Joshua title = A public antibody lineage that potently inhibits malaria infection by dual binding to the circumsporozoite protein date = 2018-03-19 pages = extension = .txt mime = text/plain words = 6576 sentences = 329 flesch = 46 summary = investigate this response at high resolution, we isolated IgM and IgG monoclonal antibodies from Tanzanian volunteers who were immunized by repeated injection of irradiated PfSPZ and who were found to be protected from controlled human malaria infection (CHMI) with infectious homologous PfSPZ. investigate this response at high resolution, we isolated IgM and IgG monoclonal antibodies from Tanzanian volunteers who were immunized by repeated injection of irradiated PfSPZ and who were found to be protected from controlled human malaria infection (CHMI) with infectious homologous PfSPZ. These findings, combined with data from peptide array experiments ( Supplementary Fig. 7) , identify the N-terminal junction binding site of the most potent neutralizing antibodies as including the first unit of the NANP repeat region and flanking non-repeat sequences, providing a molecular basis for the dual specificity of these antibodies. cache = ./cache/cord-256652-ent4vu3z.txt txt = ./txt/cord-256652-ent4vu3z.txt === reduce.pl bib === id = cord-296576-d23b9fjl author = Bernard, Serge title = Lactogenic Immunity to Transmissible Gastroenteritis (TGE) of swine induced by the attenuated nouzilly strain of TGE virus: Passive protection of piglets and detection of serum and milk antibody classes by ELISA date = 1990-01-31 pages = extension = .txt mime = text/plain words = 3028 sentences = 169 flesch = 55 summary = title: Lactogenic Immunity to Transmissible Gastroenteritis (TGE) of swine induced by the attenuated nouzilly strain of TGE virus: Passive protection of piglets and detection of serum and milk antibody classes by ELISA After natural infection or experimental oral infection of pregnant sows with a virulent strain of TGE virus, lactogenic immunity is highly protective for piglets, and neutralizing antibodies in milk are mainly associated with the IgA fraction (Bohl, 1981) . TABLE 3 Relationship between passive protection rate and titre of specific anti-TGE antibody classes ( IgG, IgA, IgM) in serum and milk, on the day and 10 days after challenge The most interesting result of the preliminary report about the immune response of sows vaccinated with N strain of TGE (Shira'i et al., 1988) was the absence of correlation between the passive protection rate of the litter and the neutralizing antibody titre in serum or milk of sows on the day of challenge. cache = ./cache/cord-296576-d23b9fjl.txt txt = ./txt/cord-296576-d23b9fjl.txt === reduce.pl bib === id = cord-010248-ln800g5z author = Sissons, J.G. Patrick title = Antibody-Mediated Destruction of Virus-Infected Cells date = 2008-02-29 pages = extension = .txt mime = text/plain words = 14994 sentences = 687 flesch = 44 summary = When lz5I-1abeled IgG antibody was bound to the surface of measles virus-infected cells at the start of the culture period, under the conditions described above for antigenic modulation, about 40% of the radioactivity was still cell associated at 12 hours and nearly all was protein bound Perrin and Oldstone, 1977) . Lysis by human serum of cells infected with HSV types 1 and 2, influenza A, parainfluenza 1, 2, 3, and 4, mumps, and measles viruses was dependent on the presence in serum of IgG antibody specific for the relevant virus and of complement (reviewed by Oldstone and Lampert, 1979) . The use of this system, composed of 11 highly purified complement proteins, provided conclusive evidence that the known proteins of the alternative and membrane attack pathways with IgG antibody are sufficient for lysis of the measles virus-infected cell, without other serum factors. It is apparent that considerably more surface-bound IgG is required to induce complement-dependent lysis of virus-infected cells than is required for antigenic modulation or antibody-dependent cell-mediated cytotoxicity. cache = ./cache/cord-010248-ln800g5z.txt txt = ./txt/cord-010248-ln800g5z.txt === reduce.pl bib === id = cord-002710-e8im13go author = Taschuk, Ryan title = Induction of PrP(Sc)-specific systemic and mucosal immune responses in white-tailed deer with an oral vaccine for chronic wasting disease date = 2017-10-02 pages = extension = .txt mime = text/plain words = 5421 sentences = 299 flesch = 41 summary = title: Induction of PrP(Sc)-specific systemic and mucosal immune responses in white-tailed deer with an oral vaccine for chronic wasting disease Oral immunization of white-tailed deer with hAd5:tgG-RL induced PrP(Sc)-specific systemic and mucosal antibody responses with an encouraging safety profile in terms of no adverse health effects nor prolonged vector shedding. To assess the immunogenicity of hAd5:tgG-RL white-tail deer (n D 5/group) were orally immunized and epitope-specific antibody titers in serum and feces were quantified with a peptide ELISA. These results confirm that oral delivery of a recombinant viral vector, expressing an appropriate DSE and carrier molecule, is capable of inducing both systemic and mucosal antibody responses in white-tailed deer. To determine if the antibodies induced by oral immunization retained the same PrP Sc specificity as previously characterized for the parenteral vaccine, serum from hAd5:tgG-RL vaccinated animals was assayed for PrP C reactivity by ELISA, using recombinant cervid PrP 90-231 for antibody capture. cache = ./cache/cord-002710-e8im13go.txt txt = ./txt/cord-002710-e8im13go.txt === reduce.pl bib === id = cord-305893-2vcy0f6i author = Bagheri, Vahid title = Neutralizing human recombinant antibodies against herpes simplex virus type 1 glycoproteins B from a phage-displayed scFv antibody library date = 2017-01-15 pages = extension = .txt mime = text/plain words = 3576 sentences = 203 flesch = 52 summary = title: Neutralizing human recombinant antibodies against herpes simplex virus type 1 glycoproteins B from a phage-displayed scFv antibody library Our present study focused on the selection of neutralizing single-chain Fv (scFv) antibodies of a phage-displayed nonimmune human scFv antibody library against gB of HSV-1. described a neutralizing scFv-phage antibody against glycoprotein D of HSV-1 with neutralizing effect of 76%, which was capable of neutralizing HSV-1 and inhibiting virus entry to host cell [21] . Here, we selected two neutralizing anti-gB scFv antibodies to inhibit cytopathic effects in Vero cells infected with HSV-1. Neutralizing human single-chain antibodies against herpes simplex virus type 1 glycoprotein D from a phage display library Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries cache = ./cache/cord-305893-2vcy0f6i.txt txt = ./txt/cord-305893-2vcy0f6i.txt === reduce.pl bib === id = cord-015683-a9a82of4 author = Gupta, Varsha title = Molecular Diagnostics date = 2016-10-23 pages = extension = .txt mime = text/plain words = 4774 sentences = 294 flesch = 52 summary = Molecular diagnostics such as Western blot , ELISA , PCR , DNA, and protein microarrays are 7 revolutionizing the clinical practice of infectious diseases. Molecular diagnostics such as Western blot , ELISA , PCR , DNA, and protein microarrays are 7 revolutionizing the clinical practice of infectious diseases. Binding of another antigen-specifi c antibody linked with enzyme results in color formation upon addition of the substrate 9.2 Diagnosis of Bacterial, Viral, and Parasitic Diseases peptide may react in some assays but not in others as some regions of a peptide may be more immunogenic than others. Because of the specifi city, homogeneity, and unlimited availability of the MAbs, vast amount of work has been carried out on the production/development The immuno-diagnoses of protozoan and parasitic diseases have signifi cantly been improved by MAb technology because the tests involving MAb as diagnostic reagents overcome the limitations of polyclonal antibodies. The sensitivity and specifi city of a PCR assay is dependent on target genes, primer sequences, PCR techniques, DNA extraction procedures, and PCR product detection methods. cache = ./cache/cord-015683-a9a82of4.txt txt = ./txt/cord-015683-a9a82of4.txt === reduce.pl bib === id = cord-282081-qaagup4d author = Flicker, Sabine title = Nanobodies—Useful Tools for Allergy Treatment? date = 2020-09-30 pages = extension = .txt mime = text/plain words = 5062 sentences = 247 flesch = 30 summary = Their superior properties such as chemical stability, high affinity to a broad spectrum of epitopes, low immunogenicity, ease of their generation, selection and production proved nanobodies also to be remarkable to investigate their efficacy for passive treatment of type I allergy, an exaggerated immune reaction to foreign antigens with increasing global prevalence. Similar to the evaluation of conventional antibodies with the focus to identify effective protective monoclones, generated nanobodies have to be assessed first for their allergen specificity, epitope recognition, cross-reactivity to homologous allergens present in related species, for their affinity to their corresponding allergens and most importantly for their ability to inhibit patients'IgE binding to these allergens (Figures 2A-C) . cache = ./cache/cord-282081-qaagup4d.txt txt = ./txt/cord-282081-qaagup4d.txt === reduce.pl bib === id = cord-255936-hfa9w2dg author = Jin, Junyeong title = The level of decoy epitope in PCV2 vaccine affects the neutralizing activity of sera in the immunized animals date = 2018-02-12 pages = extension = .txt mime = text/plain words = 3479 sentences = 208 flesch = 47 summary = In this study, we tested this hypothesis by generating an antibody specific to the decoy epitope on the capsid protein of porcine circovirus type 2 (PCV2). To monitor the reactivity of sera to the CP 169e180 epitope, enzyme immunoassays, using BSA-conjugated CP 169e180 peptides and HRPconjugated anti-guinea pig IgG antibodies (Bethyl Laboratories), were performed as described previously. In a competition enzyme immunoassay employing a microtiter plate coated with BSA-conjugated CP 169e180 peptide and HRP-conjugated anti-porcine IgG antibody, the recombinant anti-CP 169e180 antibody almost completely inhibited the binding of naturally occurring anti-CP 169e180 antibody to the peptide in a PCV2-infected pig's sera (Fig. 2) . In an enzyme immunoassay employing a microtiter plate coated with BSA-conjugated CP 169e180 peptide, sera from animals immunized with vaccine A had a significantly higher antibody titer than vaccine B-vaccinated animals (p < 0.01) (Fig. 3D) . cache = ./cache/cord-255936-hfa9w2dg.txt txt = ./txt/cord-255936-hfa9w2dg.txt === reduce.pl bib === id = cord-290783-ipoelk4h author = Crouch, C. F. title = Vaccination against enteric rota and coronaviruses in cattle and pigs: Enhancement of lactogenic immunity date = 1985-09-30 pages = extension = .txt mime = text/plain words = 4545 sentences = 254 flesch = 39 summary = This article examines methods currently used to enhance the titre and duration of specific antibody in the mammary secretions of cows and pigs with particular reference to rotavirus and coronavirus infections. The situation in neonatal piglets is less clear, rotavirus infections are apparently common 6.t4-tt, w.hilst transmissible gastroenteritis virus (TGEV), the prototype enteric coronavirus in swine, is an example of a seasonal cold-weather disease, probably related to both the thermal sensitivity of the virus ~ and the effect of cold-stress on converting subclinical to clinical infections ~8. It is apparent that the enhancement of lactogenic immunity through the vaccination of the dam provides a suitable mechanism by which neonatal pigs and calves can be protected against rotavirus and coronavirus infections. Passive immunity in calf rotavirus infections: Maternal vaccination increases and prolongs immunoglobulin G 1 antibody secretion in milk Antibody responses in serum, colostrum and milk of swine after infection or vaccination with transmissible gastroenteritis virus cache = ./cache/cord-290783-ipoelk4h.txt txt = ./txt/cord-290783-ipoelk4h.txt === reduce.pl bib === id = cord-031060-0o9agjiq author = Yuan, Tom Z title = Rapid exploration of the epitope coverage produced by an Ebola survivor to guide the discovery of therapeutic antibody cocktails date = 2020-08-01 pages = extension = .txt mime = text/plain words = 3913 sentences = 159 flesch = 36 summary = Incorporating epitope binning on hundreds of antibodies during early stage antibody characterization ensures access to a library's full epitope coverage, aids in the identification of high quality reagents within the library that recapitulate this diversity for use in other studies, and ultimately enables the rational development of therapeutic cocktails that take advantage of multiple mechanisms of action such as cooperative synergistic effects to enhance neutralization function and minimize the risk of mutagenic escape. Despite ligand attrition and the stringent requirement for premixed antibodies to achieve antigen saturation, which reduced our heat map to 52 analytes x 233 ligands, we were able in this non-optimized 'first pass' binning to assign 234 antibodies to one of seven epitope communities without the use of benchmark antibodies (Supplemental Table S1 ). cache = ./cache/cord-031060-0o9agjiq.txt txt = ./txt/cord-031060-0o9agjiq.txt === reduce.pl bib === id = cord-021770-zn7na974 author = Slifka, Mark K. title = Passive Immunization date = 2017-07-17 pages = extension = .txt mime = text/plain words = 12134 sentences = 610 flesch = 31 summary = [26] [27] [28] [29] Recent studies verify these earlier results, demonstrating a 90% to 91% vaccine efficacy against whooping cough among infants younger than 2 months of nonlymphoid tissues and to penetrate mucosal sites of infection is likely to explain why it is often considered the best immunoglobulin isotype for routine passive immunization and has shown clinical benefit ranging from reduced clinical symptoms to nearly complete protection from lethal infection in a number of infectious disease models (Table 8 .3). 118 With the recent development of polyclonal and monoclonal antibodies that show protective efficacy against tularemia in animal models, [119] [120] [121] it may be possible to incorporate both passive immunotherapy and antibiotic treatment into clinical practice not only for tularemia, but for other bacterial diseases, especially in cases in which antibiotic resistance is becoming more widespread. cache = ./cache/cord-021770-zn7na974.txt txt = ./txt/cord-021770-zn7na974.txt === reduce.pl bib === id = cord-295033-5fd9bu60 author = Parma, Y.R. title = Antibodies anti-Shiga toxin 2 B subunit from chicken egg yolk: Isolation, purification and neutralization efficacy date = 2011-09-15 pages = extension = .txt mime = text/plain words = 6045 sentences = 326 flesch = 53 summary = The data suggest that immunization of hens with Stx2B could be a strategy to obtain at low cost a relatively high concentration of anti-Stx2 egg yolk IgY, able to neutralize Stx2 lethal activity. The data suggest that immunization of hens with Stx2B could be a strategy to obtain at low cost a relatively high concentration of anti-Stx2 egg yolk IgY, able to neutralize Stx2 lethal activity. Specific anti-Stx2B polyclonal antibodies obtained from chicken egg yolk and rabbit sera recognized not only the denatured and native form of B subunit, used for immunization but the antibodies were also able to recognize the denatured and native wild type Stx2 holotoxin in western blot (Fig. 3) , indirect ELISA (Fig. 4) and sandwich ELISA (Fig. 5) . In the present report, specific egg yolk IgY antibodies with binding and neutralizing capabilities against the wild type Stx2 toxin were obtained after immunization of laying hens. cache = ./cache/cord-295033-5fd9bu60.txt txt = ./txt/cord-295033-5fd9bu60.txt === reduce.pl bib === id = cord-257465-9yrf7ofy author = Finlay, William J. J. title = Phage Display: A Powerful Technology for the Generation of High-Specificity Affinity Reagents from Alternative Immune Sources date = 2016-05-23 pages = extension = .txt mime = text/plain words = 6071 sentences = 241 flesch = 37 summary = These libraries are analogous to the naïve antibody repertoire in an animal, and selecting from them can result in the identifi cation of antibody fragments that exhibit high specifi city and occasionally high affi nity for the target protein. This process utilizes phage display for selection from germline targeting combinatorial libraries which results in the identifi cation of CDR residues amenable to human germ-lining without compromising on specifi city and affi nity. Nevertheless, phage display can be a relatively simple technology to use and when employed to harness natural repertoires of antibodies from immunized animals, it can offer a rapid path to highly specifi c, high-affi nity antibodies against problematic antigens . The immunized chickens appear to react to the proteins fully independently, as the phage display libraries generate individual scFv antibody clones that are fully specifi c by western blot and ELISA , showing no reactivity to their co-immunogens [ 37 , 59 ] . cache = ./cache/cord-257465-9yrf7ofy.txt txt = ./txt/cord-257465-9yrf7ofy.txt === reduce.pl bib === id = cord-009571-mygj2nd4 author = nan title = Proceedings of the 42nd annual meeting of the american rheumatism association a section of the arthritis foundation june 1 & 2, 1978 new york city abstracts of papers presented date = 2005-11-23 pages = extension = .txt mime = text/plain words = 46150 sentences = 2284 flesch = 49 summary = Levels of Ty cells as well as total T lymphocytes were measured in 19 patients with systemic lupus erythematosus (SLE), 11 with active and 8 with inactive disease, and in 47 normal subjects. The diagnosis of GC arthritis were studied for the presence of GC antigen (AG) and anti-in all seven patients was made by typical clinical presentation, body (AB) in serum and synovial fluid by counter-positive local culture for Ngonorrhoeae (NG) , and response to treatment. A retrospective study was instituted on 10 patients in the UCLA lupus nephritis clinic in an attempt to determine the ability of three serologic indicators-specifically immune complexes (IC), anti-DNA antibodies (DNA-ab), and C3-to predict the activity of SLE renal disease as indicated by changes in 24 hour proteinuria, serum creatinine, and creatinine clearance. cache = ./cache/cord-009571-mygj2nd4.txt txt = ./txt/cord-009571-mygj2nd4.txt === reduce.pl bib === id = cord-010570-ytv7dwr0 author = Casadevall, Arturo title = Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases date = 1995-07-17 pages = extension = .txt mime = text/plain words = 7469 sentences = 454 flesch = 31 summary = In the preantibiotic era, passive antibody administration (serum therapy) was useful for the treatment of many infectious diseases. We briefly review the use of antibody-based therapy in the early 20th century and make the case for reintroducing passive antibody administration for the treatment ofinfectious diseases. Given the diminishing efficacy of existing antimicrobials because of widespread resistance and the difficulties of treating infections in immunosuppressed individuals, the reintroduction of antibody-based therapies is an option that should be given serious consideration. Thus, antibody therapy is still widely used in medicine, but its role in the treatment of infections is limited largely to viral and toxin neutralization and replacement therapy in patients with immunoglobulin deficiencies. In the past, serum therapy was effective against various pathogens despite the fact that immune sera contained only small amounts of specific antibody. Antibody-based therapies have traditionally been most effective in infections where viral and toxin neutralization modifies the course of the disease. cache = ./cache/cord-010570-ytv7dwr0.txt txt = ./txt/cord-010570-ytv7dwr0.txt === reduce.pl bib === id = cord-277894-0qw0t78s author = NAYLOR, MJ title = Canine coronavirus in Australian dogs date = 2008-03-10 pages = extension = .txt mime = text/plain words = 3142 sentences = 170 flesch = 55 summary = Objective To estimate the frequency of serum antibodies (IgG and IgM) to canine coronavirus (CCV) in the Australian dog population and evaluate the role of CCV as a causative agent of gastroenteritis. Of those dogs that were presented with clinical signs of gastroenteritis such as diarrhoea and vomiting(n = 29), 85% were positive in the IgM ELISA and 85.7% in the IgG ELISA for antibodies to CCV. In this study we determine the prevalence of serum IgG and IgM antibodies to CCV from a larger number of dogs sampled from throughout Australia. 7, 8 In the open population of 1107 dogs tested we found 15.8% positive for anti-CCV IgG antibody, which reflects past exposure and infection with CCV whereas the electron microscopic studies detected only those dogs currently infected and shedding virus in their faeces. cache = ./cache/cord-277894-0qw0t78s.txt txt = ./txt/cord-277894-0qw0t78s.txt === reduce.pl bib === id = cord-010088-s9tfvtao author = nan title = Oral Abstracts date = 2013-11-01 pages = extension = .txt mime = text/plain words = 43522 sentences = 2257 flesch = 49 summary = These include 'incorrect blood component transfused' events, where the blood component was intended for another recipient (frequently due to errors in patient identification at the time of collection of the pre-transfusion sample, or at the time of bedside administration), or did not meet the patient's special needs (such as a patient with a red cell antibody who did not receive the required antigen-negative unit). Methods: Eligibility criteria for inclusion in the study included the following: transfusion of Rh D positive platelets, no anti D detectable before transfusion, no previous exposure to Rh D positive blood components, and results of follow-up testing of anti-D in patients serum available. In addition, the allelic frequency of Hpdel was calculated to be 0.015 by a genetic study of a limited number of the Japanese individuals, suggesting that Hp deficiency might distribute among the Japanese population as a phenotype of serum Hp. Aims: In this report, we present the results obtained from a hemovigilance survey carried out between 1998 and 2012, in which Hp deficiency was identified among Japanese patients who had experienced nonhemolytic TRs (NHTRs), and those obtained from a screening of Hp-deficient Japanese healthy blood donors. cache = ./cache/cord-010088-s9tfvtao.txt txt = ./txt/cord-010088-s9tfvtao.txt === reduce.pl bib === id = cord-300701-vkzya7uq author = Ijaz, M. K. title = Effect of different routes of immunization with bovine rotavirus on lactogenic antibody response in mice date = 1987-12-31 pages = extension = .txt mime = text/plain words = 4321 sentences = 235 flesch = 50 summary = Summary The effect of different routes of immunization with either live or killed bovine rotavirus (BRV) on the production of lactogenic antibody response in mice was evaluated. Taking this into consideration, we have utilized the murine model to study the influence of different routes of immunization with either live or killed BRV on the rate of decline of antibody titers and different subtypes in the lacteal secretions of the da-m following parturition up to eleven days. Titers of anti-rotavirus antibodies in lacteal secretions, as determined by ELISA, also revealed a similar pattern as seen in the groups immunized with killed BRV. Although administration of live or killed BRV at mucosal sites (intestine and mammary regions) not only induced a significant elevation of IgA, IgM and IgG antibodies in lacteal secretions there was also a marked increase in serum anti-rotavirus antibodies as determined by ELISA. cache = ./cache/cord-300701-vkzya7uq.txt txt = ./txt/cord-300701-vkzya7uq.txt === reduce.pl bib === id = cord-022310-yc6xtw0s author = Lappin, Michael R. title = Microbiology and Infectious Disease date = 2011-12-15 pages = extension = .txt mime = text/plain words = 14109 sentences = 913 flesch = 39 summary = 47 Because of these findings, it is currently recommended to combine serologic test results with those of blood culture or PCR assay results when evaluating clinically ill cats for bartonellosis. Because serologic test results do not accurately correlate with presence of bacteremia and individual culture or PCR assay results can be falsely negative, there is no indication for testing healthy cats for Bartonella spp. T. gondii-specific IgM is detectable in serum by ELISA in approximately 80% of subclinically ill cats 2 to 4 weeks after experimental induction of toxoplasmosis; these titers generally are negative less than 16 weeks after infection. The author, however, has demonstrated IgG antibody titers greater than 1 : 16,384 in subclinically ill cats 5 years after experimental induction In chronic disease or asymptomatic carriers, demonstration of organisms is unreliable, and a tentative diagnosis is based on clinical signs and a positive titer. gondii-specific antibodies can also be detected in the serum, CSF, and aqueous humor of healthy, infected animals, one cannot assay results in clinically ill dogs, E. cache = ./cache/cord-022310-yc6xtw0s.txt txt = ./txt/cord-022310-yc6xtw0s.txt === reduce.pl bib === id = cord-010578-uib9h1lb author = Mawle, Alison C. title = Seroepidemiology of Chronic Fatigue Syndrome: A Case-Control Study date = 1995-12-17 pages = extension = .txt mime = text/plain words = 2570 sentences = 164 flesch = 49 summary = We performed serological testing for a large number of infectious agents in 26 patients from Atlanta who had chronic fatigue syndrome (CFS) and in 50 controls matched by age, race, and sex. We performed serological testing for a large number of infectious agents in 26 patients from Atlanta who had chronic fatigue syndrome (CFS) and in 50 controls matched by age, race, and sex. We conducted serological tests for a large number of infectious agents as part of a case-control study assessing risk factors for CFS. Antibodies against human T-lymphotrophic virus types I and II were detected with an ELISA, and confirmatory testing was performed by western blotting [5] . All other agents tested were detected in ;;:::25% of CFS cases, and antibody levels were compared between cases and controls. Evidence for active Epstein-Barr virus infection in patients with persistent unexplained illness: elevated anti-early antigen antibodies cache = ./cache/cord-010578-uib9h1lb.txt txt = ./txt/cord-010578-uib9h1lb.txt === reduce.pl bib === id = cord-305039-grsv06j7 author = Flego, Michela title = Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases date = 2013-01-04 pages = extension = .txt mime = text/plain words = 10985 sentences = 476 flesch = 37 summary = As for HIV, mAbs directed against spike viral proteins, as well as against host receptors, may act at an early stage of infection by preventing the binding of the virus on the cell surface. In some chronic viral infections, virus-specific immune cells may persist in a 'non-functional' state, because of an imbalance of immunoregulatory signals involving multiple inhibitory and activating receptors, triggered by soluble factors and/or cell surface ligands. Therapeutic approaches using specific mAbs to block host immunosuppressive molecules (antagonism) or to trigger activating receptors (agonism) may be a valid strategy to restore immune cell function and treat various chronic viral infections. In a proof-of-concept passive immunization trial with humans, it has been demonstrated that a cocktail of the three broadly neutralizing mAbs -2G12, 4E10 and 2F5was able to delay viral rebound in patients whose infections were fully suppressed by antiretroviral treatment before administration of the antibodies [76] . cache = ./cache/cord-305039-grsv06j7.txt txt = ./txt/cord-305039-grsv06j7.txt === reduce.pl bib === id = cord-005409-8mbqkzpu author = Cichon, G title = Complement activation by recombinant adenoviruses date = 2002-01-24 pages = extension = .txt mime = text/plain words = 4020 sentences = 203 flesch = 40 summary = We have determined the level of C3a (the most reactive complement component) generated in isolated citrate plasma of healthy individuals after challenge with recombinant and wild-type adenoviruses in amounts corresponding to virus blood levels to be expected in patients during adenoviral gene therapy. It has been known for a long time that adenoviruses are able to induce an antibody-dependent activation of the complement system in human plasma, but the level of activation which is reached during clinical adenoviral gene therapy (especially in intravascular infusions) might have been underestimated in the past. We will show that challenge of isolated human plasma with serotype 5 adenoviruses in amounts corresponding to blood levels reached in the above-mentioned trial, generates a level of complement activation, which holds the potency to induce serious inflammatory reactions. 13 Systemic activation of the complement system, as known from patients suffering from sepsis, severe burns or injuries, could induce autodestructive inflammatory reactions, such as adult respiratory distress syndrome (ARDS) or multiple organ failure (MOF). cache = ./cache/cord-005409-8mbqkzpu.txt txt = ./txt/cord-005409-8mbqkzpu.txt === reduce.pl bib === id = cord-277076-yvsyo4l9 author = Berger, A. title = SARS date = 2019-09-12 pages = extension = .txt mime = text/plain words = 4349 sentences = 215 flesch = 45 summary = Measures including source isolation of patientswho only became infectious after onset of clinical symptomsstrict infection control in health care facilities, timely identification and quarantining of exposed contacts, and perhaps also measures to increase social distance, such as travel warnings and screening of travelers, had led to this remarkable and remarkably rapid success. A further, small SARS outbreak occurred again in Guangdong in late 2003/early 2004; molecular analysis of virus isolates from human cases and animals sampled at the same place and time confirmed that this was zoonotically acquired from Paguma larvata. The laboratory diagnosis of SARS remains a challenge; in fact, despite the rapid identification of SARS-CoV as the etiological agent, testing contributed little to the successful control of the 2003 outbreak. A negative antibody test result later than 21 days after the onset of illness is likely to indicate that no infection with SARS-CoV has taken place. cache = ./cache/cord-277076-yvsyo4l9.txt txt = ./txt/cord-277076-yvsyo4l9.txt === reduce.pl bib === === reduce.pl bib === id = cord-296928-wu14k7u9 author = Hofmann, Tim title = Greatest Hits—Innovative Technologies for High Throughput Identification of Bispecific Antibodies date = 2020-09-08 pages = extension = .txt mime = text/plain words = 7388 sentences = 326 flesch = 29 summary = In this review, we provide an overview of the most relevant methodologies for bispecific screening purposes—the DuoBody concept, paired light chain single cell production approaches, Sortase A and Transglutaminase, the SpyTag/SpyCatcher system, and inteins—and elaborate on the benefits as well as drawbacks of the different technologies. In order to overcome this bottleneck, technologies such as controlled Fab-arm exchange used for DuoBodies [22] , paired light chain single cell production approaches [23] , microbial transglutaminase [24] or Sortase A [25] mediated bioconjugation, the SpyTag/SpyCatcher system [26, 27] , or split inteins [28] were adapted to enable broad bispecific antibody screening ( Figure 1 ). In order to overcome this bottleneck, technologies such as controlled Fab-arm exchange used for DuoBodies [22] , paired light chain single cell production approaches [23] , microbial transglutaminase [24] or Sortase A [25] mediated bioconjugation, the SpyTag/SpyCatcher system [26, 27] , or split inteins [28] were adapted to enable broad bispecific antibody screening ( Figure 1 ). cache = ./cache/cord-296928-wu14k7u9.txt txt = ./txt/cord-296928-wu14k7u9.txt === reduce.pl bib === === reduce.pl bib === id = cord-268417-6eyetb5i author = Mandel, Benjamin title = Neutralization of Animal Viruses date = 1978-12-31 pages = extension = .txt mime = text/plain words = 23012 sentences = 1239 flesch = 43 summary = Somewhat earlier, Morgan (1945'1 had reported that discrepancies in the quantitative aspects of the neutralization of WEE virus by immune rabbit sera were related to the use of fresh or heated serum, and that the addition of complement to the latter tended to eliminate the discrepancies. Further studies (Radwan et al., 1973) showed that the addition of complement to virus complexed with dependent antibody eventually resulted in lysis of the viral membrane. It was also shown (Yoshino and Taniguchi, 1966 ) that antibodies induced in guinea pigs by immunization, and in humans following herpes infection, were initially dependent and later independent of complement for neutralizing activity. A relevant observation has been made in several studies; neutralization of infectious virus-antibody complexes by antiglobulin also shows a single-hit mechanism, and at a rate that exceeds the rate of the homotypic reaction. cache = ./cache/cord-268417-6eyetb5i.txt txt = ./txt/cord-268417-6eyetb5i.txt === reduce.pl bib === id = cord-048239-oluq7v0h author = Oliphant, Theodore title = Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus date = 2005-04-24 pages = extension = .txt mime = text/plain words = 6715 sentences = 341 flesch = 49 summary = Using random mutagenesis and yeast surface display, we defined individual contact residues of 14 newly generated monoclonal antibodies against domain III of the WNV E protein. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus E protein by nickel-affinity chromatography (data not shown). 24 ), yet was virus specific, as it neither recognized nor neutralized other flaviviruses including distantly related dengue and yellow fever viruses (data not shown) and closely related Japanese and St. Louis encephalitis viruses (Supplementary Table 2 Figure 1 Mapping of monoclonal antibodies to DIII with yeast. None of the mutations identified by loss-of-binding sorts for E2 or E22 had any effect on two other non-neutralizing monoclonal Individual WNV-specific monoclonal antibodies (25 µg/ml) were mixed with yeast that displayed wild-type or mutant DIII on their surface. To determine whether human antibodies specific for WNV recognize the neutralizing epitope on DIII during infection, plasma was obtained from WNV-positive individuals. cache = ./cache/cord-048239-oluq7v0h.txt txt = ./txt/cord-048239-oluq7v0h.txt === reduce.pl bib === === reduce.pl bib === id = cord-254821-px4fe7mn author = Infantino, Maria title = Diagnostic accuracy of an automated chemiluminescent immunoassay for anti‐SARS‐CoV‐2 IgM and IgG antibodies: an Italian experience date = 2020-05-10 pages = extension = .txt mime = text/plain words = 1224 sentences = 67 flesch = 42 summary = Sixty‐one COVID‐19 patients and 64 patients from a control group were tested by iFlash1800 CLIA analyzer for anti‐SARS CoV‐2 antibodies IgM and IgG. The more relaxed rules of the FDA's "Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency" issued on 16 March 2020, 9 has allowed the market easier access to these tests as well as easier and faster diagnostics, but the lack of control in the production process is also dangerous making these tests potentially less reliable. 11 The aim of the this study was to assess the diagnostic performance of a novel fully automated CLIA for the quantitative detection of anti-SARS-CoV-2 IgM and IgG antibodies. 16 As with most existing studies on the diagnostic performance of the SARS-CoV-2 antibodies, our preliminary data showed that most COVID-19 patients have both IgM and IgG, and only few of them have isolated IgG or IgM antibodies. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis Assessment of immune response to SARS-CoV-2 with fully-automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays cache = ./cache/cord-254821-px4fe7mn.txt txt = ./txt/cord-254821-px4fe7mn.txt === reduce.pl bib === id = cord-281760-34wuttqw author = Pereira, E.P.V. title = Egg yolk antibodies (IgY) and their applications in human and veterinary health: A review date = 2019-05-22 pages = extension = .txt mime = text/plain words = 9686 sentences = 431 flesch = 42 summary = Considering the fast development of IgY technology, this work aims to review its applications in human and animal health, in addition to increasing the potential use of these antibodies among researchers and consequently promoting the reduced use of non-invasive procedures on animals. extracted IgY from hens immunized with the recombinant protein FanC, from enterotoxigenic Escherichia coli (ETEC) and these antibodies bound specifically to FanC in ELISA, Western blot and Dot-blotting [59] , demanding, thus, more investigations to evaluate its viability as a potential immunotherapeutic compound. Anti-DENV2 IgY produced in goose was able to neutralize the virus in vitro and in vivo without binding to Fcγ receptors on myeloid cells and generating ADE (antibody dependent enhancement) in mice [57] . Hen egg yolk antibodies (IgY), production and use for passive immunization against bacterial enteric infections in chicken: a review Preventive effect of anti-VacA egg yolk immunoglobulin (IgY) on Helicobacter pylori-infected mice cache = ./cache/cord-281760-34wuttqw.txt txt = ./txt/cord-281760-34wuttqw.txt === reduce.pl bib === id = cord-103077-sh4w2mye author = Lu, Shuai title = Leveraging Sequential and Spatial Neighbors Information by Using CNNs Linked With GCNs for Paratope Prediction date = 2020-10-16 pages = extension = .txt mime = text/plain words = 3140 sentences = 194 flesch = 55 summary = In this article, we propose a method to identify which amino acid residues of an antibody directly interact with its associated antigen based on the features from sequence and structure. Our algorithm uses convolution neural networks (CNNs) linked with graph convolution networks (GCNs) to make use of information from both sequential and spatial neighbors to understand more about the local environment of the target amino acid residue. According to the type of selecting neighbors of target residue for representing and predicting, the machine learning-based methods can be divided into two categories, leveraging sequential neighbors or spatial neighbors. And the stateof-art method [19] represented an antibody as a graph where each amino acid residue was a node and K nearest spatial neighbors were used in the convolution operator. In this work, we utilize the sequential and spatial neighbors of the target antibody residue by using Convolutional Neural Networks (CNNs) linked with Graph Neural Networks (GCNs) for paratope prediction. cache = ./cache/cord-103077-sh4w2mye.txt txt = ./txt/cord-103077-sh4w2mye.txt === reduce.pl bib === id = cord-005913-1vo1o6w8 author = Matis, Louis A. title = Complement-specific antibodies: Designing novel anti-inflammatories date = 1995 pages = extension = .txt mime = text/plain words = 1918 sentences = 89 flesch = 30 summary = The complement system is composed of more than 20 serum proteins that interact in a precise series of enzymatic cleavage and membrane binding events leading to the generation of products with immunoprotective, immunoregulatory, and proinflammatory properties 12 • Complement can be activated through either of two distinct enzymatic cascades, referred to as the classical and alternative pathways (Fig. 1) . Using a monoclonal antibody specific for mouse CS, we have shown that systemic anti-CS monoclonal antibody administration efficiently inhibited complement in vivo (inhibiting serum haemolytic activity for as long as six to seven days after a single intravenous injection), and that treatment with anti-CS monoclonal antibody was therapeutically effective in two distinct models of immune complex nephritis and autoimmune disease (Y. In addition, humanized recombinant anti-CS monoclonal antibody and scFv that retain the binding affinity and complement inhibitory activity of their murine counterparts have been produced by CDR grafting (M. cache = ./cache/cord-005913-1vo1o6w8.txt txt = ./txt/cord-005913-1vo1o6w8.txt === reduce.pl bib === id = cord-279105-e2zjxjox author = Lee, Cheryl Yi-Pin title = Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control date = 2020-04-24 pages = extension = .txt mime = text/plain words = 3872 sentences = 212 flesch = 44 summary = With the limitations of qRT-PCR, immunoassays may offer another FIGURE 2 | Schematic illustration on the window period of detection for either viral RNA or antibodies in SARS-CoV-2-infected individuals. However, interestingly, one study demonstrated that longitudinal profiling of both antibodies in a population of 63 COVID-19 patients showed no specific chronological order in terms of IgM and IgG seroconversion (10) , which was also observed in patients infected with SARS-CoV and another human coronavirus, Middle East Respiratory Syndrome coronavirus (MERS-CoV) (22, 23) . These findings on SARS-CoV-2-specific antibodies seroconversion against the S viral protein suggest the importance to test for both IgM and IgG antibodies to confirm a positive infection. With the availability of immunoassays utilizing various coronavirus structural proteins, the use of more than one different antigen-based serological approach may be essential to establish a true positive SARS-CoV-2 infection. cache = ./cache/cord-279105-e2zjxjox.txt txt = ./txt/cord-279105-e2zjxjox.txt === reduce.pl bib === id = cord-302312-1pm17l5d author = Quinteros, Daniela A. title = Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery date = 2017-03-31 pages = extension = .txt mime = text/plain words = 10875 sentences = 493 flesch = 33 summary = In therapy, the development of targeted drug delivery represents, together with tissue repair, the main applications of antibody-conjugated nanoparticles. In addition to their own properties as pathogens or toxin neutralizers, as well as in the recruitment of immune elements (complement, improving phagocytosis, cytotoxicity antibody dependent by natural killer cells, etc.), they could carry several elements (toxins, drugs, fluorochroms, or even nanoparticles, etc.) and be used in several diagnostic procedures, or even in therapy to destroy a specific target. To treat HER2 positive breast cancer, anti-HER2 humanized Mabs are commonly used, although advances can be made in targeted cellular localization via conjugation strategy through a nano-particulate system focusing on surface modified ligand/receptor-mediated nano-therapy to target the tumor cell at the molecular level. Bio-conjugation strategies of therapeutic agents loaded nanoparticles with Mabs have exhibited a targeted drug delivery approach both in vitro and in vivo. cache = ./cache/cord-302312-1pm17l5d.txt txt = ./txt/cord-302312-1pm17l5d.txt === reduce.pl bib === id = cord-267015-mprsdi2e author = Zhu, Zhongyu title = Exceptionally Potent Cross-Reactive Neutralization of Nipah and Hendra Viruses by a Human Monoclonal Antibody date = 2008-03-15 pages = extension = .txt mime = text/plain words = 4460 sentences = 235 flesch = 52 summary = One of these antibodies, m102, which exhibited the highest level of cross-reactive neutralization of both NiV and HeV G, was affinity maturated by light-chain shuffling combined with random mutagenesis of its heavy-chain variable domain and panning against sG(HeV). We have previously identified neutralizing human monoclonal antibodies against Nipah virus (NiV) and Hendra virus (HeV) by panning a large nonimmune antibody library against a soluble form of the HeV attachment-envelope glycoprotein G (sG HeV ). One of these antibodies, m102, which exhibited the highest level of cross-reactive neutralization of both NiV and HeV G, was affinity maturated by light-chain shuffling combined with random mutagenesis of its heavychain variable domain and panning against sG HeV . To demonstrate that m102.4 measured in plasma was biologically active, serum collected on days 1, 4, and 8 was evaluated using virus neutralization assays, as described above (data not shown). Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus cache = ./cache/cord-267015-mprsdi2e.txt txt = ./txt/cord-267015-mprsdi2e.txt === reduce.pl bib === id = cord-009581-bvihkf1r author = Hurd, Eric R. title = Virus antibody levels in systemic lupus erythematosus date = 2005-11-22 pages = extension = .txt mime = text/plain words = 2370 sentences = 128 flesch = 47 summary = Antibody titers to a group of viral antigens have been determined in sera from patients with systemic lupus erythematosus (SLE), control groups with inflammatory diseases and normals. In a preliminary study in this laboratory (23) of viral antibody titers in patients with lupus nephritis and matched normal controls, complement fixing antibody titers were significantly elevated to a number of myxoviruses, coronavirus OC 43 and herpes simplex virus. In the present study, an attempt has been made to compare viral antibody titers in SLE with those of control groups with inflammatory diseases as well as normal individuals. However, it is possible that the tubular structures are evidence of chronic infection in S L E with a passenger virus of a type which might act as an adjuvant for the overall elevation in viral antibody titer observed. cache = ./cache/cord-009581-bvihkf1r.txt txt = ./txt/cord-009581-bvihkf1r.txt === reduce.pl bib === id = cord-016966-b23o5roz author = Verhoef, Jan title = Immune response in human pathology: infections caused by bacteria, viruses, fungi, and parasites date = 2005 pages = extension = .txt mime = text/plain words = 4302 sentences = 220 flesch = 43 summary = Effective treatment, however, was not possible at that time; prevention and spread of infectious diseases depended solely on proper hygienic means.At the beginning of the 20th century, passive and active vaccination procedures were developed against a number of these pathogenic micro-organisms in order to prevent the diseases in question (rabies, diphtheria, tetanus, etc.) and due to the discovery of antimicrobial chemicals (Ehrlich) and antibiotics (Fleming), the threat of infectious diseases seemed to be minimized. CYTOKINES, such as IL-2 (INTERLEUKIN-2), GM-CSF (granulocyte-macrophage colony-stimulating factor), and TNF-α (TUMOR NECROSIS FACTOR α), stimulate non-specifically the proliferation, maturation, and Immune response in human pathology: infections caused by bacteria, viruses, fungi, and parasites Jan Verhoef and Harm Snippe A7 function of the cells involved in defence (see Chapter A.4). cache = ./cache/cord-016966-b23o5roz.txt txt = ./txt/cord-016966-b23o5roz.txt === reduce.pl bib === id = cord-032598-i0jm3p1s author = Hu, Jing title = Direct imaging of antigen–antibody binding by atomic force microscopy date = 2020-09-24 pages = extension = .txt mime = text/plain words = 3133 sentences = 170 flesch = 45 summary = In this study, the morphology of biotinylated antibody-specific Immunoglobulin E (IgE) immune complexes has been successfully imaged by atomic force microscopy (AFM) in the tapping-mode. The AFM images indicated that the individual immune complex was composed of an IgE and a biotinylated antibody. To the best of our knowledge, the biotinylated antibody-specific IgE immune complexes imaged by AFM have never been reported. Meanwhile, Fig. 6d , h and l would represent the biotinylated antibody-specific IgE immune complex adsorbed on the mica surface by the IgE fragment and the two Fab fragments of biotinylated antibody. In this paper, the morphology and length of IgE, biotinylated antibodies and biotinylated antibody-specific IgE immune complexes were analyzed by AFM, respectively. The results of AFM imaging demonstrated that the immune complexes exhibited various morphologies, and we were able to identify the IgE and biotinylated antibody based on the protein morphology in most cases. cache = ./cache/cord-032598-i0jm3p1s.txt txt = ./txt/cord-032598-i0jm3p1s.txt === reduce.pl bib === id = cord-030999-27wennun author = Altmann, Daniel M title = Adaptive immunity to SARS-CoV-2 date = 2020-07-09 pages = extension = .txt mime = text/plain words = 4374 sentences = 191 flesch = 42 summary = The majority of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 exposed individuals mount an antibody response within around 2-weeks and spike antigen-binding responses correlate well with functional virus neutralization. Studies of T-cell immunity following acute infection show CD4 and CD8 responses to epitopes across diverse viral antigens, possible cross-reactivity with epitopes from the common cold human coronaviruses and large-scale activation. Since many key questions about durability of the antibody response and about correlates of protection have been hard to address in this short timeframe, there has been value in recourse to the coronavirus immunology literature, especially in relation to SARS and MERS [16] [17] [18] [19] . Experience to date with SARS-CoV-2 suggests that this may not prove to be an infection that throws up insurmountable confounders to vaccine design-approaches that can safely and durably elicit neutralizing antibody look likely to work. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals cache = ./cache/cord-030999-27wennun.txt txt = ./txt/cord-030999-27wennun.txt === reduce.pl bib === id = cord-103432-cdmoazrl author = Richardson, Eve title = A computational method for immune repertoire mining that identifies novel binders from different clonotypes, demonstrated by identifying anti-Pertussis toxoid antibodies date = 2020-06-02 pages = extension = .txt mime = text/plain words = 6556 sentences = 375 flesch = 51 summary = To test the ability of paratyping and clonotyping to group antibodies that target the same epitope we performed a test in a single-cell (paired VH/VL) data set of 1290 antibodies isolated from genetically engineered mice that have a full set of human immunoglobulin variable region genes [31] immunised with Pertussis toxoid (PTx). Each of the PTx-binders is referred to as a "probe" antibody; sequences that are within the same paratype or clonotype as the probe are predicted to bind PTx. The precision and recall of the two methods (calculated over the aggregate of predictions) for repertoire mining are comparable ( Figure 2 , Table 1 ). In a test system of transgenic mice immunised with Pertussis toxoid (PTx), we show for the first time that prediction and comparison of paratopes can be used to group antigen-specific antibodies in both an enriched, single-cell data set and non-enriched bulk heavy chain repertoires. cache = ./cache/cord-103432-cdmoazrl.txt txt = ./txt/cord-103432-cdmoazrl.txt === reduce.pl bib === id = cord-278281-bdoavpsb author = NEMOTO, Manabu title = Antibody response to equine coronavirus in horses inoculated with a bovine coronavirus vaccine date = 2017-10-06 pages = extension = .txt mime = text/plain words = 1363 sentences = 74 flesch = 59 summary = Virus neutralization tests showed that antibody titers against ECoV increased in all six horses tested at 14 days post inoculation, although the antibody titers were lower against ECoV than against BCoV. The virus-neutralizing antibody titers of horses inoculated with 1 or 2 ml of the BCoV vaccine are shown in Table 1 . In horses inoculated with 1 ml of vaccine, the geometric mean antibody titers against BCoV at 0, 7, 14, 28, 42 and 56 dpi were 4, 5, 32, 102, 645 and 323, respectively, and the geometric mean antibody titers against ECoV were 4, 6, 20, 25, 40 and 51 (Table 1) . Nevertheless, the antibody titers of all vaccinated horses in the present study were no more than 128, and we therefore consider that the BCoV vaccine will have limited efficacy against ECoV infection in horses. cache = ./cache/cord-278281-bdoavpsb.txt txt = ./txt/cord-278281-bdoavpsb.txt === reduce.pl bib === === reduce.pl bib === id = cord-274756-nnm1n09a author = Varadé, Jezabel title = Human immunology and immunotherapy: main achievements and challenges date = 2020-09-02 pages = extension = .txt mime = text/plain words = 19144 sentences = 920 flesch = 38 summary = The development of different types of immunotherapies, including vaccines (prophylactic and therapeutic), and the use of pathogens, monoclonal antibodies, recombinant proteins, cytokines, and cellular immunotherapies, are changing the way in which we approach many diseases, especially cancer. In addition to those showing the essential role of LTi cells in the formation of secondary lymphoid organs during embryogenesis and the postnatal development of intestinal lymphoid clusters, recent studies also provide evidence that subsets of ILCs express multiple factors that modulate the adaptive immune response in health and disease 27, 28 . Autoimmunity: In the case of therapeutic vaccines for autoimmune diseases, such as multiple sclerosis, diabetes, Myasthenia gravis or Guillain Barré syndrome, the intention is to induce tolerance to self-antigens through the activation of regulatory cells (Tregs and Bregs) and tolerogenic dendritic cells, thus avoiding the immune response to self-components 211 . cache = ./cache/cord-274756-nnm1n09a.txt txt = ./txt/cord-274756-nnm1n09a.txt === reduce.pl bib === id = cord-102908-sr7j8z9c author = Mersmann, Sophia F. title = Learning to count: determining the stoichiometry of bio-molecular complexes using fluorescence microscopy and statistical modelling date = 2020-07-24 pages = extension = .txt mime = text/plain words = 5244 sentences = 260 flesch = 42 summary = We used differential binary labelling and statistical modelling to extract estimates of stoichiometry, our strategy is outlined in Figure 1 ; note that this approach can be generalised to apply to many other multi-component systems (i.e. how many protein x are found in assembly y?). As described above, our experimental design utilizes antibody labelled with spectrally distinct dyes allowing binary scoring of individual virus particles as positive if they interact with at least one Ab B molecule ( Figure 1 ). We have demonstrated quantitative analysis of 9C12 interaction with individual Adv particles ( Figure 3) ; we have confirmed that differential labelling of antibody does not bias binding ( Figure 4A & B) ; and that we could detect single molecules of 9C12 Biotin allowing discrimination of positive and negative AdV-9C12 complexes ( Figure 4C & D). However, using stoichiometric estimates to calibrate fluorescent data revealed population heterogeneity with a small proportion of virus particles binding ∼200 antibody molecules. cache = ./cache/cord-102908-sr7j8z9c.txt txt = ./txt/cord-102908-sr7j8z9c.txt === reduce.pl bib === id = cord-304214-66nxk4e8 author = Sanders, John W. title = Vectored immunoprophylaxis: an emerging adjunct to traditional vaccination date = 2017-02-10 pages = extension = .txt mime = text/plain words = 3742 sentences = 173 flesch = 36 summary = Rather than passively transfering pre-formed antibodies, VIP is a process in which genes encoding previously characterized neutralizing antibodies are vectored into non-hematopoietic cells which then secrete the monoclonal antibodes encoded by those genes [1] (See Fig. 1 .) This vectored delivery and production of specified antibodies allows for protection without generating a standard immune response and results in endogenous antibody production that has the potential to be sustained [9] . Saunders, et al., used an rAAV serotype 8 vector to produce a full length IgG of a simianized form of the broadly neutralizing antibody VRC07 in macaques which was protective against simian-human immunodeficiency virus (SHIV) infection 5.5 weeks after treatment [24] . Using HIV-1-infected humanized mice, Horwitz, et al., demonstrated that following initial treatment with anti-retroviral therapy (ART), a single injection of adeno-associated virus directing expression of broadly neutralizing antibody 10-1074, produced durable viremic control after the ART was stopped [26] . cache = ./cache/cord-304214-66nxk4e8.txt txt = ./txt/cord-304214-66nxk4e8.txt === reduce.pl bib === === reduce.pl bib === id = cord-282817-vtzpf2wr author = Byrne, Hannah title = A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications date = 2013-10-02 pages = extension = .txt mime = text/plain words = 8419 sentences = 417 flesch = 34 summary = Despite significant positive clinical results, especially in the case of hematological malignancies, adverse clinical outcomes and animal studies have highlighted underlying limitations of mAbs. Accordingly, many strategies have been developed in order to improve the specificity and control the functions of antibodies. The BiTE format potentially overcomes several limiting factors relating to the biological activity of tumor-directed bsAbs. BiTEs combine the minimal binding domains (Fv fragments) of two different mAbs fused together by a short flexible linker that allows free rotation of the two arms, and thus facilitates optimal antibody:antigen interaction [28] . bsAbs are attractive in such assays because they simplify the detection steps and are currently used for the development of simple, rapid, and highly sensitive immunoassays for the detection of bacterial and viral infectious diseases and in cancer diagnostics. CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation cache = ./cache/cord-282817-vtzpf2wr.txt txt = ./txt/cord-282817-vtzpf2wr.txt === reduce.pl bib === id = cord-018840-ts2g1ux7 author = Katragkou, Aspasia title = Role of Immunoglobulin Therapy to Prevent and Treat Infections date = 2018-06-19 pages = extension = .txt mime = text/plain words = 6703 sentences = 329 flesch = 32 summary = While the main clinical applications of immunoglobulin therapy concern their use as replacement for patients with primary immunodeficiencies, or as treatment for autoimmune and inflammatory disorders, their role in infectious disease is limited largely to viral and toxin neutralization and replacement therapy in patients with immunoglobulin deficiencies. The first clinical trial, which evaluated the effect of IgMA-enriched immunoglobulin preparation (7.8 g IgM, 7.8 g IgA, and 49.4 g IgG), which have shown to contain superior antibody content against bacterial lipopolysaccharides, in an appreciable number of neutropenic patients with hematologic malignancies and sepsis or septic shock, showed that immunoglobulins had no beneficial effects [51] . A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery cache = ./cache/cord-018840-ts2g1ux7.txt txt = ./txt/cord-018840-ts2g1ux7.txt === reduce.pl bib === id = cord-275946-ofd2ipvs author = Cheng, Matthew P. title = Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus-2: A Narrative Review date = 2020-06-04 pages = extension = .txt mime = text/plain words = 5277 sentences = 282 flesch = 38 summary = Accurate serologic tests to detect host antibodies to severe acute respiratory syndrome–related coronavirus-2 (SARS-CoV-2) will be critical for the public health response to the coronavirus disease 2019 pandemic. This article discusses key use cases for SARS-CoV-2 antibody detection tests and their application to serologic studies, reviews currently available assays, highlights key areas of ongoing research, and proposes potential strategies for test implementation. Appropriately designed seroepidemiologic studies will play an essential part in the public health response to the COVID-19 pandemic by characterizing transmission dynamics, refining disease burden estimates, and providing insight into the kinetics of humoral immunity to SARS-CoV-2. Serologic surveillance studies can also assess the accumulation of persons with antibody responses over time to estimate incidence of SARS-CoV-2 infection (57, 58) and can track age-and jurisdiction-specific disease susceptibility and identify at-risk populations (59) . cache = ./cache/cord-275946-ofd2ipvs.txt txt = ./txt/cord-275946-ofd2ipvs.txt === reduce.pl bib === id = cord-285760-y37ji92k author = Connell, Anna R. title = Mumps Outbreaks in Vaccinated Populations—Is It Time to Re-assess the Clinical Efficacy of Vaccines? date = 2020-09-18 pages = extension = .txt mime = text/plain words = 13097 sentences = 622 flesch = 41 summary = Although a rise in IgG titer may also not occur in vaccinated individuals (87, 137) , numerous studies have documented a rapid, variable increase in mumps-specific IgG levels, with neutralization antibody concentrations present up to 10 months post-infection (130, 138, 139) . Potential waning immunity has been documented in the current mumps outbreaks seen in Europe and the USA, mostly affecting young adults within highly vaccinated populations attending tertiary education who have received two doses of the MMR vaccine in early childhood (40, 110, 126, 144, 145, (175) (176) (177) (178) (179) (180) (181) . Although MuV can be clinically asymptomatic in about 15-30% of those who become infected, the vaccine against mumps confers protection in a dose response manner; unvaccinated individuals saw an attack rate of Based on the reduction seen upon the introduction of a mumps vaccine, it has been proposed that MMR vaccination also prevents the transmission of the virus. cache = ./cache/cord-285760-y37ji92k.txt txt = ./txt/cord-285760-y37ji92k.txt === reduce.pl bib === === reduce.pl bib === id = cord-302974-t1t89p8y author = Mathur, Gagan title = Antibody Testing For Covid-19: Can It Be Used As A Screening Tool In Areas With Low Prevalence? date = 2020-05-15 pages = extension = .txt mime = text/plain words = 913 sentences = 58 flesch = 57 summary = Soon after detection of spread of SARS-CoV-2 in the United States (US), focus was on developing molecular nucleic acid detection tests (real-time reverse transcriptase polymerase chain reaction [RT-PCR]) for early diagnosis of infection in symptomatic patients, patients with known exposure, and patients who are at risk. The Trump administration and the media have been promoting antibody tests as a screening tool to allow individuals with positive results to get back to work and open our economy. The assumption is that the individuals with positive antibody tests have recovered from COVID-19 (symptomatic or asymptomatic) infection and have developed immunity to the virus. As of April 30, 2020, 10 antibody tests have been approved by the US Food and Drug Administration (FDA) under emergency use authorizations. Prematurely promoting antibody tests as a screening tool all over the US will give individuals, who test positive and are not actually immune to COVID-19, a false sense of protection. cache = ./cache/cord-302974-t1t89p8y.txt txt = ./txt/cord-302974-t1t89p8y.txt === reduce.pl bib === id = cord-298910-2601n7a9 author = Leu, Sy-Jye title = Generation and characterization of anti-α-enolase single-chain antibodies in chicken date = 2010-10-15 pages = extension = .txt mime = text/plain words = 5157 sentences = 278 flesch = 48 summary = The expressed heavy and light chain variable genes (VH and VL) were isolated from spleen B cells and amplified to construct phage antibody libraries containing scFv molecules. After four rounds of panning selection, the scFv antibodies of randomly chosen clones were expressed and their binding specificity to α-enolase protein was verified using competitive ELISA, flow cytometry and immunofluorescence staining. Accordingly, in the present study, we generated and characterized the anti-␣-enolase polyclonal IgY antibodies in chicken and monoclonal scFv antibodies by a phage display system using ELISA, Western blotting, flow cytometry and immunofluorescence staining. EnL2 and EnL5 scFv antibodies purified as a single band on SDS-PAGE (data not shown) were able to detect ␣-enolase protein in PE089 cells, and the binding signal is comparable to that of commercially available rabbit polyclonal antibodies specific for ␣-enolase as demonstrated in Fig. 7 . cache = ./cache/cord-298910-2601n7a9.txt txt = ./txt/cord-298910-2601n7a9.txt === reduce.pl bib === id = cord-001074-qevosik3 author = Selvarajah, Suganya title = A Neutralizing Monoclonal Antibody Targeting the Acid-Sensitive Region in Chikungunya Virus E2 Protects from Disease date = 2013-09-12 pages = extension = .txt mime = text/plain words = 7613 sentences = 359 flesch = 50 summary = C9 was determined to be a potent virus neutralizing antibody and a biosensor antibody binding study demonstrated it recognized residues on intact CHIKV VLPs. Shotgun mutagenesis alanine scanning of 98 percent of the residues in the E1 and E2 glycoproteins of CHIKV envelope showed that the epitope bound by C9 included amino-acid 162 in the acid-sensitive region (ASR) of the CHIKV E2 glycoprotein. The neutralizing epitope bound by C9 mapped to the acid-sensitive region (ASR) that is critical for the rearrangement of CHIKV E2 during fusion and viral entry into host cells. Therefore, C9 is a potent neutralizing antibody that can therapeutically protect wild-type neonate mice from a lethal dose of virus at 8 and 18 hours post CHIKV inoculation. This study describes the isolation and characterization of two human monoclonal antibodies, C9 and E8, from CHIKV infected and recovered individuals. cache = ./cache/cord-001074-qevosik3.txt txt = ./txt/cord-001074-qevosik3.txt === reduce.pl bib === id = cord-312787-j7ye7ed5 author = Loemba, H. D. title = Kinetics of humoral immune response to the major structural proteins of the porcine reproductive and respiratory syndrome virus date = 1996 pages = extension = .txt mime = text/plain words = 3411 sentences = 149 flesch = 41 summary = coli-expressed ORFs 5 to 7 gene products, suggested that antibodies directed against the envelope E protein appear by day 7 p.i., whereas antibodies directed against the nucleocapsid N and membrane M proteins can only be detected by the end of the second week p.i. No correlation could be demonstrated between VN and IIF antibody titers, viremia, and viral protein specificities of circulating antibodies at various times p.i. Summary. coli-expressed ORFs 5 to 7 gene products, suggested that antibodies directed against the envelope E protein appear by day 7 p.i., whereas antibodies directed against the nucleocapsid N and membrane M proteins can only be detected by the end of the second week p.i. No correlation could be demonstrated between VN and IIF antibody titers, viremia, and viral protein specificities of circulating antibodies at various times p.i. The porcine reproductive and respiratory syndrome virus (PRRSV) is an enveloped RNA virus which has been found to be responsible for reproductive failure in sows of any parities (late-term abortions, increased numbers of stillborn, mummified and weakborn pigs) and respiratory problems affecting pigs of all ages [8, 20] . cache = ./cache/cord-312787-j7ye7ed5.txt txt = ./txt/cord-312787-j7ye7ed5.txt === reduce.pl bib === id = cord-001726-d7iwkatn author = Henry, Kevin A. title = Beyond phage display: non-traditional applications of the filamentous bacteriophage as a vaccine carrier, therapeutic biologic, and bioconjugation scaffold date = 2015-08-04 pages = extension = .txt mime = text/plain words = 10444 sentences = 516 flesch = 39 summary = Particular emphases are placed on: (i) the advantages of the phage as a vaccine carrier, including its high immunogenicity, relative antigenic simplicity and ability to activate a range of immune responses, (ii) the phage's potential as a prophylactic and therapeutic agent for infectious and chronic diseases, (iii) the regularity of the virion major coat protein lattice, which enables a variety of bioconjugation and surface chemistry applications, particularly in nanomaterials, and (iv) the phage's large population sizes and fast generation times, which make it an excellent model system for directed protein evolution. While in some cases the results of these studies have been promising, antibody epitope-based peptide vaccines are no longer an area of active research for several reasons: (i) in many cases, peptides incompletely or inadequately mimic epitopes on folded proteins (Irving et al., 2010 ; see below); (ii) antibodies against a single epitope may be of limited utility, especially for highly variable pathogens (Van Regenmortel, 2012); and (iii) for pathogens for which protective immune responses are generated efficiently during natural infection, peptide vaccines offer few advantages over recombinant subunit and live vector vaccines, which have become easier to produce over time. cache = ./cache/cord-001726-d7iwkatn.txt txt = ./txt/cord-001726-d7iwkatn.txt === reduce.pl bib === === reduce.pl bib === id = cord-274557-2071770h author = Späth, Peter J. title = On the Dark Side of Therapies with Immunoglobulin Concentrates: The Adverse Events date = 2015-02-05 pages = extension = .txt mime = text/plain words = 10243 sentences = 530 flesch = 40 summary = i.e., cold-ethanol or ion-exchange chromatography, contaminants, route of application, i.e., intra muscular (IMIG), intravenous (IVIG), or subcutaneous (SCIG), the rate of increase of the exogenous IgG in the circulation of the recipient over time and, last but not least an eventually existing risk factor from patients' side ( Figure 1 ) as well as incorrect handling of the concentrate are factors having a role in inducing non-infectious AEs related to administration of IgG concentrates ( Table 1) . The complement-mediated AEs were considered to be caused by aggregates in the product ("spontaneous complement activation" or anti-complementary activity or ACA) or by in vivo formation of immune complexes (ICs, patient's condition related; e.g., subclinical infections or the unnoticed presence of anti-IgA antibodies) and therefore only IgG concentrates with low or absent ACA is accepted by authorities for human use. cache = ./cache/cord-274557-2071770h.txt txt = ./txt/cord-274557-2071770h.txt === reduce.pl bib === id = cord-291626-lxa8pvt3 author = Pelfrene, E. title = Monoclonal antibodies as anti-infective products: a promising future? date = 2019-01-31 pages = extension = .txt mime = text/plain words = 3867 sentences = 201 flesch = 30 summary = Additionally, the FDA recently licensed ibalizumab as a rescue therapy in heavily treatmentexperienced adults with multidrug-resistant HIV-1 infection and also previously approved raxibacumab (in 2012) and obiltoxaximab (in 2016), both intended for treatment of inhalational anthrax (in combination with appropriate antibacterial medicines) and for prophylaxis when alternative therapies are not available or are not appropriate [5e7] . François et al., 'Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in patients with severe pneumonia caused by Staphylococcus aureus: first in man trial,' abstract 1992, paper presented at European Congress of Clinical Microbiology and Infectious Diseases 2017) [34, 38] . Compassionate use Benefits seriously ill patients who cannot be treated satisfactorily or cannot enrol in ongoing clinical trials Pertains to unauthorized medicinal products for chronically, seriously debilitating or life-threatening diseases, with no satisfactory treatment authorized in EU; targeted at a group of patients rather than individual; or undergoing centralized MAA or clinical trials EMA, European Medicines Agency; FDA, US Food and Drug Administration; HTA, health technology assessment bodies; MAA, marketing authorization application; SA, scientific advice. cache = ./cache/cord-291626-lxa8pvt3.txt txt = ./txt/cord-291626-lxa8pvt3.txt === reduce.pl bib === === reduce.pl bib === id = cord-267601-3ahmyicn author = Renegar, Kathryn B. title = Passive Immunization: Systemic and Mucosal date = 2007-05-09 pages = extension = .txt mime = text/plain words = 8078 sentences = 405 flesch = 43 summary = Both rats and mice can actively transport IgG from the gut into the serum for approximately 2 weeks (see Combined Prenatal and Postnatal Transfer earlier in this chapter); thus, observed protection could be due either to antibody in the milk bathing the mucosal surfaces or to maternal antibody being transported into the serum and secretions of the offspring. Only a limited number of studies on the transport of antibodies into respiratory secretions have been reported, but the results have shown that selective transport of passively administered serum IgA into the respiratory tract is possible in sheep and mice. (1994) determined that passively administered monoclonal pIgA isotype-switch variants, generated from IgG hybridomas producing antibodies specific for bacterial respiratory tract pathogens, were selectively transported relative to IgG into both the upper and lower respiratory tract secretions of mice. To determine whether intravenously administered pIgA antiinfluenza monoclonal antibody could mediate protection against local influenza virus challenge, passively immunized mice were challenged intranasally while awake with influenza virus. cache = ./cache/cord-267601-3ahmyicn.txt txt = ./txt/cord-267601-3ahmyicn.txt === reduce.pl bib === id = cord-292874-6zjqflhz author = SØRENSEN, MORTEN DRÆBY title = Severe Acute Respiratory Syndrome (SARS): Development of Diagnostics and Antivirals date = 2006-05-10 pages = extension = .txt mime = text/plain words = 1560 sentences = 110 flesch = 54 summary = abstract: The previously unknown coronavirus that caused severe acute respiratory syndrome (SARS‐CoV) affected more than 8,000 persons worldwide and was responsible for more than 700 deaths during the first outbreak in 2002–2003. As part of the Sino‐European Project on SARS Diagnostics and Antivirals (SEPSDA), an immune phage‐display library is being created from convalescent patients in a phagemid system for the selection of single‐chain fragment variables (scFv) antibodies recognizing the SARS‐CoV. In February 2003, the new and previously unknown deadly coronavirus causing severe acute respiratory syndrome (SARS-CoV) was brought to the attention of the World Health Organization (WHO) by Dr. Carlo Urbani and his colleagues. Creation of immune phage-display libraries for immunized donors has shown a particular efficiency in selecting neutralizing antibodies (NABs) against different viruses, for example, rabies, 39 varicella-zoster, 40 hepatitis A 41 and E, 42 measles, 43 and respiratory syncytial virus. cache = ./cache/cord-292874-6zjqflhz.txt txt = ./txt/cord-292874-6zjqflhz.txt === reduce.pl bib === id = cord-009446-8keu2uay author = Kreer, Christoph title = Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies date = 2020-01-01 pages = extension = .txt mime = text/plain words = 6658 sentences = 355 flesch = 39 summary = Focusing on the development of highly potent broadly neutralizing antibodies against HIV-1, we discuss how a detailed knowledge of the human B cell repertoire may support the development of novel vaccination strategies. Indeed, the generation of optimized bait proteins [30] or native-like envelope trimers [45] were critical steps to improve the isolation of potent HIV-1 broadly neutralizing antibodies (bNAbs) by antigen-specific sorting strategies [31, [46] [47] [48] . Only a small fraction of HIV-1-infected individuals develop highly potent bNAbs and detailed analyses of B cell receptors and antibodies at a single cell level have been limited to a few dozen subjects. Thus, a detailed understanding of the naïve B cell receptor repertoire and the constantly adapting antibody response in the context of HIV-1 infection can be highly informative for vaccine design. cache = ./cache/cord-009446-8keu2uay.txt txt = ./txt/cord-009446-8keu2uay.txt === reduce.pl bib === id = cord-104226-bb4lyvhy author = nan title = Monoclonal antiprothrombinase (3D4.3) prevents mortality from murine hepatitis virus (MHV-3) infection date = 1992-09-01 pages = extension = .txt mime = text/plain words = 4669 sentences = 243 flesch = 51 summary = The induction of monocyte/macrophage procoagulant activity (PCA) has been implicated in the pathogenesis of murine hepatitis virus strain 3 (MHV-3) infection and disease. The results reported here demonstrate that a neutralizing antibody to PCA protects animals from fulminant hepatitis and death associated with MHV-3 infection, and supports the notion that PCA is a potent inflammatory mediator that plays a pivotal role in the pathogenesis of liver injury resulting from MHV-3 infection. In contrast, mice infected with MHV-3 but treated with antibody to PCA showed a marked reduction in liver disease in all groups (25, 50 , and 100/.r ( were a few small loci of inflammatory cells with no necrosis (Fig. 2 D) . No fibrin was seen in the livers of infected mice treated with 100/~g of mAb. Treatment with anti-PCA alone resulted in no detectable histological evidence of liver disease in nonirLf~ed animals. cache = ./cache/cord-104226-bb4lyvhy.txt txt = ./txt/cord-104226-bb4lyvhy.txt === reduce.pl bib === === reduce.pl bib === id = cord-283826-lgyc3sro author = Stiehm, E. Richard title = Therapeutic Use of Immunoglobulins date = 2010-11-05 pages = extension = .txt mime = text/plain words = 9752 sentences = 562 flesch = 37 summary = medical science and thereby placed in the hands of the physician a victorious weapon against illness and death.' ' Since then antibodies in multiple forms (animal and human serums, immune globulins and monoclonal antibodies) have been developed, primarily for prevention of infectious diseases, and less commonly for their treatment. Thus regular use of IVIG in antibody-deficient patients in doses of 400 to 600 mg/kg every 3 to 4 weeks or an equivalent amount given subcutaneously decreases the frequency and severity of otitis and other respiratory tract infections [27, 28] . High-dose IVIG (sufficient to increase the serum IgG levels to 1000 mg/mL) has been used successfully in immunodeficient patients with enteroviral encephalomyelitis [80] [81] [82] [83] . Because IgG represents the major defense of humoral immunity against infection, these patients also require immunoglobulin replacement therapy. Individualizing the dose of intravenous immune serum globulin for therapy of patients with primary humoral immunodeficiency cache = ./cache/cord-283826-lgyc3sro.txt txt = ./txt/cord-283826-lgyc3sro.txt === reduce.pl bib === id = cord-267736-rya9w6sh author = Kang, Xiaoping title = Development of an ELISA-array for simultaneous detection of five encephalitis viruses date = 2012-02-27 pages = extension = .txt mime = text/plain words = 2990 sentences = 178 flesch = 47 summary = The ELISA-array assay is based on a "sandwich" ELISA format and consists of viral antibodies printed directly on 96-well microtiter plates, allowing for direct detection of 5 viruses. The developed ELISA-array proved to have similar specificity and higher sensitivity compared with the conventional ELISAs. This method was validated by different viral cultures and three chicken eggs inoculated with infected patient serum. The results demonstrated that this method combined the advantage of ELISA and protein array (multiplex and ease of use) and has potential for the identification of clinical encephalitis virus. When spotting, different spotting buffers and concentrations of capture monoclonal antibodies were evaluated to optimize the ELISA-array assay. To verify the results tested by ELISA-array, RNA extracted from chicken eggs was applied to a real time-RT-PCR assay using primers and probes targeting TBEV. In this study, we developed a multiplex ELISA-based method in a double-antibody sandwich format for the simultaneous detection of five encephalitis-associated viral pathogens. cache = ./cache/cord-267736-rya9w6sh.txt txt = ./txt/cord-267736-rya9w6sh.txt === reduce.pl bib === === reduce.pl bib === id = cord-307320-fxs31d66 author = Ubah, Obinna title = Monoclonal Antibodies and Antibody Like Fragments Derived from Immunised Phage Display Libraries date = 2018-03-17 pages = extension = .txt mime = text/plain words = 8292 sentences = 365 flesch = 30 summary = However, by combining the power of immunisation with phage display, several high affinity monoclonal antibodies against "difficult" antigenic targets have been isolated from relative small antibody libraries and where traditional approaches have failed [33, 98] . The above study demonstrates the power of animal immunisation and phage display based selection strategies to isolate high affinity monoclonal antibodies towards non-antigenic targets which inherently lack properties like aromaticity and charge. Spleen samples from mice immunised with gamma inactivated Brucella melitensis strain 16 M bacteria was used to construct a phage display library and isolate monoclonal antibody fragments that specifically recognise Brucella species. Similarly high affinity neutralising antibody fragments against the protective antigen (PA) of anthrax toxin was isolated from a Macaca immunised phage display library. Lymphocytes from the bone marrow cells of two chimpanzees immunised with anthrax toxin PA, LF and Edema factor (EF) were used to construct scFv phage display libraries and neutralising antibodies were isolated against PA and LF proteins. cache = ./cache/cord-307320-fxs31d66.txt txt = ./txt/cord-307320-fxs31d66.txt === reduce.pl bib === id = cord-317501-yblzopc3 author = Kuhn, Philipp title = Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display date = 2016-06-21 pages = extension = .txt mime = text/plain words = 11086 sentences = 593 flesch = 35 summary = Panning against peptides, recombinant viral proteins, or complete virus particles has led to the identification of antibodies directed against human pathogenic viruses such as Sin nombre virus [100] , Dengue virus [101, 102] , Influenza virus [103, 104] , VEEV [105] , Norovirus [106] , SARS coronavirus [107] , or Hepatitis C [108] from naïve antibody gene libraries. A naïve human Fab-phage library was screened for NS5-specific antibody fragments using various NS5 variants from Dengue Virus serotypes 1-4 as antigens for panning and characterization [128] . [180] reported the isolation of a human monoclonal antibody against the Block 2 region of Plasmodium falciparum merozoite surface protein-1 (PfMSP-1) by phage display from a malaria patient derived scFv library. In this context, the antibody phage display offers a powerful tool for antibody selection and allows the isolation of neutralizing antibodies against complete active toxins or special domains by using different human naïve antibody libraries with high diversity [185] [186] [187] . Single chain variable fragment antibodies against Shiga toxins isolated from a human antibody phage display library cache = ./cache/cord-317501-yblzopc3.txt txt = ./txt/cord-317501-yblzopc3.txt === reduce.pl bib === id = cord-313312-h607itv2 author = Mok, Darren Z. L. title = The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines date = 2020-05-08 pages = extension = .txt mime = text/plain words = 7417 sentences = 349 flesch = 34 summary = Pre-existing antibodies, derived from either from maternal–fetal transmission, or by previous infection or vaccination, have been demonstrated to interfere with vaccine immunogenicity of measles, adenovirus, and influenza LAVs. Immune interference of LAVs can be caused by the formation of virus–antibody complexes that neutralize virus infection in antigen-presenting cells, or by the cross-linking of the B-cell receptor with the inhibitory receptor, FcγRIIB. The clinical trial finding that subjects with a limited range of cross-reactive antibodies from a prior Japanese Encephalitis vaccine were able to enhance yellow fever vaccination, by prolonging vaccine viremia duration that leads to higher antibody titers, thus hints at the possibility that whether pre-existing antibodies inhibit or augment flavivirus infection will depend on both antibody titers and the type/specificity of antibodies produced [85] . By contrast, at sub-neutralizing titers, pre-existing antibodies can enable viruses to better infect cells and increase innate immune responses that augment LAV immunogenicity. By contrast, at sub-neutralizing titers, pre-existing antibodies can enable viruses to better infect cells and increase innate immune responses that augment LAV immunogenicity. cache = ./cache/cord-313312-h607itv2.txt txt = ./txt/cord-313312-h607itv2.txt === reduce.pl bib === id = cord-319746-6bccxgbd author = Saxena, Latika title = Production and Characterization of Human Monoclonal Antibodies from the Cells of A(H1N1)pdm2009 Influenza Virus Infected Indian Donors date = 2015-12-31 pages = extension = .txt mime = text/plain words = 3526 sentences = 174 flesch = 48 summary = title: Production and Characterization of Human Monoclonal Antibodies from the Cells of A(H1N1)pdm2009 Influenza Virus Infected Indian Donors Abstract Analysis of human monoclonal antibodies (mAbs) developed from influenza infected donors have enormously contributed to the identification of neutralization sensitive epitopes of influenza virus. In this study, we generated strongly neutralizing novel human monoclonal antibodies that were selected from the immune repertoire of influenza infected seropositive patients. Monoclonal antibody 2D8 showed the maximum binding in the in vitro assays and neutralized the human isolate of the pandemic strain as well as the reference strain at lowest concentrations when compared to the 2F12 antibody. The antibodies however, showed comparative neutralization and HAI activity between the laboratory isolates of the pandemic virus and the reference strain A/Cal/07/2009(H1N1). To, the best of our knowledge, these antibodies are the first fully human monoclonal antibodies generated from the immune repertoire of Indian patients infected with A(H1N1)pdm09 virus. cache = ./cache/cord-319746-6bccxgbd.txt txt = ./txt/cord-319746-6bccxgbd.txt === reduce.pl bib === id = cord-324316-ulb8d5fe author = Bramstedt, Katrina A. title = Antibodies as Currency: COVID-19’s Golden Passport date = 2020-08-25 pages = extension = .txt mime = text/plain words = 1398 sentences = 73 flesch = 49 summary = Due to COVID-19, the fragile economy, travel restrictions, and generalized anxieties, the concept of antibodies as a "declaration of immunity" or "passport" is sweeping the world. Numerous scientific and ethical issues confound the concept of an antibody passport; nonetheless, antibodies can be seen as a potential currency to allow movement of people and resuscitation of global economics. In this way, antibodies for SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2-the COVID-19 coronavirus) are potentially the new golden passport, but the concept is a moving target with clinical unknowns, as well as legal and ethical complexity (Phelan 2020; Persad and Emanuel 2020) . With the COVID-19 pandemic causing a fragile worldwide economy and millions of people unemployed (Congressional Research Service 2020), there is a risk of antibody certificates being viewed as the "golden passport" to return to work and travel. Show me your passport: Ethical concerns about Covid-19 antibody testing as key to reopening public life cache = ./cache/cord-324316-ulb8d5fe.txt txt = ./txt/cord-324316-ulb8d5fe.txt === reduce.pl bib === id = cord-327287-e5k2gcse author = May, Jori E. title = The challenges of diagnosing heparin‐induced thrombocytopenia in patients with COVID‐19 date = 2020-08-02 pages = extension = .txt mime = text/plain words = 174 sentences = 21 flesch = 46 summary = key: cord-327287-e5k2gcse authors: May, Jori E.; Siniard, Rance C.; Marques, Marisa title: The challenges of diagnosing heparin‐induced thrombocytopenia in patients with COVID‐19 cord_uid: e5k2gcse To the Editor, Riker EIAs are sensitive, but not specific, for HIT diagnosis because they detect all anti-platelet factor 4 (PF4)/heparin antibodies, including those that are nonpathogenic. 3 In contrast, functional assays (including SRA) identify only antibodies with the pathogenic ability to activate platelets and therefore have increased specificity. 3 Given that severe COVID-19 is a hyperinflammatory state, it is plausible that the increased immunoreactivity also increases production of anti-PF4/heparin antibodies; however, they may not result in clinical HIT but may instead increase potential for false-positive EIAs. Herein, we report our experience with hospitalized patients with The authors have no conflicts of interest to disclose. Heparin-induced thrombocytopenia with thrombosis in COVID-19 adult respiratory distress syndrome COVID-19 and its implications for thrombosis and anticoagulation Testing for heparin-induced thrombocytopenia antibodies cache = ./cache/cord-327287-e5k2gcse.txt txt = ./txt/cord-327287-e5k2gcse.txt === reduce.pl bib === id = cord-321901-zpi7uis1 author = Roberts, Anjeanette title = Animal models and antibody assays for evaluating candidate SARS vaccines: Summary of a technical meeting 25–26 August 2005, London, UK date = 2006-11-30 pages = extension = .txt mime = text/plain words = 6600 sentences = 311 flesch = 40 summary = Scientists at the WHO Technical Meeting on Animal Models and Antibody Assays for Evaluating Candidate SARS Vaccines held on 25-26 August 2005 in South Mimms, UK, discussed many aspects of research pertaining to the use of animal models in vaccine development including available animal models, suitability of the various models, correlates of protection, critical components of potential vaccines, and the potential for disease enhancement in vaccinated animals following exposure to SARS-CoV. It may actually be worthwhile to enhance the virulence of a SARS-CoV isolate by serial passages in an animal model to produce a challenge virus stock for vaccine studies that would elicit more reproducible disease in the animals. Although none of the studies to date have shown enhanced respiratory disease following SARS-CoV challenge in previously immunized animals, further studies in this area are warranted in view of some of the available in vitro data. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice cache = ./cache/cord-321901-zpi7uis1.txt txt = ./txt/cord-321901-zpi7uis1.txt === reduce.pl bib === id = cord-329857-pcsuu597 author = Chan, Kuan Rong title = Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases date = 2015-11-02 pages = extension = .txt mime = text/plain words = 5862 sentences = 280 flesch = 28 summary = The binding affinity of antibodies to viruses can directly impact the efficacy of mAbs [4] , suggesting that target-specific mechanisms likely account for much of the efficacy of therapeutic mAbs. However, many studies have also highlighted the contribution of Fc-mediated immune effector functions in modulating the efficacy of these mAbs [5] . FcgRs have been shown to be important in modulating the efficacy of therapeutic mAbs [5] due to their involvement in FcgRmediated phagocytosis, cytokine production, ADCC and complement-dependent cytotoxicity (CDC) that aids in virus neutralization (FIGURE 1). Given the importance of FcgRs in mediating virus neutralization and Fc effector functions, a better understanding of how therapeutic antibodies neutralize virus infections in FcgRbearing cells will impact implementation of dosing regiments and allow development of improved therapeutic antibodies against infectious diseases. Given the importance of Fc-FcgR interaction in antibodymediated effector functions, Fc modification could lead to the development of therapeutic antibodies with improved interaction to activating FcgRs. This could enhance FcgR-mediated uptake, cytokine production, antigen presentation, ADCC and CDC. cache = ./cache/cord-329857-pcsuu597.txt txt = ./txt/cord-329857-pcsuu597.txt === reduce.pl bib === id = cord-328935-mn8r972x author = Hodgins, Douglas C. title = Mucosal Veterinary Vaccines: Comparative Vaccinology date = 2015-03-13 pages = extension = .txt mime = text/plain words = 16336 sentences = 785 flesch = 36 summary = Studies of the potential of novel adjuvants to improve vaccine efficacy against genetically unstable, immune-subverting RNA viruses, such as porcine reproductive and respiratory syndrome virus in pigs, should assist in the control of pathogens with similar characteristics in other species. However, a recent study showed that an inactivated reassortant RV strain (CDC-9 strain) formulated with aluminum phosphate and administered systemically in gnotobiotic pigs resulted in induction of serum IgG antibody titers, coinciding with partial protection against shedding and diarrhea, suggesting that adjuvant may have stimulated local specific (gut IgA antibodies) or nonspecific immune responses, which were not assessed in this study (Wang et al., 2010) . Intranasal delivery of whole cell lysate of Mycobacterium tuberculosis induces protective immune responses to a modified live porcine reproductive and respiratory syndrome virus vaccine in pigs cache = ./cache/cord-328935-mn8r972x.txt txt = ./txt/cord-328935-mn8r972x.txt === reduce.pl bib === id = cord-327883-s9nbr5y8 author = nan title = Section Virology date = 1990-03-31 pages = extension = .txt mime = text/plain words = 10576 sentences = 571 flesch = 48 summary = By improving the enzyme-linked immunosorbent assay (ELISA) for HSV-2-antibodies and additional testing of sera by Western blot, we were able to specifically identify HSV-l-and HSV-2-antibodies in serum samples. To get some insight into the molecular basis of processes controlling the viral expression we studied the sequence-specific DNA-protein interactions within the genomic regulatory regions. for Med. Microbiology, Univ., D-5300 Bonn Semiquantitative detection of Hepatitis B Virus (HBV) DNA in sera of infected individuals has become an important means of modern serological hepatitis diagnostics. THOMSSEN 1 In the course of acute Epstein-Barr virus (EBV) infection IgM antibodies always occur against two cellular antigens that were characterized as proteins with a molecular weight of 26 kD (p26) and 29 kD (p29), respectively. The frequency and specificity of antibodies to P-gene encoded proteins of human hepatitis B virus was tested in sera of acute and chronically infected patients with and without hepatocellular carcinoma (HCC). cache = ./cache/cord-327883-s9nbr5y8.txt txt = ./txt/cord-327883-s9nbr5y8.txt === reduce.pl bib === id = cord-352172-g0jiaenw author = Stoevesandt, Oda title = Protein microarrays: high-throughput tools for proteomics date = 2014-01-09 pages = extension = .txt mime = text/plain words = 7464 sentences = 373 flesch = 32 summary = While conventionally made by the spotting of purified proteins, recent advances in technology have made it possible to produce protein microarrays through in situ cell-free synthesis directly from corresponding DNA arrays. Protein microarray technology has rapidly developed into one of the most active areas in biotechnology today, and is being increasingly applied for the high-throughput discovery of molecular interactions, profiling of protein expression and monitoring of protein modifications. While genome sequencing and annotations provide comprehensive information on protein-encoding genes, and DNA arrays analyze gene expression at the mRNA level, these technologies need to be complemented by functional proteomic studies in order to better understand protein activities, expression levels and interactions at the system level. A reverse-phase micro array approach has been successfully applied to discover distinct pathway-activation differences among breast cancer cell lines, demonstrating the use of array-based ana lysis for multiple pharmacodynamic biomarkers responding to targeted kinase inhibitors [108] . cache = ./cache/cord-352172-g0jiaenw.txt txt = ./txt/cord-352172-g0jiaenw.txt === reduce.pl bib === id = cord-336280-tsx409e3 author = Byrne, Barry title = Antibody-Based Sensors: Principles, Problems and Potential for Detection of Pathogens and Associated Toxins date = 2009-06-05 pages = extension = .txt mime = text/plain words = 12263 sentences = 613 flesch = 38 summary = Particular emphasis is placed on the detection of foodborne bacterial pathogens, such as Escherichia coli and Listeria monocytogenes, and additional examples relating to the monitoring of fungal pathogens, viruses, mycotoxins, marine toxins and parasites are also provided. It describes the development of electrochemical, potentiometric, piezoelectric and optical platforms for the monitoring of foodborne bacterial pathogens by incorporating monoclonal, polyclonal or recombinant antibodies in a variety of different assay formats. Polyclonal antibodies (pAb) are typically raised in rabbits, goats or sheep [29] , and their popularity is illustrated by the fact that they are frequently selected in immunosensor-based assays for pathogen detection. Hence, the selection of a highly-specific epitope on the pathogen is a key consideration, since many bacterial strains share homologues of surface-presented proteins which can lead to the detection of multiple cell-types by a single antibody. Muhammad-Tahir and Alocilja [74] developed a conductimetric biosensor incorporating a polyclonal antibody-based sandwich assay format in which the detection antibody was labelled with polyaniline. cache = ./cache/cord-336280-tsx409e3.txt txt = ./txt/cord-336280-tsx409e3.txt === reduce.pl bib === id = cord-316287-4i1grvlr author = Yim, Sung Sun title = Rapid Isolation of Antibody from a Synthetic Human Antibody Library by Repeated Fluorescence-Activated Cell Sorting (FACS) date = 2014-10-10 pages = extension = .txt mime = text/plain words = 6372 sentences = 281 flesch = 51 summary = During the cultivation for regeneration of sorted cells, differential growth rates among various clones (particularly non-specific clones) due to unregulated protein expression and differing cell viability can decrease the library screening efficiency, resulting in more rounds of sorting (longer duration) to isolate the potential antibody candidate [12] . The whole FACS screening rounds of the synthetic human antibody library against each viral antigen could be done in one day, and these results show that repeated FACS screening without regeneration of the sorted cells can be a rapid and efficient method to isolate potential antibody candidates in case of urgent requirements. For the FACS screening of a human synthetic antibody (scFv) library, three fluorescent antigen probes were chemically synthesized: (i) FITC-CRDNWHGSNRPW as an N1 epitope of H1N1 influenza virus [13] ; (ii) FITC-NSTTFHQALLDPRVRGLYF-PAGG as a PreS2 epitope of HBV [14] ; and (iii) FITC-PVTNVRGDLQVLAQK as a VP1 epitope of FMDV [15] . cache = ./cache/cord-316287-4i1grvlr.txt txt = ./txt/cord-316287-4i1grvlr.txt === reduce.pl bib === id = cord-326673-p8qbxi57 author = Kitching, R. P. title = The interference by maternally-derived antibody with active immunization of farm animals against foot-and-mouth disease date = 1995-12-31 pages = extension = .txt mime = text/plain words = 4788 sentences = 197 flesch = 45 summary = This maternally-derived antibody (MDA) provides immediate protection against infection with FMD virus, but also interferes with the development of active immunity following vaccination. However, this maternally derived antibody (MDA) is equally effective in preventing the response to active vaccination in the young animal as it is in providing protection against disease. In the case of FMD vaccination in pigs, Francis and Black (1986) concluded that the complete immunological unresponsiveness seen in the first 2 weeks of life was due to immaturity of the immune system and antigen blockade by high titre MDA, and as this titre declined an active suppression of T and/or B cells occurred to variable degrees. Francis and Black (1984) found no evidence in the pig that vaccination in the presence of MDA depressed the specific antibody to FMD virus. The effect of maternally derived antibodies on the response of calves to vaccination against foot-and-mouth disease cache = ./cache/cord-326673-p8qbxi57.txt txt = ./txt/cord-326673-p8qbxi57.txt === reduce.pl bib === id = cord-319884-d8n0aokl author = Natesan, Mohan title = Protein Microarrays and Biomarkers of Infectious Disease date = 2010-12-16 pages = extension = .txt mime = text/plain words = 7088 sentences = 359 flesch = 36 summary = Fluorescencebased detection of protein interactions is similar to gene array methods, and data analysis often employs approaches previously developed for genome and transcription studies. A standard assay for measuring antibody interactions with proteins of the vaccinia proteome microarray was first developed with a pool of therapeutic human sera collected from vaccinia-immune individuals (VIg) and this data was compared to results obtained from individuals vaccinated against smallpox using Dryvax. Results from this study suggested that antibodies from vaccination recognized a small number of proteins shared with pathogenic viral strains, while recovery from infection also involved humoral immunity to antigens uniquely recognized within the monkeypox virus proteome (unpublished data). For example, a protein array produced from the outer membrane proteins of Pseudomonas aeruginosa was constructed [38] to study the immune response in patients, and several antibody-binding antigens were identified by this group as potential diagnostic markers. cache = ./cache/cord-319884-d8n0aokl.txt txt = ./txt/cord-319884-d8n0aokl.txt === reduce.pl bib === id = cord-354790-xx6imhzb author = Lambour, Jennifer title = Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play date = 2016-08-17 pages = extension = .txt mime = text/plain words = 6499 sentences = 324 flesch = 33 summary = 31 In addition to controlling the viral propagation by these mechanisms, the opsonization of viral particles and/or infected cells by therapeutic antiviral mAbs of the IgG type leads to the formation of immune complexes (ICs) recognizable by the FcγRs expressed on antigen-presenting cells (APCs) such as DCs. This can potentially affect the endogenous antiviral adaptive immune response of passive immunotherapy-treated individuals. Moreover, as the in vivo activity of anti-HIV-1 bNAbs, including viral load control, was recently shown to crucially depend on Fc effector functions, 53,54 an important issue is identifying that Fc-FcγRs interactions are involved in the induction of vaccinelike effects by antiviral mAbs. To understand the mechanisms underlying the enhancement of antiviral responses by ICs, several in vitro studies have addressed whether antibody-mediated viral uptake by DCs could lead to stronger activation of these cells and the development of stronger virus-specific CD4 + and CD8 + T-cell responses in an Fc-dependent manner. cache = ./cache/cord-354790-xx6imhzb.txt txt = ./txt/cord-354790-xx6imhzb.txt === reduce.pl bib === id = cord-321369-xzu2faol author = Andreano, Emanuele title = Extremely potent human monoclonal antibodies from convalescent Covid-19 patients date = 2020-10-07 pages = extension = .txt mime = text/plain words = 3685 sentences = 192 flesch = 52 summary = By single cell sorting 4277 SARS-CoV-2 spike protein specific memory B cells from 14 Covid-19 survivors, 453 neutralizing antibodies were identified and 220 of them were expressed as IgG. The three most potent monoclonal antibodies identified were able to neutralize the wild type and D614G mutant viruses with less than 10 ng/mL and are good candidates for the development of prophylactic and therapeutic tools against SARS-CoV-2. As for the authentic virus neutralization assay, supernatants containing naturally produced IgG or IgA were tested for their ability to protect the layer of Vero E6 cells from the cytopathic effect triggered by SARS-CoV-2 infection (Fig. S2) . This work describes a systematic screening of memory B cells from convalescent people to identify extremely potent human monoclonal antibodies against the spike protein of the SARS-CoV-2 virus, to be used for prevention and therapy of Covid-19. cache = ./cache/cord-321369-xzu2faol.txt txt = ./txt/cord-321369-xzu2faol.txt === reduce.pl bib === id = cord-345296-4z7yfj5s author = Ho, Mei-Shang title = Neutralizing Antibody Response and SARS Severity date = 2005-11-17 pages = extension = .txt mime = text/plain words = 4600 sentences = 190 flesch = 42 summary = Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. To adjust the time effects and other covariates of interest, the relationship between antibody titer, based on logarithmic transformation of base 2 (serum dilution) and other potential factors, i.e., age, sex, infection source, and duration of illness, was quantified by linear mixed models (18) , which took into account the correlation between repeated measurements of each study participants. In the model, patients with a more severe clinical course had earlier and higher antibody responses; we then examined the death rate of the early responders (Table 6 ). Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways cache = ./cache/cord-345296-4z7yfj5s.txt txt = ./txt/cord-345296-4z7yfj5s.txt === reduce.pl bib === id = cord-349669-o3eelqcw author = Stadlbauer, Daniel title = Anti‐SARS‐CoV‐2 Spike Antibodies are Stable in Convalescent Plasma when Stored at 4° Celsius for at Least 6 Weeks date = 2020-08-14 pages = extension = .txt mime = text/plain words = 895 sentences = 49 flesch = 54 summary = Convalescent plasma (CP) has presented another option, with its use and safety supported by numerous case series and retrospective studies [2] [3] [4] . Studies demonstrating antibody stability under refrigerated conditions have largely focused on peripheral blood samples stored for several days 7, 8 . Here, we demonstrate the long-term stability of anti-SARS-CoV-2 spike antibodies in donor CP samples collected at a local blood donor center for transfusion. After thawing of fifteen CP units, segments were sampled and anti-spike antibody titers were determined via enzyme-linked immunosorbent assays (ELISAs) 9 . While our study does not address the neutralization capacity of these antibodies, previous studies demonstrate significant correlation between spike antibody titers and neutralization capacity of plasma and serum samples 9 . Treatment of COVID-19 Patients with Convalescent Plasma Early safety indicators of COVID-19 convalescent plasma in 5,000 patients Convalescent plasma treatment of severe COVID-19: A matched control study Long-term stability of trastuzumab in plasma and whole blood samples stored under different conditions cache = ./cache/cord-349669-o3eelqcw.txt txt = ./txt/cord-349669-o3eelqcw.txt === reduce.pl bib === id = cord-330324-4hqhty5o author = Yu, Meng title = Determination and application of immunodominant regions of SARS coronavirus spike and nucleocapsid proteins recognized by sera from different animal species date = 2008-02-29 pages = extension = .txt mime = text/plain words = 5799 sentences = 284 flesch = 50 summary = title: Determination and application of immunodominant regions of SARS coronavirus spike and nucleocapsid proteins recognized by sera from different animal species In this study, we aim to search for and compare immunodominant regions of the spike (S) and nucleocapsid (N) proteins which are recognized by sera from different animal species, including mouse, rat, rabbit, civet, pig and horse. In this study we identified and characterized the major immunodominant domains of the SARS-CoV N and S proteins recognized by different animal species, and then developed competition ELISAs based on these findings. The specificity of the antibody was further confirmed using Western blot against viral antigen (data not shown) and IFAT using SARS-CoV infected Vero cells. One of the main aims of this study was to assess the feasibility of developing a competition ELISA for detection of SARS-CoV antibodies from different animal species. Inhibition of binding of mono-specific chicken antibodies to SARS-CoV by sera from different species. cache = ./cache/cord-330324-4hqhty5o.txt txt = ./txt/cord-330324-4hqhty5o.txt === reduce.pl bib === id = cord-337464-otwps68u author = Parray, Hilal Ahmed title = Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives date = 2020-05-27 pages = extension = .txt mime = text/plain words = 12204 sentences = 606 flesch = 38 summary = Even with the recent development of high throughput mAb generation technologies, hybridoma is the most favoured method due to its indigenous nature to preserve natural cognate antibody pairing information and preserves innate functions of immune cells. This review also summarizes the challenges and recent progress associated with hybridoma development, and how it has been overcome in these years to provide new insights for the isolation of mAbs. Antibodies are the glycoproteins produced by the B-cells also known as immunoglobulins, which are present in higher eukaryotes. The mice hybridoma technology is a multi-step process that takes advantage of a host animal's natural ability to produce highly specific, high-affinity and fully functional mAbs. It involves the development and optimization of specific immunogenic antigen (Ag). cache = ./cache/cord-337464-otwps68u.txt txt = ./txt/cord-337464-otwps68u.txt === reduce.pl bib === id = cord-023364-ut56gczm author = nan title = EDUCATION DAY MONDAY: PLENARY SESSION 1 MONDAY: PARALLEL SESSIONS date = 2005-06-08 pages = extension = .txt mime = text/plain words = 130049 sentences = 7334 flesch = 54 summary = • enhancement of automation/computerisation; • process control to provide an 'error-free pathway'; • (national) surveillance and trend analysis of results, preferably based on national working standards; • significantly increased sensitivity, especially from development of antigen/antibody 'combi' assays (e.g. for HIV, and recently, for HCV); • awareness of HBsAg vaccine-escape mutants and design of assays to cope with this; • extension of range of agents and markers tested for (varies in different countries); • increasing range of assays available for testing donors with a relevant history of exposure to malaria or Chagas' disease infection (for retrieval of otherwise wasted blood); • European Union's in vitro diagnostics directive: this has caused some problems and reduced flexibility. cache = ./cache/cord-023364-ut56gczm.txt txt = ./txt/cord-023364-ut56gczm.txt === reduce.pl bib === id = cord-327629-ep28ay11 author = Herron, J.B.T. title = Coronavirus antibody positive tests and continued use of personal protective equipment throughout the pandemic date = 2020-06-20 pages = extension = .txt mime = text/plain words = 1172 sentences = 74 flesch = 53 summary = authors: Herron, J.B.T.; Dennis, J.; Brennan, P.A. title: Coronavirus antibody positive tests and continued use of personal protective equipment throughout the pandemic Antibody testing has rapidly been deployed but it is creating challenges for staff and patients. Mask use has come to the forefront and human factor (HF) strategies must be examined to reduce risk associated with lack of engagement from both healthcare staff and patients. Suggested plans have included developing a cohort of immune staff to care for COVID-19 patients allowing for a relaxation of overstretched personal protection equipment (PPE) resources. Masks reduce nosocomial spread and are important, particularly for healthcare staff (19) . For the antibody test, even after the exact nature of protection is determined, basic public health measures are not forgotten and that staff feel able to challenge those in more authoritative positions regarding PPE. Personal protective equipment and Covid 19-a risk to healthcare staff? cache = ./cache/cord-327629-ep28ay11.txt txt = ./txt/cord-327629-ep28ay11.txt === reduce.pl bib === id = cord-335316-x2t5h5gu author = Madariaga, M. L. L. title = Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial date = 2020-06-23 pages = extension = .txt mime = text/plain words = 4328 sentences = 234 flesch = 47 summary = This was a prospective open label clinical study to assess the feasibility, safety and immunological impact of delivering anti-SARS-CoV-2 convalescent plasma to hospitalized patients aged 18 years or older with severe or life-threatening COVID-19 disease within 21 days from the onset of their illness. Univariate regression analysis for antibody titer (anti-RBD and anti-spike) was conducted against age, sex, body mass index (BMI), previous pregnancy, previous blood donation, blood type, symptoms (fever, cough, sore throat, dyspnea, abdominal pain, aguesia, anosmia, fatigue, myalgia, headache), co-morbidities (respiratory, cardiovascular, renal, diabetes, autoimmune disease, cancer, liver disease), smoking history, travel in the past 3 months to the United States, Asia or Europe, symptom duration, interval from symptoms resolution to plasma donation, and hospitalization. To determine predictors of anti-RBD and anti-spike antibody titer, we performed best subset multivariable analysis including age, sex, blood type, history of previous blood donation, fever, cough, fatigue, myalgia, symptom duration, hospitalization and travel in the United States within the past 3 months. cache = ./cache/cord-335316-x2t5h5gu.txt txt = ./txt/cord-335316-x2t5h5gu.txt === reduce.pl bib === id = cord-335311-l73hsik0 author = Chan, Conrad E. Z. title = The role of phage display in therapeutic antibody discovery date = 2014-08-18 pages = extension = .txt mime = text/plain words = 7044 sentences = 286 flesch = 31 summary = The defining attribute of all phage display libraries is the physical linking of antibody phenotype (specificity and affinity) with genotype (sequence) via the phage particle-this allows for in vitro selection on immobilized antigen or whole cells (Fig. 2) . In particular, a phage library constructed with the heavy chain CDR3 enriched for basic residues to improve binding to negatively charged carbohydrates produced anti-carbohydrate antibodies that had relatively high affinity (K D ≈ 50 nM) and excellent specificity (40) . Phage display is also likely to remain useful for discovery of antibodies against non-protein targets, evolution of dual-binding antibodies and for affinity maturation, due to the limitations of the natural immune system. Comparison of the efficiency of antibody selection from semi-synthetic scFv and non-immune Fab phage display libraries against protein targets for rapid development of diagnostic immunoassays The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies cache = ./cache/cord-335311-l73hsik0.txt txt = ./txt/cord-335311-l73hsik0.txt === reduce.pl bib === id = cord-339879-92esdjy9 author = Delhalle, Sylvie title = Phages and HIV-1: From Display to Interplay date = 2012-04-13 pages = extension = .txt mime = text/plain words = 21838 sentences = 978 flesch = 44 summary = The BNtAb IgG1 b12 was the first neutralizing MAb selected from a phage-displayed Fab (antibody fragment composed of one constant and one variable domain of the heavy (CH1 and VH) and the light (CL and VL) chains linked together) library derived from an HIV-1-infected donor (See section 3.1.1.1.1.) [41] . At the end of the second round, selected phages displaying longer inserts of 40 to 50 AA corresponding to the N-and C-terminal regions of Gag were identified, revealing the presence of two distinct antigenic regions in Gag. This study demonstrated that gene-fragment phage display could be used to identify epitopes targeted by polyclonal Abs. Although they occur at a very low frequency in humans, antibodies targeting host proteins involved in HIV-1 infection have been reported in immunized animals. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries cache = ./cache/cord-339879-92esdjy9.txt txt = ./txt/cord-339879-92esdjy9.txt === reduce.pl bib === id = cord-350029-1y5ex4d5 author = McDade, Thomas W. title = Beyond serosurveys: Human biology and the measurement of SARS‐Cov‐2 antibodies date = 2020-08-09 pages = extension = .txt mime = text/plain words = 2690 sentences = 129 flesch = 43 summary = Serological testing is a complementary approach that detects the presence of antibodies against SARS-CoV-2 in blood samples from exposed individuals (World Health Organization, 2020). If sufficient time has passed since the initial infection, the presence of IgM antibodies against SARS-CoV-2 antigens can be used to confirm a clinical case of COVID-19. In developing a low-cost ELISA for SARS-CoV-2 antibodies, our hope is that others can draw on the longstanding tradition of methodological innovation in human biology to promote community-based research on COVID-19. Human biologists are also well-positioned to consider a life course perspective on variation in outcomes in response to SARS-CoV-2 infection. Human biologists are uniquely positioned to make important contributions to our understanding of COVID-19, and methods that facilitate research in community-based settings globally will be central to that effort. Enzyme immunoassay for SARS-CoV-2 antibodies in dried blood spot samples: A minimally-invasive approach to facilitate community-and population-based screening cache = ./cache/cord-350029-1y5ex4d5.txt txt = ./txt/cord-350029-1y5ex4d5.txt === reduce.pl bib === id = cord-330218-l5q3n3ri author = Foss, Stian title = TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity date = 2015-10-26 pages = extension = .txt mime = text/plain words = 7824 sentences = 376 flesch = 41 summary = Neutralization of viruses by antibodies is predicted to depend on high-affinity binding to specific epitopes of surface-exposed viral proteins that are required for binding to target cell receptors (4) . These effector functions are induced upon binding of antibody-virus immune complexes to classical Fc c receptors (FccRs) expressed on the surface of hematopoietic cells such as natural killer (NK) cells, macrophages, and dendritic cells, which results in clearance and induction of T-cell responses (8) . Low antibody-virus stoichiometry may also result in inefficient FccR-mediated effector functions by immune cells as efficient phagocytosis requires the formation of immune complexes and cross-binding to cell-surface FccRs. In addition, as TRIM21 also engages IgM and IgA, it is likely to contribute to early protection, and at the gate of entry of most viral pathogens, the mucosal barrier. cache = ./cache/cord-330218-l5q3n3ri.txt txt = ./txt/cord-330218-l5q3n3ri.txt === reduce.pl bib === id = cord-354137-6oe8nj1j author = Wang, Hua title = Aspects of recent development of immunosensors date = 2008-05-20 pages = extension = .txt mime = text/plain words = 9972 sentences = 481 flesch = 23 summary = Development of microfluidic immunosensor systems for proteomics and drug discovery have also been reported in recent years where the microfluidic system integrates multiple processes in a single device to improve analytical performance by reducing the reagent consumption and the analysis time, and increasing reliability and sensitivity through automation. A capacitive immunoassay based on antibody-embedded ultra-thin alumina sol-gel fi lms (∼20 to 40 nm) was reported and used for direct determination of antigens with a detection limit as low as ϳ1 ng mL Ϫ1 [92] . reported a successful integration of the lateral fl ow immunoassay format and impedance detection for prostate-specifi c antigen of tumor marker, where the electrochemical transducer was coated with a pH-sensitive polymer layer [93] . Based on the modifi cation of mixed SAMs on gold electrodes for covalently binding antigens, another piezoelectric immunosensor has been recently developed to detect antisperm antibody [153] . cache = ./cache/cord-354137-6oe8nj1j.txt txt = ./txt/cord-354137-6oe8nj1j.txt === reduce.pl bib === id = cord-338517-1mxcssjj author = Ishay, Yuval title = Antibody response to SARS‐Co‐V‐2, diagnostic and therapeutic implications date = 2020-08-26 pages = extension = .txt mime = text/plain words = 7387 sentences = 399 flesch = 40 summary = The phage display method, allowing rapid and wide display of proteins directly correlated to their associated genes, can detect NAbs against SARS-CoV from both naïve and immune antibody libraries, capable of blocking the binding of S1 domain, thereby showing virus neutralization and prophylaxis capability either in vitro or in the animal models (31, 33, 36) . Another method, possibly allowing the production and utilization of existing NAbs, may include the use of Epstein-Barr virus (EBV) transformation of human B cells to improve the isolation of NAbs from the memory B cells harvested from the SARS-CoV infected patients (11) . Experimental and clinical data on the use of convalescent plasma products and humanized monoclonal antibodies for H5N1 influenza infection have also shown positive outcomes, and this treatment was proposed as a mean for overcoming anti-viral drug resistance (62, 79, 80) . In a study involving 20 patients with severe pandemic influenza A (H1N1) 2009 virus infection, administration of convalescent plasma reduced respiratory tract viral load, serum cytokine response, and mortality (81) . cache = ./cache/cord-338517-1mxcssjj.txt txt = ./txt/cord-338517-1mxcssjj.txt === reduce.pl bib === id = cord-331786-wgt7kg6f author = Diego-Martin, Borja title = Pilot production of SARS-CoV-2 related proteins in plants: a proof of concept for rapid repurposing of indoors farms into biomanufacturing facilities date = 2020-10-13 pages = extension = .txt mime = text/plain words = 7034 sentences = 326 flesch = 45 summary = For this purpose, we tested our ability to produce, in the framework of an academic lab and in a matter of weeks, milligram amounts of six different recombinant monoclonal antibodies against SARS-CoV-2 in Nicotiana benthamiana. In parallel, we also produced the recombinant SARS-CoV-2 N protein and its Receptor Binding Domain (RBD) in planta and used them to test the binding specificity of the recombinant mAbs. Finally, for two of the antibodies we assayed a simple scale-up production protocol based on the extraction of apoplastic fluid. Finally, we performed sandwich ELISA tests of sybody17 and nanobody72 ( Fig 5E and Fig 5F, respectively) using the total and concentrated apoplastic fluid as detection reagent against serial dilutions of crude plant extracts from RBD-producing plants, showing that this simple antibody preparation can be directly employed in detection procedures without the need of additional purification steps. cache = ./cache/cord-331786-wgt7kg6f.txt txt = ./txt/cord-331786-wgt7kg6f.txt === reduce.pl bib === id = cord-344445-slv7r9u7 author = Vakharia, Kunal title = The right to know: ethical implications of antibody testing for healthcare workers and overlooked societal implications date = 2020-06-03 pages = extension = .txt mime = text/plain words = 2415 sentences = 119 flesch = 50 summary = The discussion that has continued since the initial severe acute respiratory syndrome virus and avian influenza epidemics has focused on the potential for immunity among the general population and the moral obligation to treat that is often faced by healthcare professionals and institutions. With the growing literature and data suggesting the possibility of mutations, unequal impacts on different people and the potential repercussions of the spike protein for those with IgG immunity already, can society in good faith adopt a moral prerogative to put antibody-positive people in the front line? Healthcare workers form a group of individuals who recognise the potential of COVID-19, the impact it has had, and are still willing to go to work and continue to face the challenge. With limited knowledge about the significance of COVID-19 antibody testing at this time, it is hard to use this to stratify work in a healthcare setting or to use it for any purpose beyond epidemiological studies on the spread of the disease. cache = ./cache/cord-344445-slv7r9u7.txt txt = ./txt/cord-344445-slv7r9u7.txt === reduce.pl bib === id = cord-355610-7xy4s483 author = Hu, Dan title = A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III date = 2019-06-26 pages = extension = .txt mime = text/plain words = 6168 sentences = 307 flesch = 52 summary = Here, by using sequential antigen panning of a yeast antibody library derived from healthy donors against the DENV envelop protein domain III (DIII) combined with depletion by an entry defective DIII mutant, we identified a cross-reactive human monoclonal antibody (mAb), m366.6, which bound with high affinity to DENV DIII from all four DENV serotypes. Furthermore, as the first germline-like mAb derived from a naïve antibody library that could neutralize all four DENV serotypes, the m366.6 can be a tool for exploring mechanisms of DENV infection, and is a promising therapeutic candidate. Its fully human origin, the germline-like nature, combined with high-affinity and broad neutralizing activity toward all DENV serotypes, suggest that m366.6 is a promising candidate antiviral agent and may also provide a unique template for designing effective dengue vaccine immunogens. Two antibodies, designated as m360 and m366, bound potently to DENV DIIIs. Their scFv gene were fused with human IgG1 Fc for protein expression, and surface plasmon resonance (SPR) experiments were used to evaluate the antigens binding. cache = ./cache/cord-355610-7xy4s483.txt txt = ./txt/cord-355610-7xy4s483.txt === reduce.pl bib === id = cord-335121-ro3x3qa3 author = Ingram, George A. title = A comparative assessment of four serological methods used in the detection and measurement of anti-parasite antibodies in the serum of the amphibian, bufo viridis date = 1988-04-30 pages = extension = .txt mime = text/plain words = 3116 sentences = 180 flesch = 50 summary = Abstract Antibodies against Crithidia fasciculata choanomastigotes were detected in green toad (Bufo viridis) sera by direct agglutination, indirect haemagglutination (IHA), complement-fixation test (CFT) and enzyme-linked immunosorbent assay (ELISA), Correlation coefficients (r) were calculated for comparisons between each of the techniques and regression formulae derived in order to convert antibody levels as determined by one immunological method to that of another. In this paper we present the results of acomparative assessment of four serological tests (direct agglutination, indirect haemagglutination, complement-fixation test and ELISA) used to detect and to determine the levels of antibodies in the sera of green toads (B. fasciculata and the number of control and immune sera containing detectable antibodies were the lowest for DA and CFT, intermediate for IHA and highest for the ELISA method (Table 1) . Nevertheless the method of antigen preparation ma> not be a salient criterion for antibody estimation in immune sera because correlation values of over 89% (f'< 0.001) were found when IHA titres were compared to those of ELISA. cache = ./cache/cord-335121-ro3x3qa3.txt txt = ./txt/cord-335121-ro3x3qa3.txt === reduce.pl bib === id = cord-328753-qwdxgk4z author = Lafaye, Pierre title = Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases date = 2018-09-25 pages = extension = .txt mime = text/plain words = 4624 sentences = 251 flesch = 42 summary = The antigen-binding region of such homodimeric heavy-chain only antibodies consists of one single domain, called VHH. VHHs provide many advantages over conventional full-sized antibodies and currently used antibody-based fragments (Fab, scFv), including high specificity, stability and solubility, and small size, allowing them to recognize unusual antigenic sites and deeply penetrate tissues. The active antigen-binding fragment of heavy chain antibodies can be cloned and expressed in the form of VHH, which consists of only one domain (Fig. 1) . Gene therapy with an adenoviral vector expressing a bispecific VHH, consisting of two linked VHHs targeting different PA-neutralizing epitopes, was tested in mice, and found to protect them from anthrax toxin challenge and anthrax spore infection [55] . [92] have been found in the sera of infected camels, whereas antibodies against rabies virus, vesicular stomatitis virus, and FMD virus have been detected in llamas [93] and could lead to the possible isolation of specific broadly neutralizing VHHs. Many neutralizing VHHs that bind to different sites on the same target, including hidden antigenic sites, can be isolated from immunized or infected camelids. cache = ./cache/cord-328753-qwdxgk4z.txt txt = ./txt/cord-328753-qwdxgk4z.txt === reduce.pl bib === id = cord-339520-odly2fwg author = Madic, J. title = Isotype-specific antibody responses to bovine herpesvirus 1 in sera and mucosal secretions of calves after experimental reinfection and after reactivation date = 1995-07-31 pages = extension = .txt mime = text/plain words = 3360 sentences = 172 flesch = 49 summary = Abstract Isotype-specific antibody responses to bovine herpesvirus 1 (BHV1) were measured in sera, nasal, ocular and genital secretions of calves that were reinfected with BHV1 and 6 weeks later treated with corticosteroids to reactivate putative latent virus. The control calves, which were infected for the first time, developed an IgM antibody response in serum, nasal and ocular secretions that was first detected on PRD 8 and lasted until PRD 27. Calves in which no virus excretion after reinfection and/or corticosteroid treatment was detected yet developed an antibody response against BHVl, mainly of the IgA isotype. However, it may be the serum IgA response seems to be a much more sensitive indicator for reinfection with or reactivation of BHVl than detection of nasal and ocular virus shedding. After corticosteroid treatment, virus-positive nasal secretions were detected in 20 of 26 reinfected calves, and a significant increase in serum IgGl and IgG2 antibody titre in 17 and 12 calves, respectively. cache = ./cache/cord-339520-odly2fwg.txt txt = ./txt/cord-339520-odly2fwg.txt === reduce.pl bib === id = cord-342242-cynpob7b author = Godakova, Svetlana A. title = Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice date = 2019-08-07 pages = extension = .txt mime = text/plain words = 7485 sentences = 386 flesch = 54 summary = Based on the analysis of B11-Fc and G3-Fc clones' circulation time in the serum (presence of antibodies 14 days after injection), we decided to conduct an experiment on the survival of these mice, which previously received a single injection of the VHHs with the Fc fragment, with a repeated administration of only the lethal toxin dose 14 days after the original administration. Overall, we obtained numerous clones after two rounds of biopanning; we selected 15 clones for initial analysis based on their CDR3s, chose two clones (B11 and G3) with the best pre-mixed results in phage form in vivo, produced them in protein form, and modified their structure and characteristics by dimerization via a (Gly4Ser) 3 linker and fusion to a human IgG Fc fragment to enhance their protective activity. cache = ./cache/cord-342242-cynpob7b.txt txt = ./txt/cord-342242-cynpob7b.txt === reduce.pl bib === id = cord-354700-bdpp3qmf author = Lanzavecchia, Antonio title = Dissecting human antibody responses: useful, basic and surprising findings date = 2018-01-23 pages = extension = .txt mime = text/plain words = 3112 sentences = 114 flesch = 36 summary = I will discuss how a target‐agnostic approach based on high‐throughput screening of antibodies produced by cultured B cells and plasma cells has not only provided potent and broadly neutralizing antibodies against a range of pathogens, but has also advanced our understanding of basic aspects of the immune response, from host–pathogen interaction to the role of somatic mutations in affinity maturation and in the diversification of the antibody response. I will discuss how a target-agnostic approach based on highthroughput screening of antibodies produced by cultured B cells and plasma cells has not only provided potent and broadly neutralizing antibodies against a range of pathogens, but has also advanced our understanding of basic aspects of the immune response, from host-pathogen interaction to the role of somatic mutations in affinity maturation and in the diversification of the antibody response. cache = ./cache/cord-354700-bdpp3qmf.txt txt = ./txt/cord-354700-bdpp3qmf.txt === reduce.pl bib === id = cord-340305-jtvn9tlm author = Cimolai, Nevio title = A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19 date = 2020-09-19 pages = extension = .txt mime = text/plain words = 5105 sentences = 294 flesch = 40 summary = At this time, the best correlates with protection from natural coronavirus infections are systemic neutralizing antibody and mucosal IgA. Others have found strong correlations between neutralizing antibodies and EIA-detected antibodies to various SARS-CoV-2 antigens [41, 42] .Some have found diversity in immune responses contingent on the nature of presenting disease [38, 43] . With the availability of viral antigen, most scientists in the know-how would be able to fashion a test for antibody determination in short order and most would likely choose an enzyme immunoassay (EIA) (or nearly equivalent non-enzymebased assay) for its potential of automation and widespread use. Sensitive and specific detection of low-level antibody responses in mild Middle East Respiratory Syndrome coronavirus infections A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patients cache = ./cache/cord-340305-jtvn9tlm.txt txt = ./txt/cord-340305-jtvn9tlm.txt === reduce.pl bib === id = cord-341305-zf97tcwe author = Ge, Shikun title = Canine Parvovirus is diagnosed and neutralized by chicken IgY-scFv generated against the virus capsid protein date = 2020-09-03 pages = extension = .txt mime = text/plain words = 3690 sentences = 182 flesch = 50 summary = The CPV-VLP and CPV-VP2 protein showed similar reaction values to the purified scFv in the ELISA test, and the results of ELISA analysis using IgY-scFv toward CPV clinical samples were consistent with commercial immunochromatographic assay (ICA) and PCR detection, the scFv did not show cross reactivity with canine distemper virus (CDV) and canine coronavirus (CCV). This study revealed the feasibility of a novel functional antibody fragment development strategy by generating diversified avian IgY-scFv libraries towards the pathogenic target of interest for both detection and therapeutic purposes in veterinary medicine. Functional antibody fragments (i.e.: scFv, Fab) generated by phage-display technology have been not yet routinely evaluated and applied in the veterinary medicine despite it has been well confirmed that such engineered antibodies offer a series of advantages over polyclonal and full-length monoclonal antibodies. cache = ./cache/cord-341305-zf97tcwe.txt txt = ./txt/cord-341305-zf97tcwe.txt === reduce.pl bib === id = cord-023346-8sqbqjm1 author = nan title = MONDAY: POSTERS date = 2005-06-08 pages = extension = .txt mime = text/plain words = 130043 sentences = 7330 flesch = 54 summary = • enhancement of automation/computerisation; • process control to provide an 'error-free pathway'; • (national) surveillance and trend analysis of results, preferably based on national working standards; • significantly increased sensitivity, especially from development of antigen/antibody 'combi' assays (e.g. for HIV, and recently, for HCV); • awareness of HBsAg vaccine-escape mutants and design of assays to cope with this; • extension of range of agents and markers tested for (varies in different countries); • increasing range of assays available for testing donors with a relevant history of exposure to malaria or Chagas' disease infection (for retrieval of otherwise wasted blood); • European Union's in vitro diagnostics directive: this has caused some problems and reduced flexibility. cache = ./cache/cord-023346-8sqbqjm1.txt txt = ./txt/cord-023346-8sqbqjm1.txt === reduce.pl bib === id = cord-354325-r73datur author = Berger, Mitchell title = Therapeutic Applications of Monoclonal Antibodies date = 2002-07-31 pages = extension = .txt mime = text/plain words = 12331 sentences = 666 flesch = 41 summary = Attempts to use mouse myeloma cells to create hybrids and derive human MAbs led to the loss of human chromosomes and the inability to make human Igs. 13 Unfortunately, in vitro immunization is limited by its inability to produce a secondary response and by the absence of the affinity maturation process that occurs in vivo. In these transgenic mouse models, human antibodies with high affinity to an immunized antigen are naturally selected by the murine immune system via an affinity maturation process, and thereby show increased diversity of the MAbs. Transgenic mice may be a suitable alternative to chimeric or humanized antibody production or the use of phage display systems to create less immunogenic or novel antibodies. [43] [44] [45] Humanizing Monoclonal Antibodies Rodent MAbs with excellent affinities and specificities have been generated using conventional hybridoma technology, but their use in clinical medicine is limited due to the immune responses they elicit in humans. cache = ./cache/cord-354325-r73datur.txt txt = ./txt/cord-354325-r73datur.txt === reduce.pl bib === id = cord-023354-f2ciho6o author = nan title = TUESDAY PLENARY SESSION 3 TUESDAY: POSTERS date = 2005-06-08 pages = extension = .txt mime = text/plain words = 130046 sentences = 7333 flesch = 54 summary = • enhancement of automation/computerisation; • process control to provide an 'error-free pathway'; • (national) surveillance and trend analysis of results, preferably based on national working standards; • significantly increased sensitivity, especially from development of antigen/antibody 'combi' assays (e.g. for HIV, and recently, for HCV); • awareness of HBsAg vaccine-escape mutants and design of assays to cope with this; • extension of range of agents and markers tested for (varies in different countries); • increasing range of assays available for testing donors with a relevant history of exposure to malaria or Chagas' disease infection (for retrieval of otherwise wasted blood); • European Union's in vitro diagnostics directive: this has caused some problems and reduced flexibility. cache = ./cache/cord-023354-f2ciho6o.txt txt = ./txt/cord-023354-f2ciho6o.txt ===== Reducing email addresses cord-267744-asjvf123 cord-307320-fxs31d66 cord-341305-zf97tcwe Creating transaction Updating adr table ===== Reducing keywords cord-103432-cdmoazrl cord-255936-hfa9w2dg cord-254531-pv55re2x cord-267015-mprsdi2e cord-261274-y74smbtd cord-255683-2eq24jth cord-003435-ke0az7nf cord-016966-b23o5roz cord-254821-px4fe7mn cord-004247-lagv3tp7 cord-021770-zn7na974 cord-102908-sr7j8z9c cord-009446-8keu2uay cord-001435-ebl8yc92 cord-257465-9yrf7ofy cord-005913-1vo1o6w8 cord-010088-s9tfvtao cord-018404-jdu4h00e cord-260340-dujd28gg cord-009571-mygj2nd4 cord-022439-8wy7rpqv cord-015742-nt44jcjm cord-010991-fp8hljbq cord-282081-qaagup4d cord-048360-n9sih438 cord-009581-bvihkf1r cord-104226-bb4lyvhy cord-317501-yblzopc3 cord-004167-r2s0gks8 cord-016960-xhzvp35g cord-018811-zhwr3h07 cord-001074-qevosik3 cord-312787-j7ye7ed5 cord-267744-asjvf123 cord-001060-9g8rwsm1 cord-018840-ts2g1ux7 cord-305039-grsv06j7 cord-023731-jqgervt7 cord-002710-e8im13go cord-302312-1pm17l5d cord-277076-yvsyo4l9 cord-281760-34wuttqw cord-009690-kbwz7xop cord-010248-ln800g5z cord-002153-e0zhq18g cord-015683-a9a82of4 cord-010680-lc1onm53 cord-001566-kkaxha7d cord-268417-6eyetb5i cord-001726-d7iwkatn cord-296576-d23b9fjl cord-030999-27wennun cord-275946-ofd2ipvs cord-031060-0o9agjiq cord-298910-2601n7a9 cord-291626-lxa8pvt3 cord-022310-yc6xtw0s cord-274557-2071770h cord-290783-ipoelk4h cord-329857-pcsuu597 cord-023053-j061ywrl cord-321369-xzu2faol cord-005409-8mbqkzpu cord-048239-oluq7v0h cord-103255-4k13re9y cord-278281-bdoavpsb cord-300701-vkzya7uq cord-283641-2u16otbf cord-282817-vtzpf2wr cord-311811-nrodyagi cord-032598-i0jm3p1s cord-274756-nnm1n09a cord-010578-uib9h1lb cord-133453-23rfdkuw cord-295033-5fd9bu60 cord-279105-e2zjxjox cord-277894-0qw0t78s cord-302382-eifh95zm cord-005827-wjkbrfkn cord-102704-wfuzk2dp cord-010570-ytv7dwr0 cord-256652-ent4vu3z cord-338517-1mxcssjj cord-292874-6zjqflhz cord-021402-wq770ik9 cord-295099-ghc85pf5 cord-349669-o3eelqcw cord-336280-tsx409e3 cord-002846-la9svzml cord-269023-g21a9ik2 cord-326673-p8qbxi57 cord-342242-cynpob7b cord-285760-y37ji92k cord-327629-ep28ay11 cord-319746-6bccxgbd cord-345296-4z7yfj5s cord-330218-l5q3n3ri cord-283826-lgyc3sro cord-309067-aemjbkfj cord-267736-rya9w6sh cord-305893-2vcy0f6i cord-354137-6oe8nj1j cord-302974-t1t89p8y cord-327883-s9nbr5y8 cord-328935-mn8r972x cord-304214-66nxk4e8 cord-307320-fxs31d66 cord-297684-9q3oopaz cord-023354-f2ciho6o cord-321901-zpi7uis1 cord-354325-r73datur cord-354790-xx6imhzb cord-327287-e5k2gcse cord-267601-3ahmyicn cord-275402-z92b18mb cord-341305-zf97tcwe cord-017070-05vlz5dn cord-330324-4hqhty5o cord-344445-slv7r9u7 cord-339520-odly2fwg cord-319884-d8n0aokl cord-324316-ulb8d5fe cord-313312-h607itv2 cord-023364-ut56gczm cord-335316-x2t5h5gu cord-350029-1y5ex4d5 cord-335311-l73hsik0 cord-354700-bdpp3qmf cord-355610-7xy4s483 cord-103077-sh4w2mye cord-328753-qwdxgk4z cord-335121-ro3x3qa3 cord-296928-wu14k7u9 cord-340305-jtvn9tlm cord-023346-8sqbqjm1 cord-331786-wgt7kg6f cord-337464-otwps68u cord-316287-4i1grvlr cord-339879-92esdjy9 cord-352172-g0jiaenw Creating transaction Updating wrd table ===== Reducing urls cord-018811-zhwr3h07 cord-004167-r2s0gks8 cord-282081-qaagup4d cord-255936-hfa9w2dg cord-103432-cdmoazrl cord-279105-e2zjxjox cord-102908-sr7j8z9c cord-048360-n9sih438 cord-010088-s9tfvtao cord-311811-nrodyagi cord-001060-9g8rwsm1 cord-009690-kbwz7xop cord-292874-6zjqflhz cord-298910-2601n7a9 cord-302382-eifh95zm cord-133453-23rfdkuw cord-285760-y37ji92k cord-010680-lc1onm53 cord-001566-kkaxha7d cord-317501-yblzopc3 cord-256652-ent4vu3z cord-316287-4i1grvlr cord-331786-wgt7kg6f cord-023354-f2ciho6o cord-274756-nnm1n09a cord-335316-x2t5h5gu cord-319884-d8n0aokl cord-337464-otwps68u cord-023346-8sqbqjm1 cord-355610-7xy4s483 cord-350029-1y5ex4d5 cord-023364-ut56gczm Creating transaction Updating url table ===== Reducing named entities cord-002710-e8im13go cord-018404-jdu4h00e cord-001435-ebl8yc92 cord-022439-8wy7rpqv cord-005827-wjkbrfkn cord-010248-ln800g5z cord-005409-8mbqkzpu cord-104226-bb4lyvhy cord-022310-yc6xtw0s cord-030999-27wennun cord-001566-kkaxha7d cord-010991-fp8hljbq cord-021402-wq770ik9 cord-255683-2eq24jth cord-254531-pv55re2x cord-297684-9q3oopaz cord-010570-ytv7dwr0 cord-267601-3ahmyicn cord-010578-uib9h1lb cord-261274-y74smbtd cord-010680-lc1onm53 cord-256652-ent4vu3z cord-003435-ke0az7nf cord-255936-hfa9w2dg cord-002846-la9svzml cord-005913-1vo1o6w8 cord-295033-5fd9bu60 cord-257465-9yrf7ofy cord-009581-bvihkf1r cord-009446-8keu2uay cord-307320-fxs31d66 cord-274557-2071770h cord-018840-ts2g1ux7 cord-302974-t1t89p8y cord-001726-d7iwkatn cord-283826-lgyc3sro cord-103077-sh4w2mye cord-023731-jqgervt7 cord-017070-05vlz5dn cord-296576-d23b9fjl cord-305039-grsv06j7 cord-004167-r2s0gks8 cord-002153-e0zhq18g cord-009690-kbwz7xop cord-001060-9g8rwsm1 cord-267736-rya9w6sh cord-023053-j061ywrl cord-279105-e2zjxjox cord-312787-j7ye7ed5 cord-001074-qevosik3 cord-274756-nnm1n09a cord-295099-ghc85pf5 cord-300701-vkzya7uq cord-009571-mygj2nd4 cord-016960-xhzvp35g cord-281760-34wuttqw cord-032598-i0jm3p1s cord-018811-zhwr3h07 cord-016966-b23o5roz cord-313312-h607itv2 cord-329857-pcsuu597 cord-010088-s9tfvtao cord-296928-wu14k7u9 cord-015683-a9a82of4 cord-133453-23rfdkuw cord-048360-n9sih438 cord-290783-ipoelk4h cord-283641-2u16otbf cord-103432-cdmoazrl cord-254821-px4fe7mn cord-331786-wgt7kg6f cord-268417-6eyetb5i cord-267744-asjvf123 cord-321369-xzu2faol cord-305893-2vcy0f6i cord-302382-eifh95zm cord-302312-1pm17l5d cord-298910-2601n7a9 cord-311811-nrodyagi cord-282081-qaagup4d cord-309067-aemjbkfj cord-291626-lxa8pvt3 cord-021770-zn7na974 cord-352172-g0jiaenw cord-350029-1y5ex4d5 cord-345296-4z7yfj5s cord-327287-e5k2gcse cord-321901-zpi7uis1 cord-277076-yvsyo4l9 cord-316287-4i1grvlr cord-317501-yblzopc3 cord-267015-mprsdi2e cord-319746-6bccxgbd cord-354325-r73datur cord-324316-ulb8d5fe cord-339879-92esdjy9 cord-103255-4k13re9y cord-354790-xx6imhzb cord-277894-0qw0t78s cord-328935-mn8r972x cord-031060-0o9agjiq cord-285760-y37ji92k cord-330218-l5q3n3ri cord-337464-otwps68u cord-102908-sr7j8z9c cord-004247-lagv3tp7 cord-354137-6oe8nj1j cord-355610-7xy4s483 cord-304214-66nxk4e8 cord-275946-ofd2ipvs cord-292874-6zjqflhz cord-102704-wfuzk2dp cord-269023-g21a9ik2 cord-319884-d8n0aokl cord-278281-bdoavpsb cord-335311-l73hsik0 cord-275402-z92b18mb cord-015742-nt44jcjm cord-327883-s9nbr5y8 cord-282817-vtzpf2wr cord-354700-bdpp3qmf cord-330324-4hqhty5o cord-335316-x2t5h5gu cord-327629-ep28ay11 cord-336280-tsx409e3 cord-048239-oluq7v0h cord-342242-cynpob7b cord-335121-ro3x3qa3 cord-344445-slv7r9u7 cord-349669-o3eelqcw cord-326673-p8qbxi57 cord-339520-odly2fwg cord-023354-f2ciho6o cord-341305-zf97tcwe cord-340305-jtvn9tlm cord-260340-dujd28gg cord-328753-qwdxgk4z cord-338517-1mxcssjj cord-023364-ut56gczm cord-023346-8sqbqjm1 Creating transaction Updating ent table ===== Reducing parts of speech cord-002710-e8im13go cord-005409-8mbqkzpu cord-017070-05vlz5dn cord-001060-9g8rwsm1 cord-001566-kkaxha7d cord-048360-n9sih438 cord-267744-asjvf123 cord-018404-jdu4h00e cord-021402-wq770ik9 cord-010991-fp8hljbq cord-003435-ke0az7nf cord-010248-ln800g5z cord-010570-ytv7dwr0 cord-018840-ts2g1ux7 cord-022439-8wy7rpqv cord-002846-la9svzml cord-023053-j061ywrl cord-031060-0o9agjiq cord-010578-uib9h1lb cord-001074-qevosik3 cord-281760-34wuttqw cord-016960-xhzvp35g cord-255936-hfa9w2dg cord-277894-0qw0t78s cord-312787-j7ye7ed5 cord-009446-8keu2uay cord-009690-kbwz7xop cord-001726-d7iwkatn cord-295033-5fd9bu60 cord-296576-d23b9fjl cord-004167-r2s0gks8 cord-257465-9yrf7ofy cord-256652-ent4vu3z cord-277076-yvsyo4l9 cord-296928-wu14k7u9 cord-255683-2eq24jth cord-018811-zhwr3h07 cord-032598-i0jm3p1s cord-304214-66nxk4e8 cord-016966-b23o5roz cord-269023-g21a9ik2 cord-001435-ebl8yc92 cord-010680-lc1onm53 cord-048239-oluq7v0h cord-009571-mygj2nd4 cord-279105-e2zjxjox cord-009581-bvihkf1r cord-298910-2601n7a9 cord-103432-cdmoazrl cord-309067-aemjbkfj cord-254821-px4fe7mn cord-275402-z92b18mb cord-302974-t1t89p8y cord-267601-3ahmyicn cord-267015-mprsdi2e cord-023731-jqgervt7 cord-292874-6zjqflhz cord-282081-qaagup4d cord-274557-2071770h cord-261274-y74smbtd cord-283641-2u16otbf cord-302312-1pm17l5d cord-005827-wjkbrfkn cord-002153-e0zhq18g cord-305893-2vcy0f6i cord-021770-zn7na974 cord-307320-fxs31d66 cord-311811-nrodyagi cord-104226-bb4lyvhy cord-103255-4k13re9y cord-004247-lagv3tp7 cord-295099-ghc85pf5 cord-022310-yc6xtw0s cord-015742-nt44jcjm cord-278281-bdoavpsb cord-290783-ipoelk4h cord-015683-a9a82of4 cord-285760-y37ji92k cord-327287-e5k2gcse cord-291626-lxa8pvt3 cord-103077-sh4w2mye cord-260340-dujd28gg cord-300701-vkzya7uq cord-133453-23rfdkuw cord-337464-otwps68u cord-283826-lgyc3sro cord-010088-s9tfvtao cord-102704-wfuzk2dp cord-268417-6eyetb5i cord-102908-sr7j8z9c cord-005913-1vo1o6w8 cord-316287-4i1grvlr cord-297684-9q3oopaz cord-341305-zf97tcwe cord-354137-6oe8nj1j cord-274756-nnm1n09a cord-354700-bdpp3qmf cord-317501-yblzopc3 cord-282817-vtzpf2wr cord-302382-eifh95zm cord-321901-zpi7uis1 cord-336280-tsx409e3 cord-275946-ofd2ipvs cord-305039-grsv06j7 cord-030999-27wennun cord-330218-l5q3n3ri cord-327883-s9nbr5y8 cord-267736-rya9w6sh cord-354325-r73datur cord-338517-1mxcssjj cord-355610-7xy4s483 cord-339520-odly2fwg cord-350029-1y5ex4d5 cord-340305-jtvn9tlm cord-352172-g0jiaenw cord-335316-x2t5h5gu cord-321369-xzu2faol cord-327629-ep28ay11 cord-324316-ulb8d5fe cord-344445-slv7r9u7 cord-328935-mn8r972x cord-319746-6bccxgbd cord-345296-4z7yfj5s cord-254531-pv55re2x cord-328753-qwdxgk4z cord-330324-4hqhty5o cord-354790-xx6imhzb cord-335311-l73hsik0 cord-349669-o3eelqcw cord-335121-ro3x3qa3 cord-342242-cynpob7b cord-313312-h607itv2 cord-326673-p8qbxi57 cord-319884-d8n0aokl cord-329857-pcsuu597 cord-331786-wgt7kg6f cord-339879-92esdjy9 cord-023354-f2ciho6o cord-023346-8sqbqjm1 cord-023364-ut56gczm Creating transaction Updating pos table Building ./etc/reader.txt cord-317501-yblzopc3 cord-002846-la9svzml cord-354325-r73datur cord-021770-zn7na974 cord-354325-r73datur cord-337464-otwps68u number of items: 140 sum of words: 1,305,432 average size in words: 10,041 average readability score: 43 nouns: antibody; antibodies; blood; cells; virus; patients; cell; infection; protein; transfusion; results; antigen; donors; serum; study; disease; system; use; treatment; studies; response; plasma; vaccine; therapy; samples; methods; proteins; detection; antigens; mice; group; time; platelet; phage; responses; activity; data; development; analysis; cases; ml; number; test; expression; assay; infections; viruses; type; donor; control verbs: used; showed; binding; neutralizing; based; included; increased; detected; developed; found; provide; following; performed; associated; produced; induce; identify; tested; comparing; reduced; containing; requires; reported; demonstrated; mediated; give; obtained; determined; infected; make; suggests; occur; targets; result; observed; cause; expressing; treated; lead; evaluate; described; indicate; generated; improve; selected; related; derived; receiving; allowing; prevent adjectives: anti; human; specific; immune; high; clinical; viral; positive; monoclonal; different; single; negative; first; new; therapeutic; non; low; several; significant; many; important; red; higher; severe; recombinant; infectious; bacterial; effective; respiratory; whole; acute; available; possible; major; present; large; similar; normal; potential; passive; small; various; recent; molecular; dependent; rapid; protective; multiple; common; early adverbs: also; however; well; therefore; highly; significantly; respectively; even; previously; recently; often; still; currently; especially; usually; less; fully; now; directly; approximately; particularly; furthermore; moreover; relatively; later; first; clinically; broadly; potentially; prior; finally; rather; generally; mainly; alone; subsequently; successfully; together; specifically; rapidly; yet; probably; widely; typically; almost; commonly; frequently; naturally; much; already pronouns: it; we; their; our; they; its; them; i; he; his; her; us; one; she; itself; you; your; themselves; my; me; himself; trim21; him; ourselves; m19fc; igg1; p210bcr; igg4; mg; p24ag; mine; s; imagej; iga1; em; c5-derived; yourself; y453f; tnfsf13; tgn1412; spvb; samples:"you; s_tmhmm; rad5; phosphonylmethoxy)propyl]cytosine; particle‖; oneself; mrnas; itims; interleukin-15 proper nouns: SARS; IgG; Fc; HIV-1; sera; ELISA; C; IgA; CoV-2; HCV; T; PCR; HIV; IgM; B; RBC; mAbs; A; RNA; S; Fig; HBV; CoV; Blood; HLA; •; D; M; COVID-19; E.; mg; Hb; SLE; anti; DNA; IVIG; Fab; Table; Antibody; II; Transfusion; RHD; MAbs; scFv; Anti; Rh; CD4; FFP; G; mRNA keywords: antibody; cell; sars; virus; patient; protein; human; elisa; dna; covid-19; pcr; hiv; study; phage; infection; vaccine; rna; mabs; hla; hiv-1; hcv; display; transfusion; trali; test; response; rbd; platelet; nat; monoclonal; immune; hbv; donor; cov-2; blood; anti; animal; treatment; system; sle; rhd; result; rbc; peptide; pbs; method; library; ivig; immunoglobulin; hospital one topic; one dimension: antibody file(s): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5639826/ titles(s): Induction of PrP(Sc)-specific systemic and mucosal immune responses in white-tailed deer with an oral vaccine for chronic wasting disease three topics; one dimension: antibody; blood; antibody file(s): https://www.ncbi.nlm.nih.gov/pubmed/22606007/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169338/, https://www.ncbi.nlm.nih.gov/pubmed/107731/ titles(s): Phages and HIV-1: From Display to Interplay | EDUCATION DAY MONDAY: PLENARY SESSION 1 MONDAY: PARALLEL SESSIONS | Neutralization of Animal Viruses five topics; three dimensions: blood transfusion patients; antibody cells antibodies; antibodies antibody human; antibody virus sars; antibody antibodies used file(s): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169338/, https://www.ncbi.nlm.nih.gov/pubmed/32879472/, https://www.ncbi.nlm.nih.gov/pubmed/27198131/, https://www.ncbi.nlm.nih.gov/pubmed/107731/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162894/ titles(s): EDUCATION DAY MONDAY: PLENARY SESSION 1 MONDAY: PARALLEL SESSIONS | Human immunology and immunotherapy: main achievements and challenges | Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display | Neutralization of Animal Viruses | Development of a Nanoparticle-based Lateral Flow Strip Biosensor for Visual Detection of Whole Nervous Necrosis Virus Particles Type: cord title: keyword-antibody-cord date: 2021-05-24 time: 20:54 username: emorgan patron: Eric Morgan email: emorgan@nd.edu input: keywords:antibody ==== make-pages.sh htm files ==== make-pages.sh complex files ==== make-pages.sh named enities ==== making bibliographics id: cord-030999-27wennun author: Altmann, Daniel M title: Adaptive immunity to SARS-CoV-2 date: 2020-07-09 words: 4374.0 sentences: 191.0 pages: flesch: 42.0 cache: ./cache/cord-030999-27wennun.txt txt: ./txt/cord-030999-27wennun.txt summary: The majority of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 exposed individuals mount an antibody response within around 2-weeks and spike antigen-binding responses correlate well with functional virus neutralization. Studies of T-cell immunity following acute infection show CD4 and CD8 responses to epitopes across diverse viral antigens, possible cross-reactivity with epitopes from the common cold human coronaviruses and large-scale activation. Since many key questions about durability of the antibody response and about correlates of protection have been hard to address in this short timeframe, there has been value in recourse to the coronavirus immunology literature, especially in relation to SARS and MERS [16] [17] [18] [19] . Experience to date with SARS-CoV-2 suggests that this may not prove to be an infection that throws up insurmountable confounders to vaccine design-approaches that can safely and durably elicit neutralizing antibody look likely to work. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals abstract: The majority of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 exposed individuals mount an antibody response within around 2-weeks and spike antigen-binding responses correlate well with functional virus neutralization. A minority makes little detectable antibody, generally those with either very mild/asymptomatic disease or those with severe/lethal infection. However, in general, antibody titre correlates with viral load and duration of exposure. There is evidence for cross-reactivity with the other human coronaviruses, though the functional impact of this is as yet unclear. Therapeutic use of neutralizing monoclonal antibodies offers potential for clinical use. While there is evidence for neutralizing antibody as a correlate of protection, some cases indicate the potential for full recovery in the absence of antibody. Studies of T-cell immunity following acute infection show CD4 and CD8 responses to epitopes across diverse viral antigens, possible cross-reactivity with epitopes from the common cold human coronaviruses and large-scale activation. However, in severe cases, there is evidence for T-cell lymphopaenia as well as expression of exhaustion markers. Analysis of serum biomarkers of disease severity implicates a hyperinflammatory contribution to pathogenesis, though this has not been mechanistically delineated beyond a likely role of raised IL-6, considered a therapeutic target. Despite rapid progress, there remain pressing unknowns. It seems likely that immune memory to SARS-CoV-2 may be relatively short lived, but this will need longitudinal investigation. Also, this is a disease of highly variable presentation and time course, with some progressing to protracted, chronic symptoms, which are not understood. The contribution of immunopathological mechanisms to tissue damage, whether in the lung, kidney, heart or blood vessels, is unclear. The immunology underlying the differential susceptibility between the very young and the very old is unresolved, a question with ramifications for vaccine roll-out. The greatest challenge relates to rapid generation, testing and manufacture of vaccines that are immunogenic, protective (at least from symptomatic disease) and safe—a challenge that looks achievable. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454881/ doi: 10.1093/oxfimm/iqaa003 id: cord-321369-xzu2faol author: Andreano, Emanuele title: Extremely potent human monoclonal antibodies from convalescent Covid-19 patients date: 2020-10-07 words: 3685.0 sentences: 192.0 pages: flesch: 52.0 cache: ./cache/cord-321369-xzu2faol.txt txt: ./txt/cord-321369-xzu2faol.txt summary: By single cell sorting 4277 SARS-CoV-2 spike protein specific memory B cells from 14 Covid-19 survivors, 453 neutralizing antibodies were identified and 220 of them were expressed as IgG. The three most potent monoclonal antibodies identified were able to neutralize the wild type and D614G mutant viruses with less than 10 ng/mL and are good candidates for the development of prophylactic and therapeutic tools against SARS-CoV-2. As for the authentic virus neutralization assay, supernatants containing naturally produced IgG or IgA were tested for their ability to protect the layer of Vero E6 cells from the cytopathic effect triggered by SARS-CoV-2 infection (Fig. S2) . This work describes a systematic screening of memory B cells from convalescent people to identify extremely potent human monoclonal antibodies against the spike protein of the SARS-CoV-2 virus, to be used for prevention and therapy of Covid-19. abstract: Human monoclonal antibodies are safe, preventive and therapeutic tools, that can be rapidly developed to help restore the massive health and economic disruption caused by the Covid-19 pandemic. By single cell sorting 4277 SARS-CoV-2 spike protein specific memory B cells from 14 Covid-19 survivors, 453 neutralizing antibodies were identified and 220 of them were expressed as IgG. Up to 65,9% of monoclonals neutralized the wild type virus at a concentration of >500 ng/mL, 23,6% neutralized the virus in the range of 100 - 500 ng/mL and 9,1% had a neutralization potency in the range of 10 - 100 ng/mL. Only 1,4% neutralized the authentic virus with a potency of 1-10 ng/mL. We found that the most potent neutralizing antibodies are extremely rare and recognize the RBD, followed in potency by antibodies that recognize the S1 domain, the S-protein trimeric structure and the S2 subunit. The three most potent monoclonal antibodies identified were able to neutralize the wild type and D614G mutant viruses with less than 10 ng/mL and are good candidates for the development of prophylactic and therapeutic tools against SARS-CoV-2. One Sentence Summary Extremely potent neutralizing human monoclonal antibodies isolated from Covid-19 convalescent patients for prophylactic and therapeutic interventions. url: https://doi.org/10.1101/2020.10.07.328302 doi: 10.1101/2020.10.07.328302 id: cord-001060-9g8rwsm1 author: Arruebo, Manuel title: Assessment of the Evolution of Cancer Treatment Therapies date: 2011-08-12 words: 10511.0 sentences: 488.0 pages: flesch: 34.0 cache: ./cache/cord-001060-9g8rwsm1.txt txt: ./txt/cord-001060-9g8rwsm1.txt summary: These therapies can be used in isolation or in combination with other cancer treatments, thereby taking advantage of their ability to target tumors (actively or passively), to respond to physical or chemical stimulation (internal or external) and to deliver therapeutic genes to the cell nuclei. Compared to conventional therapies, nanoparticles show six clear advantages in cancer treatment and/or diagnosis: (1) they can be synthesized in specific sizes and with surface characteristics to penetrate tumors by taking advantage of the enhanced permeation and retention effect (EPR) (a mechanism known as passive targeting); (2) they can be engineered to target tumor cells by surface functionalization with biomolecules that attach to tumor-specific cell markers (a mechanism known as active targeting); (3) they can be engineered to penetrate cells and physiological barriers (e.g., blood-brain barrier, blood-retinal barrier); (4) they can increase the plasma half-life of carried chemotherapeutic drugs, which are usually highly hydrophobic; (5) they can protect a therapeutic payload from biological degradation; and (6) they can be synthesized as multifunctional platforms for combined imaging and therapeutic applications (theragnostic nanoparticles). abstract: Cancer therapy has been characterized throughout history by ups and downs, not only due to the ineffectiveness of treatments and side effects, but also by hope and the reality of complete remission and cure in many cases. Within the therapeutic arsenal, alongside surgery in the case of solid tumors, are the antitumor drugs and radiation that have been the treatment of choice in some instances. In recent years, immunotherapy has become an important therapeutic alternative, and is now the first choice in many cases. Nanotechnology has recently arrived on the scene, offering nanostructures as new therapeutic alternatives for controlled drug delivery, for combining imaging and treatment, applying hyperthermia, and providing directed target therapy, among others. These therapies can be applied either alone or in combination with other components (antibodies, peptides, folic acid, etc.). In addition, gene therapy is also offering promising new methods for treatment. Here, we present a review of the evolution of cancer treatments, starting with chemotherapy, surgery, radiation and immunotherapy, and moving on to the most promising cutting-edge therapies (gene therapy and nanomedicine). We offer an historical point of view that covers the arrival of these therapies to clinical practice and the market, and the promises and challenges they present. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759197/ doi: 10.3390/cancers3033279 id: cord-023053-j061ywrl author: BARLOUGH, J. E. title: Cats, coronaviruses and coronavirus antibody tests date: 2008-04-10 words: 3611.0 sentences: 156.0 pages: flesch: 35.0 cache: ./cache/cord-023053-j061ywrl.txt txt: ./txt/cord-023053-j061ywrl.txt summary: In domestic and exotic cats, FIPV is the aetiologic agent of a lethal disease-feline infectious peritonitis (FIP)-characterized by fibrinous serositis, vasculitis, and formation of disseminated pyogranulomas (Wolfe & Griesemer. Laboratory test procedures for detection of coronavirus antibody in feline sera include biological assays such as virus neutralization (VN); non-biological, immunochemical techniques such as indirect immunofluorescence assay (IFA), enzyme-linked immunosorbent assay (ELISA), and kinetics-based ELISA (KELA); and other methods such as agar gel immunodiffusion and passive haemagglutination , though the availability of such tests varies worldwide. The serodiagnostic potential of these assays (i.e., their ability to identify cats with active FIP and/or potential virus carriers/excretors) is thus limited not only by the widespread distribution of serum coronavirus antibody in the feline population, but also by the possibility that non-FIPV coronaviruses may be responsible for some of the seroconversions that they detect. abstract: Feline infectious peritonitis and other coronavirus infections of cats are briefly reviewed. Interpretation and applications of feline coronavirus antibody tests are described, and general recommendations are provided for practitioners. Some of the major unresolved questions regarding coronavirus infections of cats are delineated. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166406/ doi: 10.1111/j.1748-5827.1985.tb02210.x id: cord-305893-2vcy0f6i author: Bagheri, Vahid title: Neutralizing human recombinant antibodies against herpes simplex virus type 1 glycoproteins B from a phage-displayed scFv antibody library date: 2017-01-15 words: 3576.0 sentences: 203.0 pages: flesch: 52.0 cache: ./cache/cord-305893-2vcy0f6i.txt txt: ./txt/cord-305893-2vcy0f6i.txt summary: title: Neutralizing human recombinant antibodies against herpes simplex virus type 1 glycoproteins B from a phage-displayed scFv antibody library Our present study focused on the selection of neutralizing single-chain Fv (scFv) antibodies of a phage-displayed nonimmune human scFv antibody library against gB of HSV-1. described a neutralizing scFv-phage antibody against glycoprotein D of HSV-1 with neutralizing effect of 76%, which was capable of neutralizing HSV-1 and inhibiting virus entry to host cell [21] . Here, we selected two neutralizing anti-gB scFv antibodies to inhibit cytopathic effects in Vero cells infected with HSV-1. Neutralizing human single-chain antibodies against herpes simplex virus type 1 glycoprotein D from a phage display library Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries abstract: Abstract The HSV-1 envelope glycoprotein B (gB) plays a critical role in virus entry into host cells. Neutralizing antibodies can therefore potentially prevent virus entry into target cells and cell-to-cell spread of infection. Our present study focused on the selection of neutralizing single-chain Fv (scFv) antibodies of a phage-displayed nonimmune human scFv antibody library against gB of HSV-1. To enrich specific scFvs, two phage antibodies were isolated against amino acid residues 31–43 derived from the N-terminal part of gB using panning technique. Two scFvs, scFv-gB1 and scFv-gB2, with frequencies of 45% and 20% were obtained from scFv clones after performing PCR and MvaI fingerprinting. In phage ELISA analysis, both gB1 and gB2 scFvs demonstrated high reactivity with the gB peptide. In the neutralization assay, scFv-gB1 and scFv-gB2 represented neutralizing effects of 55% and 59%, respectively. Upon further enhancement of the neutralizing effects of these antibodies, they can be considered as new potential alternatives in the treatment and prophylaxis of HSV-1 infections. url: https://www.sciencedirect.com/science/article/pii/S0024320516306713 doi: 10.1016/j.lfs.2016.11.018 id: cord-016960-xhzvp35g author: Berencsi, György title: Fetal and Neonatal Illnesses Caused or Influenced by Maternal Transplacental IgG and/or Therapeutic Antibodies Applied During Pregnancy date: 2012-03-08 words: 17693.0 sentences: 1045.0 pages: flesch: 42.0 cache: ./cache/cord-016960-xhzvp35g.txt txt: ./txt/cord-016960-xhzvp35g.txt summary: The importance of maternal anti-idiotypic antibodies are believed to prime the fetal immune system with epitopes of etiologic agents infected the mother during her whole life before pregnancy and delivery. Neonatal lupus is a model of passively acquired autoimmunity in which a mother-, who may have systemic lupus erythematosus (SLE) or Sj€ ogren''s syndrome (SS) or may be entirely asymptomatic-synthesizes antibodies to SSA/Ro and/or SSB/ La ribonucleoproteins that enter the fetal circulation via trophoblast FcRn receptors and presumably cause tissue injury (Lee 1990 ) as mentioned above. Teplizumab (CD3-specific, hOKT3g1-Ala-Ala), a humanized Fc mutated anti-CD3 monoclonal antibody induced tolerance, on the progression of type 1 diabetes in patients with recent-onset disease even 2 years after the first diagnosis (Herold et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells abstract: The human fetus is protected by the mother’s antibodies. At the end of the pregnancy, the concentration of maternal antibodies is higher in the cord blood, than in the maternal circulation. Simultaneously, the immune system of the fetus begins to work and from the second trimester, fetal IgM is produced by the fetal immune system specific to microorganisms and antigens passing the maternal-fetal barrier. The same time the fetal immune system has to cope and develop tolerance and T(REG) cells to the maternal microchimeric cells, latent virus-carrier maternal cells and microorganisms transported through the maternal-fetal barrier. The maternal phenotypic inheritance may hide risks for the newborn, too. Antibody mediated enhancement results in dengue shock syndrome in the first 8 month of age of the baby. A series of pathologic maternal antibodies may elicit neonatal illnesses upon birth usually recovering during the first months of the life of the offspring. Certain antibodies, however, may impair the fetal or neonatal tissues or organs resulting prolonged recovery or initiating prolonged pathological processes of the children. The importance of maternal anti-idiotypic antibodies are believed to prime the fetal immune system with epitopes of etiologic agents infected the mother during her whole life before pregnancy and delivery. The chemotherapeutical and biological substances used for the therapy of the mother will be transcytosed into the fetal body during the last two trimesters of pregnancy. The long series of the therapeutic monoclonal antibodies and conjugates has not been tested systematically yet. The available data are summarised in this chapter. The innate immunity plays an important role in fetal defence. The concentration of interferon is relative high in the placenta. This is probably one reason, why the therapeutic interferon treatment of the mother does not impair the fetal development. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121401/ doi: 10.1007/978-94-007-4216-1_9 id: cord-277076-yvsyo4l9 author: Berger, A. title: SARS date: 2019-09-12 words: 4349.0 sentences: 215.0 pages: flesch: 45.0 cache: ./cache/cord-277076-yvsyo4l9.txt txt: ./txt/cord-277076-yvsyo4l9.txt summary: Measures including source isolation of patientswho only became infectious after onset of clinical symptomsstrict infection control in health care facilities, timely identification and quarantining of exposed contacts, and perhaps also measures to increase social distance, such as travel warnings and screening of travelers, had led to this remarkable and remarkably rapid success. A further, small SARS outbreak occurred again in Guangdong in late 2003/early 2004; molecular analysis of virus isolates from human cases and animals sampled at the same place and time confirmed that this was zoonotically acquired from Paguma larvata. The laboratory diagnosis of SARS remains a challenge; in fact, despite the rapid identification of SARS-CoV as the etiological agent, testing contributed little to the successful control of the 2003 outbreak. A negative antibody test result later than 21 days after the onset of illness is likely to indicate that no infection with SARS-CoV has taken place. abstract: Severe acute respiratory syndrome (SARS) emerged in southern China in late 2002. It first spread within Guangdong Province and then to other parts of China. Via air travelers, it quickly reached various countries around the globe, causing several major hospital outbreaks. Within weeks, the causative agent, a previously unknown coronavirus (SARS-CoV), was identified, thanks to an unprecedented international effort led by the World Health Organization (WHO). Its origin was quickly traced to wild animals traded locally for culinary purposes. Masked palm civet and some other species seem to have acted as intermediate hosts. Since then, SARS-like coronaviruses were found in different bat species in China and elsewhere, and bats are now regarded as the wildlife reservoir for SARS-CoV. Fortunately, the SARS outbreak could be contained within months. Until July 2003, it had caused 8096 cases, with 774 deaths. Once adequate measures such as isolating patients and quarantining their contacts were strictly adhered to, further transmission between human beings could be interrupted. SARS is an example of how rapidly an infectious agent can spread in the modern world. At the same time, it should serve as a showcase of how international cooperation and modern science can help to combat the spread of infectious diseases. url: https://api.elsevier.com/content/article/pii/B9780444639516006240 doi: 10.1016/b978-0-444-63951-6.00624-0 id: cord-354325-r73datur author: Berger, Mitchell title: Therapeutic Applications of Monoclonal Antibodies date: 2002-07-31 words: 12331.0 sentences: 666.0 pages: flesch: 41.0 cache: ./cache/cord-354325-r73datur.txt txt: ./txt/cord-354325-r73datur.txt summary: Attempts to use mouse myeloma cells to create hybrids and derive human MAbs led to the loss of human chromosomes and the inability to make human Igs. 13 Unfortunately, in vitro immunization is limited by its inability to produce a secondary response and by the absence of the affinity maturation process that occurs in vivo. In these transgenic mouse models, human antibodies with high affinity to an immunized antigen are naturally selected by the murine immune system via an affinity maturation process, and thereby show increased diversity of the MAbs. Transgenic mice may be a suitable alternative to chimeric or humanized antibody production or the use of phage display systems to create less immunogenic or novel antibodies. [43] [44] [45] Humanizing Monoclonal Antibodies Rodent MAbs with excellent affinities and specificities have been generated using conventional hybridoma technology, but their use in clinical medicine is limited due to the immune responses they elicit in humans. abstract: ABSTRACT Researchers have sought therapeutic applications for monoclonal antibodies since their development in 1975. However, murine-derived monoclonal antibodies may cause an immunogenic response in human patients, reducing their therapeutic efficacy. Chimeric and humanized antibodies have been developed that are less likely to provoke an immune reaction in human patients than are murine-derived antibodies. Antibody fragments, bispecific antibodies, and antibodies produced through the use of phage display systems and genetically modified plants and animals may aid researchers in developing new uses for monoclonal antibodies in the treatment of disease. Monoclonal antibodies may have a number of promising potential therapeutic applications in the treatment of asthma, autoimmune diseases, cancer, poisoning, septicemia, substance abuse, viral infections, and other diseases. url: https://www.ncbi.nlm.nih.gov/pubmed/12120821/ doi: 10.1097/00000441-200207000-00004 id: cord-296576-d23b9fjl author: Bernard, Serge title: Lactogenic Immunity to Transmissible Gastroenteritis (TGE) of swine induced by the attenuated nouzilly strain of TGE virus: Passive protection of piglets and detection of serum and milk antibody classes by ELISA date: 1990-01-31 words: 3028.0 sentences: 169.0 pages: flesch: 55.0 cache: ./cache/cord-296576-d23b9fjl.txt txt: ./txt/cord-296576-d23b9fjl.txt summary: title: Lactogenic Immunity to Transmissible Gastroenteritis (TGE) of swine induced by the attenuated nouzilly strain of TGE virus: Passive protection of piglets and detection of serum and milk antibody classes by ELISA After natural infection or experimental oral infection of pregnant sows with a virulent strain of TGE virus, lactogenic immunity is highly protective for piglets, and neutralizing antibodies in milk are mainly associated with the IgA fraction (Bohl, 1981) . TABLE 3 Relationship between passive protection rate and titre of specific anti-TGE antibody classes ( IgG, IgA, IgM) in serum and milk, on the day and 10 days after challenge The most interesting result of the preliminary report about the immune response of sows vaccinated with N strain of TGE (Shira''i et al., 1988) was the absence of correlation between the passive protection rate of the litter and the neutralizing antibody titre in serum or milk of sows on the day of challenge. abstract: Abstract Piglets of eight sows vaccinated by different routes with the attenuated TGE mutant coronavirus, Nouzilly (N) strain, and piglets from two field seropositive sows were challenged with a virulent TGE strain. On the day of challenge and 10 days after challenge, milk and serum samples from sows were analysed for their level of neutralizing antibodies, total immunoglobulin classes and TGE antibody classes by an ELISA. No direct relationship was seen between the level of protection of the litters and the titres of the different antibody classes on the day of challenge. However, an inverse correlation was seen 10 days after challenge between protection and the level of TGE antibodies. url: https://www.ncbi.nlm.nih.gov/pubmed/2156374/ doi: 10.1016/0165-2427(90)90076-5 id: cord-324316-ulb8d5fe author: Bramstedt, Katrina A. title: Antibodies as Currency: COVID-19’s Golden Passport date: 2020-08-25 words: 1398.0 sentences: 73.0 pages: flesch: 49.0 cache: ./cache/cord-324316-ulb8d5fe.txt txt: ./txt/cord-324316-ulb8d5fe.txt summary: Due to COVID-19, the fragile economy, travel restrictions, and generalized anxieties, the concept of antibodies as a "declaration of immunity" or "passport" is sweeping the world. Numerous scientific and ethical issues confound the concept of an antibody passport; nonetheless, antibodies can be seen as a potential currency to allow movement of people and resuscitation of global economics. In this way, antibodies for SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2-the COVID-19 coronavirus) are potentially the new golden passport, but the concept is a moving target with clinical unknowns, as well as legal and ethical complexity (Phelan 2020; Persad and Emanuel 2020) . With the COVID-19 pandemic causing a fragile worldwide economy and millions of people unemployed (Congressional Research Service 2020), there is a risk of antibody certificates being viewed as the "golden passport" to return to work and travel. Show me your passport: Ethical concerns about Covid-19 antibody testing as key to reopening public life abstract: Due to COVID-19, the fragile economy, travel restrictions, and generalized anxieties, the concept of antibodies as a “declaration of immunity” or “passport” is sweeping the world. Numerous scientific and ethical issues confound the concept of an antibody passport; nonetheless, antibodies can be seen as a potential currency to allow movement of people and resuscitation of global economics. Just as financial currency can be forged, so too is the potential for fraudulent antibody passports. This paper explores matters of science, ethics, and identity theft, as well as the problems of bias and discrimination that could promulgate a world of pandemic “golden passports.” url: https://doi.org/10.1007/s11673-020-09996-5 doi: 10.1007/s11673-020-09996-5 id: cord-336280-tsx409e3 author: Byrne, Barry title: Antibody-Based Sensors: Principles, Problems and Potential for Detection of Pathogens and Associated Toxins date: 2009-06-05 words: 12263.0 sentences: 613.0 pages: flesch: 38.0 cache: ./cache/cord-336280-tsx409e3.txt txt: ./txt/cord-336280-tsx409e3.txt summary: Particular emphasis is placed on the detection of foodborne bacterial pathogens, such as Escherichia coli and Listeria monocytogenes, and additional examples relating to the monitoring of fungal pathogens, viruses, mycotoxins, marine toxins and parasites are also provided. It describes the development of electrochemical, potentiometric, piezoelectric and optical platforms for the monitoring of foodborne bacterial pathogens by incorporating monoclonal, polyclonal or recombinant antibodies in a variety of different assay formats. Polyclonal antibodies (pAb) are typically raised in rabbits, goats or sheep [29] , and their popularity is illustrated by the fact that they are frequently selected in immunosensor-based assays for pathogen detection. Hence, the selection of a highly-specific epitope on the pathogen is a key consideration, since many bacterial strains share homologues of surface-presented proteins which can lead to the detection of multiple cell-types by a single antibody. Muhammad-Tahir and Alocilja [74] developed a conductimetric biosensor incorporating a polyclonal antibody-based sandwich assay format in which the detection antibody was labelled with polyaniline. abstract: Antibody-based sensors permit the rapid and sensitive analysis of a range of pathogens and associated toxins. A critical assessment of the implementation of such formats is provided, with reference to their principles, problems and potential for ‘on-site’ analysis. Particular emphasis is placed on the detection of foodborne bacterial pathogens, such as Escherichia coli and Listeria monocytogenes, and additional examples relating to the monitoring of fungal pathogens, viruses, mycotoxins, marine toxins and parasites are also provided. url: https://www.ncbi.nlm.nih.gov/pubmed/22408533/ doi: 10.3390/s90604407 id: cord-282817-vtzpf2wr author: Byrne, Hannah title: A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications date: 2013-10-02 words: 8419.0 sentences: 417.0 pages: flesch: 34.0 cache: ./cache/cord-282817-vtzpf2wr.txt txt: ./txt/cord-282817-vtzpf2wr.txt summary: Despite significant positive clinical results, especially in the case of hematological malignancies, adverse clinical outcomes and animal studies have highlighted underlying limitations of mAbs. Accordingly, many strategies have been developed in order to improve the specificity and control the functions of antibodies. The BiTE format potentially overcomes several limiting factors relating to the biological activity of tumor-directed bsAbs. BiTEs combine the minimal binding domains (Fv fragments) of two different mAbs fused together by a short flexible linker that allows free rotation of the two arms, and thus facilitates optimal antibody:antigen interaction [28] . bsAbs are attractive in such assays because they simplify the detection steps and are currently used for the development of simple, rapid, and highly sensitive immunoassays for the detection of bacterial and viral infectious diseases and in cancer diagnostics. CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation abstract: Artificial manipulation of antibody genes has facilitated the production of several unique recombinant antibody formats, which have highly important therapeutic and biotechnological applications. Although bispecific antibodies (bsAbs) are not new, they are coming to the forefront as our knowledge of the potential efficacy of antibody-based therapeutics expands. The next generation of bsAbs is developing due to significant improvements in recombinant antibody technologies. This review focuses on recent advances with a particular focus on improvements in format and design that are contributing to the resurgence of bsAbs, and in particular, on innovative structures applicable to next generation point-of-care (POC) devices with applicability to low resource environments. url: https://www.ncbi.nlm.nih.gov/pubmed/24094861/ doi: 10.1016/j.tibtech.2013.08.007 id: cord-010570-ytv7dwr0 author: Casadevall, Arturo title: Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases date: 1995-07-17 words: 7469.0 sentences: 454.0 pages: flesch: 31.0 cache: ./cache/cord-010570-ytv7dwr0.txt txt: ./txt/cord-010570-ytv7dwr0.txt summary: In the preantibiotic era, passive antibody administration (serum therapy) was useful for the treatment of many infectious diseases. We briefly review the use of antibody-based therapy in the early 20th century and make the case for reintroducing passive antibody administration for the treatment ofinfectious diseases. Given the diminishing efficacy of existing antimicrobials because of widespread resistance and the difficulties of treating infections in immunosuppressed individuals, the reintroduction of antibody-based therapies is an option that should be given serious consideration. Thus, antibody therapy is still widely used in medicine, but its role in the treatment of infections is limited largely to viral and toxin neutralization and replacement therapy in patients with immunoglobulin deficiencies. In the past, serum therapy was effective against various pathogens despite the fact that immune sera contained only small amounts of specific antibody. Antibody-based therapies have traditionally been most effective in infections where viral and toxin neutralization modifies the course of the disease. abstract: In the preantibiotic era, passive antibody administration (serum therapy) was useful for the treatment of many infectious diseases. The introduction of antimicrobial chemotherapy in the 1940s led to the rapid abandonment of many forms of passive antibody therapy. Chemotherapy was more effective and less toxic than antibody therapy. In this last decade of the 20th century the efficacy of antimicrobial chemotherapy is diminishing because of the rapidly escalating number of immunocompromised individuals, the emergence of new pathogens, the reemergence of old pathogens, and widespread development of resistance to antimicrobial drugs. This diminishment in the effectiveness of chemotherapy has been paralleled by advances in monoclonal antibody technology that have made feasible the generation of human antibodies. This combination of factors makes passive antibody therapy an option worthy of serious consideration. We propose that for every pathogen there exists an antibody that will modify the infection to the benefit of the host. Such antibodies are potential antimicrobial agents. Antibody-based therapies have significant advantages and disadvantages relative to standard chemotherapy. The reintroduction of antibody-based therapy would require major changes in the practices of infectious disease specialists. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197598/ doi: 10.1093/clinids/21.1.150 id: cord-335311-l73hsik0 author: Chan, Conrad E. Z. title: The role of phage display in therapeutic antibody discovery date: 2014-08-18 words: 7044.0 sentences: 286.0 pages: flesch: 31.0 cache: ./cache/cord-335311-l73hsik0.txt txt: ./txt/cord-335311-l73hsik0.txt summary: The defining attribute of all phage display libraries is the physical linking of antibody phenotype (specificity and affinity) with genotype (sequence) via the phage particle-this allows for in vitro selection on immobilized antigen or whole cells (Fig. 2) . In particular, a phage library constructed with the heavy chain CDR3 enriched for basic residues to improve binding to negatively charged carbohydrates produced anti-carbohydrate antibodies that had relatively high affinity (K D ≈ 50 nM) and excellent specificity (40) . Phage display is also likely to remain useful for discovery of antibodies against non-protein targets, evolution of dual-binding antibodies and for affinity maturation, due to the limitations of the natural immune system. Comparison of the efficiency of antibody selection from semi-synthetic scFv and non-immune Fab phage display libraries against protein targets for rapid development of diagnostic immunoassays The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies abstract: Phage display involves the expression of selected proteins on the surface of filamentous phage through fusion with phage coat protein, with the genetic sequence packaged within, linking phenotype to genotype selection. When combined with antibody libraries, phage display allows for rapid in vitro selection of antigen-specific antibodies and recovery of their corresponding coding sequence. Large non-immune and synthetic human libraries have been constructed as well as smaller immune libraries based on capturing a single individual’s immune repertoire. This completely in vitro process allows for isolation of antibodies against poorly immunogenic targets as well as those that cannot be obtained by animal immunization, thus further expanding the utility of the approach. Phage antibody display represents the first developed methodology for high throughput screening for human therapeutic antibody candidates. Recently, other methods have been developed for generation of fully human therapeutic antibodies, such as single B-cell screening, next-generation genome sequencing and transgenic mice with human germline B-cell genes. While each of these have their particular advantages, phage display has remained a key methodology for human antibody discovery due its in vitro process. Here, we review the continuing role of this technique alongside other developing technologies for therapeutic antibody discovery. url: https://www.ncbi.nlm.nih.gov/pubmed/25135889/ doi: 10.1093/intimm/dxu082 id: cord-329857-pcsuu597 author: Chan, Kuan Rong title: Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases date: 2015-11-02 words: 5862.0 sentences: 280.0 pages: flesch: 28.0 cache: ./cache/cord-329857-pcsuu597.txt txt: ./txt/cord-329857-pcsuu597.txt summary: The binding affinity of antibodies to viruses can directly impact the efficacy of mAbs [4] , suggesting that target-specific mechanisms likely account for much of the efficacy of therapeutic mAbs. However, many studies have also highlighted the contribution of Fc-mediated immune effector functions in modulating the efficacy of these mAbs [5] . FcgRs have been shown to be important in modulating the efficacy of therapeutic mAbs [5] due to their involvement in FcgRmediated phagocytosis, cytokine production, ADCC and complement-dependent cytotoxicity (CDC) that aids in virus neutralization (FIGURE 1). Given the importance of FcgRs in mediating virus neutralization and Fc effector functions, a better understanding of how therapeutic antibodies neutralize virus infections in FcgRbearing cells will impact implementation of dosing regiments and allow development of improved therapeutic antibodies against infectious diseases. Given the importance of Fc-FcgR interaction in antibodymediated effector functions, Fc modification could lead to the development of therapeutic antibodies with improved interaction to activating FcgRs. This could enhance FcgR-mediated uptake, cytokine production, antigen presentation, ADCC and CDC. abstract: The lack of vaccines against several important viral diseases necessitates the development of therapeutics to save lives and control epidemics. In recent years, therapeutic antibodies have received considerable attention due to their good safety profiles and clinical success when used against viruses such as respiratory syncytial virus, Ebola virus and Hendra virus. The binding affinity of these antibodies can directly impact their therapeutic efficacy. However, we and others have also demonstrated that the subtype of Fc-gamma receptors (FcγRs) engaged influences the stoichiometric requirement for virus neutralization. Hence, the development of therapeutic antibodies against infectious diseases should consider the FcγRs engaged and Fc-effector functions involved. This review highlights the current state of knowledge about FcγRs and FcγR effector functions involved in virus neutralization, with emphasis on factors that can affect FcγR engagement. A better understanding of Fc-FcγR interactions during virus neutralization will allow development of therapeutic antibodies that are efficacious and can be administered with minimal side effects. url: https://www.ncbi.nlm.nih.gov/pubmed/26466016/ doi: 10.1586/14787210.2015.1079127 id: cord-133453-23rfdkuw author: Chen, Jiahui title: Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies date: 2020-10-13 words: 8184.0 sentences: 485.0 pages: flesch: 54.0 cache: ./cache/cord-133453-23rfdkuw.txt txt: ./txt/cord-133453-23rfdkuw.txt summary: By integrating genetics, biophysics, deep learning, and algebraic topology, we deduce that some of the mutations such as M153I, S254F, and S255F may weaken the binding of S protein and antibodies, and potentially disrupt the efficacy and reliability of antibody therapies and vaccines in the development. The vaccination mechanism is to stimulate the primary immune response of the human body, which will activate T cells and B cells to generate the antibodies and long-lived memory cells that prevent infectious diseases, which is one of the most effective and economical means for combating with COVID-19 at this stage. Notably, understanding how mutations have changed the SARS-CoV-2 structure, function, infectivity, activity, and virulence is of great importance for coming up with life-saving strategies in virus control, containment, prevention, and medication, especially in the antibodies and vaccines development. Next, we study the BFE changes ∆∆G induced by 39 mutations on the SARS-CoV-2 S protein RBD for the antibody Fab 2-4 (PDB: 6XEY) in Figure 6 . abstract: Antibody therapeutics and vaccines are among our last resort to end the raging COVID-19 pandemic.They, however, are prone to over 1,800 mutations uncovered by a Mutation Tracker. It is urgent to understand how vaccines and antibodies in the development would be impacted by mutations. In this work, we first study the mechanism, frequency, and ratio of mutations on the spike (S) protein, which is the common target of most COVID-19 vaccines and antibody therapies. Additionally, we build a library of antibody structures and analyze their 2D and 3D characteristics. Moreover, we predict the mutation-induced binding free energy (BFE) changes for the complexes of S protein and antibodies or ACE2. By integrating genetics, biophysics, deep learning, and algebraic topology, we deduce that some of the mutations such as M153I, S254F, and S255F may weaken the binding of S protein and antibodies, and potentially disrupt the efficacy and reliability of antibody therapies and vaccines in the development. We provide a strategy to prioritize the selection of mutations for designing vaccines or antibody cocktails. url: https://arxiv.org/pdf/2010.06357v1.pdf doi: nan id: cord-255683-2eq24jth author: Chen, Weizao title: Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins date: 2010-02-04 words: 5927.0 sentences: 290.0 pages: flesch: 47.0 cache: ./cache/cord-255683-2eq24jth.txt txt: ./txt/cord-255683-2eq24jth.txt summary: Ig Ms (IgMs) are on average significantly less divergent from germline antibodies and are relevant for the development of vaccine immunogens but are underexplored compared to IgGs. Here we describe the identification and characterization of several human IgM-derived mAbs against HIV-1 which were selected from a large phage-displayed naive human antibody library constructed from blood, lymph nodes and spleens of 59 healthy donors. To find whether the activity of the antibodies is related to antibody size and how the viral infection could be affected by cross-linking of HIV-1 Envs, we generated a single-chain Fv fragment (scFv) (scFv m19) of m19 and a human IgG1 Fc-fusion protein (m19Fc) of scFv m19; m19 was selected for further characterization because its light chain was relatively less divergent from the germline ( Figure 1b) and was the only one which did not contain any somatic mutations in the CDR3 of the light chain. abstract: Elicitation of antibodies with potent and broad neutralizing activity against HIV by immunization remains a challenge. Several monoclonal antibodies (mAbs) isolated from humans with HIV-1 infection exhibit such activity but vaccine immunogens based on structures containing their epitopes have not been successful for their elicitation. All known broadly neutralizing mAbs (bnmAbs) are immunoglobulin (Ig) Gs (IgGs) and highly somatically hypermutated which could impede their elicitation. Ig Ms (IgMs) are on average significantly less divergent from germline antibodies and are relevant for the development of vaccine immunogens but are underexplored compared to IgGs. Here we describe the identification and characterization of several human IgM-derived mAbs against HIV-1 which were selected from a large phage-displayed naive human antibody library constructed from blood, lymph nodes and spleens of 59 healthy donors. These antibodies bound with high affinity to recombinant envelope glycoproteins (gp140s, Envs) of HIV-1 isolates from different clades. They enhanced or did not neutralize infection by some of the HIV-1 primary isolates using CCR5 as a coreceptor but neutralized all CXCR4 isolates tested although weakly. One of these antibodies with relatively low degree of somatic hypermutation was more extensively characterized. It bound to a highly conserved region partially overlapping with the coreceptor binding site and close to but not overlapping with the CD4 binding site. These results suggest the existence of conserved structures that could direct the immune response to non-neutralizing or even enhancing antibodies which may represent a strategy used by the virus to escape neutralizing immune responses. Further studies will show whether such a strategy plays a role in HIV infection of humans, how important that role could be, and what the mechanisms of infection enhancement are. The newly identified mAbs could be used as reagents to further characterize conserved non-neutralizing, weakly neutralizing or enhancing epitopes and modify or remove them from candidate vaccine immunogens. url: https://www.ncbi.nlm.nih.gov/pubmed/21755021/ doi: 10.3390/v2020547 id: cord-275946-ofd2ipvs author: Cheng, Matthew P. title: Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus-2: A Narrative Review date: 2020-06-04 words: 5277.0 sentences: 282.0 pages: flesch: 38.0 cache: ./cache/cord-275946-ofd2ipvs.txt txt: ./txt/cord-275946-ofd2ipvs.txt summary: Accurate serologic tests to detect host antibodies to severe acute respiratory syndrome–related coronavirus-2 (SARS-CoV-2) will be critical for the public health response to the coronavirus disease 2019 pandemic. This article discusses key use cases for SARS-CoV-2 antibody detection tests and their application to serologic studies, reviews currently available assays, highlights key areas of ongoing research, and proposes potential strategies for test implementation. Appropriately designed seroepidemiologic studies will play an essential part in the public health response to the COVID-19 pandemic by characterizing transmission dynamics, refining disease burden estimates, and providing insight into the kinetics of humoral immunity to SARS-CoV-2. Serologic surveillance studies can also assess the accumulation of persons with antibody responses over time to estimate incidence of SARS-CoV-2 infection (57, 58) and can track age-and jurisdiction-specific disease susceptibility and identify at-risk populations (59) . abstract: Accurate serologic tests to detect host antibodies to severe acute respiratory syndrome–related coronavirus-2 (SARS-CoV-2) will be critical for the public health response to the coronavirus disease 2019 pandemic. Many use cases are envisaged, including complementing molecular methods for diagnosis of active disease and estimating immunity for individuals. At the population level, carefully designed seroepidemiologic studies will aid in the characterization of transmission dynamics and refinement of disease burden estimates and will provide insight into the kinetics of humoral immunity. Yet, despite an explosion in the number and availability of serologic assays to test for antibodies against SARS-CoV-2, most have undergone minimal external validation to date. This hinders assay selection and implementation, as well as interpretation of study results. In addition, critical knowledge gaps remain regarding serologic correlates of protection from infection or disease, and the degree to which these assays cross-react with antibodies against related coronaviruses. This article discusses key use cases for SARS-CoV-2 antibody detection tests and their application to serologic studies, reviews currently available assays, highlights key areas of ongoing research, and proposes potential strategies for test implementation. url: https://doi.org/10.7326/m20-2854 doi: 10.7326/m20-2854 id: cord-260340-dujd28gg author: Chenoweth, Alicia M title: Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs date: 2020-04-12 words: 10121.0 sentences: 516.0 pages: flesch: 40.0 cache: ./cache/cord-260340-dujd28gg.txt txt: ./txt/cord-260340-dujd28gg.txt summary: This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a "scaffolding" role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. Most therapeutic mAbs are IgG in origin and the heavy-chain subclass determines many of their biological properties including their long plasma half-life 3 ; complement activation, which is important in the action of some cytotoxic mAbs [4] [5] [6] and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FccR, the subject of this review. Therapy with an IgG1 anti-cancer cell mAb may then be compromised by the inhibitory action of FccRIIb upon the ITAM signaling of the activating FccR as both types of receptor would be coengaged on such an effector cell by the mAb bound to the target cell. abstract: The human fragment crystallizable (Fc)γ receptor (R) interacts with antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emerging infections such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) requires increased effort on the development of improved and novel mAbs. A more mature appreciation of the immunobiology of individual FcγR function and the complexity of the relationships between FcγRs and antibodies is fueling efforts to develop more potent “next‐gen” therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor specificity for selective engagement of individual activating FcγRs or the inhibitory FcγRIIb or alternatively, for the ablation of FcγR interaction altogether. This review touches on recent aspects of FcγR and IgG immunobiology and its relationship with the present and future actions of therapeutic mAbs. url: https://doi.org/10.1111/imcb.12326 doi: 10.1111/imcb.12326 id: cord-005409-8mbqkzpu author: Cichon, G title: Complement activation by recombinant adenoviruses date: 2002-01-24 words: 4020.0 sentences: 203.0 pages: flesch: 40.0 cache: ./cache/cord-005409-8mbqkzpu.txt txt: ./txt/cord-005409-8mbqkzpu.txt summary: We have determined the level of C3a (the most reactive complement component) generated in isolated citrate plasma of healthy individuals after challenge with recombinant and wild-type adenoviruses in amounts corresponding to virus blood levels to be expected in patients during adenoviral gene therapy. It has been known for a long time that adenoviruses are able to induce an antibody-dependent activation of the complement system in human plasma, but the level of activation which is reached during clinical adenoviral gene therapy (especially in intravascular infusions) might have been underestimated in the past. We will show that challenge of isolated human plasma with serotype 5 adenoviruses in amounts corresponding to blood levels reached in the above-mentioned trial, generates a level of complement activation, which holds the potency to induce serious inflammatory reactions. 13 Systemic activation of the complement system, as known from patients suffering from sepsis, severe burns or injuries, could induce autodestructive inflammatory reactions, such as adult respiratory distress syndrome (ARDS) or multiple organ failure (MOF). abstract: Recombinant adenoviruses are currently the most important vector system in gene therapy. Adenoviruses frequently cause upper respiratory tract infections in humans and anti-adenoviral antibodies are found in 35–70% of the population. Therefore in the majority of potential patients receiving adenoviral gene therapy, the contact of virus particles and blood will lead to the formation of antigen–antibody complexes. These complexes have the ability to induce inflammatory reactions via an activation of the complement system. We have determined the level of C3a (the most reactive complement component) generated in isolated citrate plasma of healthy individuals after challenge with recombinant and wild-type adenoviruses in amounts corresponding to virus blood levels to be expected in patients during adenoviral gene therapy. All plasma samples containing anti-adenoviral antibodies showed a substantial, dose-dependent generation of C3a. A virus plasma level of about 7.5 × 10(9) particles/ml (which was calculated to be the highest blood level reached during clinical trials in the past) induced an average release of about 3000 ng/ml C3a (baseline levels <140 ng/ml). Analyzing the nature of anti-adenoviral antibodies showed, that not only antibodies with neutralizing properties (anti-Ad5), but also non-neutralizing anti-adenoviral antibodies are capable of complement activation. This study suggests that complement activation can be ignored in local low-dose applications of recombinant adenoviruses, but warrants attention after systemic application of large viral quantities. In clinical protocols aiming at systemic virus application, measures for monitoring and controlling the complement system should be included on a regular basis. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091591/ doi: 10.1038/sj.gt.3301611 id: cord-340305-jtvn9tlm author: Cimolai, Nevio title: A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19 date: 2020-09-19 words: 5105.0 sentences: 294.0 pages: flesch: 40.0 cache: ./cache/cord-340305-jtvn9tlm.txt txt: ./txt/cord-340305-jtvn9tlm.txt summary: At this time, the best correlates with protection from natural coronavirus infections are systemic neutralizing antibody and mucosal IgA. Others have found strong correlations between neutralizing antibodies and EIA-detected antibodies to various SARS-CoV-2 antigens [41, 42] .Some have found diversity in immune responses contingent on the nature of presenting disease [38, 43] . With the availability of viral antigen, most scientists in the know-how would be able to fashion a test for antibody determination in short order and most would likely choose an enzyme immunoassay (EIA) (or nearly equivalent non-enzymebased assay) for its potential of automation and widespread use. Sensitive and specific detection of low-level antibody responses in mild Middle East Respiratory Syndrome coronavirus infections A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patients abstract: Until either efficacious therapy or vaccination for COVID-19 is achieved, there will be a need to regain world economic stability while yet controlling the pandemic with current approaches. For those infected thus far, there is a prevailing perspective that devising recognition for protective immunity will progressively allow segments of society to return to some functionality more than is existing. At this time, the best correlates with protection from natural coronavirus infections are systemic neutralizing antibody and mucosal IgA. Serum neutralizing antibody more easily fulfills the latter requisite, but current live virus methods for neutralization prevent large-scale application. It is conceivable that the exposure of previously infected individuals can allow for the definition of protective thresholds of neutralizing antibody. Thereafter, many other antibody assays will be able to screen for surrogate protection after correlations with protective neutralizing antibody are made. Specificity of common antibody tests would benefit from confirmatory blocking systems or confirmatory immunoblotting fingerprints with well-defined antigen(s). The opportunity for the scientific community to make these assessments is evident in the current context of the COVID-19 epidemic given the large numbers of infected individuals worldwide. Such information will also be vital to guide vaccine development and/or immunotherapy. url: https://doi.org/10.1007/s42399-020-00533-4 doi: 10.1007/s42399-020-00533-4 id: cord-285760-y37ji92k author: Connell, Anna R. title: Mumps Outbreaks in Vaccinated Populations—Is It Time to Re-assess the Clinical Efficacy of Vaccines? date: 2020-09-18 words: 13097.0 sentences: 622.0 pages: flesch: 41.0 cache: ./cache/cord-285760-y37ji92k.txt txt: ./txt/cord-285760-y37ji92k.txt summary: Although a rise in IgG titer may also not occur in vaccinated individuals (87, 137) , numerous studies have documented a rapid, variable increase in mumps-specific IgG levels, with neutralization antibody concentrations present up to 10 months post-infection (130, 138, 139) . Potential waning immunity has been documented in the current mumps outbreaks seen in Europe and the USA, mostly affecting young adults within highly vaccinated populations attending tertiary education who have received two doses of the MMR vaccine in early childhood (40, 110, 126, 144, 145, (175) (176) (177) (178) (179) (180) (181) . Although MuV can be clinically asymptomatic in about 15-30% of those who become infected, the vaccine against mumps confers protection in a dose response manner; unvaccinated individuals saw an attack rate of Based on the reduction seen upon the introduction of a mumps vaccine, it has been proposed that MMR vaccination also prevents the transmission of the virus. abstract: History illustrates the remarkable public health impact of mass vaccination, by dramatically improving life expectancy and reducing the burden of infectious diseases and co-morbidities worldwide. It has been perceived that if an individual adhered to the MMR vaccine schedule that immunity to mumps virus (MuV) would be lifelong. Recent mumps outbreaks in individuals who had received two doses of the Measles Mumps Rubella (MMR) vaccine has challenged the efficacy of the MMR vaccine. However, clinical symptoms, complications, viral shedding and transmission associated with mumps infection has been shown to be reduced in vaccinated individuals, demonstrating a benefit of this vaccine. Therefore, the question of what constitutes a good mumps vaccine and how its impact is assessed in this modern era remains to be addressed. Epidemiology of the individuals most affected by the outbreaks (predominantly young adults) and variance in the circulating MuV genotype have been well-described alluding to a collection of influences such as vaccine hesitancy, heterogeneous vaccine uptake, primary, and/or secondary vaccine failures. This review aims to discuss in detail the interplay of factors thought to be contributing to the current mumps outbreaks seen in highly vaccinated populations. In addition, how mumps diagnoses has progressed and impacted the understanding of mumps infection since a mumps vaccine was first developed, the limitations of current laboratory tests in confirming protection in vaccinated individuals and how vaccine effectiveness is quantified are also considered. By highlighting knowledge gaps within this area, this state-of-the-art review proposes a change of perspective regarding the impact of a vaccine in a highly vaccinated population from a clinical, diagnostic and public perspective, highlighting a need for a paradigm shift on what is considered vaccine immunity. url: https://www.ncbi.nlm.nih.gov/pubmed/33072071/ doi: 10.3389/fimmu.2020.02089 id: cord-261274-y74smbtd author: Crouch, C. F title: Lactogenic immunity following vaccination of cattle with bovine coronavirus date: 2000-09-15 words: 4173.0 sentences: 177.0 pages: flesch: 53.0 cache: ./cache/cord-261274-y74smbtd.txt txt: ./txt/cord-261274-y74smbtd.txt summary: Abstract In order to investigate the ability of an oil adjuvanted vaccine containing bovine coronavirus antigen to enhance lactogenic immunity in the calf, pregnant cows and heifers were vaccinated and specific virus neutralising antibody levels determined in serum, colostrum and milk. Pre-existing antibody titres (as a result of natural infection) in the serum of these animals were found to be significantly increased as a result of a single shot vaccination carried out between 2 and 12 weeks before calving. This hypothesis was supported by the observations on the magnitude of the antibody titres found in the colostrum and milk of cows vaccinated at dierent times pre-calving with a vaccine containing 150 antigen units of BCoV. This report indicates that a single dose of coronavirus vaccine administered to the pregnant heifer 2 to 12 weeks before calving is capable of signi®cantly increasing the titre and duration of speci®c antibody present in colostrum and milk. abstract: Abstract In order to investigate the ability of an oil adjuvanted vaccine containing bovine coronavirus antigen to enhance lactogenic immunity in the calf, pregnant cows and heifers were vaccinated and specific virus neutralising antibody levels determined in serum, colostrum and milk. Pre-existing antibody titres (as a result of natural infection) in the serum of these animals were found to be significantly increased as a result of a single shot vaccination carried out between 2 and 12 weeks before calving. This was reflected in a similar increase in the titre and duration of specific antibody in milk and colostrum that was passed on to the calves. The overall response observed was highly dependent on an adequate antigen payload being incorporated within the single dose vaccine. No abnormal local or systemic reactions were observed as a result of vaccination. It is hoped that this approach will lead to the production of a superior commercial vaccine for the protection of neonatal calves against enteric coronavirus infection. url: https://www.ncbi.nlm.nih.gov/pubmed/10930672/ doi: 10.1016/s0264-410x(00)00177-8 id: cord-290783-ipoelk4h author: Crouch, C. F. title: Vaccination against enteric rota and coronaviruses in cattle and pigs: Enhancement of lactogenic immunity date: 1985-09-30 words: 4545.0 sentences: 254.0 pages: flesch: 39.0 cache: ./cache/cord-290783-ipoelk4h.txt txt: ./txt/cord-290783-ipoelk4h.txt summary: This article examines methods currently used to enhance the titre and duration of specific antibody in the mammary secretions of cows and pigs with particular reference to rotavirus and coronavirus infections. The situation in neonatal piglets is less clear, rotavirus infections are apparently common 6.t4-tt, w.hilst transmissible gastroenteritis virus (TGEV), the prototype enteric coronavirus in swine, is an example of a seasonal cold-weather disease, probably related to both the thermal sensitivity of the virus ~ and the effect of cold-stress on converting subclinical to clinical infections ~8. It is apparent that the enhancement of lactogenic immunity through the vaccination of the dam provides a suitable mechanism by which neonatal pigs and calves can be protected against rotavirus and coronavirus infections. Passive immunity in calf rotavirus infections: Maternal vaccination increases and prolongs immunoglobulin G 1 antibody secretion in milk Antibody responses in serum, colostrum and milk of swine after infection or vaccination with transmissible gastroenteritis virus abstract: Passive immunity against enteric viral infections is dependent upon the continual presence in the gut lumen of a protective level of specific antibodies. This article examines methods currently used to enhance the titre and duration of specific antibody in the mammary secretions of cows and pigs with particular reference to rotavirus and coronavirus infections. In addition, some of the potential problems to be found in attempting to produce vaccines against these viral infections are outlined url: https://api.elsevier.com/content/article/pii/S0264410X85900568 doi: 10.1016/s0264-410x(85)90056-8 id: cord-004167-r2s0gks8 author: Cutts, Julia C. title: Pregnancy-specific malarial immunity and risk of malaria in pregnancy and adverse birth outcomes: a systematic review date: 2020-01-16 words: 8593.0 sentences: 422.0 pages: flesch: 38.0 cache: ./cache/cord-004167-r2s0gks8.txt txt: ./txt/cord-004167-r2s0gks8.txt summary: Antibody responses to pregnancy-specific pRBC and VAR2CSA antigens, measured at delivery, were associated with placental malaria (9 studies) and may therefore represent markers of infection, rather than correlates of protection. To summarize, evidence from studies included in narrative terms suggests that whilst high avidity Abs and anti-adhesion Abs measured at delivery may be associated with protection from placental infection [65] and reduced placental parasitaemia [38] , respectively, total IgG responses to VAR2CSA antigens and pregnancy-specific pRBC are positively associated with the presence of placental malaria [34, 39, 64, [68] [69] [70] [71] [72] 76] . Overall, the majority of estimates included in this review, and studies included in narrative terms, indicate that when measured at delivery, antibody responses to pregnancy-specific pRBC and VAR2CSA antigens are associated with the presence of placental infection and may therefore represent markers of infection, rather than correlates of protection. abstract: BACKGROUND: In endemic areas, pregnant women are highly susceptible to Plasmodium falciparum malaria characterized by the accumulation of parasitized red blood cells (pRBC) in the placenta. In subsequent pregnancies, women develop protective immunity to pregnancy-associated malaria and this has been hypothesized to be due to the acquisition of antibodies to the parasite variant surface antigen VAR2CSA. In this systematic review we provide the first synthesis of the association between antibodies to pregnancy-specific P. falciparum antigens and pregnancy and birth outcomes. METHODS: We conducted a systematic review and meta-analysis of population-based studies (published up to 07 June 2019) of pregnant women living in P. falciparum endemic areas that examined antibody responses to pregnancy-specific P. falciparum antigens and outcomes including placental malaria, low birthweight, preterm birth, peripheral parasitaemia, maternal anaemia, and severe malaria. RESULTS: We searched 6 databases and identified 33 studies (30 from Africa) that met predetermined inclusion and quality criteria: 16 studies contributed estimates in a format enabling inclusion in meta-analysis and 17 were included in narrative form only. Estimates were mostly from cross-sectional data (10 studies) and were heterogeneous in terms of magnitude and direction of effect. Included studies varied in terms of antigens tested, methodology used to measure antibody responses, and epidemiological setting. Antibody responses to pregnancy-specific pRBC and VAR2CSA antigens, measured at delivery, were associated with placental malaria (9 studies) and may therefore represent markers of infection, rather than correlates of protection. Antibody responses to pregnancy-specific pRBC, but not recombinant VAR2CSA antigens, were associated with trends towards protection from low birthweight (5 studies). CONCLUSIONS: Whilst antibody responses to several antigens were positively associated with the presence of placental and peripheral infections, this review did not identify evidence that any specific antibody response is associated with protection from pregnancy-associated malaria across multiple populations. Further prospective cohort studies using standardized laboratory methods to examine responses to a broad range of antigens in different epidemiological settings and throughout the gestational period, will be necessary to identify and prioritize pregnancy-specific P. falciparum antigens to advance the development of vaccines and serosurveillance tools targeting pregnant women. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964062/ doi: 10.1186/s12916-019-1467-6 id: cord-022439-8wy7rpqv author: DENMAN, A.M. title: Viral Etiology of Polymyositis/Dermatomyositis date: 2013-11-17 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155693/ doi: 10.1016/b978-0-409-95191-2.50010-0 id: cord-103255-4k13re9y author: Daniell, Henry title: Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants date: 2001-05-01 words: 4362.0 sentences: 205.0 pages: flesch: 42.0 cache: ./cache/cord-103255-4k13re9y.txt txt: ./txt/cord-103255-4k13re9y.txt summary: The production of recombinant proteins in plants has many potential advantages for generating biopharmaceuticals relevant to clinical medicine. In the decade since the expression and assembly of immunoglobulin (Ig) heavy and light chains into functional antibodies was first shown in transgenic tobacco, plants have proven to be versatile production systems for many forms of antibodies. Other advantages of tobacco include its relative ease of genetic manipulation, production of large numbers of seeds (up to a million per plant) and an impending need to explore alternate uses for this hazardous crop. However, the most attractive species for expressing subunit vaccine components should have high levels of soluble protein that is stable during storage; seed crops such as cereals are particularly suitable. Induction of a protective antibody response to foot and mouth disease in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1 abstract: Abstract The use of plants for medicinal purposes dates back thousands of years but genetic engineering of plants to produce desired biopharmaceuticals is much more recent. As the demand for biopharmaceuticals is expected to increase, it would be wise to ensure that they will be available in significantly larger amounts, on a cost-effective basis. Currently, the cost of biopharmaceuticals limits their availability. Plant-derived biopharmaceuticals are cheap to produce and store, easy to scale up for mass production, and safer than those derived from animals. Here, we discuss recent developments in this field and possible environmental concerns. url: https://api.elsevier.com/content/article/pii/S1360138501019227 doi: 10.1016/s1360-1385(01)01922-7 id: cord-339879-92esdjy9 author: Delhalle, Sylvie title: Phages and HIV-1: From Display to Interplay date: 2012-04-13 words: 21838.0 sentences: 978.0 pages: flesch: 44.0 cache: ./cache/cord-339879-92esdjy9.txt txt: ./txt/cord-339879-92esdjy9.txt summary: The BNtAb IgG1 b12 was the first neutralizing MAb selected from a phage-displayed Fab (antibody fragment composed of one constant and one variable domain of the heavy (CH1 and VH) and the light (CL and VL) chains linked together) library derived from an HIV-1-infected donor (See section 3.1.1.1.1.) [41] . At the end of the second round, selected phages displaying longer inserts of 40 to 50 AA corresponding to the N-and C-terminal regions of Gag were identified, revealing the presence of two distinct antigenic regions in Gag. This study demonstrated that gene-fragment phage display could be used to identify epitopes targeted by polyclonal Abs. Although they occur at a very low frequency in humans, antibodies targeting host proteins involved in HIV-1 infection have been reported in immunized animals. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries abstract: The complex hide-and-seek game between HIV-1 and the host immune system has impaired the development of an efficient vaccine. In addition, the high variability of the virus impedes the long-term control of viral replication by small antiviral drugs. For more than 20 years, phage display technology has been intensively used in the field of HIV-1 to explore the epitope landscape recognized by monoclonal and polyclonal HIV-1-specific antibodies, thereby providing precious data about immunodominant and neutralizing epitopes. In parallel, biopanning experiments with various combinatorial or antibody fragment libraries were conducted on viral targets as well as host receptors to identify HIV-1 inhibitors. Besides these applications, phage display technology has been applied to characterize the enzymatic specificity of the HIV-1 protease. Phage particles also represent valuable alternative carriers displaying various HIV-1 antigens to the immune system and eliciting antiviral responses. This review presents and summarizes the different studies conducted with regard to the nature of phage libraries, target display mode and biopanning procedures. url: https://www.ncbi.nlm.nih.gov/pubmed/22606007/ doi: 10.3390/ijms13044727 id: cord-275402-z92b18mb author: Diamant, Eran title: Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs date: 2015-05-29 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Monoclonal antibodies (MAbs) are among the fastest-growing therapeutics and are being developed for a broad range of indications, including the neutralization of toxins, bacteria and viruses. Nevertheless, MAbs potency is still relatively low when compared to conventional polyclonal Ab preparations. Moreover, the efficacy of an individual neutralizing MAb may significantly be hampered by the potential absence or modification of its target epitope in a mutant or subtype of the infectious agent. These limitations of individual neutralizing MAbs can be overcome by using oligoclonal combinations of several MAbs with different specificities to the target antigen. Studies conducted in our lab and by others show that such combined MAb preparation may present substantial synergy in its potency over the calculated additive potency of its individual MAb components. Moreover, oligoclonal preparation is expected to be better suited to compensating for reduced efficacy due to epitope variation. In this review, the synergistic neutralization properties of combined oligoclonal Ab preparations are described. The effect of Ab affinity, autologous Fc fraction, and targeting a critical number of epitopes, as well as the unexpected contribution of non-neutralizing clones to the synergistic neutralizing effect are presented and discussed. url: https://doi.org/10.3390/toxins7061854 doi: 10.3390/toxins7061854 id: cord-331786-wgt7kg6f author: Diego-Martin, Borja title: Pilot production of SARS-CoV-2 related proteins in plants: a proof of concept for rapid repurposing of indoors farms into biomanufacturing facilities date: 2020-10-13 words: 7034.0 sentences: 326.0 pages: flesch: 45.0 cache: ./cache/cord-331786-wgt7kg6f.txt txt: ./txt/cord-331786-wgt7kg6f.txt summary: For this purpose, we tested our ability to produce, in the framework of an academic lab and in a matter of weeks, milligram amounts of six different recombinant monoclonal antibodies against SARS-CoV-2 in Nicotiana benthamiana. In parallel, we also produced the recombinant SARS-CoV-2 N protein and its Receptor Binding Domain (RBD) in planta and used them to test the binding specificity of the recombinant mAbs. Finally, for two of the antibodies we assayed a simple scale-up production protocol based on the extraction of apoplastic fluid. Finally, we performed sandwich ELISA tests of sybody17 and nanobody72 ( Fig 5E and Fig 5F, respectively) using the total and concentrated apoplastic fluid as detection reagent against serial dilutions of crude plant extracts from RBD-producing plants, showing that this simple antibody preparation can be directly employed in detection procedures without the need of additional purification steps. abstract: The current CoVid-19 crisis is revealing the strengths and the weaknesses of the world’s capacity to respond to a global health crisis. A critical weakness has resulted from the excessive centralization of the current biomanufacturing capacities, a matter of great concern, if not a source of nationalistic tensions. On the positive side, scientific data and information have been shared at an unprecedented speed fuelled by the preprint phenomena, and this has considerably strengthened our ability to develop new technology-based solutions. In this work we explore how, in a context of rapid exchange of scientific information, plant biofactories can serve as a rapid and easily adaptable solution for local manufacturing of bioreagents, more specifically recombinant antibodies. For this purpose, we tested our ability to produce, in the framework of an academic lab and in a matter of weeks, milligram amounts of six different recombinant monoclonal antibodies against SARS-CoV-2 in Nicotiana benthamiana. For the design of the antibodies we took advantage, among other data sources, of the DNA sequence information made rapidly available by other groups in preprint publications. mAbs were all engineered as single-chain fragments fused to a human gamma Fc and transiently expressed using a viral vector. In parallel, we also produced the recombinant SARS-CoV-2 N protein and its Receptor Binding Domain (RBD) in planta and used them to test the binding specificity of the recombinant mAbs. Finally, for two of the antibodies we assayed a simple scale-up production protocol based on the extraction of apoplastic fluid. Our results indicate that gram amounts of anti-SARS-CoV-2 antibodies could be easily produced in little more than 6 weeks in repurposed greenhouses with little infrastructure requirements using N. benthamiana as production platform. Similar procedures could be easily deployed to produce diagnostic reagents and, eventually, could be adapted for rapid therapeutic responses. url: https://doi.org/10.1101/2020.10.13.331306 doi: 10.1101/2020.10.13.331306 id: cord-017070-05vlz5dn author: Dimitrov, Dimiter S. title: Human Monoclonal Antibodies Against HIV and Emerging Viruses date: 2008 words: 6662.0 sentences: 299.0 pages: flesch: 38.0 cache: ./cache/cord-017070-05vlz5dn.txt txt: ./txt/cord-017070-05vlz5dn.txt summary: These antibodies also protected uninfected animals from SARS-CoV infection, e.g., passive transfer of immune serum to naive mice prevented virus replication in the lower respiratory tract following intranasal challenge (61) . Recently, an improved method for Epstein-Barr virus transformation of human B cells has been developed based on CpG oligonucleotide (CpG 2006) that increases the B cell immortalization efficiency from 1-2% to 30-100%, and used for selection of hmAbs specific for SARS-CoV proteins (68) . We have recently identified a novel cross-reactive potent SARS-CoV-neutralizing hmAb, m396, by using a fragment containing residues 317 through 518 as a selecting antigen for panning of a large human antibody library constructed from the B lymphocytes of healthy volunteers (75) . These antibodies specific for SARS-CoV, HeV, and NiV have potential for further development into a clinically useful product for prophylaxis and perhaps treatment of the diseases caused by these infections. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121542/ doi: 10.1007/978-1-59745-569-5_34 id: cord-297684-9q3oopaz author: Dobaño, Carlota title: Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A and G against SARS-CoV-2 antigens date: 2020-06-12 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Reliable serological tests are required to determine the prevalence of antibodies against SARS-CoV-2 antigens and to characterise immunity to the disease in order to address key knowledge gaps in the context of the COVID-19 pandemic. Quantitative suspension array technology (qSAT) assays based on the xMAP Luminex platform overcome the limitations of rapid diagnostic tests and ELISA with their higher precision, dynamic range, throughput, miniaturization, cost-efficacy and multiplexing capacity. We developed three qSAT assays to detect IgM, IgA and IgG to a panel of eight SARS-CoV-2 antigens including spike (S), nucleoprotein (N) and membrane (M) protein constructs. The assays were optimized to minimize processing time and maximize signal to noise ratio. We evaluated the performance of the assays using 128 plasmas obtained before the COVID-19 pandemic (negative controls) and 115 plasmas from individuals with SARS-CoV-2 diagnosis (positive controls), of whom 8 were asymptomatic, 58 had mild symptoms and 49 were hospitalized. Pre-existing IgG antibodies recognizing N, M and S2 proteins were detected in negative controls suggestive of cross-reactive to common cold coronaviruses. The best performing antibody isotype/antigen signatures had specificities of 100% and sensitivities of 94.94% at ≥14 days since the onset of symptoms and 96.08% at ≥21 days since the onset of symptoms, with AUC of 0.992 and 0.999, respectively. Combining multiple antibody markers as assessed by qSAT assays has the highest efficiency, breadth and versatility to accurately detect low-level antibody responses for obtaining reliable data on prevalence of exposure to novel pathogens in a population. Our assays will allow gaining insights into antibody correlates of immunity required for vaccine development to combat pandemics like the COVID-19. url: https://doi.org/10.1101/2020.06.11.147363 doi: 10.1101/2020.06.11.147363 id: cord-018404-jdu4h00e author: DuBourdieu, Dan title: Colostrum Antibodies, Egg Antibodies and Monoclonal Antibodies Providing Passive Immunity for Animals date: 2019-03-11 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Passive immunity can be provided to animals by several sources of antibodies including from colostrum, avian eggs, and monoclonal sources. These antibodies have been shown protect production and companion animals from a number of pathogens. This chapter reviews the immune system for the principles of immune response to antigens and the synthesis of immunoglobulins of the five classes of antibodies in the body. Colostrum antibodies are described for passive immunity protection in animals such as calves. Chicken egg antibodies are another source of antibodies for passive immunity. Therapeutic monoclonal antibodies are also used to provide passive immunity in the veterinary field. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123268/ doi: 10.1007/978-3-030-04624-8_18 id: cord-023731-jqgervt7 author: FENNER, FRANK title: Laboratory Diagnosis of Viral Diseases date: 2014-06-27 words: 6992.0 sentences: 320.0 pages: flesch: 39.0 cache: ./cache/cord-023731-jqgervt7.txt txt: ./txt/cord-023731-jqgervt7.txt summary: Having allocated it to a particular family (e.g., Adenoviridae), one can then go on to determine the species or serotype (e.g., canine Immunodiffusion Antibody neutralizes infectivity of virion; inhibits cytopathology, reduces plaques, or protects animals Antibody inhibits viral hemagglutination Antigen-antibody complex binds complement, which is thereafter unavailable for the lysis of hemolysissensitized sheep red blood cells Antibody-aggregated virions are visible by electron microscopy Antibody labeled with fluorochrome binds to intracellular antigen; fluoresces by UV microscopy Peroxidase-labeled antibody binds to intracellular antigen; colored precipitate forms on adding substrate Enzyme-labeled antibody (or antigen) binds to antigen (or antibody); substrate changes color Radiolabeled antibody (or antigen) binds to antigen (or antibody), e.g., attached to solid phase Antibodies and soluble antigens produce visible lines of precipitate in a gel adenovirus 1) by more discriminating serological procedures. abstract: Tests for the specific diagnosis of a viral infection in an animal are of two general types: (1) those that demonstrate the presence of the virus and (2) those that demonstrate the presence of specific viral antibody. The provision, by a single laboratory, of a comprehensive service for the diagnosis of viral infections of domestic animals is a formidable undertaking. There are about 200 individual viral species in some 20 different viral families that infect the eight major domestic animal species. If antigenic types within an individual viral species are considered and the number of animal species is broadened to include turkey, duck, and zoo and laboratory animals, then the number of individual viruses exceeds 1000. It is, therefore, not surprising that few single laboratories could have available the necessary specific reagents, skills, and experience for the diagnosis of such a large number of infections. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173550/ doi: 10.1016/b978-0-12-253055-5.50017-7 id: cord-257465-9yrf7ofy author: Finlay, William J. J. title: Phage Display: A Powerful Technology for the Generation of High-Specificity Affinity Reagents from Alternative Immune Sources date: 2016-05-23 words: 6071.0 sentences: 241.0 pages: flesch: 37.0 cache: ./cache/cord-257465-9yrf7ofy.txt txt: ./txt/cord-257465-9yrf7ofy.txt summary: These libraries are analogous to the naïve antibody repertoire in an animal, and selecting from them can result in the identifi cation of antibody fragments that exhibit high specifi city and occasionally high affi nity for the target protein. This process utilizes phage display for selection from germline targeting combinatorial libraries which results in the identifi cation of CDR residues amenable to human germ-lining without compromising on specifi city and affi nity. Nevertheless, phage display can be a relatively simple technology to use and when employed to harness natural repertoires of antibodies from immunized animals, it can offer a rapid path to highly specifi c, high-affi nity antibodies against problematic antigens . The immunized chickens appear to react to the proteins fully independently, as the phage display libraries generate individual scFv antibody clones that are fully specifi c by western blot and ELISA , showing no reactivity to their co-immunogens [ 37 , 59 ] . abstract: Antibodies are critical reagents in many fundamental biochemical methods such as affinity chromatography, enzyme-linked immunosorbent assays (ELISA), flow cytometry, western blotting, immunoprecipitation, and immunohistochemistry techniques. As our understanding of the proteome becomes more complex, demand is rising for rapidly generated antibodies of higher specificity than ever before. It is therefore surprising that few investigators have moved beyond the classical methods of antibody production in their search for new reagents. Despite their long-standing efficacy, recombinant antibody generation technologies such as phage display are still largely the tools of biotechnology companies or research groups with a direct interest in protein engineering. In this chapter, we discuss the inherent limitations of classical polyclonal and monoclonal antibody generation and highlight an attractive alternative: generating high-specificity, high-affinity recombinant antibodies from alternative immune sources such as chickens, via phage display. url: https://www.ncbi.nlm.nih.gov/pubmed/27730550/ doi: 10.1007/978-1-4939-6412-3_6 id: cord-305039-grsv06j7 author: Flego, Michela title: Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases date: 2013-01-04 words: 10985.0 sentences: 476.0 pages: flesch: 37.0 cache: ./cache/cord-305039-grsv06j7.txt txt: ./txt/cord-305039-grsv06j7.txt summary: As for HIV, mAbs directed against spike viral proteins, as well as against host receptors, may act at an early stage of infection by preventing the binding of the virus on the cell surface. In some chronic viral infections, virus-specific immune cells may persist in a ''non-functional'' state, because of an imbalance of immunoregulatory signals involving multiple inhibitory and activating receptors, triggered by soluble factors and/or cell surface ligands. Therapeutic approaches using specific mAbs to block host immunosuppressive molecules (antagonism) or to trigger activating receptors (agonism) may be a valid strategy to restore immune cell function and treat various chronic viral infections. In a proof-of-concept passive immunization trial with humans, it has been demonstrated that a cocktail of the three broadly neutralizing mAbs -2G12, 4E10 and 2F5was able to delay viral rebound in patients whose infections were fully suppressed by antiretroviral treatment before administration of the antibodies [76] . abstract: Today there are many licensed antiviral drugs, but the emergence of drug resistant strains sometimes invalidates the effects of the current therapies used in the treatment of infectious diseases. Compared to conventional antiviral drugs, monoclonal antibodies (mAbs) used as pharmacological molecules have particular physical characteristics and modes of action, and, therefore, they should be considered as a distinct therapeutic class. Despite being historically validated, antibodies may represent a novel tool for combatting infectious diseases. The current high cost of mAbs' production, storage and administration (by injection only) and the consequent obstacles to development are outweighed by mAbs' clinical advantages. These are related to a low toxicity combined with high specificity and versatility, which allows a specific antibody to mediate various biological effects, ranging from the virus neutralization mechanisms to the modulation of immune responses. This review briefly summarizes the recent technological advances in the field of immunoglobulin research, and the current status of mAb-based drugs in clinical trials for HIV and HCV diseases. For each clinical trial the available data are reported and the emerging conceptual problems of the employed mAbs are highlighted. This overview helps to give a clear picture of the efficacy and challenges of the mAbs in the field of these two infectious diseases which have such a global impact. url: https://www.ncbi.nlm.nih.gov/pubmed/23289632/ doi: 10.1186/1741-7015-11-4 id: cord-282081-qaagup4d author: Flicker, Sabine title: Nanobodies—Useful Tools for Allergy Treatment? date: 2020-09-30 words: 5062.0 sentences: 247.0 pages: flesch: 30.0 cache: ./cache/cord-282081-qaagup4d.txt txt: ./txt/cord-282081-qaagup4d.txt summary: Their superior properties such as chemical stability, high affinity to a broad spectrum of epitopes, low immunogenicity, ease of their generation, selection and production proved nanobodies also to be remarkable to investigate their efficacy for passive treatment of type I allergy, an exaggerated immune reaction to foreign antigens with increasing global prevalence. Similar to the evaluation of conventional antibodies with the focus to identify effective protective monoclones, generated nanobodies have to be assessed first for their allergen specificity, epitope recognition, cross-reactivity to homologous allergens present in related species, for their affinity to their corresponding allergens and most importantly for their ability to inhibit patients''IgE binding to these allergens (Figures 2A-C) . abstract: In the last decade single domain antibodies (nanobodies, V(H)H) qualified through their unique characteristics have emerged as accepted and even advantageous alternative to conventional antibodies and have shown great potential as diagnostic and therapeutic tools. Currently nanobodies find their main medical application area in the fields of oncology and neurodegenerative diseases. According to late-breaking information, nanobodies specific for coronavirus spikes have been generated these days to test their suitability as useful therapeutics for future outbreaks. Their superior properties such as chemical stability, high affinity to a broad spectrum of epitopes, low immunogenicity, ease of their generation, selection and production proved nanobodies also to be remarkable to investigate their efficacy for passive treatment of type I allergy, an exaggerated immune reaction to foreign antigens with increasing global prevalence. url: https://doi.org/10.3389/fimmu.2020.576255 doi: 10.3389/fimmu.2020.576255 id: cord-330218-l5q3n3ri author: Foss, Stian title: TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity date: 2015-10-26 words: 7824.0 sentences: 376.0 pages: flesch: 41.0 cache: ./cache/cord-330218-l5q3n3ri.txt txt: ./txt/cord-330218-l5q3n3ri.txt summary: Neutralization of viruses by antibodies is predicted to depend on high-affinity binding to specific epitopes of surface-exposed viral proteins that are required for binding to target cell receptors (4) . These effector functions are induced upon binding of antibody-virus immune complexes to classical Fc c receptors (FccRs) expressed on the surface of hematopoietic cells such as natural killer (NK) cells, macrophages, and dendritic cells, which results in clearance and induction of T-cell responses (8) . Low antibody-virus stoichiometry may also result in inefficient FccR-mediated effector functions by immune cells as efficient phagocytosis requires the formation of immune complexes and cross-binding to cell-surface FccRs. In addition, as TRIM21 also engages IgM and IgA, it is likely to contribute to early protection, and at the gate of entry of most viral pathogens, the mucosal barrier. abstract: Antibodies are key molecules in the fight against infections. Although previously thought to mediate protection solely in the extracellular environment, recent research has revealed that antibody-mediated protection extends to the cytosolic compartment of cells. This postentry viral defense mechanism requires binding of the antibody to a cytosolic Fc receptor named tripartite motif containing 21 (TRIM21). In contrast to other Fc receptors, TRIM21 shows remarkably broad isotype specificity as it does not only bind IgG but also IgM and IgA. When viral pathogens coated with these antibody isotypes enter the cytosol, TRIM21 is rapidly recruited and efficient neutralization occurs before the virus has had the time to replicate. In addition, inflammatory signaling is induced. As such, TRIM21 acts as a cytosolic sensor that engages antibodies that have failed to protect against infection in the extracellular environment. Here, we summarize our current understanding of how TRIM21 orchestrates humoral immunity in the cytosolic environment. url: https://www.ncbi.nlm.nih.gov/pubmed/26497531/ doi: 10.1111/imr.12363 id: cord-015742-nt44jcjm author: Garwes, D.J. title: Antigenicity of structural components from porcine transmissible gastroenteritis virus date: 2002-11-13 words: 3604.0 sentences: 177.0 pages: flesch: 43.0 cache: ./cache/cord-015742-nt44jcjm.txt txt: ./txt/cord-015742-nt44jcjm.txt summary: Incubation of 3H-uridine TGEV with sera from sows inoculated with viral antigen resulted in the formation of immune complexes that were retained by membrane filters (Fig. 2) . Sera from sows inoculated with whole virus, SP antigen or SVP antigen preparations produced virus complexes that were retained most efficient Samples of 3H-uridine labelled TGEV containing 4000 ct/min were incubated for 2 h at 37°C in dilutions of test sera followed by incubation with rabbit anti-porcine IgG serum. Analysis of the immunoglobulin classes responsible for neutralising activity after inoculation of sows by the intramammary route showed that IgG was the predominant antibody species in both serum and colostrum, consistent with previous findings with inactivated TGEV Lucas et al., 1974) but differing from the stimulation of IgA to ferritin reported by Bourne et al. 9, which received SP antigen, produced neutralising antibody of the IgA class in the colostrum and was the only animal capable of protecting her piglets against challenge with live virus. abstract: Pregnant sows were inoculated with inactivated transmissible gastroenteritis virus and with preparations of virus surface projections and subviral particles derived by detergent treatment of the virus. Neutralising antibody was demonstrated in serum and colostrum from animals that received whole virus or preparations of surface projections whereas subviral particles failed to stimulate neutralising antibody formation. Similar results were obtained with serum from rabbits inoculated with whole virus and structural components. All three preparations stimulated the formation of agglutinating antibodies, as demonstrated by sedimentation analysis and filtration studies with radiolabelled virus. The immunoglobulin classes responsible for neutralising antibody activity in sows inoculated by the intramammary route were examined. In each case where the immunoglobulin class was determined, IgG was found. One sow that received surface projections also had IgA with neutralising activity in her colostrum. In contrast, infection of sows with live whole virus resulted in neutralising antibody of the IgG, IgM and IgA classes. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117557/ doi: 10.1016/0378-1135(79)90034-8 id: cord-341305-zf97tcwe author: Ge, Shikun title: Canine Parvovirus is diagnosed and neutralized by chicken IgY-scFv generated against the virus capsid protein date: 2020-09-03 words: 3690.0 sentences: 182.0 pages: flesch: 50.0 cache: ./cache/cord-341305-zf97tcwe.txt txt: ./txt/cord-341305-zf97tcwe.txt summary: The CPV-VLP and CPV-VP2 protein showed similar reaction values to the purified scFv in the ELISA test, and the results of ELISA analysis using IgY-scFv toward CPV clinical samples were consistent with commercial immunochromatographic assay (ICA) and PCR detection, the scFv did not show cross reactivity with canine distemper virus (CDV) and canine coronavirus (CCV). This study revealed the feasibility of a novel functional antibody fragment development strategy by generating diversified avian IgY-scFv libraries towards the pathogenic target of interest for both detection and therapeutic purposes in veterinary medicine. Functional antibody fragments (i.e.: scFv, Fab) generated by phage-display technology have been not yet routinely evaluated and applied in the veterinary medicine despite it has been well confirmed that such engineered antibodies offer a series of advantages over polyclonal and full-length monoclonal antibodies. abstract: Canine parvovirus (CPV) can cause acute and highly contagious bloody enteritis in dog. To obtain antibodies against CPV, hens were immunized with virus-like particles (VLP) of CPV-VP2. The IgY single chain fragment variables (scFv) were generated by T7 phage display system and expressed in E. coli system. The titer of the primary scFv library reached to 1.5 × 10(6) pfu/mL, and 95% of the phages contained the target fragments. The CPV-VLP and CPV-VP2 protein showed similar reaction values to the purified scFv in the ELISA test, and the results of ELISA analysis using IgY-scFv toward CPV clinical samples were consistent with commercial immunochromatographic assay (ICA) and PCR detection, the scFv did not show cross reactivity with canine distemper virus (CDV) and canine coronavirus (CCV). IgY-scFv was successfully expressed in CRFK cells, and in the virus suppression assay, 55% of CPV infections were eliminated within 24 h. Docking results demonstrated that the number of amino acids of the binding sides between scFv and VP2 were AA37 and AA40, respectively. This study revealed the feasibility of a novel functional antibody fragment development strategy by generating diversified avian IgY-scFv libraries towards the pathogenic target of interest for both detection and therapeutic purposes in veterinary medicine. url: https://doi.org/10.1186/s13567-020-00832-7 doi: 10.1186/s13567-020-00832-7 id: cord-342242-cynpob7b author: Godakova, Svetlana A. title: Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice date: 2019-08-07 words: 7485.0 sentences: 386.0 pages: flesch: 54.0 cache: ./cache/cord-342242-cynpob7b.txt txt: ./txt/cord-342242-cynpob7b.txt summary: Based on the analysis of B11-Fc and G3-Fc clones'' circulation time in the serum (presence of antibodies 14 days after injection), we decided to conduct an experiment on the survival of these mice, which previously received a single injection of the VHHs with the Fc fragment, with a repeated administration of only the lethal toxin dose 14 days after the original administration. Overall, we obtained numerous clones after two rounds of biopanning; we selected 15 clones for initial analysis based on their CDR3s, chose two clones (B11 and G3) with the best pre-mixed results in phage form in vivo, produced them in protein form, and modified their structure and characteristics by dimerization via a (Gly4Ser) 3 linker and fusion to a human IgG Fc fragment to enhance their protective activity. abstract: The bacterium Clostridium botulinum is the causative agent of botulism—a severe intoxication caused by botulinum neurotoxin (BoNT) and characterized by damage to the nervous system. In an effort to develop novel C. botulinum immunotherapeutics, camelid single-domain antibodies (sdAbs, VHHs, or nanobodies) could be used due to their unique structure and characteristics. In this study, VHHs were produced using phage display technology. A total of 15 different monoclonal VHHs were selected based on their comlementarity-determining region 3 (CDR3) sequences. Different toxin lethal dose (LD(50)) challenges with each selected phage clone were conducted in vivo to check their neutralizing potency. We demonstrated that modification of neutralizing VHHs with a human immunoglobulin G (IgG)1 Fc (fragment crystallizable) fragment (fusionbody, VHH-Fc) significantly increased the circulation time in the blood (up to 14 days). At the same time, VHH-Fc showed the protective activity 1000 times higher than monomeric form when challenged with 5 LD(50). Moreover, VHH-Fcs remained protective even 14 days after antibody administration. These results indicate that this VHH-Fc could be used as an effective long term antitoxin protection against botulinum type A. url: https://doi.org/10.3390/toxins11080464 doi: 10.3390/toxins11080464 id: cord-015683-a9a82of4 author: Gupta, Varsha title: Molecular Diagnostics date: 2016-10-23 words: 4774.0 sentences: 294.0 pages: flesch: 52.0 cache: ./cache/cord-015683-a9a82of4.txt txt: ./txt/cord-015683-a9a82of4.txt summary: Molecular diagnostics such as Western blot , ELISA , PCR , DNA, and protein microarrays are 7 revolutionizing the clinical practice of infectious diseases. Molecular diagnostics such as Western blot , ELISA , PCR , DNA, and protein microarrays are 7 revolutionizing the clinical practice of infectious diseases. Binding of another antigen-specifi c antibody linked with enzyme results in color formation upon addition of the substrate 9.2 Diagnosis of Bacterial, Viral, and Parasitic Diseases peptide may react in some assays but not in others as some regions of a peptide may be more immunogenic than others. Because of the specifi city, homogeneity, and unlimited availability of the MAbs, vast amount of work has been carried out on the production/development The immuno-diagnoses of protozoan and parasitic diseases have signifi cantly been improved by MAb technology because the tests involving MAb as diagnostic reagents overcome the limitations of polyclonal antibodies. The sensitivity and specifi city of a PCR assay is dependent on target genes, primer sequences, PCR techniques, DNA extraction procedures, and PCR product detection methods. abstract: Effective and early management of diseases requires record of the history, behavioral parameters, and travel information. These are helpful for the diagnosis, prevention, and control of the disease. There have been several advancements in the methods for diagnosing infectious diseases. The wide spectrum of tests such as biochemical evaluation, microbiological tools, immunological and molecular biology techniques, etc., is available. Each type of diagnostic technique is strong and reliable in its own sense but poses certain limitations. These limitations may be complemented by using a combination of tests. Older techniques such as microscopy and culturing of organisms from clinical specimens are error-free but are very labor intensive and extremely time consuming. There is a need to develop rapid and sensitive tests that can be used in both high- and low-resource settings. Molecular diagnostics such as Western blot, ELISA, PCR, DNA, and protein microarrays are revolutionizing the clinical practice of infectious diseases. Their effects are significant in acute-care settings where timely and accurate diagnostic tools are critical for patient treatment decisions and outcomes. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115026/ doi: 10.1007/978-981-10-0875-7_9 id: cord-001726-d7iwkatn author: Henry, Kevin A. title: Beyond phage display: non-traditional applications of the filamentous bacteriophage as a vaccine carrier, therapeutic biologic, and bioconjugation scaffold date: 2015-08-04 words: 10444.0 sentences: 516.0 pages: flesch: 39.0 cache: ./cache/cord-001726-d7iwkatn.txt txt: ./txt/cord-001726-d7iwkatn.txt summary: Particular emphases are placed on: (i) the advantages of the phage as a vaccine carrier, including its high immunogenicity, relative antigenic simplicity and ability to activate a range of immune responses, (ii) the phage''s potential as a prophylactic and therapeutic agent for infectious and chronic diseases, (iii) the regularity of the virion major coat protein lattice, which enables a variety of bioconjugation and surface chemistry applications, particularly in nanomaterials, and (iv) the phage''s large population sizes and fast generation times, which make it an excellent model system for directed protein evolution. While in some cases the results of these studies have been promising, antibody epitope-based peptide vaccines are no longer an area of active research for several reasons: (i) in many cases, peptides incompletely or inadequately mimic epitopes on folded proteins (Irving et al., 2010 ; see below); (ii) antibodies against a single epitope may be of limited utility, especially for highly variable pathogens (Van Regenmortel, 2012); and (iii) for pathogens for which protective immune responses are generated efficiently during natural infection, peptide vaccines offer few advantages over recombinant subunit and live vector vaccines, which have become easier to produce over time. abstract: For the past 25 years, phage display technology has been an invaluable tool for studies of protein–protein interactions. However, the inherent biological, biochemical, and biophysical properties of filamentous bacteriophage, as well as the ease of its genetic manipulation, also make it an attractive platform outside the traditional phage display canon. This review will focus on the unique properties of the filamentous bacteriophage and highlight its diverse applications in current research. Particular emphases are placed on: (i) the advantages of the phage as a vaccine carrier, including its high immunogenicity, relative antigenic simplicity and ability to activate a range of immune responses, (ii) the phage’s potential as a prophylactic and therapeutic agent for infectious and chronic diseases, (iii) the regularity of the virion major coat protein lattice, which enables a variety of bioconjugation and surface chemistry applications, particularly in nanomaterials, and (iv) the phage’s large population sizes and fast generation times, which make it an excellent model system for directed protein evolution. Despite their ubiquity in the biosphere, metagenomics work is just beginning to explore the ecology of filamentous and non-filamentous phage, and their role in the evolution of bacterial populations. Thus, the filamentous phage represents a robust, inexpensive, and versatile microorganism whose bioengineering applications continue to expand in new directions, although its limitations in some spheres impose obstacles to its widespread adoption and use. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4523942/ doi: 10.3389/fmicb.2015.00755 id: cord-327629-ep28ay11 author: Herron, J.B.T. title: Coronavirus antibody positive tests and continued use of personal protective equipment throughout the pandemic date: 2020-06-20 words: 1172.0 sentences: 74.0 pages: flesch: 53.0 cache: ./cache/cord-327629-ep28ay11.txt txt: ./txt/cord-327629-ep28ay11.txt summary: authors: Herron, J.B.T.; Dennis, J.; Brennan, P.A. title: Coronavirus antibody positive tests and continued use of personal protective equipment throughout the pandemic Antibody testing has rapidly been deployed but it is creating challenges for staff and patients. Mask use has come to the forefront and human factor (HF) strategies must be examined to reduce risk associated with lack of engagement from both healthcare staff and patients. Suggested plans have included developing a cohort of immune staff to care for COVID-19 patients allowing for a relaxation of overstretched personal protection equipment (PPE) resources. Masks reduce nosocomial spread and are important, particularly for healthcare staff (19) . For the antibody test, even after the exact nature of protection is determined, basic public health measures are not forgotten and that staff feel able to challenge those in more authoritative positions regarding PPE. Personal protective equipment and Covid 19-a risk to healthcare staff? abstract: The COVID-19 pandemic has thrust not only a novel virus onto the world, but new challenges resulting in novel approaches. Governments have reduced regulation in order to facilitate timely advances to combat the disease. Antibody testing has rapidly been deployed but it is creating challenges for staff and patients. Mask use has come to the forefront and human factor (HF) strategies must be examined to reduce risk associated with lack of engagement from both healthcare staff and patients. In this we explore these issues and suggest some solutions. url: https://www.sciencedirect.com/science/article/pii/S0266435620302801?v=s5 doi: 10.1016/j.bjoms.2020.06.021 id: cord-345296-4z7yfj5s author: Ho, Mei-Shang title: Neutralizing Antibody Response and SARS Severity date: 2005-11-17 words: 4600.0 sentences: 190.0 pages: flesch: 42.0 cache: ./cache/cord-345296-4z7yfj5s.txt txt: ./txt/cord-345296-4z7yfj5s.txt summary: Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. To adjust the time effects and other covariates of interest, the relationship between antibody titer, based on logarithmic transformation of base 2 (serum dilution) and other potential factors, i.e., age, sex, infection source, and duration of illness, was quantified by linear mixed models (18) , which took into account the correlation between repeated measurements of each study participants. In the model, patients with a more severe clinical course had earlier and higher antibody responses; we then examined the death rate of the early responders (Table 6 ). Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways abstract: Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. With a linear mixed model, neutralizing antibody titer was shown to peak between week 5 and week 8 after onset and to decline thereafter, with a half-life of 6.4 weeks. Patients with a longer illness showed a lower neutralizing antibody response than patients with a shorter illness duration (p = 0.008). When early responders were compared with most patients, who seroconverted on and after week 3 of illness, the small proportion (17.4%) of early responders (antibody detectable within 2 weeks) had a higher death rate (29.6% vs. 7.8%) (Fisher exact test, p = 0.004), had a shorter survival time of <2 weeks (Fisher exact test, p = 0.013), and were more likely to be > 60 years of age (Fisher exact test, p = 0.01). Our findings have implications for understanding the pathogenesis of SARS and for SARS vaccine research and development. url: https://www.ncbi.nlm.nih.gov/pubmed/16318725/ doi: 10.3201/eid1111.040659 id: cord-328935-mn8r972x author: Hodgins, Douglas C. title: Mucosal Veterinary Vaccines: Comparative Vaccinology date: 2015-03-13 words: 16336.0 sentences: 785.0 pages: flesch: 36.0 cache: ./cache/cord-328935-mn8r972x.txt txt: ./txt/cord-328935-mn8r972x.txt summary: Studies of the potential of novel adjuvants to improve vaccine efficacy against genetically unstable, immune-subverting RNA viruses, such as porcine reproductive and respiratory syndrome virus in pigs, should assist in the control of pathogens with similar characteristics in other species. However, a recent study showed that an inactivated reassortant RV strain (CDC-9 strain) formulated with aluminum phosphate and administered systemically in gnotobiotic pigs resulted in induction of serum IgG antibody titers, coinciding with partial protection against shedding and diarrhea, suggesting that adjuvant may have stimulated local specific (gut IgA antibodies) or nonspecific immune responses, which were not assessed in this study (Wang et al., 2010) . Intranasal delivery of whole cell lysate of Mycobacterium tuberculosis induces protective immune responses to a modified live porcine reproductive and respiratory syndrome virus vaccine in pigs abstract: Infections of mucosal surfaces are major causes of morbidity, mortality, and economic loss in species of veterinary interest, and a concern for animal welfare. Vaccines are used extensively in veterinary medicine, and innovative vaccine technologies such as recombinant DNA-vectored and distinguishing infected from vaccinated animals (DIVA) vaccines and automated in ovo vaccination (of embryonated chicken eggs) have been rapidly adopted commercially. Immunological research using outbred, nonrodent animal models has contributed to a broader understanding of mucosal defenses, and has provided the initial impetus for investigation of the common mucosal immune system. Studies of the potential of novel adjuvants to improve vaccine efficacy against genetically unstable, immune-subverting RNA viruses, such as porcine reproductive and respiratory syndrome virus in pigs, should assist in the control of pathogens with similar characteristics in other species. Successful development of vaccines to prevent and treat ascending infections of the reproductive tract of cattle set a precedent for applications in other species including humans. Studies of mucosal adjuvants and delivery systems continue at the interface between passive and active immunity, with the goal of inducing the earliest possible protection against enteric and respiratory pathogens of neonates. url: https://api.elsevier.com/content/article/pii/B9780124158474000689 doi: 10.1016/b978-0-12-415847-4.00068-9 id: cord-296928-wu14k7u9 author: Hofmann, Tim title: Greatest Hits—Innovative Technologies for High Throughput Identification of Bispecific Antibodies date: 2020-09-08 words: 7388.0 sentences: 326.0 pages: flesch: 29.0 cache: ./cache/cord-296928-wu14k7u9.txt txt: ./txt/cord-296928-wu14k7u9.txt summary: In this review, we provide an overview of the most relevant methodologies for bispecific screening purposes—the DuoBody concept, paired light chain single cell production approaches, Sortase A and Transglutaminase, the SpyTag/SpyCatcher system, and inteins—and elaborate on the benefits as well as drawbacks of the different technologies. In order to overcome this bottleneck, technologies such as controlled Fab-arm exchange used for DuoBodies [22] , paired light chain single cell production approaches [23] , microbial transglutaminase [24] or Sortase A [25] mediated bioconjugation, the SpyTag/SpyCatcher system [26, 27] , or split inteins [28] were adapted to enable broad bispecific antibody screening ( Figure 1 ). In order to overcome this bottleneck, technologies such as controlled Fab-arm exchange used for DuoBodies [22] , paired light chain single cell production approaches [23] , microbial transglutaminase [24] or Sortase A [25] mediated bioconjugation, the SpyTag/SpyCatcher system [26, 27] , or split inteins [28] were adapted to enable broad bispecific antibody screening ( Figure 1 ). abstract: Recent years have shown a tremendous increase and diversification in antibody-based therapeutics with advances in production techniques and formats. The plethora of currently investigated bi- to multi-specific antibody architectures can be harnessed to elicit a broad variety of specific modes of actions in oncology and immunology, spanning from enhanced selectivity to effector cell recruitment, all of which cannot be addressed by monospecific antibodies. Despite continuously growing efforts and methodologies, the identification of an optimal bispecific antibody as the best possible combination of two parental monospecific binders, however, remains challenging, due to tedious cloning and production, often resulting in undesired extended development times and increased expenses. Although automated high throughput screening approaches have matured for pharmaceutical small molecule development, it was only recently that protein bioconjugation technologies have been developed for the facile generation of bispecific antibodies in a ‘plug and play’ manner. In this review, we provide an overview of the most relevant methodologies for bispecific screening purposes—the DuoBody concept, paired light chain single cell production approaches, Sortase A and Transglutaminase, the SpyTag/SpyCatcher system, and inteins—and elaborate on the benefits as well as drawbacks of the different technologies. url: https://doi.org/10.3390/ijms21186551 doi: 10.3390/ijms21186551 id: cord-004247-lagv3tp7 author: Hooft van Huijsduijnen, Rob title: Reassessing therapeutic antibodies for neglected and tropical diseases date: 2020-01-30 words: 6756.0 sentences: 314.0 pages: flesch: 42.0 cache: ./cache/cord-004247-lagv3tp7.txt txt: ./txt/cord-004247-lagv3tp7.txt summary: This mAb was protective in an in vitro, antigen-dependent, cellular cytotoxicity assay with rat macrophages or eosinophils and also in vivo during the early phase of infection Second, beyond the cell-surface proteins, schistosomes also express a large number of glycans as part of their glycoprotein and glycolipid repertoire, and an antibody response against those glycans is mounted by the infected host [80] . In addition to antibodies that directly target and inhibit the fungal pathogen, mAbs can be directed to checkpoints that control the host immune response. In addition to highlighting the potential of mAbs as therapeutics, these studies have demonstrated the diversity of inhibitory actions that mAbs can perform on cryptococcal cells, which can include opsonization and increased phagocytosis, inhibition of fungal growth, capsular polysaccharide release and biofilm formation, antibody-mediated target cleavage, and augmentation of the host response [104] [105] [106] [107] . abstract: In the past two decades there has been a significant expansion in the number of new therapeutic monoclonal antibodies (mAbs) that are approved by regulators. The discovery of these new medicines has been driven primarily by new approaches in inflammatory diseases and oncology, especially in immuno-oncology. Other recent successes have included new antibodies for use in viral diseases, including HIV. The perception of very high costs associated with mAbs has led to the assumption that they play no role in prophylaxis for diseases of poverty. However, improvements in antibody-expression yields and manufacturing processes indicate this is a cost-effective option for providing protection from many types of infection that should be revisited. Recent technology developments also indicate that several months of protection could be achieved with a single dose. Moreover, new methods in B cell sorting now enable the systematic identification of high-quality antibodies from humanized mice, or patients. This Review discusses the potential for passive immunization against schistosomiasis, fungal infections, dengue, and other neglected diseases. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991954/ doi: 10.1371/journal.pntd.0007860 id: cord-001435-ebl8yc92 author: Hoppe, Sebastian title: Identification of Antigenic Proteins of the Nosocomial Pathogen Klebsiella pneumoniae date: 2014-10-21 words: 9619.0 sentences: 545.0 pages: flesch: 50.0 cache: ./cache/cord-001435-ebl8yc92.txt txt: ./txt/cord-001435-ebl8yc92.txt summary: Hence, a cDNA-based expression library was constructed and screened via microarrays to detect novel antigens of Klebsiella pneumoniae, a prominent agent of nosocomial infections well-known for its extensive antibiotics resistance, especially by extended-spectrum beta-lactamases (ESBL). After specificity analysis, homology survey and 3d structural modelling, one epitope sequence GAVVALSTTFA of KPN_00363, an ion channel protein, was identified harboring specificity for K. By identifying several novel antigens and their linear epitope sites, we have paved the way for crucial future research and applications including the design of point-of-care devices, vaccine development and serological screenings for a highly relevant nosocomial pathogen. Incubation with antibodies reactive to either of those two bacterial species resulted in signal intensities in the neighbourhood of the negative control independent of sequence alterations, see Figure 11 . In contrast, the other two proteins displaying linear epitopes, KPN_00363 and KPN_00459, indicated some specificity with the antibodies tested and two linear consensus sequences could be derived, GAVVALSTTFA and GIAFGAVELFD, respectively. abstract: The continuous expansion of nosocomial infections around the globe has become a precarious situation. Key challenges include mounting dissemination of multiple resistances to antibiotics, the easy transmission and the growing mortality rates of hospital-acquired bacterial diseases. Thus, new ways to rapidly detect these infections are vital. Consequently, researchers around the globe pursue innovative approaches for point-of-care devices. In many cases the specific interaction of an antigen and a corresponding antibody is pivotal. However, the knowledge about suitable antigens is lacking. The aim of this study was to identify novel antigens as specific diagnostic markers. Additionally, these proteins might be aptly used for the generation of vaccines to improve current treatment options. Hence, a cDNA-based expression library was constructed and screened via microarrays to detect novel antigens of Klebsiella pneumoniae, a prominent agent of nosocomial infections well-known for its extensive antibiotics resistance, especially by extended-spectrum beta-lactamases (ESBL). After screening 1536 clones, 14 previously unknown immunogenic proteins were identified. Subsequently, each protein was expressed in full-length and its immunodominant character examined by ELISA and microarray analyses. Consequently, six proteins were selected for epitope mapping and three thereof possessed linear epitopes. After specificity analysis, homology survey and 3d structural modelling, one epitope sequence GAVVALSTTFA of KPN_00363, an ion channel protein, was identified harboring specificity for K. pneumoniae. The remaining epitopes showed ambiguous results regarding the specificity for K. pneumoniae. The approach adopted herein has been successfully utilized to discover novel antigens of Campylobacter jejuni and Salmonella enterica antigens before. Now, we have transferred this knowledge to the key nosocomial agent, K. pneumoniae. By identifying several novel antigens and their linear epitope sites, we have paved the way for crucial future research and applications including the design of point-of-care devices, vaccine development and serological screenings for a highly relevant nosocomial pathogen. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4205017/ doi: 10.1371/journal.pone.0110703 id: cord-355610-7xy4s483 author: Hu, Dan title: A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III date: 2019-06-26 words: 6168.0 sentences: 307.0 pages: flesch: 52.0 cache: ./cache/cord-355610-7xy4s483.txt txt: ./txt/cord-355610-7xy4s483.txt summary: Here, by using sequential antigen panning of a yeast antibody library derived from healthy donors against the DENV envelop protein domain III (DIII) combined with depletion by an entry defective DIII mutant, we identified a cross-reactive human monoclonal antibody (mAb), m366.6, which bound with high affinity to DENV DIII from all four DENV serotypes. Furthermore, as the first germline-like mAb derived from a naïve antibody library that could neutralize all four DENV serotypes, the m366.6 can be a tool for exploring mechanisms of DENV infection, and is a promising therapeutic candidate. Its fully human origin, the germline-like nature, combined with high-affinity and broad neutralizing activity toward all DENV serotypes, suggest that m366.6 is a promising candidate antiviral agent and may also provide a unique template for designing effective dengue vaccine immunogens. Two antibodies, designated as m360 and m366, bound potently to DENV DIIIs. Their scFv gene were fused with human IgG1 Fc for protein expression, and surface plasmon resonance (SPR) experiments were used to evaluate the antigens binding. abstract: Dengue is the most widespread vector-borne viral disease caused by dengue virus (DENV) for which there are no safe, effective drugs approved for clinical use. Here, by using sequential antigen panning of a yeast antibody library derived from healthy donors against the DENV envelop protein domain III (DIII) combined with depletion by an entry defective DIII mutant, we identified a cross-reactive human monoclonal antibody (mAb), m366.6, which bound with high affinity to DENV DIII from all four DENV serotypes. Immunogenetic analysis indicated that m366.6 is a germline-like mAb with very few somatic mutations from the closest VH and Vλ germline genes. Importantly, we demonstrated that it potently neutralized DENV both in vitro and in the mouse models of DENV infection without detectable antibody-dependent enhancement (ADE) effect. The epitope of m366.6 was mapped to the highly conserved regions on DIII, which may guide the design of effective dengue vaccine immunogens. Furthermore, as the first germline-like mAb derived from a naïve antibody library that could neutralize all four DENV serotypes, the m366.6 can be a tool for exploring mechanisms of DENV infection, and is a promising therapeutic candidate. url: https://www.ncbi.nlm.nih.gov/pubmed/31242272/ doi: 10.1371/journal.ppat.1007836 id: cord-032598-i0jm3p1s author: Hu, Jing title: Direct imaging of antigen–antibody binding by atomic force microscopy date: 2020-09-24 words: 3133.0 sentences: 170.0 pages: flesch: 45.0 cache: ./cache/cord-032598-i0jm3p1s.txt txt: ./txt/cord-032598-i0jm3p1s.txt summary: In this study, the morphology of biotinylated antibody-specific Immunoglobulin E (IgE) immune complexes has been successfully imaged by atomic force microscopy (AFM) in the tapping-mode. The AFM images indicated that the individual immune complex was composed of an IgE and a biotinylated antibody. To the best of our knowledge, the biotinylated antibody-specific IgE immune complexes imaged by AFM have never been reported. Meanwhile, Fig. 6d , h and l would represent the biotinylated antibody-specific IgE immune complex adsorbed on the mica surface by the IgE fragment and the two Fab fragments of biotinylated antibody. In this paper, the morphology and length of IgE, biotinylated antibodies and biotinylated antibody-specific IgE immune complexes were analyzed by AFM, respectively. The results of AFM imaging demonstrated that the immune complexes exhibited various morphologies, and we were able to identify the IgE and biotinylated antibody based on the protein morphology in most cases. abstract: Direct observation of antigen–antibody binding at the nanoscale has always been a considerable challenging problem, and researchers have made tremendous efforts on it. In this study, the morphology of biotinylated antibody-specific Immunoglobulin E (IgE) immune complexes has been successfully imaged by atomic force microscopy (AFM) in the tapping-mode. The AFM images indicated that the individual immune complex was composed of an IgE and a biotinylated antibody. Excitingly, it is the first time that we have actually seen the IgE binding to biotinylated antibody. Alternatively, information on the length of IgE, biotinylated antibodies and biotinylated antibody-specific IgE immune complexes were also obtained, respectively. These results indicate the versatility of AFM technology in the identification of antigen–antibody binding. This work not only lays the basis for the direct imaging of the biotinylated antibody-IgE by AFM, but also offers valuable information for studying the targeted therapy and vaccine development in the future. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13204-020-01558-w) contains supplementary material, which is available to authorized users. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511526/ doi: 10.1007/s13204-020-01558-w id: cord-009581-bvihkf1r author: Hurd, Eric R. title: Virus antibody levels in systemic lupus erythematosus date: 2005-11-22 words: 2370.0 sentences: 128.0 pages: flesch: 47.0 cache: ./cache/cord-009581-bvihkf1r.txt txt: ./txt/cord-009581-bvihkf1r.txt summary: Antibody titers to a group of viral antigens have been determined in sera from patients with systemic lupus erythematosus (SLE), control groups with inflammatory diseases and normals. In a preliminary study in this laboratory (23) of viral antibody titers in patients with lupus nephritis and matched normal controls, complement fixing antibody titers were significantly elevated to a number of myxoviruses, coronavirus OC 43 and herpes simplex virus. In the present study, an attempt has been made to compare viral antibody titers in SLE with those of control groups with inflammatory diseases as well as normal individuals. However, it is possible that the tubular structures are evidence of chronic infection in S L E with a passenger virus of a type which might act as an adjuvant for the overall elevation in viral antibody titer observed. abstract: Antibody titers to a group of viral antigens have been determined in sera from patients with systemic lupus erythematosus (SLE), control groups with inflammatory diseases and normals. Mean titers in SLE sera for all viruses tested were significantly greater than in four control groups, but not greater than in active tuberculosis, both by the complement‐fixation (CF) and hemagglutination‐inhibition (HI) methods. By the CF method, only measles virus showed significantly higher titers in SLE than in all control groups; by the HI method, measles antibody titers were higher in SLE than in all groups but tuberculosis. There was no correlation between antibody titers and gammaglobulin levels. The results indicated a moderate though variable overall hypereactivity in SLE to the viral antigens tested. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159734/ doi: 10.1002/art.1780150308 id: cord-300701-vkzya7uq author: Ijaz, M. K. title: Effect of different routes of immunization with bovine rotavirus on lactogenic antibody response in mice date: 1987-12-31 words: 4321.0 sentences: 235.0 pages: flesch: 50.0 cache: ./cache/cord-300701-vkzya7uq.txt txt: ./txt/cord-300701-vkzya7uq.txt summary: Summary The effect of different routes of immunization with either live or killed bovine rotavirus (BRV) on the production of lactogenic antibody response in mice was evaluated. Taking this into consideration, we have utilized the murine model to study the influence of different routes of immunization with either live or killed BRV on the rate of decline of antibody titers and different subtypes in the lacteal secretions of the da-m following parturition up to eleven days. Titers of anti-rotavirus antibodies in lacteal secretions, as determined by ELISA, also revealed a similar pattern as seen in the groups immunized with killed BRV. Although administration of live or killed BRV at mucosal sites (intestine and mammary regions) not only induced a significant elevation of IgA, IgM and IgG antibodies in lacteal secretions there was also a marked increase in serum anti-rotavirus antibodies as determined by ELISA. abstract: Summary The effect of different routes of immunization with either live or killed bovine rotavirus (BRV) on the production of lactogenic antibody response in mice was evaluated. The routes of immunization were intramuscular (IM), oral (O) or intradermal in the mammary region (IMam). Following immunization, serum antibody responses were monitored by an enzyme linked immunosorbent assay (ELISA). Following whelping, the mice were allowed to stay with their mother until sacrificed on alternate days post-parturition from day 1–11. Milk from their stomach was collected for antibody titration by ELISA and virus neutralization test. Regardless of the routes of immunization, a rapid increase in serum anti-rotavirus antibody titers was observed for the first 5 wk after immunization followed by a gradual decline. After parturition, the mean antibody titer of lacteal secretions, as determined by ELISA, increased gradually for 7 days with the greatest increase on day 9, followed by a decrease in anti-rotavirus antibody. These titers also correlated with antibody titers in milk as measured by virus neutralization test. The best lactogenic antibody response was observed when IMam × IM × 2 route of immunization was used with live BRV as the antigen. Interestingly, immunization via the oral route with killed BRV also resulted in good antibody responses. In contrast, in the group where killed BRV was used, animals receiving 3× orally had the highest antibody titer. The distribution of different antibody subtypes in milk samples revealed IgG to be the predominant antibody followed by IgM and IgA. Irrespective of the route of administration, there was an increase in IgA on day 9 as compared to day 1 in most of the groups. The significant role played by mucosal immunity in passive protection and the possible ways to modulate subtype specific lactogenic immune response are discussed. Animals models; Lactogenic immunity; Rotaviruses url: https://www.ncbi.nlm.nih.gov/pubmed/2837143/ doi: 10.1016/s0166-3542(87)80006-2 id: cord-254821-px4fe7mn author: Infantino, Maria title: Diagnostic accuracy of an automated chemiluminescent immunoassay for anti‐SARS‐CoV‐2 IgM and IgG antibodies: an Italian experience date: 2020-05-10 words: 1224.0 sentences: 67.0 pages: flesch: 42.0 cache: ./cache/cord-254821-px4fe7mn.txt txt: ./txt/cord-254821-px4fe7mn.txt summary: Sixty‐one COVID‐19 patients and 64 patients from a control group were tested by iFlash1800 CLIA analyzer for anti‐SARS CoV‐2 antibodies IgM and IgG. The more relaxed rules of the FDA''s "Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency" issued on 16 March 2020, 9 has allowed the market easier access to these tests as well as easier and faster diagnostics, but the lack of control in the production process is also dangerous making these tests potentially less reliable. 11 The aim of the this study was to assess the diagnostic performance of a novel fully automated CLIA for the quantitative detection of anti-SARS-CoV-2 IgM and IgG antibodies. 16 As with most existing studies on the diagnostic performance of the SARS-CoV-2 antibodies, our preliminary data showed that most COVID-19 patients have both IgM and IgG, and only few of them have isolated IgG or IgM antibodies. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis Assessment of immune response to SARS-CoV-2 with fully-automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays abstract: A pandemic of coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been spreading throughout the world. Though molecular diagnostic tests are the gold standard for COVID‐19, serological testing is emerging as a potential surveillance tool, in addition to its complementary role in COVID‐19 diagnostics. Indubitably quantitative serological testing provides greater advantages than qualitative tests but today there is still little known about serological diagnostics and what the most appropriate role quantitative tests might play. Sixty‐one COVID‐19 patients and 64 patients from a control group were tested by iFlash1800 CLIA analyzer for anti‐SARS CoV‐2 antibodies IgM and IgG. All COVID‐19 patients were hospitalized in San Giovanni di Dio Hospital (Florence, Italy) and had a positive oro/nasopharyngeal swab reverse‐transcription polymerase chain reaction result. The highest sensitivity with a very good specificity performance was reached at a cutoff value of 10.0 AU/mL for IgM and of 7.1 for IgG antibodies, hence near to the manufacturer's cutoff values of 10 AU/mL for both isotypes. The receiver operating characteristic curves showed area under the curve values of 0.918 and 0.980 for anti‐SARS CoV‐2 antibodies IgM and IgG, respectively. iFlash1800 CLIA analyzer has shown highly accurate results for the anti‐SARS‐CoV‐2 antibodies profile and can be considered an excellent tool for COVID‐19 diagnostics. url: https://www.ncbi.nlm.nih.gov/pubmed/32330291/ doi: 10.1002/jmv.25932 id: cord-335121-ro3x3qa3 author: Ingram, George A. title: A comparative assessment of four serological methods used in the detection and measurement of anti-parasite antibodies in the serum of the amphibian, bufo viridis date: 1988-04-30 words: 3116.0 sentences: 180.0 pages: flesch: 50.0 cache: ./cache/cord-335121-ro3x3qa3.txt txt: ./txt/cord-335121-ro3x3qa3.txt summary: Abstract Antibodies against Crithidia fasciculata choanomastigotes were detected in green toad (Bufo viridis) sera by direct agglutination, indirect haemagglutination (IHA), complement-fixation test (CFT) and enzyme-linked immunosorbent assay (ELISA), Correlation coefficients (r) were calculated for comparisons between each of the techniques and regression formulae derived in order to convert antibody levels as determined by one immunological method to that of another. In this paper we present the results of acomparative assessment of four serological tests (direct agglutination, indirect haemagglutination, complement-fixation test and ELISA) used to detect and to determine the levels of antibodies in the sera of green toads (B. fasciculata and the number of control and immune sera containing detectable antibodies were the lowest for DA and CFT, intermediate for IHA and highest for the ELISA method (Table 1) . Nevertheless the method of antigen preparation ma> not be a salient criterion for antibody estimation in immune sera because correlation values of over 89% (f''< 0.001) were found when IHA titres were compared to those of ELISA. abstract: Abstract Antibodies against Crithidia fasciculata choanomastigotes were detected in green toad (Bufo viridis) sera by direct agglutination, indirect haemagglutination (IHA), complement-fixation test (CFT) and enzyme-linked immunosorbent assay (ELISA), Correlation coefficients (r) were calculated for comparisons between each of the techniques and regression formulae derived in order to convert antibody levels as determined by one immunological method to that of another. The highest mean titre obtained by ELISA was approximately 1.5–3.5 times greater than those obtained by the other techniques whilst CFT gave the lowest values. IHA and ELISA titres were affected by different preparations of the crithidial antigen extracts. Highly significant r values were determined for control sera when IHA was compared to ELISA (r > 0.79), and to both CFT and ELISA with immune animals (r > 0.96). ELISA would seem most applicable for screening other lower vertebrates for anti-parasite antibodies especially in areas of human disease prevalence. url: https://api.elsevier.com/content/article/pii/0020751988901476 doi: 10.1016/0020-7519(88)90147-6 id: cord-338517-1mxcssjj author: Ishay, Yuval title: Antibody response to SARS‐Co‐V‐2, diagnostic and therapeutic implications date: 2020-08-26 words: 7387.0 sentences: 399.0 pages: flesch: 40.0 cache: ./cache/cord-338517-1mxcssjj.txt txt: ./txt/cord-338517-1mxcssjj.txt summary: The phage display method, allowing rapid and wide display of proteins directly correlated to their associated genes, can detect NAbs against SARS-CoV from both naïve and immune antibody libraries, capable of blocking the binding of S1 domain, thereby showing virus neutralization and prophylaxis capability either in vitro or in the animal models (31, 33, 36) . Another method, possibly allowing the production and utilization of existing NAbs, may include the use of Epstein-Barr virus (EBV) transformation of human B cells to improve the isolation of NAbs from the memory B cells harvested from the SARS-CoV infected patients (11) . Experimental and clinical data on the use of convalescent plasma products and humanized monoclonal antibodies for H5N1 influenza infection have also shown positive outcomes, and this treatment was proposed as a mean for overcoming anti-viral drug resistance (62, 79, 80) . In a study involving 20 patients with severe pandemic influenza A (H1N1) 2009 virus infection, administration of convalescent plasma reduced respiratory tract viral load, serum cytokine response, and mortality (81) . abstract: The immune response against SARS‐CoV‐2 is comprised of both cellular and humoral arms. While current diagnostic methods are mainly based on PCR, they suffer from insensitivity. Therefore, antibody‐based serological tests are being developed to achieve higher sensitivity and specificity. Current efforts in treating SARS‐CoV‐2 infection include blocking of viral entry into the host cells, prohibiting viral replication and survival in the host cells, or reducing the exaggerated host immune response. Administration of convalescent plasma containing anti‐viral antibodies was proposed to improve the outcome in severe cases. In this paper, we review some of the aspects associated with the development of antibodies against SARS‐CoV‐2 and their potential use for improved diagnosis and therapy. url: https://doi.org/10.1002/hep4.1600 doi: 10.1002/hep4.1600 id: cord-255936-hfa9w2dg author: Jin, Junyeong title: The level of decoy epitope in PCV2 vaccine affects the neutralizing activity of sera in the immunized animals date: 2018-02-12 words: 3479.0 sentences: 208.0 pages: flesch: 47.0 cache: ./cache/cord-255936-hfa9w2dg.txt txt: ./txt/cord-255936-hfa9w2dg.txt summary: In this study, we tested this hypothesis by generating an antibody specific to the decoy epitope on the capsid protein of porcine circovirus type 2 (PCV2). To monitor the reactivity of sera to the CP 169e180 epitope, enzyme immunoassays, using BSA-conjugated CP 169e180 peptides and HRPconjugated anti-guinea pig IgG antibodies (Bethyl Laboratories), were performed as described previously. In a competition enzyme immunoassay employing a microtiter plate coated with BSA-conjugated CP 169e180 peptide and HRP-conjugated anti-porcine IgG antibody, the recombinant anti-CP 169e180 antibody almost completely inhibited the binding of naturally occurring anti-CP 169e180 antibody to the peptide in a PCV2-infected pig''s sera (Fig. 2) . In an enzyme immunoassay employing a microtiter plate coated with BSA-conjugated CP 169e180 peptide, sera from animals immunized with vaccine A had a significantly higher antibody titer than vaccine B-vaccinated animals (p < 0.01) (Fig. 3D) . abstract: Abstract Viral pathogens have evolved a wide range of tactics to evade host immune responses and thus propagate effectively. One efficient tactic is to divert host immune responses toward an immunodominant decoy epitope and to induce non-neutralizing antibodies toward this epitope. Therefore, it is expected that the amount of decoy epitope in a subunit vaccine can affect the level of neutralizing antibody in an immunized animal. In this study, we tested this hypothesis by generating an antibody specific to the decoy epitope on the capsid protein of porcine circovirus type 2 (PCV2). Using this antibody, we found that two commercial vaccines contained statistically different amounts of the decoy epitope. The vaccine with lower levels of decoy epitope induced a significantly higher level of neutralizing antibody after immunization. This antibody can be used as an analytical tool to monitor the quality of a vaccine from batch to batch. url: https://api.elsevier.com/content/article/pii/S0006291X18301621 doi: 10.1016/j.bbrc.2018.01.141 id: cord-267736-rya9w6sh author: Kang, Xiaoping title: Development of an ELISA-array for simultaneous detection of five encephalitis viruses date: 2012-02-27 words: 2990.0 sentences: 178.0 pages: flesch: 47.0 cache: ./cache/cord-267736-rya9w6sh.txt txt: ./txt/cord-267736-rya9w6sh.txt summary: The ELISA-array assay is based on a "sandwich" ELISA format and consists of viral antibodies printed directly on 96-well microtiter plates, allowing for direct detection of 5 viruses. The developed ELISA-array proved to have similar specificity and higher sensitivity compared with the conventional ELISAs. This method was validated by different viral cultures and three chicken eggs inoculated with infected patient serum. The results demonstrated that this method combined the advantage of ELISA and protein array (multiplex and ease of use) and has potential for the identification of clinical encephalitis virus. When spotting, different spotting buffers and concentrations of capture monoclonal antibodies were evaluated to optimize the ELISA-array assay. To verify the results tested by ELISA-array, RNA extracted from chicken eggs was applied to a real time-RT-PCR assay using primers and probes targeting TBEV. In this study, we developed a multiplex ELISA-based method in a double-antibody sandwich format for the simultaneous detection of five encephalitis-associated viral pathogens. abstract: Japanese encephalitis virus(JEV), tick-borne encephalitis virus(TBEV), and eastern equine encephalitis virus (EEEV) can cause symptoms of encephalitis. Establishment of accurate and easy methods by which to detect these viruses is essential for the prevention and treatment of associated infectious diseases. Currently, there are still no multiple antigen detection methods available clinically. An ELISA-array, which detects multiple antigens, is easy to handle, and inexpensive, has enormous potential in pathogen detection. An ELISA-array method for the simultaneous detection of five encephalitis viruses was developed in this study. Seven monoclonal antibodies against five encephalitis-associated viruses were prepared and used for development of the ELISA-array. The ELISA-array assay is based on a "sandwich" ELISA format and consists of viral antibodies printed directly on 96-well microtiter plates, allowing for direct detection of 5 viruses. The developed ELISA-array proved to have similar specificity and higher sensitivity compared with the conventional ELISAs. This method was validated by different viral cultures and three chicken eggs inoculated with infected patient serum. The results demonstrated that the developed ELISA-array is sensitive and easy to use, which would have potential for clinical use. url: https://www.ncbi.nlm.nih.gov/pubmed/22369052/ doi: 10.1186/1743-422x-9-56 id: cord-018840-ts2g1ux7 author: Katragkou, Aspasia title: Role of Immunoglobulin Therapy to Prevent and Treat Infections date: 2018-06-19 words: 6703.0 sentences: 329.0 pages: flesch: 32.0 cache: ./cache/cord-018840-ts2g1ux7.txt txt: ./txt/cord-018840-ts2g1ux7.txt summary: While the main clinical applications of immunoglobulin therapy concern their use as replacement for patients with primary immunodeficiencies, or as treatment for autoimmune and inflammatory disorders, their role in infectious disease is limited largely to viral and toxin neutralization and replacement therapy in patients with immunoglobulin deficiencies. The first clinical trial, which evaluated the effect of IgMA-enriched immunoglobulin preparation (7.8 g IgM, 7.8 g IgA, and 49.4 g IgG), which have shown to contain superior antibody content against bacterial lipopolysaccharides, in an appreciable number of neutropenic patients with hematologic malignancies and sepsis or septic shock, showed that immunoglobulins had no beneficial effects [51] . A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery abstract: Immunoglobulins have been used widely in medicine for a variety of diseases including infectious diseases. While the main clinical applications of immunoglobulin therapy concern their use as replacement for patients with primary immunodeficiencies, or as treatment for autoimmune and inflammatory disorders, their role in infectious disease is limited largely to viral and toxin neutralization and replacement therapy in patients with immunoglobulin deficiencies. Many aspects of the therapeutic regimen of immunoglobulins even in the established indications remain open. Recently, due to the worldwide surge of immunosuppression caused by AIDS, organ transplantation, cancer, and autoimmune therapies, as well as the emergence of multidrug-resistant bacteria, there has been renewed interest in the use of antibody preparation to prevent infections in high-risk groups. Knowing the limitations of the current anti-infective armamentarium, approaches that target the host through manipulations to augment the host immune response provide a helpful aid to conventional treatment options. A substantial body of evidence has demonstrated that strategies aiming to support or stimulate immune response could be feasible approaches that would benefit immunocompromised patients. In the present chapter, we present contemporary indications of immunoglobulin administration for therapy and prophylaxis of infections in the immunocompromised population. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123824/ doi: 10.1007/978-3-319-77674-3_17 id: cord-309067-aemjbkfj author: Kennedy, Melissa title: Methodology in diagnostic virology date: 2005-03-01 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Selection of proper assays and appropriate interpretation of results can be a challenge to the veterinary clinician. Assays vary in methodology, sensitivity, and specificity. These assays can be invaluable in attaining the correct diagnosis, but a clear understanding of the assay and the results is essential. To this end, communication with the laboratory personnel is crucial. Optimal sample selection, shipping recommendations, assay selection, and interpretation should be discussed with the laboratory staff. url: https://api.elsevier.com/content/article/pii/S1094919404000702 doi: 10.1016/j.cvex.2004.09.009 id: cord-326673-p8qbxi57 author: Kitching, R. P. title: The interference by maternally-derived antibody with active immunization of farm animals against foot-and-mouth disease date: 1995-12-31 words: 4788.0 sentences: 197.0 pages: flesch: 45.0 cache: ./cache/cord-326673-p8qbxi57.txt txt: ./txt/cord-326673-p8qbxi57.txt summary: This maternally-derived antibody (MDA) provides immediate protection against infection with FMD virus, but also interferes with the development of active immunity following vaccination. However, this maternally derived antibody (MDA) is equally effective in preventing the response to active vaccination in the young animal as it is in providing protection against disease. In the case of FMD vaccination in pigs, Francis and Black (1986) concluded that the complete immunological unresponsiveness seen in the first 2 weeks of life was due to immaturity of the immune system and antigen blockade by high titre MDA, and as this titre declined an active suppression of T and/or B cells occurred to variable degrees. Francis and Black (1984) found no evidence in the pig that vaccination in the presence of MDA depressed the specific antibody to FMD virus. The effect of maternally derived antibodies on the response of calves to vaccination against foot-and-mouth disease abstract: Summary Foot-and-mouth disease (FMD) is a highly contagious disease affectingruminants and pigs. In countries in which control of FMD relies predominantly on vaccination, young stock ingest specific anti-FMD virus antibodies in the colostrum. This maternally-derived antibody (MDA) provides immediate protection against infection with FMD virus, but also interferes with the development of active immunity following vaccination. However, susceptibility to infection precedes the ability to respond to vaccination in the presence of MDA. Currently available vaccines cannot overcome this inhibitory effect of MDA, and protection of young stock can only be provided by their- isolation from FMD virus. url: https://www.ncbi.nlm.nih.gov/pubmed/7552194/ doi: 10.1016/s0007-1935(95)80127-8 id: cord-009446-8keu2uay author: Kreer, Christoph title: Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies date: 2020-01-01 words: 6658.0 sentences: 355.0 pages: flesch: 39.0 cache: ./cache/cord-009446-8keu2uay.txt txt: ./txt/cord-009446-8keu2uay.txt summary: Focusing on the development of highly potent broadly neutralizing antibodies against HIV-1, we discuss how a detailed knowledge of the human B cell repertoire may support the development of novel vaccination strategies. Indeed, the generation of optimized bait proteins [30] or native-like envelope trimers [45] were critical steps to improve the isolation of potent HIV-1 broadly neutralizing antibodies (bNAbs) by antigen-specific sorting strategies [31, [46] [47] [48] . Only a small fraction of HIV-1-infected individuals develop highly potent bNAbs and detailed analyses of B cell receptors and antibodies at a single cell level have been limited to a few dozen subjects. Thus, a detailed understanding of the naïve B cell receptor repertoire and the constantly adapting antibody response in the context of HIV-1 infection can be highly informative for vaccine design. abstract: The human antibody repertoire is generated by the recombination of different gene segments as well as by processes of somatic mutation. Together these mechanisms result in a tremendous diversity of antibodies that are able to combat various pathogens including viruses and bacteria, or malignant cells. In this review, we summarize the opportunities and challenges that are associated with the analyses of the B cell receptor repertoire and the antigen-specific B cell response. We will discuss how recent advances have increased our understanding of the antibody response and how repertoire analyses can be exploited to inform on vaccine strategies, particularly against HIV-1. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157687/ doi: 10.3390/vaccines8010013 id: cord-317501-yblzopc3 author: Kuhn, Philipp title: Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display date: 2016-06-21 words: 11086.0 sentences: 593.0 pages: flesch: 35.0 cache: ./cache/cord-317501-yblzopc3.txt txt: ./txt/cord-317501-yblzopc3.txt summary: Panning against peptides, recombinant viral proteins, or complete virus particles has led to the identification of antibodies directed against human pathogenic viruses such as Sin nombre virus [100] , Dengue virus [101, 102] , Influenza virus [103, 104] , VEEV [105] , Norovirus [106] , SARS coronavirus [107] , or Hepatitis C [108] from naïve antibody gene libraries. A naïve human Fab-phage library was screened for NS5-specific antibody fragments using various NS5 variants from Dengue Virus serotypes 1-4 as antigens for panning and characterization [128] . [180] reported the isolation of a human monoclonal antibody against the Block 2 region of Plasmodium falciparum merozoite surface protein-1 (PfMSP-1) by phage display from a malaria patient derived scFv library. In this context, the antibody phage display offers a powerful tool for antibody selection and allows the isolation of neutralizing antibodies against complete active toxins or special domains by using different human naïve antibody libraries with high diversity [185] [186] [187] . Single chain variable fragment antibodies against Shiga toxins isolated from a human antibody phage display library abstract: Antibodies are valuable molecules for the diagnostic and treatment of diseases caused by pathogens and toxins. Traditionally, these antibodies are generated by hybridoma technology. An alternative to hybridoma technology is the use of antibody phage display to generate recombinant antibodies. This in vitro technology circumvents the limitations of the immune system and allows—in theory—the generation of antibodies against all conceivable molecules. Phage display technology enables obtaining human antibodies from naïve antibody gene libraries when either patients are not available or immunization is not ethically feasible. On the other hand, if patients or immunized/infected animals are available, it is common to construct immune phage display libraries to select in vivo affinity‐matured antibodies. Because the phage packaged DNA sequence encoding the antibodies is directly available, the antibodies can be smoothly engineered according to the requirements of the final application. In this review, an overview of phage display derived recombinant antibodies against bacterial, viral, and eukaryotic pathogens as well as toxins for diagnostics and therapy is given. url: https://www.ncbi.nlm.nih.gov/pubmed/27198131/ doi: 10.1002/prca.201600002 id: cord-328753-qwdxgk4z author: Lafaye, Pierre title: Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases date: 2018-09-25 words: 4624.0 sentences: 251.0 pages: flesch: 42.0 cache: ./cache/cord-328753-qwdxgk4z.txt txt: ./txt/cord-328753-qwdxgk4z.txt summary: The antigen-binding region of such homodimeric heavy-chain only antibodies consists of one single domain, called VHH. VHHs provide many advantages over conventional full-sized antibodies and currently used antibody-based fragments (Fab, scFv), including high specificity, stability and solubility, and small size, allowing them to recognize unusual antigenic sites and deeply penetrate tissues. The active antigen-binding fragment of heavy chain antibodies can be cloned and expressed in the form of VHH, which consists of only one domain (Fig. 1) . Gene therapy with an adenoviral vector expressing a bispecific VHH, consisting of two linked VHHs targeting different PA-neutralizing epitopes, was tested in mice, and found to protect them from anthrax toxin challenge and anthrax spore infection [55] . [92] have been found in the sera of infected camels, whereas antibodies against rabies virus, vesicular stomatitis virus, and FMD virus have been detected in llamas [93] and could lead to the possible isolation of specific broadly neutralizing VHHs. Many neutralizing VHHs that bind to different sites on the same target, including hidden antigenic sites, can be isolated from immunized or infected camelids. abstract: Camelids produce both conventional heterotetrameric antibodies and homodimeric heavy-chain only antibodies. The antigen-binding region of such homodimeric heavy-chain only antibodies consists of one single domain, called VHH. VHHs provide many advantages over conventional full-sized antibodies and currently used antibody-based fragments (Fab, scFv), including high specificity, stability and solubility, and small size, allowing them to recognize unusual antigenic sites and deeply penetrate tissues. Since their discovery, VHHs have been used extensively in diagnostics and therapy. In recent decades, the number of outbreaks of diseases transmissible from animals to humans has been on the rise. In this review, we evaluate the status of VHHs as diagnostic and therapeutic biomolecular agents for the detection and treatment of zoonotic diseases, such as bacterial, parasitic, and viral zoonosis. VHHs show great adaptability to inhibit or neutralize pathogenic agents for the creation of multifunctional VHH-based diagnostic and therapeutic molecules against zoonotic diseases. url: https://doi.org/10.1016/j.cimid.2018.09.009 doi: 10.1016/j.cimid.2018.09.009 id: cord-354790-xx6imhzb author: Lambour, Jennifer title: Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play date: 2016-08-17 words: 6499.0 sentences: 324.0 pages: flesch: 33.0 cache: ./cache/cord-354790-xx6imhzb.txt txt: ./txt/cord-354790-xx6imhzb.txt summary: 31 In addition to controlling the viral propagation by these mechanisms, the opsonization of viral particles and/or infected cells by therapeutic antiviral mAbs of the IgG type leads to the formation of immune complexes (ICs) recognizable by the FcγRs expressed on antigen-presenting cells (APCs) such as DCs. This can potentially affect the endogenous antiviral adaptive immune response of passive immunotherapy-treated individuals. Moreover, as the in vivo activity of anti-HIV-1 bNAbs, including viral load control, was recently shown to crucially depend on Fc effector functions, 53,54 an important issue is identifying that Fc-FcγRs interactions are involved in the induction of vaccinelike effects by antiviral mAbs. To understand the mechanisms underlying the enhancement of antiviral responses by ICs, several in vitro studies have addressed whether antibody-mediated viral uptake by DCs could lead to stronger activation of these cells and the development of stronger virus-specific CD4 + and CD8 + T-cell responses in an Fc-dependent manner. abstract: Monoclonal antibodies (mAbs), which currently constitute the main class of biotherapeutics, are now recognized as major medical tools that are increasingly being considered to fight severe viral infections. Indeed, the number of antiviral mAbs developed in recent years has grown exponentially. Although their direct effects on viral blunting have been studied in detail, their potential immunomodulatory actions have been overlooked until recently. The ability of antiviral mAbs to modulate antiviral immune responses in infected organisms has recently been revealed. More specifically, upon recognition of their cognate antigens, mAbs form immune complexes (ICs) that can be recognized by the Fc receptors expressed on different immune cells of infected individuals. This binding may be followed by the modulation of the host immune responses. Harnessing this immunomodulatory property may facilitate improvements in the therapeutic potential of antiviral mAbs. This review focuses on the role of ICs formed with different viral determinants and mAbs in the induction of antiviral immune responses in the context of both passive immunotherapies and vaccination strategies. Potential deleterious effects of ICs on the host immune response are also discussed. url: https://doi.org/10.1038/emi.2016.97 doi: 10.1038/emi.2016.97 id: cord-354700-bdpp3qmf author: Lanzavecchia, Antonio title: Dissecting human antibody responses: useful, basic and surprising findings date: 2018-01-23 words: 3112.0 sentences: 114.0 pages: flesch: 36.0 cache: ./cache/cord-354700-bdpp3qmf.txt txt: ./txt/cord-354700-bdpp3qmf.txt summary: I will discuss how a target‐agnostic approach based on high‐throughput screening of antibodies produced by cultured B cells and plasma cells has not only provided potent and broadly neutralizing antibodies against a range of pathogens, but has also advanced our understanding of basic aspects of the immune response, from host–pathogen interaction to the role of somatic mutations in affinity maturation and in the diversification of the antibody response. I will discuss how a target-agnostic approach based on highthroughput screening of antibodies produced by cultured B cells and plasma cells has not only provided potent and broadly neutralizing antibodies against a range of pathogens, but has also advanced our understanding of basic aspects of the immune response, from host-pathogen interaction to the role of somatic mutations in affinity maturation and in the diversification of the antibody response. abstract: Human memory B cells and plasma cells represent a rich source of antibodies that have been selected in response to human pathogens. In the last decade, different methods have been developed to interrogate the human memory repertoire and isolate monoclonal antibodies. I will discuss how a target‐agnostic approach based on high‐throughput screening of antibodies produced by cultured B cells and plasma cells has not only provided potent and broadly neutralizing antibodies against a range of pathogens, but has also advanced our understanding of basic aspects of the immune response, from host–pathogen interaction to the role of somatic mutations in affinity maturation and in the diversification of the antibody response. Most surprisingly, this approach has also revealed a new mechanism of diversification based on templated insertion of non‐Ig DNA into antibody genes that we discovered in the context of the immune response to malaria infection. url: https://doi.org/10.15252/emmm.201808879 doi: 10.15252/emmm.201808879 id: cord-022310-yc6xtw0s author: Lappin, Michael R. title: Microbiology and Infectious Disease date: 2011-12-15 words: 14109.0 sentences: 913.0 pages: flesch: 39.0 cache: ./cache/cord-022310-yc6xtw0s.txt txt: ./txt/cord-022310-yc6xtw0s.txt summary: 47 Because of these findings, it is currently recommended to combine serologic test results with those of blood culture or PCR assay results when evaluating clinically ill cats for bartonellosis. Because serologic test results do not accurately correlate with presence of bacteremia and individual culture or PCR assay results can be falsely negative, there is no indication for testing healthy cats for Bartonella spp. T. gondii-specific IgM is detectable in serum by ELISA in approximately 80% of subclinically ill cats 2 to 4 weeks after experimental induction of toxoplasmosis; these titers generally are negative less than 16 weeks after infection. The author, however, has demonstrated IgG antibody titers greater than 1 : 16,384 in subclinically ill cats 5 years after experimental induction In chronic disease or asymptomatic carriers, demonstration of organisms is unreliable, and a tentative diagnosis is based on clinical signs and a positive titer. gondii-specific antibodies can also be detected in the serum, CSF, and aqueous humor of healthy, infected animals, one cannot assay results in clinically ill dogs, E. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155555/ doi: 10.1016/b978-1-4377-0657-4.00015-6 id: cord-279105-e2zjxjox author: Lee, Cheryl Yi-Pin title: Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control date: 2020-04-24 words: 3872.0 sentences: 212.0 pages: flesch: 44.0 cache: ./cache/cord-279105-e2zjxjox.txt txt: ./txt/cord-279105-e2zjxjox.txt summary: With the limitations of qRT-PCR, immunoassays may offer another FIGURE 2 | Schematic illustration on the window period of detection for either viral RNA or antibodies in SARS-CoV-2-infected individuals. However, interestingly, one study demonstrated that longitudinal profiling of both antibodies in a population of 63 COVID-19 patients showed no specific chronological order in terms of IgM and IgG seroconversion (10) , which was also observed in patients infected with SARS-CoV and another human coronavirus, Middle East Respiratory Syndrome coronavirus (MERS-CoV) (22, 23) . These findings on SARS-CoV-2-specific antibodies seroconversion against the S viral protein suggest the importance to test for both IgM and IgG antibodies to confirm a positive infection. With the availability of immunoassays utilizing various coronavirus structural proteins, the use of more than one different antigen-based serological approach may be essential to establish a true positive SARS-CoV-2 infection. abstract: Since December 2019, the novel coronavirus, SARS-CoV-2, has garnered global attention due to its rapid transmission, which has infected more than two million people worldwide. Early detection of SARS-CoV-2 is one of the crucial interventions to control virus spread and dissemination. Molecular assays have been the gold standard to directly detect for the presence of viral genetic material in infected individuals. However, insufficient viral RNA at the point of detection may lead to false negative results. As such, it is important to also employ immune-based assays to determine one's exposure to SARS-CoV-2, as well as to assist in the surveillance of individuals with prior exposure to SARS-CoV-2. Within a span of 4 months, extensive studies have been done to develop serological systems to characterize the antibody profiles, as well as to identify and generate potentially neutralizing antibodies during SARS-CoV-2 infection. The vast diversity of novel findings has added value to coronavirus research, and a strategic consolidation is crucial to encompass the latest advances and developments. This review aims to provide a concise yet extensive collation of current immunoassays for SARS-CoV-2, while discussing the strengths, limitations and applications of antibody detection in SARS-CoV-2 research and control. url: https://www.ncbi.nlm.nih.gov/pubmed/32391022/ doi: 10.3389/fimmu.2020.00879 id: cord-267744-asjvf123 author: Lee, Yu-Ching title: Chicken single-chain variable fragments against the SARS-CoV spike protein date: 2007-07-23 words: 4057.0 sentences: 212.0 pages: flesch: 52.0 cache: ./cache/cord-267744-asjvf123.txt txt: ./txt/cord-267744-asjvf123.txt summary: Following the immunization of chickens with these recombinant spike proteins, two single-chain variable fragment (scFv) antibody libraries were established with short or long linkers to contain 5 × 10(7) and 9 × 10(6) transformants, respectively. In a comparison of nucleotide sequences with the chicken germline gene, we found that all clones varied in the complementarity-determining regions, that two scFv antibodies reacted significantly with SARS-CoV-infected Vero cells, and that those two specific scFv antibodies recognized the same region of the spike protein spanning amino acid residues 750–1000. The current study aimed to show that monoclonal IgY scFv antibodies which bind specifically to the S protein and SARS-CoV-infected Vero cells can be isolated from chickens immunized with Escherichia coli-derived S proteins. Cellular lysates containing single-chain variable fragment (scFv) antibodies from various Ssc (A) and Lsc (B) library clones were examined for their binding to SARS-CoV-infected cell lysates using a commercially available kit. abstract: The major concern for severe acute respiratory syndrome (SARS), caused by the SARS-associated coronavirus (SARS-CoV), is the lack of diagnostic and therapeutic agents. Using a phage display technology in a chicken system, high-affinity monoclonal antibody fragments against the SARS-CoV spike protein were characterized. Ten truncated spike protein gene fragments were expressed in Escherichia coli cells. Following the immunization of chickens with these recombinant spike proteins, two single-chain variable fragment (scFv) antibody libraries were established with short or long linkers to contain 5 × 10(7) and 9 × 10(6) transformants, respectively. After four rounds of panning selection, the scFv antibodies of randomly chosen clones were demonstrated by Coomassie blue staining, and verified by western blot analysis. In a comparison of nucleotide sequences with the chicken germline gene, we found that all clones varied in the complementarity-determining regions, that two scFv antibodies reacted significantly with SARS-CoV-infected Vero cells, and that those two specific scFv antibodies recognized the same region of the spike protein spanning amino acid residues 750–1000. In conclusion, the results suggest that the chicken scFv phage display system can be a potential model for mass production of high-affinity antibodies against the SARS-CoV spike protein. url: https://api.elsevier.com/content/article/pii/S0166093407002236 doi: 10.1016/j.jviromet.2007.06.010 id: cord-298910-2601n7a9 author: Leu, Sy-Jye title: Generation and characterization of anti-α-enolase single-chain antibodies in chicken date: 2010-10-15 words: 5157.0 sentences: 278.0 pages: flesch: 48.0 cache: ./cache/cord-298910-2601n7a9.txt txt: ./txt/cord-298910-2601n7a9.txt summary: The expressed heavy and light chain variable genes (VH and VL) were isolated from spleen B cells and amplified to construct phage antibody libraries containing scFv molecules. After four rounds of panning selection, the scFv antibodies of randomly chosen clones were expressed and their binding specificity to α-enolase protein was verified using competitive ELISA, flow cytometry and immunofluorescence staining. Accordingly, in the present study, we generated and characterized the anti-␣-enolase polyclonal IgY antibodies in chicken and monoclonal scFv antibodies by a phage display system using ELISA, Western blotting, flow cytometry and immunofluorescence staining. EnL2 and EnL5 scFv antibodies purified as a single band on SDS-PAGE (data not shown) were able to detect ␣-enolase protein in PE089 cells, and the binding signal is comparable to that of commercially available rabbit polyclonal antibodies specific for ␣-enolase as demonstrated in Fig. 7 . abstract: It was previously reported that up-regulation of α-enolase protein was detected in 65% of patients with non-small cell lung cancers (NSCLC). Moreover, a high titer of anti-α-enolase antibodies was developed in a smaller proportion (7.4%) of these patients than in non-tumor-associated patients and healthy subjects. In the present study, we characterized polyclonal and single-chain variable fragment (scFv) anti-α-enolase antibodies from immunized chickens. The E. coli-derived recombinant α-enolase protein was purified to its high homogenicity as verified by SDS-PAGE. After the 4th immunization, a high titer of specific polyclonal anti-α-enolase antibodies was elicited in immunized chickens and specifically recognized the purified human α-enolase antigen as determined by Western blot and ELISA. The expressed heavy and light chain variable genes (VH and VL) were isolated from spleen B cells and amplified to construct phage antibody libraries containing scFv molecules. After four rounds of panning selection, the scFv antibodies of randomly chosen clones were expressed and their binding specificity to α-enolase protein was verified using competitive ELISA, flow cytometry and immunofluorescence staining. Nucleotide sequence analysis from 10 α-enolase binding clones showed that 3 (30%) clones used identical heavy and light genes for scFv antibody expression, as represented by EnL5. Notably, amino acid changes in complementarity-determining regions (CDRs) were more frequently observed than those in framework regions (FRs) in all clones, indicating a strong affinity selection through mutations. All together, it is believed that these polyclonal and scFv IgY antibodies may be helpful in the development of molecular diagnostic and therapeutic agents for lung cancers in the future. url: https://www.ncbi.nlm.nih.gov/pubmed/20655599/ doi: 10.1016/j.vetimm.2010.06.001 id: cord-312787-j7ye7ed5 author: Loemba, H. D. title: Kinetics of humoral immune response to the major structural proteins of the porcine reproductive and respiratory syndrome virus date: 1996 words: 3411.0 sentences: 149.0 pages: flesch: 41.0 cache: ./cache/cord-312787-j7ye7ed5.txt txt: ./txt/cord-312787-j7ye7ed5.txt summary: coli-expressed ORFs 5 to 7 gene products, suggested that antibodies directed against the envelope E protein appear by day 7 p.i., whereas antibodies directed against the nucleocapsid N and membrane M proteins can only be detected by the end of the second week p.i. No correlation could be demonstrated between VN and IIF antibody titers, viremia, and viral protein specificities of circulating antibodies at various times p.i. Summary. coli-expressed ORFs 5 to 7 gene products, suggested that antibodies directed against the envelope E protein appear by day 7 p.i., whereas antibodies directed against the nucleocapsid N and membrane M proteins can only be detected by the end of the second week p.i. No correlation could be demonstrated between VN and IIF antibody titers, viremia, and viral protein specificities of circulating antibodies at various times p.i. The porcine reproductive and respiratory syndrome virus (PRRSV) is an enveloped RNA virus which has been found to be responsible for reproductive failure in sows of any parities (late-term abortions, increased numbers of stillborn, mummified and weakborn pigs) and respiratory problems affecting pigs of all ages [8, 20] . abstract: The kinetics of appearance of antibodies directed to the major structural proteins N, M and E of porcine reproductive and respiratory syndrome virus (PRRSV) was followed in pigs naturally- and experimentally-exposed to the virus. Specific IgM antibody titers were first detected by indirect immunofluorescence (IIF) at the end of the first week of PRRSV infection, peaked by day 14 to 21 post-inoculation (p.i.), then rapidly decreased to undetectable levels by day 35 to 42 p.i. On the other hand, specific IgG antibody titers peaked by day 21 to 28 p.i. and remained unchanged to the end of the 6- or 9-week observation period; in addition, a persistent viremia was observed. Virus neutralizing (VN) antibody titers >8 were not detected until 3 to 4 weeks p.i. Taken together, the results obtained by Western blotting analyses using purified virus andE. coli-expressed ORFs 5 to 7 gene products, suggested that antibodies directed against the envelope E protein appear by day 7 p.i., whereas antibodies directed against the nucleocapsid N and membrane M proteins can only be detected by the end of the second week p.i. No correlation could be demonstrated between VN and IIF antibody titers, viremia, and viral protein specificities of circulating antibodies at various times p.i. url: https://www.ncbi.nlm.nih.gov/pubmed/8645111/ doi: 10.1007/bf01718333 id: cord-103077-sh4w2mye author: Lu, Shuai title: Leveraging Sequential and Spatial Neighbors Information by Using CNNs Linked With GCNs for Paratope Prediction date: 2020-10-16 words: 3140.0 sentences: 194.0 pages: flesch: 55.0 cache: ./cache/cord-103077-sh4w2mye.txt txt: ./txt/cord-103077-sh4w2mye.txt summary: In this article, we propose a method to identify which amino acid residues of an antibody directly interact with its associated antigen based on the features from sequence and structure. Our algorithm uses convolution neural networks (CNNs) linked with graph convolution networks (GCNs) to make use of information from both sequential and spatial neighbors to understand more about the local environment of the target amino acid residue. According to the type of selecting neighbors of target residue for representing and predicting, the machine learning-based methods can be divided into two categories, leveraging sequential neighbors or spatial neighbors. And the stateof-art method [19] represented an antibody as a graph where each amino acid residue was a node and K nearest spatial neighbors were used in the convolution operator. In this work, we utilize the sequential and spatial neighbors of the target antibody residue by using Convolutional Neural Networks (CNNs) linked with Graph Neural Networks (GCNs) for paratope prediction. abstract: Antibodies consisting of variable and constant regions, are a special type of proteins playing a vital role in immune system of the vertebrate. They have the remarkable ability to bind a large range of diverse antigens with extraordinary affinity and specificity. This malleability of binding makes antibodies an important class of biological drugs and biomarkers. In this article, we propose a method to identify which amino acid residues of an antibody directly interact with its associated antigen based on the features from sequence and structure. Our algorithm uses convolution neural networks (CNNs) linked with graph convolution networks (GCNs) to make use of information from both sequential and spatial neighbors to understand more about the local environment of the target amino acid residue. Furthermore, we process the antigen partner of an antibody by employing an attention layer. Our method improves on the state-of-the-art methodology. url: https://doi.org/10.1101/2020.10.15.339168 doi: 10.1101/2020.10.15.339168 id: cord-335316-x2t5h5gu author: Madariaga, M. L. L. title: Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial date: 2020-06-23 words: 4328.0 sentences: 234.0 pages: flesch: 47.0 cache: ./cache/cord-335316-x2t5h5gu.txt txt: ./txt/cord-335316-x2t5h5gu.txt summary: This was a prospective open label clinical study to assess the feasibility, safety and immunological impact of delivering anti-SARS-CoV-2 convalescent plasma to hospitalized patients aged 18 years or older with severe or life-threatening COVID-19 disease within 21 days from the onset of their illness. Univariate regression analysis for antibody titer (anti-RBD and anti-spike) was conducted against age, sex, body mass index (BMI), previous pregnancy, previous blood donation, blood type, symptoms (fever, cough, sore throat, dyspnea, abdominal pain, aguesia, anosmia, fatigue, myalgia, headache), co-morbidities (respiratory, cardiovascular, renal, diabetes, autoimmune disease, cancer, liver disease), smoking history, travel in the past 3 months to the United States, Asia or Europe, symptom duration, interval from symptoms resolution to plasma donation, and hospitalization. To determine predictors of anti-RBD and anti-spike antibody titer, we performed best subset multivariable analysis including age, sex, blood type, history of previous blood donation, fever, cough, fatigue, myalgia, symptom duration, hospitalization and travel in the United States within the past 3 months. abstract: Background: Convalescent plasma therapy for COVID-19 relies on the transfer of anti-viral antibody from donors to recipients via plasma transfusion. The relationship between clinical characteristics and antibody response to COVID-19 is not well defined. We investigated predictors of convalescent antibody production and quantified recipient antibody response in a convalescent plasma therapy clinical trial. Methods: Multivariable analysis of clinical and serological parameters in 103 confirmed COVID-19 convalescent plasma donors 28 days or more following symptom resolution was performed. Mixed effects regression models with piecewise linear trends were used to characterize serial antibody responses in 10 convalescent plasma recipients with severe COVID-19. Results: Mean symptom duration of plasma donors was 11.9 and 7.8% (8/103) had been hospitalized. Antibody titers ranged from 0 to 1:3,892 (anti-receptor binding domain (RBD)) and 0 to 1:3,289 (anti-spike). Multivariable analysis demonstrated that higher anti-RBD and anti-spike titer were associated with increased age, hospitalization for COVID-19, fever, and absence of myalgia (all p<0.05). Fatigue was significantly associated with anti-RBD (p=0.03) but not anti-spike antibody titer (p=0.11). In pairwise comparison among ABO blood types, AB donors had higher anti-RBD titer than O negative donors (p=0.048) and higher anti-spike titer than O negative (p=0.015) or O positive (p=0.037) donors. Eight of the ten recipients were discharged, one remains on ECMO and one died on ECMO. No toxicity was associated with plasma transfusion. After excluding two ECMO patients and adjusting for donor antibody titer, recipient anti-RBD antibody titer increased on average 31% per day during the first three days post-transfusion (p=0.01) and anti-spike antibody titer by 40.3% (p=0.02). Conclusion: Advanced age, fever, absence of myalgia, fatigue, blood type and hospitalization were associated with higher convalescent antibody titer to COVID-19. Despite variability in donor titer, 80% of convalescent plasma recipients showed significant increase in antibody levels post-transfusion. A more complete understanding of the dose-response effect of plasma transfusion among COVID-19 patients is needed to determine the clinical efficacy of this therapy. url: http://medrxiv.org/cgi/content/short/2020.06.21.20132944v1?rss=1 doi: 10.1101/2020.06.21.20132944 id: cord-339520-odly2fwg author: Madic, J. title: Isotype-specific antibody responses to bovine herpesvirus 1 in sera and mucosal secretions of calves after experimental reinfection and after reactivation date: 1995-07-31 words: 3360.0 sentences: 172.0 pages: flesch: 49.0 cache: ./cache/cord-339520-odly2fwg.txt txt: ./txt/cord-339520-odly2fwg.txt summary: Abstract Isotype-specific antibody responses to bovine herpesvirus 1 (BHV1) were measured in sera, nasal, ocular and genital secretions of calves that were reinfected with BHV1 and 6 weeks later treated with corticosteroids to reactivate putative latent virus. The control calves, which were infected for the first time, developed an IgM antibody response in serum, nasal and ocular secretions that was first detected on PRD 8 and lasted until PRD 27. Calves in which no virus excretion after reinfection and/or corticosteroid treatment was detected yet developed an antibody response against BHVl, mainly of the IgA isotype. However, it may be the serum IgA response seems to be a much more sensitive indicator for reinfection with or reactivation of BHVl than detection of nasal and ocular virus shedding. After corticosteroid treatment, virus-positive nasal secretions were detected in 20 of 26 reinfected calves, and a significant increase in serum IgGl and IgG2 antibody titre in 17 and 12 calves, respectively. abstract: Abstract Isotype-specific antibody responses to bovine herpesvirus 1 (BHV1) were measured in sera, nasal, ocular and genital secretions of calves that were reinfected with BHV1 and 6 weeks later treated with corticosteroids to reactivate putative latent virus. After reinfection and after reactivation, no BHV1-specific IgM antibody response was detected. The serum IgA response was only transiently detectable after reinfection and again appeared rapidly after reactivation in most calves. Most calves showed an increase in nasal and ocular IgA titres after reinfection and reactivation; some calves also had IgA antibodies in genital secretions. A salient finding was that after reinfection and reactivation more calves showed a serum IgA response than virus shedding or an increase in serum IgG1 or IgG2 titres. This suggests that the serum IgA response would be the most sensitive indicator to detect BHV1 reinfection and reactivation. No correlation was found between nasal IgA titre at the time of reinfection or corticosteroid treatment and the period of virus shedding, suggesting that nasal IgA does not play a major role in protection against reinfection with BHV1. url: https://api.elsevier.com/content/article/pii/0165242794053797 doi: 10.1016/0165-2427(94)05379-7 id: cord-268417-6eyetb5i author: Mandel, Benjamin title: Neutralization of Animal Viruses date: 1978-12-31 words: 23012.0 sentences: 1239.0 pages: flesch: 43.0 cache: ./cache/cord-268417-6eyetb5i.txt txt: ./txt/cord-268417-6eyetb5i.txt summary: Somewhat earlier, Morgan (1945''1 had reported that discrepancies in the quantitative aspects of the neutralization of WEE virus by immune rabbit sera were related to the use of fresh or heated serum, and that the addition of complement to the latter tended to eliminate the discrepancies. Further studies (Radwan et al., 1973) showed that the addition of complement to virus complexed with dependent antibody eventually resulted in lysis of the viral membrane. It was also shown (Yoshino and Taniguchi, 1966 ) that antibodies induced in guinea pigs by immunization, and in humans following herpes infection, were initially dependent and later independent of complement for neutralizing activity. A relevant observation has been made in several studies; neutralization of infectious virus-antibody complexes by antiglobulin also shows a single-hit mechanism, and at a rate that exceeds the rate of the homotypic reaction. abstract: Publisher Summary Various aspects of the interaction of bacterial viruses and antibody were studied by Andrewes and Elford in England. Similar studies, as well as studies on animal viruses, were carried out in Australia by Burnet and his colleagues. One result of their extensive studies, which were summarized in great detail, was the conclusion that, with respect to their interaction with antibody, bacterial and animal viruses were basically different. Specifically, the difference resided in the stability of the union of virus and antibody, whereas bacterial viruses formed stable complexes, animal viruses formed complexes that tended to dissociate readily. The introduction of animal cell cultures as host systems greatly aided in the study of animal viruses, with respect to fewer and more readily controlled variables, and by the use of the plaque assay in enhanced quantitative reliability. In 1956, Dulbecco et al. described the interaction of two animal viruses with their respective antibodies. The results of these studies led these investigators to conclude, among other things, that animal viruses, at least the two they studied, reacted with antibodies to form complexes that did not dissociate spontaneously. This interpretation was challenged by Fazekas de St. Groth and Reid. As more animal virus-antibody systems were studied by many investigators, there seemed to be a greater accord for irreversible, rather than reversible, interaction. For this reason, in this chapter it is assumed that there are no differences between bacterial viruses, as one category, and animal viruses, as a separate category, concerning their interaction with antibodies. Rather, differences, when they exist, are considered to be related to the viruses per se. Although this chapter is intended to survey the neutralization of animal viruses, occasional reference is made to the studies on bacterial viruses when these studies are pertinent and illuminating to the topic at hand. url: https://www.ncbi.nlm.nih.gov/pubmed/107731/ doi: 10.1016/s0065-3527(08)60101-3 id: cord-302974-t1t89p8y author: Mathur, Gagan title: Antibody Testing For Covid-19: Can It Be Used As A Screening Tool In Areas With Low Prevalence? date: 2020-05-15 words: 913.0 sentences: 58.0 pages: flesch: 57.0 cache: ./cache/cord-302974-t1t89p8y.txt txt: ./txt/cord-302974-t1t89p8y.txt summary: Soon after detection of spread of SARS-CoV-2 in the United States (US), focus was on developing molecular nucleic acid detection tests (real-time reverse transcriptase polymerase chain reaction [RT-PCR]) for early diagnosis of infection in symptomatic patients, patients with known exposure, and patients who are at risk. The Trump administration and the media have been promoting antibody tests as a screening tool to allow individuals with positive results to get back to work and open our economy. The assumption is that the individuals with positive antibody tests have recovered from COVID-19 (symptomatic or asymptomatic) infection and have developed immunity to the virus. As of April 30, 2020, 10 antibody tests have been approved by the US Food and Drug Administration (FDA) under emergency use authorizations. Prematurely promoting antibody tests as a screening tool all over the US will give individuals, who test positive and are not actually immune to COVID-19, a false sense of protection. abstract: nan url: https://doi.org/10.1093/ajcp/aqaa082 doi: 10.1093/ajcp/aqaa082 id: cord-005913-1vo1o6w8 author: Matis, Louis A. title: Complement-specific antibodies: Designing novel anti-inflammatories date: 1995 words: 1918.0 sentences: 89.0 pages: flesch: 30.0 cache: ./cache/cord-005913-1vo1o6w8.txt txt: ./txt/cord-005913-1vo1o6w8.txt summary: The complement system is composed of more than 20 serum proteins that interact in a precise series of enzymatic cleavage and membrane binding events leading to the generation of products with immunoprotective, immunoregulatory, and proinflammatory properties 12 • Complement can be activated through either of two distinct enzymatic cascades, referred to as the classical and alternative pathways (Fig. 1) . Using a monoclonal antibody specific for mouse CS, we have shown that systemic anti-CS monoclonal antibody administration efficiently inhibited complement in vivo (inhibiting serum haemolytic activity for as long as six to seven days after a single intravenous injection), and that treatment with anti-CS monoclonal antibody was therapeutically effective in two distinct models of immune complex nephritis and autoimmune disease (Y. In addition, humanized recombinant anti-CS monoclonal antibody and scFv that retain the binding affinity and complement inhibitory activity of their murine counterparts have been produced by CDR grafting (M. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095943/ doi: 10.1038/nm0895-839 id: cord-010578-uib9h1lb author: Mawle, Alison C. title: Seroepidemiology of Chronic Fatigue Syndrome: A Case-Control Study date: 1995-12-17 words: 2570.0 sentences: 164.0 pages: flesch: 49.0 cache: ./cache/cord-010578-uib9h1lb.txt txt: ./txt/cord-010578-uib9h1lb.txt summary: We performed serological testing for a large number of infectious agents in 26 patients from Atlanta who had chronic fatigue syndrome (CFS) and in 50 controls matched by age, race, and sex. We performed serological testing for a large number of infectious agents in 26 patients from Atlanta who had chronic fatigue syndrome (CFS) and in 50 controls matched by age, race, and sex. We conducted serological tests for a large number of infectious agents as part of a case-control study assessing risk factors for CFS. Antibodies against human T-lymphotrophic virus types I and II were detected with an ELISA, and confirmatory testing was performed by western blotting [5] . All other agents tested were detected in ;;:::25% of CFS cases, and antibody levels were compared between cases and controls. Evidence for active Epstein-Barr virus infection in patients with persistent unexplained illness: elevated anti-early antigen antibodies abstract: We performed serological testing for a large number of infectious agents in 26 patients from Atlanta who had chronic fatigue syndrome (CFS) and in 50 controls matched by age, race, and sex. We did not find any agent associated with CFS. In addition, we did not find elevated levels of antibody to any of a wide range of agents examined. In particular, we did not find elevated titers of antibody to any herpesvirus, nor did we find evidence of enteroviral exposure in this group of patients. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197952/ doi: 10.1093/clinids/21.6.1386 id: cord-327287-e5k2gcse author: May, Jori E. title: The challenges of diagnosing heparin‐induced thrombocytopenia in patients with COVID‐19 date: 2020-08-02 words: 174.0 sentences: 21.0 pages: flesch: 46.0 cache: ./cache/cord-327287-e5k2gcse.txt txt: ./txt/cord-327287-e5k2gcse.txt summary: key: cord-327287-e5k2gcse authors: May, Jori E.; Siniard, Rance C.; Marques, Marisa title: The challenges of diagnosing heparin‐induced thrombocytopenia in patients with COVID‐19 cord_uid: e5k2gcse To the Editor, Riker EIAs are sensitive, but not specific, for HIT diagnosis because they detect all anti-platelet factor 4 (PF4)/heparin antibodies, including those that are nonpathogenic. 3 In contrast, functional assays (including SRA) identify only antibodies with the pathogenic ability to activate platelets and therefore have increased specificity. 3 Given that severe COVID-19 is a hyperinflammatory state, it is plausible that the increased immunoreactivity also increases production of anti-PF4/heparin antibodies; however, they may not result in clinical HIT but may instead increase potential for false-positive EIAs. Herein, we report our experience with hospitalized patients with The authors have no conflicts of interest to disclose. Heparin-induced thrombocytopenia with thrombosis in COVID-19 adult respiratory distress syndrome COVID-19 and its implications for thrombosis and anticoagulation Testing for heparin-induced thrombocytopenia antibodies abstract: nan url: https://www.ncbi.nlm.nih.gov/pubmed/32838112/ doi: 10.1002/rth2.12416 id: cord-350029-1y5ex4d5 author: McDade, Thomas W. title: Beyond serosurveys: Human biology and the measurement of SARS‐Cov‐2 antibodies date: 2020-08-09 words: 2690.0 sentences: 129.0 pages: flesch: 43.0 cache: ./cache/cord-350029-1y5ex4d5.txt txt: ./txt/cord-350029-1y5ex4d5.txt summary: Serological testing is a complementary approach that detects the presence of antibodies against SARS-CoV-2 in blood samples from exposed individuals (World Health Organization, 2020). If sufficient time has passed since the initial infection, the presence of IgM antibodies against SARS-CoV-2 antigens can be used to confirm a clinical case of COVID-19. In developing a low-cost ELISA for SARS-CoV-2 antibodies, our hope is that others can draw on the longstanding tradition of methodological innovation in human biology to promote community-based research on COVID-19. Human biologists are also well-positioned to consider a life course perspective on variation in outcomes in response to SARS-CoV-2 infection. Human biologists are uniquely positioned to make important contributions to our understanding of COVID-19, and methods that facilitate research in community-based settings globally will be central to that effort. Enzyme immunoassay for SARS-CoV-2 antibodies in dried blood spot samples: A minimally-invasive approach to facilitate community-and population-based screening abstract: nan url: https://doi.org/10.1002/ajhb.23483 doi: 10.1002/ajhb.23483 id: cord-102908-sr7j8z9c author: Mersmann, Sophia F. title: Learning to count: determining the stoichiometry of bio-molecular complexes using fluorescence microscopy and statistical modelling date: 2020-07-24 words: 5244.0 sentences: 260.0 pages: flesch: 42.0 cache: ./cache/cord-102908-sr7j8z9c.txt txt: ./txt/cord-102908-sr7j8z9c.txt summary: We used differential binary labelling and statistical modelling to extract estimates of stoichiometry, our strategy is outlined in Figure 1 ; note that this approach can be generalised to apply to many other multi-component systems (i.e. how many protein x are found in assembly y?). As described above, our experimental design utilizes antibody labelled with spectrally distinct dyes allowing binary scoring of individual virus particles as positive if they interact with at least one Ab B molecule ( Figure 1 ). We have demonstrated quantitative analysis of 9C12 interaction with individual Adv particles ( Figure 3) ; we have confirmed that differential labelling of antibody does not bias binding ( Figure 4A & B) ; and that we could detect single molecules of 9C12 Biotin allowing discrimination of positive and negative AdV-9C12 complexes ( Figure 4C & D). However, using stoichiometric estimates to calibrate fluorescent data revealed population heterogeneity with a small proportion of virus particles binding ∼200 antibody molecules. abstract: Cellular biology occurs through myriad interactions between diverse molecular components, many of which assemble in to specific complexes. Various techniques can provide a qualitative survey of which components are found in a given complex. However, quantitative analysis of the absolute number of molecules within a complex (known as stoichiometry) remains challenging. Here we provide a novel method that combines fluorescence microscopy and statistical modelling to derive accurate molecular counts. We have devised a system in which a given biomolecule is differentially labelled with spectrally distinct fluorescent dyes (label A or B), which are then mixed such that B-labelled molecules are vastly outnumbered by those with label A. Complexes, containing this component, are then simply scored as either being positive or negative for label B. The frequency of positive complexes is directly related to the stoichiometry of interaction and molecular counts can be inferred by statistical modelling. We demonstrate this method using complexes of Adenovirus particles and monoclonal antibodies, achieving counts that are in excellent agreement with previous estimates. Beyond virology, this approach is readily transferable to other experimental systems and, therefore, provides a powerful tool for quantitative molecular biology. The statistical models used in our analysis are available here: https://github.com/sophiamersmann/molecular-counting, the raw data used for molecular counting can be found here: 10.5281/zenodo.3955142. url: https://doi.org/10.1101/2020.07.23.217745 doi: 10.1101/2020.07.23.217745 id: cord-254531-pv55re2x author: Mestecky, Jiri title: Specific antibody activity, glycan heterogeneity and polyreactivity contribute to the protective activity of S-IgA at mucosal surfaces date: 2009-06-04 words: 4108.0 sentences: 237.0 pages: flesch: 36.0 cache: ./cache/cord-254531-pv55re2x.txt txt: ./txt/cord-254531-pv55re2x.txt summary: In addition to mechanical barriers and a variety of innate defense factors, mucosal immunoglobulins (Igs) provide protection by two complementary mechanisms: specific antibody activity and innate, Ig glycan-mediated binding, both of which serve to contain the mucosal microbiota in its physiological niche. Bacteria Table 1 Examples of glycans as adhesion sites and receptors for selected bacteria and viruses that colonize, or infect, mucosal surfaces (adapted from [1, 26, 29, [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] 132] endogenous to the intestinal tract, oral cavity, and probably also the respiratory and genital tracts, are coated in vivo with S-IgA [9, 13, 17, [31] [32] [33] [34] [35] [36] [37] [38] [39] that limits their epithelial adherence and penetration, thereby confining them to the mucosal surfaces. Parallel structural and functional exploration of the principles of adaptive (specific antibody) and innate (glycan) S-IgA-mediated immunity is likely to generate novel approaches to the design of broadly protective compounds that work by selectively interfering with the adherence and penetration of pathogens, or that contain the commensal microbiota residing at mucosal surfaces. abstract: An explanation of the principles and mechanisms involved in peaceful co-existence between animals and the huge, diverse, and ever-changing microbiota that resides on their mucosal surfaces represents a challenging puzzle that is fundamental in everyday survival. In addition to mechanical barriers and a variety of innate defense factors, mucosal immunoglobulins (Igs) provide protection by two complementary mechanisms: specific antibody activity and innate, Ig glycan-mediated binding, both of which serve to contain the mucosal microbiota in its physiological niche. Thus, the interaction of bacterial ligands with IgA glycans constitutes a discrete mechanism that is independent of antibody specificity and operates primarily in the intestinal tract. This mucosal site is by far the most heavily colonized with an enormously diverse bacterial population, as well as the most abundant production site for antibodies, predominantly of the IgA isotype, in the entire immune system. In embodying both adaptive and innate immune mechanisms within a single molecule, S-IgA maintains comprehensive protection of mucosal surfaces with economy of structure and function. url: https://api.elsevier.com/content/article/pii/S0165247809000893 doi: 10.1016/j.imlet.2009.03.013 id: cord-102704-wfuzk2dp author: Meza, Diana K. title: Predicting the presence and titer of rabies virus neutralizing antibodies from low-volume serum samples in low-containment facilities date: 2020-04-30 words: 3183.0 sentences: 192.0 pages: flesch: 43.0 cache: ./cache/cord-102704-wfuzk2dp.txt txt: ./txt/cord-102704-wfuzk2dp.txt summary: Despite small conflicts, titer predictions were correlated across tests repeated on different dates both for dog samples (r = 0.93), and for a second dataset of sera from wild common vampire bats (r = 0.72, N = 41), indicating repeatability. The pmRFFIT enables high-throughput detection of rabies virus neutralizing antibodies in low-biocontainment settings and is suited to studies in wild or captive animals where large serum volumes cannot be obtained. The binomial and log-normal models fit to 193 this data subset included only the fixed effect of the virus-infected N2A cell counts, but the random 194 effects were identical to those explained above (i.e. test date and field). A final distinction is that 316 instead of scoring microscope field or wells as virus positive or negative, the pmRFFIT predicts 317 serological status and RVNA titer from infected cell counts in a single serum dilution using statistical 318 abstract: Serology is a core component of the surveillance and management of viral zoonoses. Virus neutralization tests are a gold standard serological diagnostic, but requirements for large volumes of serum and high biosafety containment can limit widespread use. Here, focusing on Rabies lyssavirus, a globally important zoonosis, we developed a pseudotype micro-neutralization rapid fluorescent focus inhibition test (pmRFFIT) that overcomes these limitations. Specifically, we adapted an existing micro-neutralization test to use a green fluorescent protein–tagged murine leukemia virus pseudotype in lieu of pathogenic rabies virus, reducing the need for specialized reagents for antigen detection and enabling use in low-containment laboratories. We further used statistical analysis to generate rapid, quantitative predictions of the probability and titer of rabies virus neutralizing antibodies from microscopic imaging of neutralization outcomes. Using 47 serum samples from domestic dogs with neutralizing antibody titers estimated using the fluorescent antibody virus neutralization test (FAVN), pmRFFIT showed moderate sensitivity (78.79%) and high specificity (84.62%). Despite small conflicts, titer predictions were correlated across tests repeated on different dates both for dog samples (r = 0.93), and for a second dataset of sera from wild common vampire bats (r = 0.72, N = 41), indicating repeatability. Our test uses a starting volume of 3.5 μL of serum, estimates titers from a single dilution of serum rather than requiring multiple dilutions and end point titration, and may be adapted to target neutralizing antibodies against alternative lyssavirus species. The pmRFFIT enables high-throughput detection of rabies virus neutralizing antibodies in low-biocontainment settings and is suited to studies in wild or captive animals where large serum volumes cannot be obtained. url: https://doi.org/10.1101/2020.04.24.060095 doi: 10.1101/2020.04.24.060095 id: cord-313312-h607itv2 author: Mok, Darren Z. L. title: The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines date: 2020-05-08 words: 7417.0 sentences: 349.0 pages: flesch: 34.0 cache: ./cache/cord-313312-h607itv2.txt txt: ./txt/cord-313312-h607itv2.txt summary: Pre-existing antibodies, derived from either from maternal–fetal transmission, or by previous infection or vaccination, have been demonstrated to interfere with vaccine immunogenicity of measles, adenovirus, and influenza LAVs. Immune interference of LAVs can be caused by the formation of virus–antibody complexes that neutralize virus infection in antigen-presenting cells, or by the cross-linking of the B-cell receptor with the inhibitory receptor, FcγRIIB. The clinical trial finding that subjects with a limited range of cross-reactive antibodies from a prior Japanese Encephalitis vaccine were able to enhance yellow fever vaccination, by prolonging vaccine viremia duration that leads to higher antibody titers, thus hints at the possibility that whether pre-existing antibodies inhibit or augment flavivirus infection will depend on both antibody titers and the type/specificity of antibodies produced [85] . By contrast, at sub-neutralizing titers, pre-existing antibodies can enable viruses to better infect cells and increase innate immune responses that augment LAV immunogenicity. By contrast, at sub-neutralizing titers, pre-existing antibodies can enable viruses to better infect cells and increase innate immune responses that augment LAV immunogenicity. abstract: Live-attenuated vaccines (LAVs) have achieved remarkable successes in controlling virus spread, as well as for other applications such as cancer immunotherapy. However, with rapid increases in international travel, globalization, geographic spread of viral vectors, and widespread use of vaccines, there is an increasing need to consider how pre-exposure to viruses which share similar antigenic regions can impact vaccine efficacy. Pre-existing antibodies, derived from either from maternal–fetal transmission, or by previous infection or vaccination, have been demonstrated to interfere with vaccine immunogenicity of measles, adenovirus, and influenza LAVs. Immune interference of LAVs can be caused by the formation of virus–antibody complexes that neutralize virus infection in antigen-presenting cells, or by the cross-linking of the B-cell receptor with the inhibitory receptor, FcγRIIB. On the other hand, pre-existing antibodies can augment flaviviral LAV efficacy such as that of dengue and yellow fever virus, especially when pre-existing antibodies are present at sub-neutralizing levels. The increased vaccine immunogenicity can be facilitated by antibody-dependent enhancement of virus infection, enhancing virus uptake in antigen-presenting cells, and robust induction of innate immune responses that promote vaccine immunogenicity. This review examines the literature on this topic and examines the circumstances where pre-existing antibodies can inhibit or enhance LAV efficacy. A better knowledge of the underlying mechanisms involved could allow us to better manage immunization in seropositive individuals and even identify possibilities that could allow us to exploit pre-existing antibodies to boost vaccine-induced responses for improved vaccine efficacy. url: https://www.ncbi.nlm.nih.gov/pubmed/32397218/ doi: 10.3390/v12050520 id: cord-269023-g21a9ik2 author: Mukherjee, Siddhartha title: Before Virus, After Virus: A Reckoning date: 2020-10-15 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: The 2020 Lasker Awards, a celebration of one of the most prestigious international prizes given to individuals for extraordinary contributions to Basic and Clinical Medical Research, Pubic Health, and Special Achievement, was cancelled because of the COVID-19 pandemic. Typically, essays on the awardees and their scientific and medical contributions are solicited and published in Cell in collaboration with the Lasker Committee. This year, the Lasker Committee commissioned an essay to reflect on the historic contributions that scientists and physicians have made to our understanding of immunology and virology, and future directions in medical and basic research that have been highlighted by COVID-19 pandemic. url: https://www.ncbi.nlm.nih.gov/pubmed/33064987/ doi: 10.1016/j.cell.2020.09.042 id: cord-277894-0qw0t78s author: NAYLOR, MJ title: Canine coronavirus in Australian dogs date: 2008-03-10 words: 3142.0 sentences: 170.0 pages: flesch: 55.0 cache: ./cache/cord-277894-0qw0t78s.txt txt: ./txt/cord-277894-0qw0t78s.txt summary: Objective To estimate the frequency of serum antibodies (IgG and IgM) to canine coronavirus (CCV) in the Australian dog population and evaluate the role of CCV as a causative agent of gastroenteritis. Of those dogs that were presented with clinical signs of gastroenteritis such as diarrhoea and vomiting(n = 29), 85% were positive in the IgM ELISA and 85.7% in the IgG ELISA for antibodies to CCV. In this study we determine the prevalence of serum IgG and IgM antibodies to CCV from a larger number of dogs sampled from throughout Australia. 7, 8 In the open population of 1107 dogs tested we found 15.8% positive for anti-CCV IgG antibody, which reflects past exposure and infection with CCV whereas the electron microscopic studies detected only those dogs currently infected and shedding virus in their faeces. abstract: Objective To estimate the frequency of serum antibodies (IgG and IgM) to canine coronavirus (CCV) in the Australian dog population and evaluate the role of CCV as a causative agent of gastroenteritis. Design A serological survey of antibodies to CCV among different dog populations. Procedure The development and characterisation of an indirect ELISA for the detection of antibodies (IgG and IgM) to CCV was undertaken. Sera collected from both diarrhoeal and non‐diarrhoeal dogs from various populations throughout Australia were tested for these antibodies to CCV. Results Serum samples (1396) collected from 1984 to 1998 were tested for the presence of IgG antibodies to CCV. Samples were divided into two categories on the basis of the number of dogs housed together. The groups were either an open population containing dogs housed as groups of three or less, or kennel populations. Sera from 15.8% of the open population and 40.8% of kennelled dogs were positive for CCV antibodies. The prevalence of antibodies varied from zero to 76% in kennelled dogs. About 23% of 128 dogs positive for IgG antibodies to CCV were also positive for IgM antibodies to CCV, indicating recent CCV infection. Of those dogs that were presented with clinical signs of gastroenteritis such as diarrhoea and vomiting(n = 29), 85% were positive in the IgM ELISA and 85.7% in the IgG ELISA for antibodies to CCV. In comparison, for those dogs presented without any history of gastroenteritis only 15% were positive for IgM and 30% positive for IgG. Conclusion Serological evidence indicates that infection with CCV in dogs is widespread throughout the Australian mainland. The prevalence of antibodies varies greatly among different populations, with an average of 40.8% positive in kennelled populations and 15.8% in the open population. url: https://www.ncbi.nlm.nih.gov/pubmed/11256282/ doi: 10.1111/j.1751-0813.2001.tb10718.x id: cord-278281-bdoavpsb author: NEMOTO, Manabu title: Antibody response to equine coronavirus in horses inoculated with a bovine coronavirus vaccine date: 2017-10-06 words: 1363.0 sentences: 74.0 pages: flesch: 59.0 cache: ./cache/cord-278281-bdoavpsb.txt txt: ./txt/cord-278281-bdoavpsb.txt summary: Virus neutralization tests showed that antibody titers against ECoV increased in all six horses tested at 14 days post inoculation, although the antibody titers were lower against ECoV than against BCoV. The virus-neutralizing antibody titers of horses inoculated with 1 or 2 ml of the BCoV vaccine are shown in Table 1 . In horses inoculated with 1 ml of vaccine, the geometric mean antibody titers against BCoV at 0, 7, 14, 28, 42 and 56 dpi were 4, 5, 32, 102, 645 and 323, respectively, and the geometric mean antibody titers against ECoV were 4, 6, 20, 25, 40 and 51 (Table 1) . Nevertheless, the antibody titers of all vaccinated horses in the present study were no more than 128, and we therefore consider that the BCoV vaccine will have limited efficacy against ECoV infection in horses. abstract: A vaccine for equine coronavirus (ECoV) is so far unavailable. Bovine coronavirus (BCoV) is antigenically related to ECoV; it is therefore possible that BCoV vaccine will induce antibodies against ECoV in horses. This study investigated antibody response to ECoV in horses inoculated with BCoV vaccine. Virus neutralization tests showed that antibody titers against ECoV increased in all six horses tested at 14 days post inoculation, although the antibody titers were lower against ECoV than against BCoV. This study showed that BCoV vaccine provides horses with antibodies against ECoV to some extent. It is unclear whether antibodies provided by BCoV vaccine are effective against ECoV, and therefore ECoV challenge studies are needed to evaluate efficacy of the vaccine in the future. url: https://www.ncbi.nlm.nih.gov/pubmed/28993568/ doi: 10.1292/jvms.17-0414 id: cord-319884-d8n0aokl author: Natesan, Mohan title: Protein Microarrays and Biomarkers of Infectious Disease date: 2010-12-16 words: 7088.0 sentences: 359.0 pages: flesch: 36.0 cache: ./cache/cord-319884-d8n0aokl.txt txt: ./txt/cord-319884-d8n0aokl.txt summary: Fluorescencebased detection of protein interactions is similar to gene array methods, and data analysis often employs approaches previously developed for genome and transcription studies. A standard assay for measuring antibody interactions with proteins of the vaccinia proteome microarray was first developed with a pool of therapeutic human sera collected from vaccinia-immune individuals (VIg) and this data was compared to results obtained from individuals vaccinated against smallpox using Dryvax. Results from this study suggested that antibodies from vaccination recognized a small number of proteins shared with pathogenic viral strains, while recovery from infection also involved humoral immunity to antigens uniquely recognized within the monkeypox virus proteome (unpublished data). For example, a protein array produced from the outer membrane proteins of Pseudomonas aeruginosa was constructed [38] to study the immune response in patients, and several antibody-binding antigens were identified by this group as potential diagnostic markers. abstract: Protein microarrays are powerful tools that are widely used in systems biology research. For infectious diseases, proteome microarrays assembled from proteins of pathogens will play an increasingly important role in discovery of diagnostic markers, vaccines, and therapeutics. Distinct formats of protein microarrays have been developed for different applications, including abundance-based and function-based methods. Depending on the application, design issues should be considered, such as the need for multiplexing and label or label free detection methods. New developments, challenges, and future demands in infectious disease research will impact the application of protein microarrays for discovery and validation of biomarkers. url: https://doi.org/10.3390/ijms11125165 doi: 10.3390/ijms11125165 id: cord-048239-oluq7v0h author: Oliphant, Theodore title: Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus date: 2005-04-24 words: 6715.0 sentences: 341.0 pages: flesch: 49.0 cache: ./cache/cord-048239-oluq7v0h.txt txt: ./txt/cord-048239-oluq7v0h.txt summary: Using random mutagenesis and yeast surface display, we defined individual contact residues of 14 newly generated monoclonal antibodies against domain III of the WNV E protein. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus E protein by nickel-affinity chromatography (data not shown). 24 ), yet was virus specific, as it neither recognized nor neutralized other flaviviruses including distantly related dengue and yellow fever viruses (data not shown) and closely related Japanese and St. Louis encephalitis viruses (Supplementary Table 2 Figure 1 Mapping of monoclonal antibodies to DIII with yeast. None of the mutations identified by loss-of-binding sorts for E2 or E22 had any effect on two other non-neutralizing monoclonal Individual WNV-specific monoclonal antibodies (25 µg/ml) were mixed with yeast that displayed wild-type or mutant DIII on their surface. To determine whether human antibodies specific for WNV recognize the neutralizing epitope on DIII during infection, plasma was obtained from WNV-positive individuals. abstract: Neutralization of West Nile virus (WNV) in vivo correlates with the development of an antibody response against the viral envelope (E) protein. Using random mutagenesis and yeast surface display, we defined individual contact residues of 14 newly generated monoclonal antibodies against domain III of the WNV E protein. Monoclonal antibodies that strongly neutralized WNV localized to a surface patch on the lateral face of domain III. Convalescent antibodies from individuals who had recovered from WNV infection also detected this epitope. One monoclonal antibody, E16, neutralized 10 different strains in vitro, and showed therapeutic efficacy in mice, even when administered as a single dose 5 d after infection. A humanized version of E16 was generated that retained antigen specificity, avidity and neutralizing activity. In postexposure therapeutic trials in mice, a single dose of humanized E16 protected mice against WNV-induced mortality, and may therefore be a viable treatment option against WNV infection in humans. SUPPLEMENTARY INFORMATION: The online version of this article (doi:10.1038/nm1240) contains supplementary material, which is available to authorized users. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1458527/ doi: 10.1038/nm1240 id: cord-302382-eifh95zm author: Owji, Hajar title: Immunotherapeutic approaches to curtail COVID-19 date: 2020-08-21 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: COVID-19, the disease induced by the recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has imposed an unpredictable burden on the world. Drug repurposing has been employed to rapidly find a cure; but despite great efforts, no drug or vaccine is presently available for treating or prevention of COVID-19. Apart from antivirals, immunotherapeutic strategies are suggested considering the role of the immune response as the host defense again the virus, and the fact that SARS-CoV-2 suppresses interferon induction as an immune evasion strategy. Active immunization through vaccines, interferon administration, passive immunotherapy by convalescent plasma or synthesized monoclonal and polyclonal antibodies, as well as immunomodulatory drugs, are different immunotherapeutic approaches that will be mentioned in this review. The focus would be on passive immunotherapeutic interventions. Interferons might be helpful in some stages. Vaccine development has been followed with unprecedented speed. Some of these vaccines have been advanced to human clinical trials. Convalescent plasma therapy is already practiced in many countries to help save the lives of severely ill patients. Different antibodies that target various steps of SARS-CoV-2 pathogenesis or the associated immune responses are also proposed. For treating the cytokine storm induced at a late stage of the disease in some patients, immune modulation through JAK inhibitors, corticosteroids, and some other cognate classes are evaluated. Given the changing pattern of cytokine induction and immune responses throughout the COVID-19 disease course, different adapted approaches are needed to help patients. Gaining more knowledge about the detailed pathogenesis of SARS-CoV-2, its interplay with the immune system, and viral-mediated responses are crucial to identify efficient preventive and therapeutic approaches. A systemic approach seems essential in this regard. url: https://www.sciencedirect.com/science/article/pii/S1567576920324309?v=s5 doi: 10.1016/j.intimp.2020.106924 id: cord-018811-zhwr3h07 author: Oxford, John title: Influenza Vaccines Have a Short but Illustrious History of Dedicated Science Enabling the Rapid Global Production of A/Swine (H1N1) Vaccine in the Current Pandemic date: 2010-06-18 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Vaccines for the swine flu pandemic of 2009 have been produced in an exquisitely short time frame. This speed of production comes because of 50 years of hard work by virologists worldwide in pharma groups, research laboratories, and government licensing units. The present chapter presents the background framework of influenza vaccine production and its evolution over 50 years. Isolation of the causative virus of influenza in 1933, followed by the discovery of embryonated hen eggs as a substrate, quickly led to the formulation of vaccines. Virus-containing allantoic fluid was inactivated with formalin. The phenomenon of antigenic drift of the virus HA was soon recognized and as WHO began to coordinate the world influenza surveillance, it became easier for manufacturers to select an up-to-date virus. Influenza vaccines remain unique in that the virus strain composition is reviewed yearly, but modern attempts are being made to free manufacturers from this yolk by investigating internal virus proteins including M2e and NP as “universal” vaccines covering all virus subtypes. Recent technical innovations have been the use of Vero and MDCK cells as the virus cell substrate, the testing of two new adjuvants, and the exploration of new presentations to the nose or epidermal layers as DNA or antigen mixtures. The international investment into public health measures for a global human outbreak of avian H5N1 influenza together with a focus of swine influenza H1N1 is leading to enhanced production of conventional vaccine and to a new research searchlight on T-cell epitope vaccines, viral live-attenuated carriers of influenza proteins, and even more innovative substrates to cultivate virus, including plant cells. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123788/ doi: 10.1007/978-3-0346-0279-2_6 id: cord-295033-5fd9bu60 author: Parma, Y.R. title: Antibodies anti-Shiga toxin 2 B subunit from chicken egg yolk: Isolation, purification and neutralization efficacy date: 2011-09-15 words: 6045.0 sentences: 326.0 pages: flesch: 53.0 cache: ./cache/cord-295033-5fd9bu60.txt txt: ./txt/cord-295033-5fd9bu60.txt summary: The data suggest that immunization of hens with Stx2B could be a strategy to obtain at low cost a relatively high concentration of anti-Stx2 egg yolk IgY, able to neutralize Stx2 lethal activity. The data suggest that immunization of hens with Stx2B could be a strategy to obtain at low cost a relatively high concentration of anti-Stx2 egg yolk IgY, able to neutralize Stx2 lethal activity. Specific anti-Stx2B polyclonal antibodies obtained from chicken egg yolk and rabbit sera recognized not only the denatured and native form of B subunit, used for immunization but the antibodies were also able to recognize the denatured and native wild type Stx2 holotoxin in western blot (Fig. 3) , indirect ELISA (Fig. 4) and sandwich ELISA (Fig. 5) . In the present report, specific egg yolk IgY antibodies with binding and neutralizing capabilities against the wild type Stx2 toxin were obtained after immunization of laying hens. abstract: Shiga toxins (Stx1 and Stx2) are the main virulence factors of enterohemorrhagic Escherichia coli (EHEC), a foodborne pathogen associated with diarrhea, hemorrhagic colitis and hemolytic uremic syndrome. The aim of this study was to evaluate the antibodies against Stx2 obtained from egg yolks of laying hens immunized with a recombinant Stx2B subunit. A high specific response in serum was observed 25 days after the first immunization and IgY antibodies were extracted from day 47th and purified from egg yolk. A concentration of 0.84 mg of total IgY/ml of egg yolk was obtained, of which 8% were antigen specific. The ability of anti-Stx2B IgY to recognize Stx2B and Stx2 either in solid-phase or in solution were evaluated and compared with anti-Stx2B rabbit antibodies by Western blotting and ELISA. The protective efficacy of IgY against Stx2 was determined by in vitro and in vivo experiments. The results show that IgY was able to recognize Stx2B and Stx2 in denatured conditions, attached to a solid-phase and free in solution. The anti-Stx2B IgY could effectively block the biological activity of Stx2 on Vero cells and protect mice from Stx2 challenge. The data suggest that immunization of hens with Stx2B could be a strategy to obtain at low cost a relatively high concentration of anti-Stx2 egg yolk IgY, able to neutralize Stx2 lethal activity. IgY technology could be an useful tool for research, diagnosis and therapy of EHEC infection. url: https://www.sciencedirect.com/science/article/pii/S0041010111002273 doi: 10.1016/j.toxicon.2011.07.009 id: cord-337464-otwps68u author: Parray, Hilal Ahmed title: Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives date: 2020-05-27 words: 12204.0 sentences: 606.0 pages: flesch: 38.0 cache: ./cache/cord-337464-otwps68u.txt txt: ./txt/cord-337464-otwps68u.txt summary: Even with the recent development of high throughput mAb generation technologies, hybridoma is the most favoured method due to its indigenous nature to preserve natural cognate antibody pairing information and preserves innate functions of immune cells. This review also summarizes the challenges and recent progress associated with hybridoma development, and how it has been overcome in these years to provide new insights for the isolation of mAbs. Antibodies are the glycoproteins produced by the B-cells also known as immunoglobulins, which are present in higher eukaryotes. The mice hybridoma technology is a multi-step process that takes advantage of a host animal''s natural ability to produce highly specific, high-affinity and fully functional mAbs. It involves the development and optimization of specific immunogenic antigen (Ag). abstract: The advancements in technology and manufacturing processes have allowed the development of new derivatives, biosimilar or advanced improved versions for approved antibodies each year for treatment regimen. There are more than 700 antibody-based molecules that are in different stages of phase I/II/ III clinical trials targeting new unique targets. To date, approximately more than 80 monoclonal antibodies (mAbs) have been approved. A total of 7 novel antibody therapeutics had been granted the first approval either in the United States or European Union in the year 2019, representing approximately 20% of the total number of approved drugs. Most of these licenced mAbs or their derivatives are either of hybridoma origin or their improvised engineered versions. Even with the recent development of high throughput mAb generation technologies, hybridoma is the most favoured method due to its indigenous nature to preserve natural cognate antibody pairing information and preserves innate functions of immune cells. The recent advent of antibody engineering technology has superseded the species level barriers and has shown success in isolation of hybridoma across phylogenetically distinct species. This has led to the isolation of monoclonal antibodies against human targets that are conserved and non-immunogenic in the rodent. In this review, we have discussed in detail about hybridoma technology, its expansion towards different animal species, the importance of antibodies isolated from different animal sources that are useful in biological applications, advantages, and limitations. This review also summarizes the challenges and recent progress associated with hybridoma development, and how it has been overcome in these years to provide new insights for the isolation of mAbs. url: https://api.elsevier.com/content/article/pii/S156757692031105X doi: 10.1016/j.intimp.2020.106639 id: cord-010680-lc1onm53 author: Patel, Ami title: In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies date: 2020-03-10 words: 13044.0 sentences: 659.0 pages: flesch: 41.0 cache: ./cache/cord-010680-lc1onm53.txt txt: ./txt/cord-010680-lc1onm53.txt summary: Some of these hurdles may be overcome through transient in vivo gene delivery platforms, such as non-viral synthetic plasmid DNA and messenger RNA vectors that are engineered to encode optimized mAb genes. In this review, we focus on nucleic acid delivery of antibody employing synthetic plasmid DNA vector platforms, and RNA delivery, these being important approaches that are advancing simple, rapid, in vivo expression and having an impact in animal models of infectious diseases and cancer, among others. The original studies surrounding in vivo antibody gene delivery focused primarily on gene delivery using recombinant viral vectors such as AAV and adenovirus (Ad), which were advanced clinically, building on work in the traditional gene therapy-based field. Additional studies to help evaluate fully human pDNA-mAbs in mouse models would be highly informative for both non-viral and viral delivery and provide an important path forward for preclinical evaluation of in vivo-delivered antibodies [109] . abstract: Antibody immunotherapy is revolutionizing modern medicine. The field has advanced dramatically over the past 40 years, driven in part by major advances in isolation and manufacturing technologies that have brought these important biologics to the forefront of modern medicine. However, the global uptake of monoclonal antibody (mAb) biologics is impeded by biophysical and biochemical liabilities, production limitations, the need for cold-chain storage and transport, as well as high costs of manufacturing and distribution. Some of these hurdles may be overcome through transient in vivo gene delivery platforms, such as non-viral synthetic plasmid DNA and messenger RNA vectors that are engineered to encode optimized mAb genes. These approaches turn the body into a biological factory for antibody production, eliminating many of the steps involved in bioprocesses and providing several other significant advantages, and differ from traditional gene therapy (permanent delivery) approaches. In this review, we focus on nucleic acid delivery of antibody employing synthetic plasmid DNA vector platforms, and RNA delivery, these being important approaches that are advancing simple, rapid, in vivo expression and having an impact in animal models of infectious diseases and cancer, among others. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211204/ doi: 10.1007/s40259-020-00412-3 id: cord-291626-lxa8pvt3 author: Pelfrene, E. title: Monoclonal antibodies as anti-infective products: a promising future? date: 2019-01-31 words: 3867.0 sentences: 201.0 pages: flesch: 30.0 cache: ./cache/cord-291626-lxa8pvt3.txt txt: ./txt/cord-291626-lxa8pvt3.txt summary: Additionally, the FDA recently licensed ibalizumab as a rescue therapy in heavily treatmentexperienced adults with multidrug-resistant HIV-1 infection and also previously approved raxibacumab (in 2012) and obiltoxaximab (in 2016), both intended for treatment of inhalational anthrax (in combination with appropriate antibacterial medicines) and for prophylaxis when alternative therapies are not available or are not appropriate [5e7] . François et al., ''Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in patients with severe pneumonia caused by Staphylococcus aureus: first in man trial,'' abstract 1992, paper presented at European Congress of Clinical Microbiology and Infectious Diseases 2017) [34, 38] . Compassionate use Benefits seriously ill patients who cannot be treated satisfactorily or cannot enrol in ongoing clinical trials Pertains to unauthorized medicinal products for chronically, seriously debilitating or life-threatening diseases, with no satisfactory treatment authorized in EU; targeted at a group of patients rather than individual; or undergoing centralized MAA or clinical trials EMA, European Medicines Agency; FDA, US Food and Drug Administration; HTA, health technology assessment bodies; MAA, marketing authorization application; SA, scientific advice. abstract: Abstract Background The paucity of licensed monoclonal antibodies (mAbs) in the infectious diseases arena strongly contrasts with the ready availability of these therapeutics for use in other conditions. Aims This narrative review aims to assess the potential of monoclonal antibody-based interventions for infectious diseases. Sources A review of the literature via the Medline database was performed and complemented by published official documents on licensed anti-infective mAbs. In addition, ongoing trials were identified through a search of the clinical trial registration platform ClinicalTrials.gov. Content We identified the few infections for which mAbs have been added to the therapeutic armamentarium and stressed their potential in representing a readily available protection tool against biothreats and newly emerging and reemerging infectious agents. In reviewing the historical context and main features of mAbs, we assert a potentially wider applicability and cite relevant examples of ongoing therapeutic developments. Factors hindering successful introduction of mAbs on a larger scale are outlined and thoughts are offered on how to possibly address some of these limitations. Implications mAbs may represent important tools in treating or preventing infections occurring with reasonably sufficient prevalence to justify demand and for which existing alternatives are not deemed fully adequate. Future initiatives need to address the prohibitive costs encountered in the development process. The feasibility of more large-scale administration of alternative modalities merits further exploration. In order to ensure optimal prospect of regulatory success, an early dialogue with competent authorities is encouraged. url: https://doi.org/10.1016/j.cmi.2018.04.024 doi: 10.1016/j.cmi.2018.04.024 id: cord-281760-34wuttqw author: Pereira, E.P.V. title: Egg yolk antibodies (IgY) and their applications in human and veterinary health: A review date: 2019-05-22 words: 9686.0 sentences: 431.0 pages: flesch: 42.0 cache: ./cache/cord-281760-34wuttqw.txt txt: ./txt/cord-281760-34wuttqw.txt summary: Considering the fast development of IgY technology, this work aims to review its applications in human and animal health, in addition to increasing the potential use of these antibodies among researchers and consequently promoting the reduced use of non-invasive procedures on animals. extracted IgY from hens immunized with the recombinant protein FanC, from enterotoxigenic Escherichia coli (ETEC) and these antibodies bound specifically to FanC in ELISA, Western blot and Dot-blotting [59] , demanding, thus, more investigations to evaluate its viability as a potential immunotherapeutic compound. Anti-DENV2 IgY produced in goose was able to neutralize the virus in vitro and in vivo without binding to Fcγ receptors on myeloid cells and generating ADE (antibody dependent enhancement) in mice [57] . Hen egg yolk antibodies (IgY), production and use for passive immunization against bacterial enteric infections in chicken: a review Preventive effect of anti-VacA egg yolk immunoglobulin (IgY) on Helicobacter pylori-infected mice abstract: Egg yolk constitutes a relevant alternative source of antibodies. It presents some advantages over mammalian serum immunoglobulins regarding productivity, animal welfare and specificity. The main immunoglobulin present in avian blood (IgY) is transmitted to their offspring and accumulates in egg yolks, which enables the non-invasive harvesting of high amounts of antibodies. Moreover, due to structural differences and phylogenetic distance, IgY is more suitable for diagnostic purposes than mammalian antibodies, since it does not react with certain components of the human immune system and displays greater avidity for mammalian conserved proteins. IgY has been extensively used in health researches, as both therapeutic and diagnostic tool. This article aims to review its applications in both human and veterinary health. url: https://api.elsevier.com/content/article/pii/S1567576919302206 doi: 10.1016/j.intimp.2019.05.015 id: cord-302312-1pm17l5d author: Quinteros, Daniela A. title: Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery date: 2017-03-31 words: 10875.0 sentences: 493.0 pages: flesch: 33.0 cache: ./cache/cord-302312-1pm17l5d.txt txt: ./txt/cord-302312-1pm17l5d.txt summary: In therapy, the development of targeted drug delivery represents, together with tissue repair, the main applications of antibody-conjugated nanoparticles. In addition to their own properties as pathogens or toxin neutralizers, as well as in the recruitment of immune elements (complement, improving phagocytosis, cytotoxicity antibody dependent by natural killer cells, etc.), they could carry several elements (toxins, drugs, fluorochroms, or even nanoparticles, etc.) and be used in several diagnostic procedures, or even in therapy to destroy a specific target. To treat HER2 positive breast cancer, anti-HER2 humanized Mabs are commonly used, although advances can be made in targeted cellular localization via conjugation strategy through a nano-particulate system focusing on surface modified ligand/receptor-mediated nano-therapy to target the tumor cell at the molecular level. Bio-conjugation strategies of therapeutic agents loaded nanoparticles with Mabs have exhibited a targeted drug delivery approach both in vitro and in vivo. abstract: Monoclonal antibodies are routinely used in several fields but the great challenge has been their use as therapeutic agents for the treatment of diseases, such as breast cancer, leukemia, asthma, macular degeneration, arthritis, Crohn’s disease, and transplants, among others. Monoclonal antibodies are protein molecules made in the laboratory from hybridoma cells by recombinant DNA technology. Important advances have been made over the past decade to improve some critical points, such as safety and efficacy of the first generation of therapeutic antibodies. This type of molecules presents a significant challenge from the pharmaceutical point of view due to their characteristics, such as molecular size, stability, and solubility. In this chapter we have attempted to identify the major issues associated with therapeutic approaches, formulating drawbacks and delivering antibody drugs, particularly focused on the challenges and opportunities that these present for the future. url: https://api.elsevier.com/content/article/pii/B9780323461436000257 doi: 10.1016/b978-0-323-46143-6.00025-7 id: cord-010991-fp8hljbq author: Rather, Shabeer Ahmad title: Antibodies generated against dextransucrase exhibit potential anticariostatic properties in Streptococcus mutans date: 2020-01-03 words: 6593.0 sentences: 363.0 pages: flesch: 48.0 cache: ./cache/cord-010991-fp8hljbq.txt txt: ./txt/cord-010991-fp8hljbq.txt summary: For vaccine development, attention was paid on the purified antigens involved in the pathogenesis of dental caries for the development of potentially safer vaccines, which may reduce the viability of bacteria in the saliva, impairing the surface adhesion and inhibiting the metabolically active enzymes involved in caries formation (Chen and Wang 2010) . mutans have shown encouraging results related to dental caries protection, but were limited by the cross-reactive epitopes against human heart and skeleton muscle tissues as detected by indirect immunofluorescence and crossed immunoelectrophoresis (Kt et al. In the present study, we have tried to evaluate the effect of anti-dextransucrase antibodies on caries formation by using purified dextransucrase as the antigen from S. Protein samples of the liver, heart, spleen, kidney of mice, rat and liver, kidney of rabbit were analysed by western blot analysis to evaluate the cross reactivity of purified antibody with mammalian tissues Fig. 5a . abstract: Streptococcus mutans is a common principal causative agent of dental caries. In this communication, we describe that the antibodies raised against purified dextransucrase effectively inhibited the growth of S. mutans. The purified enzyme showed 58-fold enrichment, 17.5% yield and a specific activity of 3.96 units/mg protein. Purified IgG fraction of the antibody showed significant affinity with the antigenic protein. Immunotritation of the enzyme with dextransucrase antibody showed a gradual increase in inhibition of dextransucrase activity. The growth of S. mutans was also inhibited by 85% in the presence of 28 μg of IgG fraction of the antibody. Antibodies also impaired glucosyltransferase activity (72.8%) and biofilm formation by 92.6% in S. mutans. Western blot analysis revealed no cross reactivity with the various tissues of mice, rat, rabbit and humans. Dot blot analysis showed little reactivity with Lactobacillus acidophilus and Staphylococcus aureus and there was no reactivity with other bacterial strains like Enterococcus faecalis, Escherichia coli and Salmonella typhimurium. These findings suggest that antibody raised against dextransucrase exhibit inhibitory effects on the growth of S. mutans and biofilm formation with no reactivity with various mammalian tissues, thus it could be an effective anticariogenic agent. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223241/ doi: 10.1007/s00253-019-10327-x id: cord-021402-wq770ik9 author: Relford, Roberta L. title: New Diagnostic Tools for Infectious Disease date: 2009-05-15 words: 3166.0 sentences: 157.0 pages: flesch: 36.0 cache: ./cache/cord-021402-wq770ik9.txt txt: ./txt/cord-021402-wq770ik9.txt summary: The most common laboratory methodologies used to identify an infectious agent include visualization of the organism via cytology/biopsy, isolation of the agent in microbiological culture, immunodiagnostics/serology, and nucleic acid technology. Fluorescent antibody and immunoblot assays are performed in commercial laboratories, whereas numerous patient-side rapid ELISA and latex agglutination kits are available for antigen detection. Until the introduction of nucleic acid amplification by the PCR, detection of an organism''s DNA or RNA often was impossible because of the small amount of antigen present in a sample. In the ELISA and IFA antibody assays, a specific antigen from the infectious agent in question is fixed to a solid surface (microtiter plate or glass slide, respectively) and the patient''s serum is added. The SVN assay evaluates the ability of antibodies in a patient''s serum to prevent the infection of culture cells or embryonated eggs with a known specific virus. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149580/ doi: 10.1016/b0-72-160423-4/50009-3 id: cord-267601-3ahmyicn author: Renegar, Kathryn B. title: Passive Immunization: Systemic and Mucosal date: 2007-05-09 words: 8078.0 sentences: 405.0 pages: flesch: 43.0 cache: ./cache/cord-267601-3ahmyicn.txt txt: ./txt/cord-267601-3ahmyicn.txt summary: Both rats and mice can actively transport IgG from the gut into the serum for approximately 2 weeks (see Combined Prenatal and Postnatal Transfer earlier in this chapter); thus, observed protection could be due either to antibody in the milk bathing the mucosal surfaces or to maternal antibody being transported into the serum and secretions of the offspring. Only a limited number of studies on the transport of antibodies into respiratory secretions have been reported, but the results have shown that selective transport of passively administered serum IgA into the respiratory tract is possible in sheep and mice. (1994) determined that passively administered monoclonal pIgA isotype-switch variants, generated from IgG hybridomas producing antibodies specific for bacterial respiratory tract pathogens, were selectively transported relative to IgG into both the upper and lower respiratory tract secretions of mice. To determine whether intravenously administered pIgA antiinfluenza monoclonal antibody could mediate protection against local influenza virus challenge, passively immunized mice were challenged intranasally while awake with influenza virus. abstract: nan url: https://www.sciencedirect.com/science/article/pii/B9780124915435500504 doi: 10.1016/b978-012491543-5/50050-4 id: cord-103432-cdmoazrl author: Richardson, Eve title: A computational method for immune repertoire mining that identifies novel binders from different clonotypes, demonstrated by identifying anti-Pertussis toxoid antibodies date: 2020-06-02 words: 6556.0 sentences: 375.0 pages: flesch: 51.0 cache: ./cache/cord-103432-cdmoazrl.txt txt: ./txt/cord-103432-cdmoazrl.txt summary: To test the ability of paratyping and clonotyping to group antibodies that target the same epitope we performed a test in a single-cell (paired VH/VL) data set of 1290 antibodies isolated from genetically engineered mice that have a full set of human immunoglobulin variable region genes [31] immunised with Pertussis toxoid (PTx). Each of the PTx-binders is referred to as a "probe" antibody; sequences that are within the same paratype or clonotype as the probe are predicted to bind PTx. The precision and recall of the two methods (calculated over the aggregate of predictions) for repertoire mining are comparable ( Figure 2 , Table 1 ). In a test system of transgenic mice immunised with Pertussis toxoid (PTx), we show for the first time that prediction and comparison of paratopes can be used to group antigen-specific antibodies in both an enriched, single-cell data set and non-enriched bulk heavy chain repertoires. abstract: Due to their shared genetic history, antibodies from the same clonotype often bind to the same epitope. This knowledge is used in immune repertoire mining, where known binders are used to search bulk sequencing repertoires to identify new binders. However current computational methods cannot identify epitope convergence between antibodies from different clonotypes, limiting the sequence diversity of antigen-specific antibodies which can be identified. We describe how the antibody binding site, the paratope, can be used to cluster antibodies with common antigen reactivity from different clonotypes. Our method, paratyping, uses the predicted paratope to identify these novel cross clonotype matches. We experimentally validated our predictions on a Pertussis toxoid dataset. Our results show that even the simplest abstraction of the antibody binding site, using only the length of the loops involved and predicted binding residues, is sufficient to group antigen-specific antibodies and provide additional information to conventional clonotype analysis. url: https://doi.org/10.1101/2020.06.02.121129 doi: 10.1101/2020.06.02.121129 id: cord-321901-zpi7uis1 author: Roberts, Anjeanette title: Animal models and antibody assays for evaluating candidate SARS vaccines: Summary of a technical meeting 25–26 August 2005, London, UK date: 2006-11-30 words: 6600.0 sentences: 311.0 pages: flesch: 40.0 cache: ./cache/cord-321901-zpi7uis1.txt txt: ./txt/cord-321901-zpi7uis1.txt summary: Scientists at the WHO Technical Meeting on Animal Models and Antibody Assays for Evaluating Candidate SARS Vaccines held on 25-26 August 2005 in South Mimms, UK, discussed many aspects of research pertaining to the use of animal models in vaccine development including available animal models, suitability of the various models, correlates of protection, critical components of potential vaccines, and the potential for disease enhancement in vaccinated animals following exposure to SARS-CoV. It may actually be worthwhile to enhance the virulence of a SARS-CoV isolate by serial passages in an animal model to produce a challenge virus stock for vaccine studies that would elicit more reproducible disease in the animals. Although none of the studies to date have shown enhanced respiratory disease following SARS-CoV challenge in previously immunized animals, further studies in this area are warranted in view of some of the available in vitro data. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice abstract: Abstract Severe acute respiratory syndrome (SARS) emerged in the Guangdong province of China in late 2002 and spread to 29 countries. By the end of the outbreak in July 2003, the CDC and WHO reported 8437 cases with a 9.6% case fatality rate. The disease was caused by a previously unrecognized coronavirus, SARS-CoV. Drawing on experience with animal coronavirus vaccines, several vaccine candidates have been developed and evaluated in pre-clinical trials. Available data suggest that vaccines should be based on the the 180kDa viral spike protein, S, the only significant neutralization antigen capable of inducing protective immune responses in animals. In the absence of clinical cases of SARS, candidate vaccines should be evaluated for efficacy in animal models, and although it is uncertain whether the United States Food and Drug Administration's “animal rule” would apply to licensure of a SARS vaccine, it is important to develop standardized animal models and immunological assays in preparation for this eventuality. This report summarizes the recommendations from a WHO Technical Meeting on Animal Models and Antibody Assays for Evaluating Candidate SARS Vaccines held on 25–26 August 2005 in South Mimms, UK, provides guidance on the use of animal models, and outlines the steps to develop standard reagents and assays for immunological evaluation of candidate SARS vaccines. url: https://www.sciencedirect.com/science/article/pii/S0264410X06008231 doi: 10.1016/j.vaccine.2006.07.009 id: cord-304214-66nxk4e8 author: Sanders, John W. title: Vectored immunoprophylaxis: an emerging adjunct to traditional vaccination date: 2017-02-10 words: 3742.0 sentences: 173.0 pages: flesch: 36.0 cache: ./cache/cord-304214-66nxk4e8.txt txt: ./txt/cord-304214-66nxk4e8.txt summary: Rather than passively transfering pre-formed antibodies, VIP is a process in which genes encoding previously characterized neutralizing antibodies are vectored into non-hematopoietic cells which then secrete the monoclonal antibodes encoded by those genes [1] (See Fig. 1 .) This vectored delivery and production of specified antibodies allows for protection without generating a standard immune response and results in endogenous antibody production that has the potential to be sustained [9] . Saunders, et al., used an rAAV serotype 8 vector to produce a full length IgG of a simianized form of the broadly neutralizing antibody VRC07 in macaques which was protective against simian-human immunodeficiency virus (SHIV) infection 5.5 weeks after treatment [24] . Using HIV-1-infected humanized mice, Horwitz, et al., demonstrated that following initial treatment with anti-retroviral therapy (ART), a single injection of adeno-associated virus directing expression of broadly neutralizing antibody 10-1074, produced durable viremic control after the ART was stopped [26] . abstract: The successful development of effective vaccines has been elusive for many of the world’s most important infectious diseases. Additionally, much of the population, such as the aged or immunocompromised, are unable to mount an effective immunologic response for existing vaccines. Vectored Immunoprophylaxis (VIP) is a novel approach designed to address these challenges. Rather than utilizing an antigen to trigger a response from the host’s immune system as is normally done with traditional vaccines, VIP genetically engineers the production of tailored antibodies from non-hematopoietic cells, bypassing the humoral immune system. Direct administration of genes encoding for neutralizing antibodies has proven to be effective in both preventing and treating several infectious diseases in animal models. While, a significant amount of work has focused on HIV, including an ongoing clinical trial, the approach has also been shown to be effective for malaria, dengue, hepatitis C, influenza, and more. In addition to presenting itself as a potentially efficient approach to solving long-standing vaccine challenges, the approach may be the best, if not only, method to vaccinate immunocompromised individuals. Many issues still need to be addressed, including which tissue(s) makes the most suitable platform, which vector(s) are most efficient at transducing the platform tissue used to secrete the antibodies, and what are the long-term effects of such a treatment. Here we provide a brief overview of this approach, and its potential application in treating some of the world’s most intractable infectious diseases. url: https://www.ncbi.nlm.nih.gov/pubmed/28883973/ doi: 10.1186/s40794-017-0046-0 id: cord-319746-6bccxgbd author: Saxena, Latika title: Production and Characterization of Human Monoclonal Antibodies from the Cells of A(H1N1)pdm2009 Influenza Virus Infected Indian Donors date: 2015-12-31 words: 3526.0 sentences: 174.0 pages: flesch: 48.0 cache: ./cache/cord-319746-6bccxgbd.txt txt: ./txt/cord-319746-6bccxgbd.txt summary: title: Production and Characterization of Human Monoclonal Antibodies from the Cells of A(H1N1)pdm2009 Influenza Virus Infected Indian Donors Abstract Analysis of human monoclonal antibodies (mAbs) developed from influenza infected donors have enormously contributed to the identification of neutralization sensitive epitopes of influenza virus. In this study, we generated strongly neutralizing novel human monoclonal antibodies that were selected from the immune repertoire of influenza infected seropositive patients. Monoclonal antibody 2D8 showed the maximum binding in the in vitro assays and neutralized the human isolate of the pandemic strain as well as the reference strain at lowest concentrations when compared to the 2F12 antibody. The antibodies however, showed comparative neutralization and HAI activity between the laboratory isolates of the pandemic virus and the reference strain A/Cal/07/2009(H1N1). To, the best of our knowledge, these antibodies are the first fully human monoclonal antibodies generated from the immune repertoire of Indian patients infected with A(H1N1)pdm09 virus. abstract: Abstract Analysis of human monoclonal antibodies (mAbs) developed from influenza infected donors have enormously contributed to the identification of neutralization sensitive epitopes of influenza virus. The HA protein is a crucial target of neutralizing antibodies and at monoclonal level only Abs binding to HA have been able to neutralize the virus. In this study, eight A (H1N1)pdm 2009 seropositive patients within the age range of 20-50 years (median=36 years) were recruited. Two anti-HA mAbs secreting stable clones, 2D8 and 2F12 were established under optimized conditions from the peripheral blood mononuclear cells (PBMCs) of the volunteers. These antibodies efficiently neutralized the homologous laboratory isolated strain of the pandemic virus as well as the reference strain. Our study suggests that the anti-HA antibodies derived from infected Indian patients display neutralization potential against the A(H1N1)pdm 2009 virus. This is the first ever study of generation of mAbs against the pandemic influenza virus involving the immune repertoire if Indian patients. Molecular characterization of the target regions will help in identifying potential immunogens in the Indian pandemic isolates and confer protective immunity against this virus. url: https://api.elsevier.com/content/article/pii/S1877282X15000107 doi: 10.1016/j.provac.2015.05.009 id: cord-003435-ke0az7nf author: Schlake, Thomas title: mRNA as novel technology for passive immunotherapy date: 2018-10-17 words: 15190.0 sentences: 850.0 pages: flesch: 40.0 cache: ./cache/cord-003435-ke0az7nf.txt txt: ./txt/cord-003435-ke0az7nf.txt summary: Recombinant technologies further expanded the available therapies based on mAbs. In vitro antibody selection technologies like phage or ribosome display were developed to enable the generation of highly specific human mAbs out of libraries that may even be naïve for the specific antigens [31] [32] [33] [34] [35] [36] 1 Schematic illustration comparing active immunization and passive antibody immunotherapies. While T cell engineering for adoptive transfer inevitably requires the use of nucleic acids encoding a target-specific receptor, antibody immunotherapy can deploy recombinant proteins. However, the effects of mRNA modifications on translation, immunostimulation and resulting protein expression appear to be variable, for instance dependent on the type of target cells. In comparison to a single transfer of cells with retroviral CAR expression, an mRNA-encoded receptor required three consecutive lymphocyte infusions to obtain a comparable antitumor effect [262] . abstract: While active immunization elicits a lasting immune response by the body, passive immunotherapy transiently equips the body with exogenously generated immunological effectors in the form of either target-specific antibodies or lymphocytes functionalized with target-specific receptors. In either case, administration or expression of recombinant proteins plays a fundamental role. mRNA prepared by in vitro transcription (IVT) is increasingly appreciated as a drug substance for delivery of recombinant proteins. With its biological role as transient carrier of genetic information translated into protein in the cytoplasm, therapeutic application of mRNA combines several advantages. For example, compared to transfected DNA, mRNA harbors inherent safety features. It is not associated with the risk of inducing genomic changes and potential adverse effects are only temporary due to its transient nature. Compared to the administration of recombinant proteins produced in bioreactors, mRNA allows supplying proteins that are difficult to manufacture and offers extended pharmacokinetics for short-lived proteins. Based on great progress in understanding and manipulating mRNA properties, efficacy data in various models have now demonstrated that IVT mRNA constitutes a potent and flexible platform technology. Starting with an introduction into passive immunotherapy, this review summarizes the current status of IVT mRNA technology and its application to such immunological interventions. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339677/ doi: 10.1007/s00018-018-2935-4 id: cord-005827-wjkbrfkn author: Schmidt, Rüdiger title: Antiphospholipidantikörpersyndrom date: 1999 words: 3372.0 sentences: 429.0 pages: flesch: 28.0 cache: ./cache/cord-005827-wjkbrfkn.txt txt: ./txt/cord-005827-wjkbrfkn.txt summary: Other clinical manifestations associated with APA include migraine, chorea, hemolytic anemia, heart valve disease, Budd-Chiari syndrome, perpetual pancreatitic episodes, intestinal infarctions, malignant hypertension, livedo reticularis, pre-eclampsia, fetal growth retardation or catastrophic antiphospholipid syndrome. 1Kfidiger Schmidt I , Ernst-Heinrich Scheuermann ~ , Achim Viertel 1, Helmut Geiger 1 , lnge Scharrer 2 Budd-Chiari-Syndrom, rezidivierende Pankreaufiden, intestinale Apoplexie, maligne Hypertonie;Livedo reticularis, Pr~ieklampsie, fetate WachstumsverzSgenmgen oder das sogenannte,,katastrophale Antiphospholipidantik6rpersy ndrom,_ Ira Gegensatzzum ,prim~en Antiphospholipidantik6rpersyndrom''" rinden sich Lupusantikoagulanziea und An¡250 beim ,,se-kund~iren Antiphospholipidantik/Srpersyndrom" im t(ahmen ron Autoimmun-erkrankutlget1, von.Neoplasfen und Infektionen oder sind mit dem Gebrauch bestimmter Medikamente assoziiert. Other clinical manifestations associated with APA include migraine, ch0rea, hemolytic anemia, heart Valve disease, Budd-Chiari syndrome, perpemal pancreatitic episodes, intestinal infarcfions, malignant hypertension, livedo reticularis, pre-eclampsia, fetal growth retardation or catastrophic anfiphos[10] ; dieses zeigt zudem eine fa-mili~ire H~iufung [48] sowie eine Assoziation mit HLA DR.7, DR4, DQw7 und DR.w53 [75] . el al Antiphospholipid antibodies and the anti-phospholipid syndrome in systemic lupus erythematosus abstract: □ BACKGROUND: Antiphospholipid antibodies comprise a family of auto-antibodies mainly characterized by the presence of the lupus anticoagulant (LA) and anticardiolipin antibodies (ACA). □ CLINICAL APPEARANCE: The antiphospholipid antibody syndrome is defined by the appearance of frequent thromboses, repeated fetal losses and thrombocytopenia. Other clinical manifestations associated with APA include migraine, chorea, hemolytic anemia, heart valve disease, Budd-Chiari syndrome, perpetual pancreatitic episodes, intestinal infarctions, malignant hypertension, livedo reticularis, pre-eclampsia, fetal growth retardation or catastrophic antiphospholipid syndrome. LA and ACA occur in a variety of clinical conditions (secondary antiphospholipid antibody syndrome, SAPS), including other autoimmune disorders, infectious diseases, neoplastic disorders, in association with the use of certain drugs or in otherwise healthy individuals (primary antiphospholipid antibody syndrome, PAPS). □ TREATMENT: Patients with thrombosis associated with APA should receive long-term anticoagulation therapy, whereas treatment of asymptomatic patients seems to be not indicated, because only approximately 10% of patients with APA may develop thrombotic complications. In patients with PAPS there is no evidence that the prophylactic administration of immunosuppressive drugs will prevent thromboembolic events. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095803/ doi: 10.1007/bf03044707 id: cord-311811-nrodyagi author: Schutzer, Steven E. title: The use of host factors in microbial forensics date: 2019-12-06 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Advances have been made in the forensic analysis of microbes and toxins. An underdeveloped and underutilized area in microbial forensics is how the host interacts with microorganisms in a way that provides unique signatures for forensic use. For forensic purposes, an immediate goal is to distinguish a potential victim and innocent person from a perpetrator, and to distinguish between a naturally acquired or intentional infection. Principal methods that are sufficiently developed are characterization of the humoral immune response to microbial antigens including vaccine-induced immunity and detection of antibiotics that may be present in a possible perpetrator. This chapter presents central elements of the host response in a simplified fashion and describes a representative example, which, in the appropriate context, has a high potential of providing evidence that may aid an investigation to distinguish a perpetrator from a victim. This chapter also presents information about the immune system so that the interested reader can have a fuller understanding of the immune response in general. url: https://www.sciencedirect.com/science/article/pii/B9780128153796000143 doi: 10.1016/b978-0-12-815379-6.00014-3 id: cord-001074-qevosik3 author: Selvarajah, Suganya title: A Neutralizing Monoclonal Antibody Targeting the Acid-Sensitive Region in Chikungunya Virus E2 Protects from Disease date: 2013-09-12 words: 7613.0 sentences: 359.0 pages: flesch: 50.0 cache: ./cache/cord-001074-qevosik3.txt txt: ./txt/cord-001074-qevosik3.txt summary: C9 was determined to be a potent virus neutralizing antibody and a biosensor antibody binding study demonstrated it recognized residues on intact CHIKV VLPs. Shotgun mutagenesis alanine scanning of 98 percent of the residues in the E1 and E2 glycoproteins of CHIKV envelope showed that the epitope bound by C9 included amino-acid 162 in the acid-sensitive region (ASR) of the CHIKV E2 glycoprotein. The neutralizing epitope bound by C9 mapped to the acid-sensitive region (ASR) that is critical for the rearrangement of CHIKV E2 during fusion and viral entry into host cells. Therefore, C9 is a potent neutralizing antibody that can therapeutically protect wild-type neonate mice from a lethal dose of virus at 8 and 18 hours post CHIKV inoculation. This study describes the isolation and characterization of two human monoclonal antibodies, C9 and E8, from CHIKV infected and recovered individuals. abstract: The mosquito-borne alphavirus, chikungunya virus (CHIKV), has recently reemerged, producing the largest epidemic ever recorded for this virus, with up to 6.5 million cases of acute and chronic rheumatic disease. There are currently no licensed vaccines for CHIKV and current anti-inflammatory drug treatment is often inadequate. Here we describe the isolation and characterization of two human monoclonal antibodies, C9 and E8, from CHIKV infected and recovered individuals. C9 was determined to be a potent virus neutralizing antibody and a biosensor antibody binding study demonstrated it recognized residues on intact CHIKV VLPs. Shotgun mutagenesis alanine scanning of 98 percent of the residues in the E1 and E2 glycoproteins of CHIKV envelope showed that the epitope bound by C9 included amino-acid 162 in the acid-sensitive region (ASR) of the CHIKV E2 glycoprotein. The ASR is critical for the rearrangement of CHIKV E2 during fusion and viral entry into host cells, and we predict that C9 prevents these events from occurring. When used prophylactically in a CHIKV mouse model, C9 completely protected against CHIKV viremia and arthritis. We also observed that when administered therapeutically at 8 or 18 hours post-CHIKV challenge, C9 gave 100% protection in a pathogenic mouse model. Given that targeting this novel neutralizing epitope in E2 can potently protect both in vitro and in vivo, it is likely to be an important region both for future antibody and vaccine-based interventions against CHIKV. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772074/ doi: 10.1371/journal.pntd.0002423 id: cord-010248-ln800g5z author: Sissons, J.G. Patrick title: Antibody-Mediated Destruction of Virus-Infected Cells date: 2008-02-29 words: 14994.0 sentences: 687.0 pages: flesch: 44.0 cache: ./cache/cord-010248-ln800g5z.txt txt: ./txt/cord-010248-ln800g5z.txt summary: When lz5I-1abeled IgG antibody was bound to the surface of measles virus-infected cells at the start of the culture period, under the conditions described above for antigenic modulation, about 40% of the radioactivity was still cell associated at 12 hours and nearly all was protein bound Perrin and Oldstone, 1977) . Lysis by human serum of cells infected with HSV types 1 and 2, influenza A, parainfluenza 1, 2, 3, and 4, mumps, and measles viruses was dependent on the presence in serum of IgG antibody specific for the relevant virus and of complement (reviewed by Oldstone and Lampert, 1979) . The use of this system, composed of 11 highly purified complement proteins, provided conclusive evidence that the known proteins of the alternative and membrane attack pathways with IgG antibody are sufficient for lysis of the measles virus-infected cell, without other serum factors. It is apparent that considerably more surface-bound IgG is required to induce complement-dependent lysis of virus-infected cells than is required for antigenic modulation or antibody-dependent cell-mediated cytotoxicity. abstract: This chapter describes the effect of antibody on virus-infected cells with special reference to the human system. The destruction by antibody of the infected cells through the mediation of complement is described in detail based in considerable part on the contributions of the authors. Activation of the alternative pathway by the various infected cells is of special interest. The interesting effect of the antibody-dependent cell-mediated cytotoxicity (ADCC) system involving viral antigens in cell killing is also presented. Multiple additional topics are also covered, such as the effect of antibody on the expression of viral proteins both on the surface of the cell and intracellularly. Serum antibody, produced in response to virus infections, is of major importance in preventing the spread of infection by virtue of neutralizing free virus in extracellular fluids. Virus neutralization by antibody is enhanced by complement. Antibody binding to the surface of virus-infected cells can affect virus production and release in the absence of an effector system. Immunoglobulin (IgG) antibody can mediate the destruction of virus-infected cells in conjunction with complement or cytotoxic lymphocytes. In addition, at a conceptual level there is evidence to suggest that antibody may enhance and confer specificity on basic nonspecific humoral and cell-mediated defense mechanisms. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173112/ doi: 10.1016/s0065-2776(08)60045-0 id: cord-021770-zn7na974 author: Slifka, Mark K. title: Passive Immunization date: 2017-07-17 words: 12134.0 sentences: 610.0 pages: flesch: 31.0 cache: ./cache/cord-021770-zn7na974.txt txt: ./txt/cord-021770-zn7na974.txt summary: [26] [27] [28] [29] Recent studies verify these earlier results, demonstrating a 90% to 91% vaccine efficacy against whooping cough among infants younger than 2 months of nonlymphoid tissues and to penetrate mucosal sites of infection is likely to explain why it is often considered the best immunoglobulin isotype for routine passive immunization and has shown clinical benefit ranging from reduced clinical symptoms to nearly complete protection from lethal infection in a number of infectious disease models (Table 8 .3). 118 With the recent development of polyclonal and monoclonal antibodies that show protective efficacy against tularemia in animal models, [119] [120] [121] it may be possible to incorporate both passive immunotherapy and antibiotic treatment into clinical practice not only for tularemia, but for other bacterial diseases, especially in cases in which antibiotic resistance is becoming more widespread. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151993/ doi: 10.1016/b978-0-323-35761-6.00008-0 id: cord-274557-2071770h author: Späth, Peter J. title: On the Dark Side of Therapies with Immunoglobulin Concentrates: The Adverse Events date: 2015-02-05 words: 10243.0 sentences: 530.0 pages: flesch: 40.0 cache: ./cache/cord-274557-2071770h.txt txt: ./txt/cord-274557-2071770h.txt summary: i.e., cold-ethanol or ion-exchange chromatography, contaminants, route of application, i.e., intra muscular (IMIG), intravenous (IVIG), or subcutaneous (SCIG), the rate of increase of the exogenous IgG in the circulation of the recipient over time and, last but not least an eventually existing risk factor from patients'' side ( Figure 1 ) as well as incorrect handling of the concentrate are factors having a role in inducing non-infectious AEs related to administration of IgG concentrates ( Table 1) . The complement-mediated AEs were considered to be caused by aggregates in the product ("spontaneous complement activation" or anti-complementary activity or ACA) or by in vivo formation of immune complexes (ICs, patient''s condition related; e.g., subclinical infections or the unnoticed presence of anti-IgA antibodies) and therefore only IgG concentrates with low or absent ACA is accepted by authorities for human use. abstract: Therapy by human immunoglobulin G (IgG) concentrates is a success story ongoing for decades with an ever increasing demand for this plasma product. The success of IgG concentrates on a clinical level is documented by the slowly increasing number of registered indication and the more rapid increase of the off-label uses, a topic dealt with in another contribution to this special issue of Frontiers in Immunology. A part of the success is the adverse event (AE) profile of IgG concentrates which is, even at life-long need for therapy, excellent. Transmission of pathogens in the last decade could be entirely controlled through the antecedent introduction by authorities of a regulatory network and installing quality standards by the plasma fractionation industry. The cornerstone of the regulatory network is current good manufacturing practice. Non-infectious AEs occur rarely and mainly are mild to moderate. However, in recent times, the increase in frequency of hemolytic and thrombotic AEs raised worrying questions on the possible background for these AEs. Below, we review elements of non-infectious AEs, and particularly focus on hemolysis and thrombosis. We discuss how the introduction of plasma fractionation by ion-exchange chromatography and polishing by immunoaffinity chromatographic steps might alter repertoire of specificities and influence AE profiles and efficacy of IgG concentrates. url: https://www.ncbi.nlm.nih.gov/pubmed/25699039/ doi: 10.3389/fimmu.2015.00011 id: cord-349669-o3eelqcw author: Stadlbauer, Daniel title: Anti‐SARS‐CoV‐2 Spike Antibodies are Stable in Convalescent Plasma when Stored at 4° Celsius for at Least 6 Weeks date: 2020-08-14 words: 895.0 sentences: 49.0 pages: flesch: 54.0 cache: ./cache/cord-349669-o3eelqcw.txt txt: ./txt/cord-349669-o3eelqcw.txt summary: Convalescent plasma (CP) has presented another option, with its use and safety supported by numerous case series and retrospective studies [2] [3] [4] . Studies demonstrating antibody stability under refrigerated conditions have largely focused on peripheral blood samples stored for several days 7, 8 . Here, we demonstrate the long-term stability of anti-SARS-CoV-2 spike antibodies in donor CP samples collected at a local blood donor center for transfusion. After thawing of fifteen CP units, segments were sampled and anti-spike antibody titers were determined via enzyme-linked immunosorbent assays (ELISAs) 9 . While our study does not address the neutralization capacity of these antibodies, previous studies demonstrate significant correlation between spike antibody titers and neutralization capacity of plasma and serum samples 9 . Treatment of COVID-19 Patients with Convalescent Plasma Early safety indicators of COVID-19 convalescent plasma in 5,000 patients Convalescent plasma treatment of severe COVID-19: A matched control study Long-term stability of trastuzumab in plasma and whole blood samples stored under different conditions abstract: nan url: https://doi.org/10.1111/trf.16047 doi: 10.1111/trf.16047 id: cord-283826-lgyc3sro author: Stiehm, E. Richard title: Therapeutic Use of Immunoglobulins date: 2010-11-05 words: 9752.0 sentences: 562.0 pages: flesch: 37.0 cache: ./cache/cord-283826-lgyc3sro.txt txt: ./txt/cord-283826-lgyc3sro.txt summary: medical science and thereby placed in the hands of the physician a victorious weapon against illness and death.'' '' Since then antibodies in multiple forms (animal and human serums, immune globulins and monoclonal antibodies) have been developed, primarily for prevention of infectious diseases, and less commonly for their treatment. Thus regular use of IVIG in antibody-deficient patients in doses of 400 to 600 mg/kg every 3 to 4 weeks or an equivalent amount given subcutaneously decreases the frequency and severity of otitis and other respiratory tract infections [27, 28] . High-dose IVIG (sufficient to increase the serum IgG levels to 1000 mg/mL) has been used successfully in immunodeficient patients with enteroviral encephalomyelitis [80] [81] [82] [83] . Because IgG represents the major defense of humoral immunity against infection, these patients also require immunoglobulin replacement therapy. Individualizing the dose of intravenous immune serum globulin for therapy of patients with primary humoral immunodeficiency abstract: nan url: https://www.sciencedirect.com/science/article/pii/S006531011000006X doi: 10.1016/j.yapd.2010.08.005 id: cord-352172-g0jiaenw author: Stoevesandt, Oda title: Protein microarrays: high-throughput tools for proteomics date: 2014-01-09 words: 7464.0 sentences: 373.0 pages: flesch: 32.0 cache: ./cache/cord-352172-g0jiaenw.txt txt: ./txt/cord-352172-g0jiaenw.txt summary: While conventionally made by the spotting of purified proteins, recent advances in technology have made it possible to produce protein microarrays through in situ cell-free synthesis directly from corresponding DNA arrays. Protein microarray technology has rapidly developed into one of the most active areas in biotechnology today, and is being increasingly applied for the high-throughput discovery of molecular interactions, profiling of protein expression and monitoring of protein modifications. While genome sequencing and annotations provide comprehensive information on protein-encoding genes, and DNA arrays analyze gene expression at the mRNA level, these technologies need to be complemented by functional proteomic studies in order to better understand protein activities, expression levels and interactions at the system level. A reverse-phase micro array approach has been successfully applied to discover distinct pathway-activation differences among breast cancer cell lines, demonstrating the use of array-based ana lysis for multiple pharmacodynamic biomarkers responding to targeted kinase inhibitors [108] . abstract: Protein microarrays are versatile tools for parallel, miniaturized screening of binding events involving large numbers of immobilized proteins in a time- and cost-effective manner. They are increasingly applied for high-throughput protein analyses in many research areas, such as protein interactions, expression profiling and target discovery. While conventionally made by the spotting of purified proteins, recent advances in technology have made it possible to produce protein microarrays through in situ cell-free synthesis directly from corresponding DNA arrays. This article reviews recent developments in the generation of protein microarrays and their applications in proteomics and diagnostics. url: https://www.ncbi.nlm.nih.gov/pubmed/19385942/ doi: 10.1586/epr.09.2 id: cord-002846-la9svzml author: Strohl, William R. title: Current progress in innovative engineered antibodies date: 2017-08-18 words: 13114.0 sentences: 605.0 pages: flesch: 43.0 cache: ./cache/cord-002846-la9svzml.txt txt: ./txt/cord-002846-la9svzml.txt summary: The second most targeted protein is CD3E, found in 32 clinical stage or approved molecules, of which 26 are T cell-redirecting bispecific antibody candidates (Table 6) . For example, 10 of them bind two soluble antigens such as IL13 and IL4 (e.g., SAR156597; NCT02345070), nine bind two receptors on the , IgG-scFv fusion, Mabtyrin (IgG with non-antibody binding scaffold "centyrin" fused to C-terminal end of heavy chains); (C) IgGs to which additional antigen combining sites have been added within the structure (e.g., two-in-one antibodies, MAT "Modular Antibody Technology" platform from F-Star); (D) Engineered antibody fragments linked by short peptide linkers which can be made into bivalent, trivalent, or tetravalent formats addressing two to three targets (e.g., bispecific T-cell engager (BiTE), Nanobody platform, dual-affinity re-targeting (DART) antibodies, "tandem antibody" structures (TandAbs)); (E) Chemically coupled IgGs. Brennan et al., 1985; Garrido et al., 1990 Innovative antibodies Mack et al., 1995; Schlereth et al., 2005; Baeuerle et al., 2008 TandAb Antibody fragmentWilliam R. abstract: As of May 1, 2017, 74 antibody-based molecules have been approved by a regulatory authority in a major market. Additionally, there are 70 and 575 antibody-based molecules in phase III and phase I/II clinical trials, respectively. These total 719 antibody-based clinical stage molecules include 493 naked IgGs, 87 antibody-drug conjugates, 61 bispecific antibodies, 37 total Fc fusion proteins, 17 radioimmunoglobulins, 13 antibody fragments, and 11 immunocytokines. New uses for these antibodies are being discovered each year. For oncology, many of the exciting new approaches involve antibody modulation of T-cells. There are over 80 antibodies in clinical trials targeting T cell checkpoints, 26 T-cell-redirected bispecific antibodies, and 145 chimeric antigen receptor (CAR) cell-based candidates (all currently in phase I or II clinical trials), totaling more than 250 T cell interacting clinical stage antibody-based candidates. Finally, significant progress has been made recently on routes of delivery, including delivery of proteins across the blood-brain barrier, oral delivery to the gut, delivery to the cellular cytosol, and gene- and viral-based delivery of antibodies. Thus, there are currently at least 864 antibody-based clinical stage molecules or cells, with incredible diversity in how they are constructed and what activities they impart. These are followed by a next wave of novel molecules, approaches, and new methods and routes of delivery, demonstrating that the field of antibody-based biologics is very innovative and diverse in its approaches to fulfill their promise to treat unmet medical needs. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777977/ doi: 10.1007/s13238-017-0457-8 id: cord-295099-ghc85pf5 author: Sun, Zehua title: Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies date: 2018-01-02 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: HIV/AIDS has become a worldwide pandemic. Before an effective HIV-1 vaccine eliciting broadly neutralizing monoclonal antibodies (bnmAbs) is fully developed, passive immunization for prevention and treatment of HIV-1 infection may alleviate the burden caused by the pandemic. Among HIV-1 infected individuals, about 20% of them generated cross-reactive neutralizing antibodies two to four years after infection, the details of which could provide knowledge for effective vaccine design. Recent progress in techniques for isolation of human broadly neutralizing antibodies has facilitated the study of passive immunization. The isolation and characterization of large panels of potent human broadly neutralizing antibodies has revealed new insights into the principles of antibody-mediated neutralization of HIV. In this paper, we review the current effective techniques in broadly neutralizing antibody isolation. url: https://doi.org/10.1016/j.virusres.2017.10.011 doi: 10.1016/j.virusres.2017.10.011 id: cord-292874-6zjqflhz author: SØRENSEN, MORTEN DRÆBY title: Severe Acute Respiratory Syndrome (SARS): Development of Diagnostics and Antivirals date: 2006-05-10 words: 1560.0 sentences: 110.0 pages: flesch: 54.0 cache: ./cache/cord-292874-6zjqflhz.txt txt: ./txt/cord-292874-6zjqflhz.txt summary: abstract: The previously unknown coronavirus that caused severe acute respiratory syndrome (SARS‐CoV) affected more than 8,000 persons worldwide and was responsible for more than 700 deaths during the first outbreak in 2002–2003. As part of the Sino‐European Project on SARS Diagnostics and Antivirals (SEPSDA), an immune phage‐display library is being created from convalescent patients in a phagemid system for the selection of single‐chain fragment variables (scFv) antibodies recognizing the SARS‐CoV. In February 2003, the new and previously unknown deadly coronavirus causing severe acute respiratory syndrome (SARS-CoV) was brought to the attention of the World Health Organization (WHO) by Dr. Carlo Urbani and his colleagues. Creation of immune phage-display libraries for immunized donors has shown a particular efficiency in selecting neutralizing antibodies (NABs) against different viruses, for example, rabies, 39 varicella-zoster, 40 hepatitis A 41 and E, 42 measles, 43 and respiratory syncytial virus. abstract: abstract: The previously unknown coronavirus that caused severe acute respiratory syndrome (SARS‐CoV) affected more than 8,000 persons worldwide and was responsible for more than 700 deaths during the first outbreak in 2002–2003. For reasons unknown, the SARS virus is less severe and the clinical progression a great deal milder in children younger than 12 years of age. In contrast, the mortality rate can exceed 50% for persons at or above the age of 60. As part of the Sino‐European Project on SARS Diagnostics and Antivirals (SEPSDA), an immune phage‐display library is being created from convalescent patients in a phagemid system for the selection of single‐chain fragment variables (scFv) antibodies recognizing the SARS‐CoV. url: https://www.ncbi.nlm.nih.gov/pubmed/16804033/ doi: 10.1196/annals.1354.072 id: cord-256652-ent4vu3z author: Tan, Joshua title: A public antibody lineage that potently inhibits malaria infection by dual binding to the circumsporozoite protein date: 2018-03-19 words: 6576.0 sentences: 329.0 pages: flesch: 46.0 cache: ./cache/cord-256652-ent4vu3z.txt txt: ./txt/cord-256652-ent4vu3z.txt summary: investigate this response at high resolution, we isolated IgM and IgG monoclonal antibodies from Tanzanian volunteers who were immunized by repeated injection of irradiated PfSPZ and who were found to be protected from controlled human malaria infection (CHMI) with infectious homologous PfSPZ. investigate this response at high resolution, we isolated IgM and IgG monoclonal antibodies from Tanzanian volunteers who were immunized by repeated injection of irradiated PfSPZ and who were found to be protected from controlled human malaria infection (CHMI) with infectious homologous PfSPZ. These findings, combined with data from peptide array experiments ( Supplementary Fig. 7) , identify the N-terminal junction binding site of the most potent neutralizing antibodies as including the first unit of the NANP repeat region and flanking non-repeat sequences, providing a molecular basis for the dual specificity of these antibodies. abstract: Immunization with attenuated Plasmodium falciparum sporozoites (PfSPZ) has been shown to be protective, but the features of the antibody response induced by this treatment remain unclear. To investigate this response at high resolution, we isolated IgM and IgG monoclonal antibodies from Tanzanian volunteers who were immunized by repeated injection of irradiated PfSPZ and who were found to be protected from controlled human malaria infection (CHMI) with infectious homologous PfSPZ. All IgG monoclonals isolated bound to P. falciparum circumsporozoite protein (PfCSP) and recognized distinct epitopes in the N-terminus, NANP repeat region, and C-terminus. Strikingly, the most effective antibodies, as assessed in a humanized mouse model, bound not only to the repeat region, but also to a minimal peptide at the PfCSP N-terminal junction that is not in the RTS,S vaccine. These dual-specific antibodies were isolated from different donors and used VH3-30 or VH3-33 alleles carrying tryptophan or arginine at position 52. Using structural and mutational data, we describe the elements required for germline recognition and affinity maturation. Our study provides potent neutralizing antibodies and relevant information for lineage-targeted vaccine design and immunization strategies. url: https://doi.org/10.1038/nm.4513 doi: 10.1038/nm.4513 id: cord-002710-e8im13go author: Taschuk, Ryan title: Induction of PrP(Sc)-specific systemic and mucosal immune responses in white-tailed deer with an oral vaccine for chronic wasting disease date: 2017-10-02 words: 5421.0 sentences: 299.0 pages: flesch: 41.0 cache: ./cache/cord-002710-e8im13go.txt txt: ./txt/cord-002710-e8im13go.txt summary: title: Induction of PrP(Sc)-specific systemic and mucosal immune responses in white-tailed deer with an oral vaccine for chronic wasting disease Oral immunization of white-tailed deer with hAd5:tgG-RL induced PrP(Sc)-specific systemic and mucosal antibody responses with an encouraging safety profile in terms of no adverse health effects nor prolonged vector shedding. To assess the immunogenicity of hAd5:tgG-RL white-tail deer (n D 5/group) were orally immunized and epitope-specific antibody titers in serum and feces were quantified with a peptide ELISA. These results confirm that oral delivery of a recombinant viral vector, expressing an appropriate DSE and carrier molecule, is capable of inducing both systemic and mucosal antibody responses in white-tailed deer. To determine if the antibodies induced by oral immunization retained the same PrP Sc specificity as previously characterized for the parenteral vaccine, serum from hAd5:tgG-RL vaccinated animals was assayed for PrP C reactivity by ELISA, using recombinant cervid PrP 90-231 for antibody capture. abstract: The ongoing epidemic of chronic wasting disease (CWD) within cervid populations indicates the need for novel approaches for disease management. A vaccine that either reduces susceptibility to infection or reduces shedding of prions by infected animals, or a combination of both, could be of benefit for disease control. The development of such a vaccine is challenged by the unique nature of prion diseases and the requirement for formulation and delivery in an oral format for application in wildlife settings. To address the unique nature of prions, our group targets epitopes, termed disease specific epitopes (DSEs), whose exposure for antibody binding depends on disease-associated misfolding of PrP(C) into PrP(Sc). Here, a DSE corresponding to the rigid loop (RL) region, which was immunogenic following parenteral vaccination, was translated into an oral vaccine. This vaccine consists of a replication-incompetent human adenovirus expressing a truncated rabies glycoprotein G recombinant fusion with the RL epitope (hAd5:tgG-RL). Oral immunization of white-tailed deer with hAd5:tgG-RL induced PrP(Sc)-specific systemic and mucosal antibody responses with an encouraging safety profile in terms of no adverse health effects nor prolonged vector shedding. By building upon proven strategies of formulation for wildlife vaccines, these efforts generate a particular PrP(Sc)-specific oral vaccine for CWD as well as providing a versatile platform, in terms of carrier protein and biological vector, for generation of other oral, peptide-based CWD vaccines. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5639826/ doi: 10.1080/19336896.2017.1367083 id: cord-009690-kbwz7xop author: Toubanaki, Dimitra K. title: Development of a Nanoparticle-based Lateral Flow Strip Biosensor for Visual Detection of Whole Nervous Necrosis Virus Particles date: 2020-04-16 words: 6767.0 sentences: 381.0 pages: flesch: 47.0 cache: ./cache/cord-009690-kbwz7xop.txt txt: ./txt/cord-009690-kbwz7xop.txt summary: title: Development of a Nanoparticle-based Lateral Flow Strip Biosensor for Visual Detection of Whole Nervous Necrosis Virus Particles The principle of viral particles detection based on lateral flow biosensor with functionalized nanoparticles is presented in Fig. 1 . Nodavirus intact particles (virions), obtained either from SSN-1 cell culture supernatants or homogenized tissue samples, are directly applied on the LFB. The sample contains the nodavirus particles (virions) and is applied on the conjugation pad next to functionalized gold nanoparticles (Au) with polyclonal anti-nodavirus antibody. Application of that conjugate on the LFB resulted in a strong signal in the control zone, confirming the successful conjugation of anti-nodavirus antibody to Au nanoparticles (Fig. 2e) . To enable on site analysis of nodavirus, we developed and optimized a paper LFB based on gold nanoparticles for easy, specific and sensitive visual detection of nodavirus viral particles (virions) in biological samples. abstract: Effective analysis of pathogens causing human and veterinary diseases demands rapid, specific and sensitive detection methods which can be applied in research laboratory setups and in field for routine diagnosis. Paper lateral flow biosensors (LFBs) have been established as attractive tools for such analytical applications. In the present study a prototype LFB was designed for whole particles (virions) detection of nodavirus or fish nervous necrosis virus. Nodavirus is an important threat in the aquaculture industry, causing severe economic losses and environmental problems. The LFB was based on polyclonal antibodies conjugated on gold nanoparticles for signal visualization. Brain and retinas from fish samples were homogenized, centrifuged and the supernatant was directly applied on the LFB. Formation of a red test line was indicative of nodavirus virions presence. Nodavirus visual detection was completed in short time (30 min). Key factors of the LFB development influencing the assays’ detection limit were characterized and the optimum parameters were determined, enabling increased efficiency, excluding non-specific interactions. Therefore, the proposed LFB assay consists a robust, simple, low cost and accurate method for detection of nodavirus virions in fish samples. The proposed biosensor is ideal for development of a commercial kit to be used on aquaculture facilities by fish farmers. It is anticipated that disease monitoring and environmental safety will benefit from the simplification of time consuming and costly procedures. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162894/ doi: 10.1038/s41598-020-63553-z id: cord-307320-fxs31d66 author: Ubah, Obinna title: Monoclonal Antibodies and Antibody Like Fragments Derived from Immunised Phage Display Libraries date: 2018-03-17 words: 8292.0 sentences: 365.0 pages: flesch: 30.0 cache: ./cache/cord-307320-fxs31d66.txt txt: ./txt/cord-307320-fxs31d66.txt summary: However, by combining the power of immunisation with phage display, several high affinity monoclonal antibodies against "difficult" antigenic targets have been isolated from relative small antibody libraries and where traditional approaches have failed [33, 98] . The above study demonstrates the power of animal immunisation and phage display based selection strategies to isolate high affinity monoclonal antibodies towards non-antigenic targets which inherently lack properties like aromaticity and charge. Spleen samples from mice immunised with gamma inactivated Brucella melitensis strain 16 M bacteria was used to construct a phage display library and isolate monoclonal antibody fragments that specifically recognise Brucella species. Similarly high affinity neutralising antibody fragments against the protective antigen (PA) of anthrax toxin was isolated from a Macaca immunised phage display library. Lymphocytes from the bone marrow cells of two chimpanzees immunised with anthrax toxin PA, LF and Edema factor (EF) were used to construct scFv phage display libraries and neutralising antibodies were isolated against PA and LF proteins. abstract: Morbidity and mortality associated with infectious diseases are always on the rise, especially in poorer countries and in the aging population. The inevitable, but unpredictable emergence of new infectious diseases has become a global threat. HIV/AIDS, severe acute respiratory syndrome (SARS), and the more recent H1N1 influenza are only a few of the numerous examples of emerging infectious diseases in the modern era. However despite advances in diagnostics, therapeutics and vaccines, there is need for more specific, efficacious, cost-effective and less toxic treatment and preventive drugs. In this chapter, we discuss a powerful combinatorial technology in association with animal immunisation that is capable of generating biologic drugs with high affinity, efficacy and limited off-site toxicity, and diagnostic tools with great precision. Although time consuming, immunisation still remains the preferred route for the isolation of high-affinity antibodies and antibody-like fragments. Phage display is a molecular diversity technology that allows the presentation of large peptide and protein libraries on the surface of filamentous phage. The selection of binding fragments from phage display libraries has proven significant for routine isolation of invaluable peptides, antibodies, and antibody-like domains for diagnostic and therapeutic applications. Here we highlight the many benefits of combining immunisation with phage display in combating infectious diseases, and how our knowledge of antibody engineering has played a crucial role in fully exploiting these platforms in generating therapeutic and diagnostic biologics towards antigenic targets of infectious organisms. url: https://www.ncbi.nlm.nih.gov/pubmed/29549637/ doi: 10.1007/978-3-319-72077-7_6 id: cord-283641-2u16otbf author: Vainionpää, R. title: Diagnostic Techniques: Serological and Molecular Approaches date: 2015-03-06 words: 4400.0 sentences: 222.0 pages: flesch: 40.0 cache: ./cache/cord-283641-2u16otbf.txt txt: ./txt/cord-283641-2u16otbf.txt summary: For diagnostic purposes the following approaches can be used: demonstration of presence of infectious virus or its structural components directly from a patient''s specimens or investigation of specific antibody response in serum specimens. Glossary EIA Enzyme immunoassays are methods used to estimate virus-specific IgG and IgM antibodies or virus antigens by enzyme-labeled conjugates. Nucleic acid testing has become the main approach for the demonstration of the presence of virus while cultivation is used by fewer specialized laboratories and antigen detection methods have moved to the point of care. Diagnostic applications of the measurement of the avidity of IgG antibodies against specific antigens have been developed to help distinguish serological responses due to acute infections from those of chronic or past infections. In immunofluorescence tests, cells from a clinical specimen are fixed on a glass slide and viral antigens present in the cells are detected by fluorescein-labeled virus-specific antibodies. abstract: Virus laboratory diagnostics has an increasingly important role in modern patient care. Virological methods are needed to investigate the etiology of acute viral infection or the reactivation of a latent infection, as well as to follow virus load in antiviral treatments. Serological assays are also used for screening of blood products for the risk of certain chronic infections, evaluation of the immune status, and need for prophylactic treatments in connection with organ transplantations. For diagnostic purposes the following approaches can be used: demonstration of presence of infectious virus or its structural components directly from a patient's specimens or investigation of specific antibody response in serum specimens. Amplification techniques, most commonly polymerase chain reaction (PCR) is currently the workhorse of nucleic acid testing for the detection and quantitation of virus genomes. Virus isolation is used to demonstrate infectious virus in a patient's specimens, whereas virus antigens are investigated by antigen detection assays. Serological diagnosis is based on either the demonstration of the presence of virus-specific IgM antibodies or a significant increase in the levels and/or avidity of specific IgG antibodies. Immunoassays are the most commonly used serological assays. Point-of-care tests (POC tests), for antigens, antibodies, and also nucleic acids are also becoming more and more common in diagnostic use. In order to reach the best diagnostic efficiency for each patient it is important to select the most suitable method using the right sample collected at the right time. url: https://www.sciencedirect.com/science/article/pii/B9780128012383025587 doi: 10.1016/b978-0-12-801238-3.02558-7 id: cord-344445-slv7r9u7 author: Vakharia, Kunal title: The right to know: ethical implications of antibody testing for healthcare workers and overlooked societal implications date: 2020-06-03 words: 2415.0 sentences: 119.0 pages: flesch: 50.0 cache: ./cache/cord-344445-slv7r9u7.txt txt: ./txt/cord-344445-slv7r9u7.txt summary: The discussion that has continued since the initial severe acute respiratory syndrome virus and avian influenza epidemics has focused on the potential for immunity among the general population and the moral obligation to treat that is often faced by healthcare professionals and institutions. With the growing literature and data suggesting the possibility of mutations, unequal impacts on different people and the potential repercussions of the spike protein for those with IgG immunity already, can society in good faith adopt a moral prerogative to put antibody-positive people in the front line? Healthcare workers form a group of individuals who recognise the potential of COVID-19, the impact it has had, and are still willing to go to work and continue to face the challenge. With limited knowledge about the significance of COVID-19 antibody testing at this time, it is hard to use this to stratify work in a healthcare setting or to use it for any purpose beyond epidemiological studies on the spread of the disease. abstract: After the initial surge in cases of coronavirus (COVID-19), the outbreak has been managed differently in different countries. In the USA, it has been managed in many different ways between states, cities and even counties. This disparity is slowly becoming more and more pronounced with the advent of antibody testing. Although many argue over the potential merits of antibody testing as an immunity passport to allow the economy to restart, there are other implications that stand at the heart of the bioethical debate that are often overlooked. Particularly with COVID-19, there are many uncertainties and the discourse alone of antibodies presumes misinformation that may outweigh the epidemiological benefits of antibody testing. Although this paper does not seek to eliminate antibody testing, it does highlight the need for appropriate counselling both on a personal level with each patient but on a more global level. This moral standard of appropriate education is key to allowing the continued autonomy needed during this pandemic. url: https://www.ncbi.nlm.nih.gov/pubmed/32493712/ doi: 10.1136/medethics-2020-106467 id: cord-274756-nnm1n09a author: Varadé, Jezabel title: Human immunology and immunotherapy: main achievements and challenges date: 2020-09-02 words: 19144.0 sentences: 920.0 pages: flesch: 38.0 cache: ./cache/cord-274756-nnm1n09a.txt txt: ./txt/cord-274756-nnm1n09a.txt summary: The development of different types of immunotherapies, including vaccines (prophylactic and therapeutic), and the use of pathogens, monoclonal antibodies, recombinant proteins, cytokines, and cellular immunotherapies, are changing the way in which we approach many diseases, especially cancer. In addition to those showing the essential role of LTi cells in the formation of secondary lymphoid organs during embryogenesis and the postnatal development of intestinal lymphoid clusters, recent studies also provide evidence that subsets of ILCs express multiple factors that modulate the adaptive immune response in health and disease 27, 28 . Autoimmunity: In the case of therapeutic vaccines for autoimmune diseases, such as multiple sclerosis, diabetes, Myasthenia gravis or Guillain Barré syndrome, the intention is to induce tolerance to self-antigens through the activation of regulatory cells (Tregs and Bregs) and tolerogenic dendritic cells, thus avoiding the immune response to self-components 211 . abstract: The immune system is a fascinating world of cells, soluble factors, interacting cells, and tissues, all of which are interconnected. The highly complex nature of the immune system makes it difficult to view it as a whole, but researchers are now trying to put all the pieces of the puzzle together to obtain a more complete picture. The development of new specialized equipment and immunological techniques, genetic approaches, animal models, and a long list of monoclonal antibodies, among many other factors, are improving our knowledge of this sophisticated system. The different types of cell subsets, soluble factors, membrane molecules, and cell functionalities are some aspects that we are starting to understand, together with their roles in health, aging, and illness. This knowledge is filling many of the gaps, and in some cases, it has led to changes in our previous assumptions; e.g., adaptive immune cells were previously thought to be unique memory cells until trained innate immunity was observed, and several innate immune cells with features similar to those of cytokine-secreting T cells have been discovered. Moreover, we have improved our knowledge not only regarding immune-mediated illnesses and how the immune system works and interacts with other systems and components (such as the microbiome) but also in terms of ways to manipulate this system through immunotherapy. The development of different types of immunotherapies, including vaccines (prophylactic and therapeutic), and the use of pathogens, monoclonal antibodies, recombinant proteins, cytokines, and cellular immunotherapies, are changing the way in which we approach many diseases, especially cancer. url: https://www.ncbi.nlm.nih.gov/pubmed/32879472/ doi: 10.1038/s41423-020-00530-6 id: cord-016966-b23o5roz author: Verhoef, Jan title: Immune response in human pathology: infections caused by bacteria, viruses, fungi, and parasites date: 2005 words: 4302.0 sentences: 220.0 pages: flesch: 43.0 cache: ./cache/cord-016966-b23o5roz.txt txt: ./txt/cord-016966-b23o5roz.txt summary: Effective treatment, however, was not possible at that time; prevention and spread of infectious diseases depended solely on proper hygienic means.At the beginning of the 20th century, passive and active vaccination procedures were developed against a number of these pathogenic micro-organisms in order to prevent the diseases in question (rabies, diphtheria, tetanus, etc.) and due to the discovery of antimicrobial chemicals (Ehrlich) and antibiotics (Fleming), the threat of infectious diseases seemed to be minimized. CYTOKINES, such as IL-2 (INTERLEUKIN-2), GM-CSF (granulocyte-macrophage colony-stimulating factor), and TNF-α (TUMOR NECROSIS FACTOR α), stimulate non-specifically the proliferation, maturation, and Immune response in human pathology: infections caused by bacteria, viruses, fungi, and parasites Jan Verhoef and Harm Snippe A7 function of the cells involved in defence (see Chapter A.4). abstract: Despite the introduction of effective health measurements, vaccination and antimicrobial therapy infectious diseases continue to threaten human life. The reasons are numerous and diverse: antibiotic resistance, hospital-invading pathogens, new emerging infectious diseases, bioterrorism, biological warfare. This chapter is an introduction to several aspects of infectious diseases viewed from the host as well as from the pathogen (bacterium, virus and parasite). Furthermore the basic principles of INNATE and ADAPTIVE IMMUNE RESPONSES, especially in debilitated patients, are described. Detailed information is given on the pathogenesis of septic shock, AIDS and vaccination strategies. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121408/ doi: 10.1007/3-7643-7408-x_7 id: cord-048360-n9sih438 author: Villard, Viviane title: Rapid Identification of Malaria Vaccine Candidates Based on α-Helical Coiled Coil Protein Motif date: 2007-07-25 words: 4794.0 sentences: 228.0 pages: flesch: 45.0 cache: ./cache/cord-048360-n9sih438.txt txt: ./txt/cord-048360-n9sih438.txt summary: To identify malaria antigens for vaccine development, we selected α-helical coiled coil domains of proteins predicted to be present in the parasite erythrocytic stage. Here, we focus on the Pf parasite erythrocytic stage, a target of protective antibodies and describe a straightforward, rapid procedure based on bioinformatic analysis of a-helical coiled-coil motifs and peptide synthesis. With regard to the structural features and cellular location prediction of the proteins corresponding to the peptides selected for ADCI assays ( Table 1) , 15 of the proteins contain a pentapeptide conforming to the PEXEL consensus [19, 20; 21, 22] , but that none of these have a position within the amino acid sequence that conforms to the location of known active PEXEL motifs (see Materials and Methods and membrane segments, and none of them has a GPI anchor. In conclusion, an approach combining a genome-wide search by bioinformatics of a-helical coiled coil protein motifs and chemical synthesis can lead to the rapid identification and development of new malaria vaccine candidates. abstract: To identify malaria antigens for vaccine development, we selected α-helical coiled coil domains of proteins predicted to be present in the parasite erythrocytic stage. The corresponding synthetic peptides are expected to mimic structurally “native” epitopes. Indeed the 95 chemically synthesized peptides were all specifically recognized by human immune sera, though at various prevalence. Peptide specific antibodies were obtained both by affinity-purification from malaria immune sera and by immunization of mice. These antibodies did not show significant cross reactions, i.e., they were specific for the original peptide, reacted with native parasite proteins in infected erythrocytes and several were active in inhibiting in vitro parasite growth. Circular dichroism studies indicated that the selected peptides assumed partial or high α-helical content. Thus, we demonstrate that the bioinformatics/chemical synthesis approach described here can lead to the rapid identification of molecules which target biologically active antibodies, thus identifying suitable vaccine candidates. This strategy can be, in principle, extended to vaccine discovery in a wide range of other pathogens. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1920550/ doi: 10.1371/journal.pone.0000645 id: cord-354137-6oe8nj1j author: Wang, Hua title: Aspects of recent development of immunosensors date: 2008-05-20 words: 9972.0 sentences: 481.0 pages: flesch: 23.0 cache: ./cache/cord-354137-6oe8nj1j.txt txt: ./txt/cord-354137-6oe8nj1j.txt summary: Development of microfluidic immunosensor systems for proteomics and drug discovery have also been reported in recent years where the microfluidic system integrates multiple processes in a single device to improve analytical performance by reducing the reagent consumption and the analysis time, and increasing reliability and sensitivity through automation. A capacitive immunoassay based on antibody-embedded ultra-thin alumina sol-gel fi lms (∼20 to 40 nm) was reported and used for direct determination of antigens with a detection limit as low as ϳ1 ng mL Ϫ1 [92] . reported a successful integration of the lateral fl ow immunoassay format and impedance detection for prostate-specifi c antigen of tumor marker, where the electrochemical transducer was coated with a pH-sensitive polymer layer [93] . Based on the modifi cation of mixed SAMs on gold electrodes for covalently binding antigens, another piezoelectric immunosensor has been recently developed to detect antisperm antibody [153] . abstract: This chapter focuses on the recent developments in the field of immunosensors. Immunosensors incorporate the specific immunochemical reaction with the modern transducers including electrochemical (potentiometric, conductometric, capacitative, impedance, amperometric), optical (fluorescence, luminescence, refractive index), and microgravimetric transducers. These immunosensor devices with dramatic improvements in the sensitivity and selectivity possess the abilities to investigate the reaction dynamics of antibody–antigen binding and the potential to revolutionize conventional immunoassay techniques. With the rapid development of immunological reagents and detection equipments, immunosensors have allowed an increasing range of analytes to be identified and quantified and in particular, simple-to-use, inexpensive, and reliable immunosensing systems have been developed for areas such as outpatient monitoring, large screening programs, and remote environmental surveillance. Immunosensors with lowered detection limits and increased sensitivities have been developed in various fields, particularly in clinical analysis. A noticeable development trend is also observed in the development of immunosensors combining with other techniques such as flow injection analysis (FIA) or capillary electrophoretic (CE) analysis, which complement and improve the present immunoassay methods. Belov et al. have proposed a novel immunophenotyping method for leukemias which uses a cluster of differentiation antibody microarray, and a microarray of enzyme-linked immunosorbent assay has been developed for autoimmune diagnosis of systematic rheumatic disease. Development of microfluidic immunosensor systems for proteomics and drug discovery have also been reported in recent years where the microfluidic system integrates multiple processes in a single device to improve analytical performance by reducing the reagent consumption and the analysis time, and increasing reliability and sensitivity through automation. url: https://api.elsevier.com/content/article/pii/B9780123737380500118 doi: 10.1016/b978-012373738-0.50011-8 id: cord-002153-e0zhq18g author: Yang, Danlin title: Efficient Qualitative and Quantitative Determination of Antigen-induced Immune Responses date: 2016-07-29 words: 7931.0 sentences: 369.0 pages: flesch: 43.0 cache: ./cache/cord-002153-e0zhq18g.txt txt: ./txt/cord-002153-e0zhq18g.txt summary: Our workflow consists of the following two steps: 1) the use of surface plasmon resonance to quantify antigen-specific antibodies and evaluate their apparent binding affinities, and 2) the recovery of serum IgGs using an automated small scale purification system, followed by the determination of their epitope diversity using hydrogen deuterium exchange coupled with mass spectrometry. To increase the efficiency of our therapeutic antibody generation process to achieve long term success, we developed alternative methods for assessing the quality of polyclonal antibodies in immune sera, surface plasmon resonance (SPR) 2 and hydrogen deuterium exchange (HDX) coupled with mass spectrometry. In this report, we describe the following: the method development and establishment of the detection limits of our techniques, a proof-of-concept study using sera from IL-13 immunized mice, the creation of a workflow named Quality of Antibody Response (QAR), and finally the implementation of this workflow for a therapeutic anti-B-cell activating factor (BAFF) antibody generation campaign to guide the selection of optimal animal donors for hybridoma generation. abstract: To determine the effectiveness of immunization strategies used in therapeutic antibody or vaccine development, it is critical to assess the quality of immunization-induced polyclonal antibody responses. Here, we developed a workflow that uses sensitive methods to quantitatively and qualitatively assess immune responses against foreign antigens with regard to antibody binding affinity and epitope diversity. The application of such detailed assessments throughout an immunization campaign can significantly reduce the resources required to generate highly specific antibodies. Our workflow consists of the following two steps: 1) the use of surface plasmon resonance to quantify antigen-specific antibodies and evaluate their apparent binding affinities, and 2) the recovery of serum IgGs using an automated small scale purification system, followed by the determination of their epitope diversity using hydrogen deuterium exchange coupled with mass spectrometry. We showed that these methods were sensitive enough to detect antigen-specific IgGs in the nanogram/μl range and that they provided information for differentiating the antibody responses of the various immunized animals that could not be obtained by conventional methods. We also showed that this workflow can guide the selection of an animal that produces high affinity antibodies with a desired epitope coverage profile, resulting in the generation of potential therapeutic monoclonal antibody clones with desirable functional profiles. We postulate that this workflow will be an important tool in the development of effective vaccines to combat the highly sophisticated evasion mechanisms of pathogens. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965583/ doi: 10.1074/jbc.m116.736660 id: cord-316287-4i1grvlr author: Yim, Sung Sun title: Rapid Isolation of Antibody from a Synthetic Human Antibody Library by Repeated Fluorescence-Activated Cell Sorting (FACS) date: 2014-10-10 words: 6372.0 sentences: 281.0 pages: flesch: 51.0 cache: ./cache/cord-316287-4i1grvlr.txt txt: ./txt/cord-316287-4i1grvlr.txt summary: During the cultivation for regeneration of sorted cells, differential growth rates among various clones (particularly non-specific clones) due to unregulated protein expression and differing cell viability can decrease the library screening efficiency, resulting in more rounds of sorting (longer duration) to isolate the potential antibody candidate [12] . The whole FACS screening rounds of the synthetic human antibody library against each viral antigen could be done in one day, and these results show that repeated FACS screening without regeneration of the sorted cells can be a rapid and efficient method to isolate potential antibody candidates in case of urgent requirements. For the FACS screening of a human synthetic antibody (scFv) library, three fluorescent antigen probes were chemically synthesized: (i) FITC-CRDNWHGSNRPW as an N1 epitope of H1N1 influenza virus [13] ; (ii) FITC-NSTTFHQALLDPRVRGLYF-PAGG as a PreS2 epitope of HBV [14] ; and (iii) FITC-PVTNVRGDLQVLAQK as a VP1 epitope of FMDV [15] . abstract: Antibodies and their derivatives are the most important agents in therapeutics and diagnostics. Even after the significant progress in the technology for antibody screening from huge libraries, it takes a long time to isolate an antibody, which prevents a prompt action against the spread of a disease. Here, we report a new strategy for isolating desired antibodies from a combinatorial library in one day by repeated fluorescence-activated cell sorting (FACS). First, we constructed a library of synthetic human antibody in which single-chain variable fragment (scFv) was expressed in the periplasm of Escherichia coli. After labeling the cells with fluorescent antigen probes, the highly fluorescent cells were sorted by using a high-speed cell sorter, and these cells were reused without regeneration in the next round of sorting. After repeating this sorting, the positive clones were completely enriched in several hours. Thus, we screened the library against three viral antigens, including the H1N1 influenza virus, Hepatitis B virus, and Foot-and-mouth disease virus. Finally, the potential antibody candidates, which show K(D) values between 10 and 100 nM against the target antigens, could be successfully isolated even though the library was relatively small (∼10(6)). These results show that repeated FACS screening without regeneration of the sorted cells can be a powerful method when a rapid response to a spreading disease is required. url: https://doi.org/10.1371/journal.pone.0108225 doi: 10.1371/journal.pone.0108225 id: cord-330324-4hqhty5o author: Yu, Meng title: Determination and application of immunodominant regions of SARS coronavirus spike and nucleocapsid proteins recognized by sera from different animal species date: 2008-02-29 words: 5799.0 sentences: 284.0 pages: flesch: 50.0 cache: ./cache/cord-330324-4hqhty5o.txt txt: ./txt/cord-330324-4hqhty5o.txt summary: title: Determination and application of immunodominant regions of SARS coronavirus spike and nucleocapsid proteins recognized by sera from different animal species In this study, we aim to search for and compare immunodominant regions of the spike (S) and nucleocapsid (N) proteins which are recognized by sera from different animal species, including mouse, rat, rabbit, civet, pig and horse. In this study we identified and characterized the major immunodominant domains of the SARS-CoV N and S proteins recognized by different animal species, and then developed competition ELISAs based on these findings. The specificity of the antibody was further confirmed using Western blot against viral antigen (data not shown) and IFAT using SARS-CoV infected Vero cells. One of the main aims of this study was to assess the feasibility of developing a competition ELISA for detection of SARS-CoV antibodies from different animal species. Inhibition of binding of mono-specific chicken antibodies to SARS-CoV by sera from different species. abstract: Abstract Knowledge of immunodominant regions in major viral antigens is important for rational design of effective vaccines and diagnostic tests. Although there have been many reports of such work done for SARS–CoV, these were mainly focused on the immune responses of humans and mice. In this study, we aim to search for and compare immunodominant regions of the spike (S) and nucleocapsid (N) proteins which are recognized by sera from different animal species, including mouse, rat, rabbit, civet, pig and horse. Twelve overlapping recombinant protein fragments were produced in Escherichia coli, six each for the S and N proteins, which covered the entire coding region of the two proteins. Using a membrane-strip based Western blot approach, the reactivity of each antigen fragment against a panel of animal sera was determined. Immunodominant regions containing linear epitopes, which reacted with sera from all the species tested, were identified for both proteins. The S3 fragment (aa 402–622) and the N4 fragment (aa 220–336) were the most immunodominant among the six S and N fragments, respectively. Antibodies raised against the S3 fragment were able to block the binding of a panel of S-specific monoclonal antibodies (mAb) to SARS–CoV in ELISA, further demonstrating the immunodominance of this region. Based on these findings, one-step competition ELISAs were established which were able to detect SARS–CoV antibodies from human and at least seven different animal species. Considering that a large number of animal species are known to be susceptible to SARS–CoV, these assays will be a useful tool to trace the origin and transmission of SARS–CoV and to minimise the risk of animal-to-human transmission. url: https://doi.org/10.1016/j.jim.2007.11.009 doi: 10.1016/j.jim.2007.11.009 id: cord-031060-0o9agjiq author: Yuan, Tom Z title: Rapid exploration of the epitope coverage produced by an Ebola survivor to guide the discovery of therapeutic antibody cocktails date: 2020-08-01 words: 3913.0 sentences: 159.0 pages: flesch: 36.0 cache: ./cache/cord-031060-0o9agjiq.txt txt: ./txt/cord-031060-0o9agjiq.txt summary: Incorporating epitope binning on hundreds of antibodies during early stage antibody characterization ensures access to a library''s full epitope coverage, aids in the identification of high quality reagents within the library that recapitulate this diversity for use in other studies, and ultimately enables the rational development of therapeutic cocktails that take advantage of multiple mechanisms of action such as cooperative synergistic effects to enhance neutralization function and minimize the risk of mutagenic escape. Despite ligand attrition and the stringent requirement for premixed antibodies to achieve antigen saturation, which reduced our heat map to 52 analytes x 233 ligands, we were able in this non-optimized ''first pass'' binning to assign 234 antibodies to one of seven epitope communities without the use of benchmark antibodies (Supplemental Table S1 ). abstract: BACKGROUND: Development of successful neutralizing antibodies is dependent upon broad epitope coverage to increase the likelihood of achieving therapeutic function. Recent advances in synthetic biology have allowed us to conduct an epitope binning study on a large panel of antibodies identified to bind to Ebola virus glycoprotein with only published sequences. METHODS AND RESULTS: A rapid, first-pass epitope binning experiment revealed seven distinct epitope families that overlapped with known structural epitopes from the literature. A focused set of antibodies was selected from representative clones per bin to guide a second-pass binning that revealed previously unassigned epitopes, confirmed epitopes known to be associated with neutralizing antibodies, and demonstrated asymmetric blocking of EBOV GP from allosteric effectors reported from literature. CONCLUSIONS: Critically, this workflow allows us to probe the epitope landscape of EBOV GP without any prior structural knowledge of the antigen or structural benchmark clones. Incorporating epitope binning on hundreds of antibodies during early stage antibody characterization ensures access to a library’s full epitope coverage, aids in the identification of high quality reagents within the library that recapitulate this diversity for use in other studies, and ultimately enables the rational development of therapeutic cocktails that take advantage of multiple mechanisms of action such as cooperative synergistic effects to enhance neutralization function and minimize the risk of mutagenic escape. The use of high-throughput epitope binning during new outbreaks such as the current COVID-19 pandemic is particularly useful in accelerating timelines due to the large amount of information gained in a single experiment. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454256/ doi: 10.1093/abt/tbaa016 id: cord-001566-kkaxha7d author: Zhang, Mao-Yu title: Development of Monoclonal Antibodies in China: Overview and Prospects date: 2015-02-25 words: 3524.0 sentences: 196.0 pages: flesch: 44.0 cache: ./cache/cord-001566-kkaxha7d.txt txt: ./txt/cord-001566-kkaxha7d.txt summary: This paper aims to provide a comprehensive review of mAbs development in China through systematic analysis of drug registry, patent applications, clinical trials, academic publication, and ongoing R&D projects. Over the past three decades, monoclonal antibodies (mAbs) have achieved a dramatic development from scientific tools to powerful human therapeutic agents [1] (see Figure 1 ). Development of this class of therapeutic agents started as early as 1980s but achieved no clinical or commercial success until 2002 when adalimumab became the first human mAb approved by the US Food and Drug Administration (FDA) [14] . R&D of mAbs in China began in the 1980s [16] and the first mAb therapeutic agent (Murine Monoclonal Antibody against Human CD3 Antigen of T Lymphocyte for Injection) was introduced in 1999 [17] . This paper aims to provide a comprehensive review of mAb development in China through systematic analysis of product registry, patent application, clinical trials, academic publication, and ongoing R&D projects. abstract: Monoclonal antibodies (mAbs) have become increasingly important as human therapeutic agents. Yet, current research concentrates on technology itself and pays attention to developed countries. This paper aims to provide a comprehensive review of mAbs development in China through systematic analysis of drug registry, patent applications, clinical trials, academic publication, and ongoing R&D projects. The trends in therapeutic areas and industrialization process are also highlighted. Development and research trends of mAbs are analyzed to provide a future perspective of mAbs as therapeutic agents in China. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355554/ doi: 10.1155/2015/168935 id: cord-267015-mprsdi2e author: Zhu, Zhongyu title: Exceptionally Potent Cross-Reactive Neutralization of Nipah and Hendra Viruses by a Human Monoclonal Antibody date: 2008-03-15 words: 4460.0 sentences: 235.0 pages: flesch: 52.0 cache: ./cache/cord-267015-mprsdi2e.txt txt: ./txt/cord-267015-mprsdi2e.txt summary: One of these antibodies, m102, which exhibited the highest level of cross-reactive neutralization of both NiV and HeV G, was affinity maturated by light-chain shuffling combined with random mutagenesis of its heavy-chain variable domain and panning against sG(HeV). We have previously identified neutralizing human monoclonal antibodies against Nipah virus (NiV) and Hendra virus (HeV) by panning a large nonimmune antibody library against a soluble form of the HeV attachment-envelope glycoprotein G (sG HeV ). One of these antibodies, m102, which exhibited the highest level of cross-reactive neutralization of both NiV and HeV G, was affinity maturated by light-chain shuffling combined with random mutagenesis of its heavychain variable domain and panning against sG HeV . To demonstrate that m102.4 measured in plasma was biologically active, serum collected on days 1, 4, and 8 was evaluated using virus neutralization assays, as described above (data not shown). Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus abstract: We have previously identified neutralizing human monoclonal antibodies against Nipah virus (NiV) and Hendra virus (HeV) by panning a large nonimmune antibody library against a soluble form of the HeV attachment-envelope glycoprotein G (sG(HeV)). One of these antibodies, m102, which exhibited the highest level of cross-reactive neutralization of both NiV and HeV G, was affinity maturated by light-chain shuffling combined with random mutagenesis of its heavy-chain variable domain and panning against sG(HeV). One of the selected antibody Fab clones, m102.4, had affinity of binding to sG(HeV) that was equal to or higher than that of the other Fabs; it was converted to IgG1 and tested against infectious NiV and HeV. It exhibited exceptionally potent and cross-reactive inhibitory activity with 50% inhibitory concentrations below 0.04 and 0.6 μg/mL, respectively. The virus-neutralizing activity correlated with the binding affinity of the antibody to sG(HeV) and sG(NiV). m102.4 bound a soluble form of NiV G (sG(NiV)) better than it bound sG(HeV), and it neutralized NiV better than HeV, despite being originally selected against sG(HeV). These results suggest that m102.4 has potential as a therapeutic agent for the treatment of diseases caused by henipaviruses. It could be also used for prophylaxis and diagnosis, and as a research reagent url: https://www.ncbi.nlm.nih.gov/pubmed/18271743/ doi: 10.1086/528801 id: cord-009571-mygj2nd4 author: nan title: Proceedings of the 42nd annual meeting of the american rheumatism association a section of the arthritis foundation june 1 & 2, 1978 new york city abstracts of papers presented date: 2005-11-23 words: 46150.0 sentences: 2284.0 pages: flesch: 49.0 cache: ./cache/cord-009571-mygj2nd4.txt txt: ./txt/cord-009571-mygj2nd4.txt summary: Levels of Ty cells as well as total T lymphocytes were measured in 19 patients with systemic lupus erythematosus (SLE), 11 with active and 8 with inactive disease, and in 47 normal subjects. The diagnosis of GC arthritis were studied for the presence of GC antigen (AG) and anti-in all seven patients was made by typical clinical presentation, body (AB) in serum and synovial fluid by counter-positive local culture for Ngonorrhoeae (NG) , and response to treatment. A retrospective study was instituted on 10 patients in the UCLA lupus nephritis clinic in an attempt to determine the ability of three serologic indicators-specifically immune complexes (IC), anti-DNA antibodies (DNA-ab), and C3-to predict the activity of SLE renal disease as indicated by changes in 24 hour proteinuria, serum creatinine, and creatinine clearance. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159665/ doi: 10.1002/art.1780210508 id: cord-010088-s9tfvtao author: nan title: Oral Abstracts date: 2013-11-01 words: 43522.0 sentences: 2257.0 pages: flesch: 49.0 cache: ./cache/cord-010088-s9tfvtao.txt txt: ./txt/cord-010088-s9tfvtao.txt summary: These include ''incorrect blood component transfused'' events, where the blood component was intended for another recipient (frequently due to errors in patient identification at the time of collection of the pre-transfusion sample, or at the time of bedside administration), or did not meet the patient''s special needs (such as a patient with a red cell antibody who did not receive the required antigen-negative unit). Methods: Eligibility criteria for inclusion in the study included the following: transfusion of Rh D positive platelets, no anti D detectable before transfusion, no previous exposure to Rh D positive blood components, and results of follow-up testing of anti-D in patients serum available. In addition, the allelic frequency of Hpdel was calculated to be 0.015 by a genetic study of a limited number of the Japanese individuals, suggesting that Hp deficiency might distribute among the Japanese population as a phenotype of serum Hp. Aims: In this report, we present the results obtained from a hemovigilance survey carried out between 1998 and 2012, in which Hp deficiency was identified among Japanese patients who had experienced nonhemolytic TRs (NHTRs), and those obtained from a screening of Hp-deficient Japanese healthy blood donors. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169312/ doi: 10.1111/vox.12100_1 id: cord-023346-8sqbqjm1 author: nan title: MONDAY: POSTERS date: 2005-06-08 words: 130043.0 sentences: 7330.0 pages: flesch: 54.0 cache: ./cache/cord-023346-8sqbqjm1.txt txt: ./txt/cord-023346-8sqbqjm1.txt summary: • enhancement of automation/computerisation; • process control to provide an ''error-free pathway''; • (national) surveillance and trend analysis of results, preferably based on national working standards; • significantly increased sensitivity, especially from development of antigen/antibody ''combi'' assays (e.g. for HIV, and recently, for HCV); • awareness of HBsAg vaccine-escape mutants and design of assays to cope with this; • extension of range of agents and markers tested for (varies in different countries); • increasing range of assays available for testing donors with a relevant history of exposure to malaria or Chagas'' disease infection (for retrieval of otherwise wasted blood); • European Union''s in vitro diagnostics directive: this has caused some problems and reduced flexibility. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169255/ doi: 10.1111/j.1423-0410.2005.00652.x id: cord-023354-f2ciho6o author: nan title: TUESDAY PLENARY SESSION 3 TUESDAY: POSTERS date: 2005-06-08 words: 130046.0 sentences: 7333.0 pages: flesch: 54.0 cache: ./cache/cord-023354-f2ciho6o.txt txt: ./txt/cord-023354-f2ciho6o.txt summary: • enhancement of automation/computerisation; • process control to provide an ''error-free pathway''; • (national) surveillance and trend analysis of results, preferably based on national working standards; • significantly increased sensitivity, especially from development of antigen/antibody ''combi'' assays (e.g. for HIV, and recently, for HCV); • awareness of HBsAg vaccine-escape mutants and design of assays to cope with this; • extension of range of agents and markers tested for (varies in different countries); • increasing range of assays available for testing donors with a relevant history of exposure to malaria or Chagas'' disease infection (for retrieval of otherwise wasted blood); • European Union''s in vitro diagnostics directive: this has caused some problems and reduced flexibility. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169300/ doi: 10.1111/j.1423-0410.2005.00654.x id: cord-023364-ut56gczm author: nan title: EDUCATION DAY MONDAY: PLENARY SESSION 1 MONDAY: PARALLEL SESSIONS date: 2005-06-08 words: 130049.0 sentences: 7334.0 pages: flesch: 54.0 cache: ./cache/cord-023364-ut56gczm.txt txt: ./txt/cord-023364-ut56gczm.txt summary: • enhancement of automation/computerisation; • process control to provide an ''error-free pathway''; • (national) surveillance and trend analysis of results, preferably based on national working standards; • significantly increased sensitivity, especially from development of antigen/antibody ''combi'' assays (e.g. for HIV, and recently, for HCV); • awareness of HBsAg vaccine-escape mutants and design of assays to cope with this; • extension of range of agents and markers tested for (varies in different countries); • increasing range of assays available for testing donors with a relevant history of exposure to malaria or Chagas'' disease infection (for retrieval of otherwise wasted blood); • European Union''s in vitro diagnostics directive: this has caused some problems and reduced flexibility. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169338/ doi: 10.1111/j.1423-0410.2005.00651.x id: cord-104226-bb4lyvhy author: nan title: Monoclonal antiprothrombinase (3D4.3) prevents mortality from murine hepatitis virus (MHV-3) infection date: 1992-09-01 words: 4669.0 sentences: 243.0 pages: flesch: 51.0 cache: ./cache/cord-104226-bb4lyvhy.txt txt: ./txt/cord-104226-bb4lyvhy.txt summary: The induction of monocyte/macrophage procoagulant activity (PCA) has been implicated in the pathogenesis of murine hepatitis virus strain 3 (MHV-3) infection and disease. The results reported here demonstrate that a neutralizing antibody to PCA protects animals from fulminant hepatitis and death associated with MHV-3 infection, and supports the notion that PCA is a potent inflammatory mediator that plays a pivotal role in the pathogenesis of liver injury resulting from MHV-3 infection. In contrast, mice infected with MHV-3 but treated with antibody to PCA showed a marked reduction in liver disease in all groups (25, 50 , and 100/.r ( were a few small loci of inflammatory cells with no necrosis (Fig. 2 D) . No fibrin was seen in the livers of infected mice treated with 100/~g of mAb. Treatment with anti-PCA alone resulted in no detectable histological evidence of liver disease in nonirLf~ed animals. abstract: The induction of monocyte/macrophage procoagulant activity (PCA) has been implicated in the pathogenesis of murine hepatitis virus strain 3 (MHV-3) infection and disease. Previously, we have shown that induction of PCA by MHV-3 correlated with resistance/susceptibility to infection in different mouse strains. In this study, all BALB/cJ mice that were infected with 10(3) plaque-forming units of MHV-3 developed severe liver disease and died within 96-120 h. Examination of the livers of these animals showed marked hepatic necrosis, deposition of fibrin, and cellular expression of PCA by direct immunofluorescence staining in areas of necrosis as well as in hepatic sinusoids. Splenic mononuclear cells recovered from these mice expressed high concentrations of PCA with time after infection. Infusion into mice of a high-titered monoclonal antibody that neutralized PCA (3D4.3) attenuated the development of hepatic necrosis and enhanced survival in a dose- dependent manner. All of the animals receiving 100 micrograms, and 44% and 22% of the animals that received 50 and 25 micrograms per day, respectively, survived for 10 d and made a full recovery. Administration of the antibody resulted in a dose-dependent reduction in fibrin deposition, PCA expression as detected by direct immunofluorescence staining and by a functional assay. In animals treated with high concentrations of antibody, titers of antibody to PCA fell from 87 +/- 15 micrograms/ml to 100 +/- 7 ng/ml during the active phase of the disease, consistent with sequestration due to binding of the immunoglobulin to cells expressing PCA. Surviving animals, when rechallenged with MHV-3, had a 40% mortality, consistent with the known rates of metabolism of immunoglobulin. This further suggested that protection was by a passive mechanism. The results reported here demonstrate that a neutralizing antibody to PCA protects animals from fulminant hepatitis and death associated with MHV-3 infection, and supports the notion that PCA is a potent inflammatory mediator that plays a pivotal role in the pathogenesis of liver injury resulting from MHV-3 infection. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119354/ doi: nan id: cord-327883-s9nbr5y8 author: nan title: Section Virology date: 1990-03-31 words: 10576.0 sentences: 571.0 pages: flesch: 48.0 cache: ./cache/cord-327883-s9nbr5y8.txt txt: ./txt/cord-327883-s9nbr5y8.txt summary: By improving the enzyme-linked immunosorbent assay (ELISA) for HSV-2-antibodies and additional testing of sera by Western blot, we were able to specifically identify HSV-l-and HSV-2-antibodies in serum samples. To get some insight into the molecular basis of processes controlling the viral expression we studied the sequence-specific DNA-protein interactions within the genomic regulatory regions. for Med. Microbiology, Univ., D-5300 Bonn Semiquantitative detection of Hepatitis B Virus (HBV) DNA in sera of infected individuals has become an important means of modern serological hepatitis diagnostics. THOMSSEN 1 In the course of acute Epstein-Barr virus (EBV) infection IgM antibodies always occur against two cellular antigens that were characterized as proteins with a molecular weight of 26 kD (p26) and 29 kD (p29), respectively. The frequency and specificity of antibodies to P-gene encoded proteins of human hepatitis B virus was tested in sera of acute and chronically infected patients with and without hepatocellular carcinoma (HCC). abstract: nan url: https://www.sciencedirect.com/science/article/pii/S0934884011800393 doi: 10.1016/s0934-8840(11)80039-3 ==== make-pages.sh questions [ERIC WAS HERE] ==== make-pages.sh search /data-disk/reader-compute/reader-cord/bin/make-pages.sh: line 77: /data-disk/reader-compute/reader-cord/tmp/search.htm: No such file or directory Traceback (most recent call last): File "/data-disk/reader-compute/reader-cord/bin/tsv2htm-search.py", line 51, in with open( TEMPLATE, 'r' ) as handle : htm = handle.read() FileNotFoundError: [Errno 2] No such file or directory: '/data-disk/reader-compute/reader-cord/tmp/search.htm' ==== make-pages.sh topic modeling corpus Zipping study carrel